Identification of proteins associated with cancerous and invasive phenotypes of breast and melanoma cells using proteomic approaches by Maurya, Priyanka
 i 
Identification of Proteins Associated 
with Cancerous and Invasive 
Phenotypes of Breast and Melanoma 
Cells using Proteomic approaches 
 
 
 
 
 
 
Priyanka Maurya 
 
 
 
 
Ph.D        2009 
 ii 
 
Identification of Proteins Associated 
with Cancerous and Invasive 
Phenotypes of Breast and Melanoma 
Cells using Proteomic approaches 
 
 
A thesis submitted for the degree of Ph.D. 
Dublin City University 
 
By 
Priyanka Maurya M.Sc. (Biotechnology) 
 
The research work described in this thesis was performed under 
the supervision of 
 
Prof. Martin Clynes  
and 
Dr. Paula Meleady 
 
National Institute for Cellular Biotechnology 
Dublin City University 
 
2009 
 
 iii 
 
 
 
 
 
 
 
 
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of Ph.D. is entirely my own work and has not been taken 
from the work of others save and to the extent that such work has been cited and 
acknowledged within the text of my work.  
 
 
 
 
Signed: ____________________ (Candidate) ID No.: 54166462  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
Acknowledgements 
 
I am glad to have this opportunity to thank people who, in many ways, contributed to 
the completion of this thesis.  
 
First of all, I would like to express my deep and sincere gratitude to my supervisor, 
Prof. Martin Clynes, for giving me the opportunity to conduct my PhD under his 
outstanding supervision in the National Institute for Cellular Biotechnology (NICB) at 
Dublin City University (DCU). His extensive discussions around my work have been 
very helpful to me in elaborating our findings from this study. His understanding, 
encouraging and personal guidance have always provided a good basis for the present 
thesis. 
 
I would like to thank my co-supervisor, Dr. Paula Meleady, for her valuable advice and 
friendly help and also for all the insightful comments she gave me at different stages of 
this thesis. During this period, I learned a lot from Dr. Paula Meleady and I am very 
grateful for having a chance to work with her.  
 
I would like to thank Dr. Paul Dowling for giving valuable insights in to my project in 
dealing with the challenges in SELDI work. He has been very helping and supporting 
all-round. 
I am grateful to Dr. Joanne Keenan for helping me in learning siRNA transfection, 
designing experiments and critical analysis of results.  
I am very thankful to Mick who has always been helping in Mass Spectrometry Lab. 
I would like to thank Mr. Alex Eustace for discussing invasion assay results from his 
work and providing cell lines for this study. Also thanks to Dr. Lorraine O'Driscoll, Dr. 
Paudraig Doolan and Dr. Annemarie Larkin for their help and advices at various stage 
of thesis. 
 
 v 
I know its not enough, but still I would like to say thanks to Dr. Niraj Kumar. I have 
been benefited by his experience at every stage as he was 2 months ahead of me during 
the period of PhD. He has helped me in learning various things including proteomics 
and molecular biology techniques as well as in keeping me positive throughout the 
period.  
 
I owe my loving thanks to my father, mother, sisters and jiju. I know they were always 
missing me, but never expressed. Without their encouragement and understanding, it 
would have been impossible for me to finish this work.  
 
Huge thanks to Carol and Yvonne in the office for constant support and help through 
out the period, and special thanks to Maired for getting every bill clear as soon as 
possible every time. Also thanks to Joe for keeping the prep room going and Ultan for 
storing the reagents many times properly in my absence. 
 
Thank you to everyone in the centre for all the help at various stages.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
Abstract 
Breast cancer is the most commonly diagnosed cancer in women. To identify proteins 
that may be involved in transformation of normal cells into cancerous cells and invasion 
in breast cells, the proteomic profiles for cell lysates, conditioned media and membrane 
& membrane-associated proteins from normal mammary epithelial cells (HMEC), non-
tumourigenic mammary immortalized cells (MCF-10A), non-invasive breast cancer 
cells (MCF7) and invasive breast cancer cells (BT20) were investigated using 2D-DIGE 
coupled with mass spectrometry. Thirty one interesting proteins (either not previously 
reported as associated with breast cancer or with limited information in the literature) 
were identified from this study. These include cytosolic proteins (EIF4A3, SERPINB1, 
UQCRC1, DCI and SOD1), secreted proteins (PDIA4, SERPINB1, SERPINB7, CTSA, 
NUCB1 and FHC) and membrane & membrane-associated proteins (IMMT, UQCRC1 
S100A14 and FKBP5). A few cytosolic proteins (TXNRD1, 3-PGDH, TALDO1, CLP, 
ERp29 and QPRT), secreted proteins (TALDO1 and GSS) and membrane & 
membrane-associated proteins (GANAB, WDR1, RUVBL2 and C20ORF3) were 
identified that could be associated with invasion of both normal and cancer cells. We 
also identified cytosolic proteins (CLIC1, PSME1 and RAD23B), secreted proteins 
(DDAH1 and NUCB2) and membrane & membrane-associated proteins (ATP5B, 
RUVBL2, CES1, TALDO1 and AHCY) that could associated with breast cancer 
invasion.  
The expression of two cellular proteins TXNRD1 and RAD23B which were observed 
differentially regulated from the cell lysates study, were down-regulated using siRNA. 
The knock down of TXNRD1 reduced invasion of the invasive cancer cell lines, SKBR-
3 and MDA-MB 231 whereas down-regulation of RAD23B enhanced invasion of 
cancer and normal non-invasive cell lines (MCF-7 and MCF-10A). This suggests that 
TXNRD1 and RAD23B may play important roles in the regulation of invasion in the 
breast cancer cells. 
 
New biomarkers could be valuable for the early detection of melanoma. The analysis of 
conditioned media from melanocytes, melanoma, normal mammary epithelial, breast 
and lung cancer cell lines using SELDI-ToF MS revealed that a small protein/peptide, 
identified as a possible fragment of bovine transferrin at 7.6kDa, was expressed only in 
 vii 
the melanoma cell lines. Gelatin zymography and specific inhibitor studies suggested 
that MMP 2 and MMP 9 secreted by melanoma cell lines are responsible for cleavage of 
the transferrin protein in the culture medium. We also investigated a number of other 
proteins/peptides (7.4kDa, 8.5kDa, 11.9kDa and 12kDa) that were up-regulated in 
conditioned media from the melanoma cell lines compared to melanocytes. The 8.5kDa 
protein was identified as ubiquitin. The transferrin fragment and ubiquitin could be 
valuable biomarkers for detection of melanoma. Thus proteomics approches are the 
power full tools for cancer biomarker discovery. 
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1.1 General Introduction 
More than 11 million people are diagnosed with cancer every year. It is estimated that 
there will be 16 million new cases every year by 2020. From a total of 58 million deaths 
worldwide in 2005, cancer accounts for 7.6 million (or 13%) of the global mortality 
(Cho 2007). Deaths from cancer in the world are projected to continue rising, with an 
estimated 9 million people dying from cancer in 2015 and 11.4 million dying in 2030. 
Cancer is a disease of uncontrolled cell growth caused by exposure to carcinogens 
(cancer-causing substances), genetic defects and/or viruses. These cells can multiply 
and form a large mass of tissue called a tumor. Some tumours are limited to one 
location and can be surgically removed. These tumors may cause little harm and are 
therefore called benign. Cancer cells of other tumors may invade to surrounding tissue 
and spread to the other organs of the body. Such aggressive tumors are called malignant 
or cancer.  
Cancer is today recognized as a highly heterogeneous disease. More than 100 distinct 
types of human cancer have been described, and various tumour subtypes can be found 
within specific organs (Grizzi and Chiriva-Internati 2006, Brafford and Herlyn 2005). In 
addition, tumours have somatic mutations and epigenetic changes, many of which are 
specific to the individual neoplasm (Ramaswamy 2004). It is now recognized that this 
genetic and phenotypical variability primarily determines the growth and invasiveness 
of cells (Grizzi and Chiriva-Internati 2006). The metastatic potential of neoplastic 
disease and its response or resistance to therapy could also be dependent on the genetic 
and phenotypical variability of cells. Therefore it seems that the multi-level complexity 
of cancer explains the clinical diversity of histologically similar neoplasia.  
During the development of most types of human cancer, primary tumours produces cells 
that move out, invade adjacent tissues, and travel to distant sites where they may 
succeed in founding new colonies. These distant settlements of tumour cells, 
metastases, are the cause of 90% of human cancer deaths (Sporn 1996). The capability 
for invasion and metastasis enables cancer cells to escape the primary tumour mass and 
colonize a new terrain in the body where, at least initially, nutrients and space are not 
limiting.  
Invasion and metastasis are exceedingly complex processes, and their genetic and 
biochemical determinants remain incompletely understood. At the mechanistic level, 
they are closely allied processes, which justify their association with one another as one 
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general capability of cancer cells. Both utilize similar operational strategies, involving 
changes in the physical coupling of cells to their microenvironment and activation of 
extracellular proteases. A cascade of complex interactions between the cancer cell and 
its surroundings results in the metastatic cascade. For successful metastasis, cells must 
penetrate the vessels (intravasation), travel through the blood stream or lymph system 
and then exit the vessels at the new site (extravasation), and proliferate.  The series of 
steps of this metastatic cascade are depicted in Figure 1.1. 
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Figure 1.1. Invasion and metastasis. During the metastatic process, cancer cells 
proceed through a series of distinct steps to form a secondary tumour. Cells detach from 
the primary tumour, invade adjacent tissue and then enter the lymphatic or circulatory 
system. Size constraints cause the cells to be arrested in distant organs, where they 
extravasate and enter the surrounding microenvironment. At this point, the cell might 
proliferate to form a clinically detectable metastasis or it might remain dormant as a 
single cell or micrometastasis. The specific factors governing the fate of disseminated 
cells are as yet unknown; however, it is thought to be largely dependent on favourable 
interactions between the tumour cell and its microenvironment (McGee et al. 2006). 
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1.2 Invasion  
It has been established that the expression of the invasive phenotype is not caused by 
one single gene or protein. The invasive process involves genetic deregulation of the 
tumour cells leading to an imbalance of stimulatory and inhibitory physiological events. 
This deregulation occurs in a small subset of tumour cells; less than 0.05% of 
circulating tumour cells establish invasion (Nicolson 1991). Generally the invasion 
process requires local attachment, proteolysis of the extracellular matrix, and cell 
migration (Albelda 1993). 
 
1.2.1 Attachment of cells  
The extracellular matrix (ECM) and adhesion molecules play an important role in the 
regulation of cell attachment during invasion.  
 
1.2.1.1 The extracellular matrix (ECM) 
Invasive cancer cells must degrade natural tissue barriers. The most important natural 
barriers is ECM which is composed of basement membrane and interstitial connective 
tissue and plays an important role in cell and tissue support, anatomic 
compartmentalisation and cellular differentiation (Duffy 1987, Liotta 1986, Kalluri 
2003). ECM consists of 4 main components; structural proteins (collagens), specialised 
proteins (fibronectin and laminin), proteoglycans and glycosaminoglycans.  
 
1.2.1.1.1 Collagen 
The collagens are the major protein comprising the ECM. There are at least 12 types of 
collagen. Type I, II and III are the most abundant and form fibrils of similar structure. 
These collagens are characterised by their long and helical structures. Three alpha 
chains coil together to form a triple superhelix. Collagens are also rich in proline and 
hydroxyproline. Collagens organise the extracellular matrix and give it resilience 
(Tryggvason et al. 1987).  
 
1.2.1.1.2 Fibronectin 
Fibronectin is a large glycoprotein that is found in all vertebrates and the first well-
characterised adhesive protein. Fibronectin contains at least six folded domains, each 
with a high affinity for collagen, heparin, fibrin, specific integrins and receptors on the 
surfaces of various types of cells. Expression of fibronectin has been shown to directly 
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influence the establishment and maintenance of the transformed phenotype (Brown et 
al. 2006).  
 
1.2.1.1.3 Laminin 
Laminins are flexible four-armed, glycoproteins and anchor cell surfaces to the basal 
lamina. Laminin monomers polymerise into 3D structures in a time- and concentration- 
dependent manner. Laminins interact with cells through various receptors that mostly 
belong to the family of integrins (Ruoslahti 1999). Many epithelial tumours exhibit 
altered localisation or expression of laminin-binding integrins (e.g. α6β4/α6β1). This 
promotes invasion through the basement membrane and increases motility in the 
stroma, where tumour cells can remodel the matrix by depositing laminin (Colognato 
and Yurchenco 2000, Holler 2005).  
 
1.2.1.2 Adhesion molecules in cell attachment 
For invading, tumours cells must be able to attach to extracellular matrix components 
and to other cells (of the same or different type). These interactions either among cells 
(cell-cell) or between cells and substratum components (cell-matrix) are mediated by 
adhesion molecules, such as integrins, CD44, immunoglobulin superfamily (IgSF) and 
cadherins (Hood and Cheresh 2002).  
 
1.2.1.2.1 Integrins 
Integrins are transmembrane receptors that bind to a variety of ECM molecules 
including laminin, fibronectin and collagens and have an essential role in the invasion 
process. Integrins are formed from 18α and 8β subunits, which dimerise to yield at least 
24 different integrin heterodimers, each with distinct ligand binding and signalling 
properties (Okado and Hawley 1995, Lu et al. 2002). These heterodimers are integral 
cell membrane receptors that form focal adhesion contacts with various ECM-ligands, 
such as collagens, fibronectin, laminin, vitronectin. Ligand binding specificity depends 
on the specific α and β chains present in the heterocomplex. Changes in the expression 
pattern of integrins such as α2β1, α5β1 and αVβ3 in breast cancer have been reported in 
several studies (Hood and Cheresh 2002).  
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1.2.1.2.2 CD44 
The CD44 protein is a type I transmembrane glycoprotein receptor involved in cell-to-
cell interactions, cell adhesion and migration (Zutter et al. 1990 & 1993, Holler 2005, 
Sloan et al. 2006). The principal ligand of CD44 is hyaluronic acid, an integral 
component of the ECM. Other CD44 ligands include osteopontin, serglycin, collagens, 
fibronectin and laminin. Activation of CD44 by one of its various ligands results in 
intracellular signalling involving Rho/Ras and activated tyrosine kinase pathways which 
plays a significant role in cancer and invasion (Nagano et al. 2004).  
 
1.2.1.2.3 Immunoglobulin superfamily (IgSF) 
The immunoglobulin of adhesion superfamily of adhesion receptors is composed of 
numerous molecules of the cell surface which contain the typical immunoglobulin-like 
domains in the extracellular portion of the molecule (Ponta et al. 2003). The most 
important member of the IgSF, vascular cell adhesion molecule-1 (VCAM-1), has been 
associated with invasion and malignant progression via binding to its integrin ligand, 
α4β1 (VLA-4) (Hunkapiller and Hood 1989). The alterations in the expression of some 
other cell adhesion molecules, like neural cell adhesion molecule (NCAM), have been 
observed to facilitate invasion and disseminating metastasis in tumour (Zimmerman et 
al. 1992, Cartwright et al. 1995). 
 
1.2.1.2.4 E-cadherin  
A number of cadherin molecules have been identified and characterized, but there are 
three main members of this family: E-cadherin (epithelial), N-cadherin (neural) and P-
cadherin (placental) (Skubitz 2002). Of these, it is E-cadherin which has the most 
obvious involvement in cancer development since more than 90% of human cancers are 
carcinomas arising from epithelial tissues.  
 
1.2.2 Proteolysis of extracellular matrix 
The process of invasion is an active and dynamic process that requires protein synthesis 
and degradation. Tumour cells secrete proteolytic enzymes to degrade the extracellular 
matrix barriers in order to intravasate successfully. Matrix degrading proteases can be 
classified into the four major classes (matrix metalloproteinases, serine proteinases, 
cysteine proteinases and aspartyl proteinases), depending on the nature of the active 
sites. 
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1.2.2.1 Matrix metalloproteinases (MMPs) 
Matrix metalloproteinases (MMPs) are a family of zinc-binding enzymes that cleave 
ECM components. The expression levels of MMPs are often correlated with 
invasiveness and therefore hold promise as therapeutic targets in the treatment of cancer 
(Takeichi 1991, Behrens et al. 1992). MMPs are secreted as proenzymes that require 
extracellular activation. Currently there are over 20 known members, which share 
functional and structural characteristics and can be categorised into the collagenases, 
gelatinases, stromelysin and membrane-type MMP sub families (Table 1.1). 
 
Table 1.1 Family of matrix metalloproteinases (MMPs) 
Group  Enzyme name 
Stromelysins MMP-3, MMP-7, MMP-10, MMP-11, MMP-12 
Collagenases MMP-1, MMP-8, MMP-13 
Gelatinases MMP-2 , MMP-9 
Membrane-type MMPs MMP-15,MMP-14, MMP-16, MMP-17, MMP-24  
Other MMPs MMP-18, MMP-19,MMP-20, MMP-21, MMP-23 
 
Members of all classes of the MMP family are inhibited by endogenous inhibitors called 
tissue inhibitors of metalloproteinases (TIMPs). Specific cellular mechanisms have 
evolved allowing for activation of MMP proenzymes and also confining MMP activity 
to the peritumoural microenvironment. These mechanisms comprise (1) the expression 
of membrane-type MMPs; (2) the binding of soluble MMPs by membrane-tethered 
receptors; and (3) cell surface receptor-mediated activation of MMP proenzymes 
(Stetler-Stevenson et al. 1996).  
 
1.2.2.2 Serine proteinases 
Members of this class of endopeptidases are characterised by a serine residue at the 
active site and are produced in an inactive pro-form. Important members of the family 
include trypsin, thrombin, plasmin, cathepsin G and urokinase type plasminogen 
activator (uPA). uPA, which is the most extensively studied member of this group, 
catalyses the conversion of inactive plasminogen to the highly potent, broad-spectrum 
protease plasmin. Plasmin can degrade a wide variety of ECM components and also is 
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able to activate several latent proteases (including pro-collagenases) (Chen and Wang 
1999, Deryugina and Quigley 2006).  
 
1.2.2.3 Cysteine proteinases  
Cathepsin B and L, characterised by a cysteine residue at their active site, are the two 
cysteine proteases most implicated in cancer metastasis. These are lysosomal proteases 
that can degrade a variety of ECM components at a neutral pH, but whose optimal 
activity is at an acid pH. Cathepsin B can activate certain MMPs and also receptor-
bound uPA (Testa and Quigley 1990). It displays preferential binding to cell membranes 
in malignant tumours, but it is unknown if it has a membrane-bound receptor similar to 
uPA. 
 
1.2.2.4 Aspartyl proteinases 
Cathepsin D, like Cathepsin B, is a lysosomal protease whose optimum activity is at an 
acid pH. It degrades a large variety of endocytosed proteins and has been implicated in 
cancer invasion and metastasis, where relapse and metastatic disease correlate with high 
levels of Cathepsin D expression (Sloane 1990).  
 
1.2.3 Cell migration  
Active tumour cell motility, coupled with proteolysis, is required for the penetration of 
basement membranes and interstitial stroma during the transition from in-situ to 
invasive carcinoma. Certain factors contribute to metastasis by stimulation of motility. 
The factors that are secreted by the tumour cells themselves are autocrine motility 
factors. At least 11 autocrine motility factors have been identified, although only 3 have 
been cloned and purified to homogeneity: hepatocyte growth factor/scatter factor 
(HGF/SF), insulin-like growth factor II (IGF-II), and autotaxin (ATX). HGF/SF 
normally acts as a paracrine growth factor, but in tumour cells it can act as an autocrine 
motility factor (Ohri et al. 2008, Johnson et al. 1993). The receptor for HGF/SF is c-
Met oncogene which could induce phosphorylation of PI-3 kinase, GAP, PLC , src, ras, 
and MAP kinase (Gherardi and Stoker 1991, El-Badry et al. 1990, Stracke et al. 1992, 
Gupta et al. 2008, Liou et al. 2007). The ATX autocrine motility factor is a potent 
stimulator of motility (Naldini et al. 1991, Garcia-Guzman et al. 2000). ATX has been 
demonstrated to exhibit phosphodiesterase activity, although it is not known how this 
enzymatic activity translates into cell motility (Santos et al. 1993, Nam et al. 2000). 
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Other tumour motility factors are host-secreted growth factors such as insulin-like 
growth factor-I (IGF-I), interleukin-8 (IL-8) and histamine. Many of these factors also 
act as mitogens for the tumour cells in which they cause motility.  
 
1.3 Breast Cancer 
Breast cancer is the second leading cause of cancer deaths in women (after lung cancer) 
and is the most common cancer among women. It is a disease of the middle and late 
ages of life as 75% of breast cancer is diagnosed in women over the age of 50. Although 
breast cancer is less common at a young age, younger women tend to have a more 
aggressive form of the disease than older women. 
 
1.3.1 Mammary gland and breast cancer 
Breast cancer develops from uncontrolled growth of the mammary gland and almost all 
instances of breast cancer originate in the lobules or ducts of the mammary glands. The 
breast contains two compartments: the glandular portion, which is involved in 
production and transportation of milk, and the stromal and connective tissues. The 
glandular part of the mammary gland has 15–20 lobes, and within each lobe there are 
many smaller lobules ending in dozens of tiny bulbs that can produce milk. The lobules 
are all linked by thin tubes called ducts, and all ducts lead to the nipple. The cells 
forming the ducts and lobules are epithelial cells whose main function is to produce and 
to secrete the various constituents of milk. In addition, epithelial cells are surrounded by 
a layer of myoepithelial cells, attached on a basal membrane, whose role is to maintain 
the tubular structure of ducts and lobules. Surrounding the lobules and ducts, connective 
and fat tissues are composed of fibroblasts, with their abundant extracellular matrix, and 
adipocytes. In addition, both blood vessels and lymph vessels irrigate the mammary 
gland, and nerve fibers, mostly sensory and sympathetic, are also present (Murata et al. 
1994). 
To acquire their functionality, the epithelial cells must receive proper signals from 
hormones (estrogens, progesterone) as well as from nearby cells and components of its 
microenvironment (growth factors). Before epithelial cells can produce milk, they 
develop into lobuloalveoli (functional units) through morphogenesis involving cell 
proliferation, invasion, and differentiation (Hondermarck 2003). The cyclic 
development of the mammary gland reflects the fact that it is only needed during well-
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defined periods of life. Thus, mammary epithelium undergoes repeated cycles of 
growth, differentiation, and regression. Continuous cycling leads to the formation of a 
ductal tree. Multiplication of breast epithelial cells occurs constantly, stimulated by 
estrogens during menstrual cycle and pregnancy. After parturition, functional 
differentiation of the epithelial cells takes place. During lactation, these cells produce 
large amounts of milk, and after weaning, the gland regresses by a process of extensive 
cell death and tissue remodeling. Therefore, the mammary gland is a cellular ecosystem 
in which each represented cell type is subject to a constant turnover. This is particularly 
the case for the epithelial cells, which are subject to various hormone and growth factor 
stimulation throughout their lifetime, with correlative changes in morphology and 
metabolism. Most breast tumours are of epithelial origin (Sternlicht 2006), and therefore 
the large majority of malignant breast tumours are classified as carcinomas (malignant 
epithelial tumours). Sarcomas (malignant tumours arising from connective tissue) are 
rarely observed in the breast. 
 
1.3.2 Classification of Breast cancer 
Breast cancer broadly can be divided into non-invasive and invasive cancer. (Refer to 
“Pathology Reporting in Breast Cancer Screening”, National Coordinating Group for 
Breast Screening Pathology. NHSBSP publications, Third edition, 2005) 
 
1.3.2.1 Non-invasive breast cancer 
Non-invasive breast cancer has been divided into two main classes of in situ 
carcinomas, ductal carcinomas in situ (DCIS) and lobular carcinomas in situ (LCIS).  
 
1.3.2.1.1 Ductal carcinomas in situ (DCIS)  
Ductal carcinoma in situ (DCIS) is a proliferation of epithelial cells with cytological 
features of malignancy within parenchymal structures of the breast and refers to the 
most common type of non-invasive breast cancer in women. DCIS presents with a range 
of architectural forms, with differing growth rates, patterns, and cytological features.  
 
1.3.2.1.2 Lobular carcinoma in situ (LCIS) 
Lobular carcinoma in situ (LCIS) occurs within the lobules located at the end of the 
breast ducts. LCIS arises when the entire cell population of the lobular units consist of 
characteristic small rounded cells with granular or hyperchromatic nuclei, 
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inconspicuous nucleoli and high nucleo-cytoplasmic ratio. Most cancer experts do not 
consider lobular carcinoma in situ to be a cancer. Rather, it is considered an area of 
abnormal tissue growth that signals an increased risk of developing invasive breast 
cancer later on.  
 
1.3.2.2 Invasive breast cancer 
The invasive breast cancers have been divided into following categories  
 
1.3.2.2.1 Invasive (infiltrating) ductal carcinoma 
Invasive or infiltrating ductal carcinoma is the most common form of invasive breast 
cancer. This type of breast cancer is characterized by its solid core, which is usually 
hard and firm on palpation. Invasive ductal carcinoma commonly spreads to the 
regional lymph nodes and carries the poorest prognosis of the various ductal 
carcinomas. 
 
1.3.2.2.2 Invasive lobular carcinoma  
This form of breast cancer is relatively uncommon, comprising only 5–10% of invasive 
breast tumours. Invasive lobular carcinomas are characterized by a greater proportion of 
multicentricity in the same or contralateral breast. The lesions tend to have ill-defined 
margins, and occasionally the only evidence is subtle thickening or induration. Patients 
with infiltrating lobular carcinoma are especially prone to having bilateral carcinoma. 
Stage by stage, invasive lobular carcinoma has a similar prognosis to infiltrating ductal 
carcinoma. 
 
1.3.2.2.3 Tubular carcinoma 
Tubular carcinoma comprises about 5% of all invasive breast cancers, although the 
incidence is increasing due to earlier detection through screening. It usually presents as 
a small, ill-defined or spiculated mass on mammogram. Tubular carcinoma is a well-
differentiated tumour characterized by well-defined, open, angulated glands that invade 
through breast parenchyma. Lymph node metastasis is rare and the prognosis is good 
(around 90% at 5 years).  
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1.3.2.2.4 Medullary carcinoma  
Medullary carcinoma accounts for around 5% of invasive breast cancers and is the most 
common in younger women; it tends to appear as a distinct, well-circumscribed mass on 
mammography. The diagnosis is based on the finding of high-grade tumour cells 
arranged in a syncytial pattern with a pushing border, with a prominent lymphocyte 
infiltrate. The prognosis is generally better than for invasive ductal cancer. 
 
1.3.2.2.5 Mucinous carcinoma 
Mucinous carcinoma, also known as colloid carcinoma, is a rare form of invasive breast 
cancer. It has a good prognosis in the pure form, but if it gets mixed with infiltrating 
ductal cancer, it takes on the prognosis of the worst component. The tumour presents as 
a well-circumscribed mass, generally in older women, and may be mistaken for a 
fibroadenoma. Histologically, mucinous carcinoma is characterized by abundant 
extravasated mucin that dissects throughout the breast parenchyma. 
 
1.3.2.2.6 Inflammatory breast carcinoma 
Inflammatory breast carcinoma is uncommon, accounting for 1–3% of invasive breast 
cancers. It is characterized by diffuse skin edema, skin and breast redness, and firmness 
of the underlying tissue without a palpable mass. The clinical manifestation is primarily 
due to tumour cells embolizing in the dermal lymph channels, with associated 
engorgement of superficial capillaries.  
 
1.3.2.2.7 Invasive cribriform carcinoma 
These carcinomas are composed of masses of small regular cells, as seen in tubular 
carcinoma. The invasive islands, however, exhibit a cribriform rather than a tubular 
appearance. Apical snouting is often present. Nuclei should not show high grade 
degrees of atypia. More than 90% of the lesion should exhibit the cribriform appearance 
except in cases where the only coexistent pattern is tubular carcinoma, when over 50% 
must be of the cribriform appearance in order to be classified as an invasive cribriform 
type. 
 
1.3.2.2.8 Clinically relevant subgroups 
Efforts have been made to use gene expression patterns to classify breast tumors into 
clinically relevant subgroups (luminal A, luminal B, basal, ERBB2-overexpressing, and 
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normal-like) (Young et al. 2004). Recently the molecular taxonomy has been confirmed 
by protein expression profiling (Sorlie et al. 2001).  
 
1.3.2.2.8.1 Luminal  
 They are estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, 
cytokeratin 18-positive and have a good prognosis (even though subtype B which has 
lower ER and a higher proliferative profile, has a poor prognosis in comparison to 
subtype A).  This subtype comprises the majority of breast cancers (≈85%) (Abd El-
Rehim et al. 2005). 
 
1.3.2.2.8.2 Basal  
 They are estrogen receptor (ER)-negative, progesterone receptor (PR)- negative, 
cytokeratin 18-negative and cytokeratin 5-positive. This subtype considered as poor 
prognosis subtypes and comprising 3–15% of breast cancers (Horwitz et al. 2008). The 
subgroup of "basal-type" breast cancer is Triple-negative which does not express the 
genes for estrogen receptor (ER), progesterone receptor (PR) or HER2. This subtype of 
breast cancer is clinically characterised as more aggressive and less responsive to 
standard treatment and associated poorer overall patient prognosis (Goncalves et al. 
2008). 
 
1.3.2.2.8.3 ERBB2-overexpessing  
ERBB2, also known as HER-2/neu (HER-2), estrogen receptor (ER)-negative, include 
tumours which show increased expression of HER-2 gene/protein. This represents 15% 
to 25% of invasive breast carcinomas and is associated with a worse clinical outcome 
(Perou et al. 2000).   
 
1.3.2.2.8.4 Normal-like 
 The normal-like types have high expression of genes characteristic of basal epithelial 
and adipose cells such as keratin 5, keratin 17, integrin-β4 and laminin, and the low 
expression of genes characteristic of luminal epithelial cells such as keratins 8/18 and 
transcription factors (Bundred 2001, Brenton et al. 2005). 
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1.4 Breast cancer biomarkers 
Biological markers (biomarkers) have been defined as “cellular, biochemical or 
molecular alterations that are measurable in biological media such as human tissues, 
cells or fluids” (Perou et al. 2000) Recently, the definition has been broadened to 
include biological characteristics that can be objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacological 
responses to a therapeutic intervention (Hulka 1990). In practice, biomarkers include 
tools and technologies that can aid in understanding the prediction, cause, diagnosis, 
progression, regression or outcome of treatment of disease. There are three types of 
disease biomarkers: screening, diagnosis and disease progression. The potential uses of 
these biomarkers include: 1) identification of individuals destined to become affected or 
who are in the “preclinical” stages of the illness, 2) reduction in disease heterogeneity in 
clinical trials or epidemiologic studies, 3) reflection of the natural history of disease 
encompassing the phases of induction, latency and detection, and 4) target for a clinical 
trial. 
The breast cancer biomarkers that are currently recommended for use to certain degrees 
in the clinical setting have been discribed in Table 1.2. 
 
Table 1.2: Serum and tissue biomarker for breast cancer 
Origin Biomarkers 
Serum biomarkers CA 15-3,CA 27.29, CEA 
Tissue biomarkers ER, PR, HER2, uPA and PAI-1 
Other potential biomarkers BRCA1, BRCA2, Cyclin E and p53 
 
1.4.1 Serum Biomarkers 
Serum biomarkers including members of the MUC1 family of mucin glycoproteins (CA 
15-3 and CA 27.29, MCA, CA549) and carcinoembryonic antigen (CEA) have been 
described for breast cancer. 
 
1.4.1.1 CA 15-3 and CA 27.29 
The members of the MUC1 family are large glycosylated molecules and are the most 
widely used serum tumour biomarkers in breast cancer (Naylor 2003). The 
physiological functions of MUC1 are still unclear but it has been implicated in cell 
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adhesion, immunity and metastasis. Two members, CA 15-3 and CA 27.29, are the 
most useful serum biomarkers for breast cancer (Bieglmayer et al. 1991, Price et al. 
1998). The sensitivity of these markers is significantly higher in patients with advanced 
disease (Bieglmayer et al. 1991, Price et al. 1998). Therefore, CA 15-3 and CA 27.29 
cannot be recommended for screening or early diagnosis (Gion et al. 2001, Safi et al. 
1991). The main applications of CA 15-3 and CA 27.29 include the prediction of 
surveillance of patients with diagnosed breast cancer and monitoring therapy in 
advanced disease (Molina et al. 2005). 
 
1.4.1.2 Carcinoembryonic antigen (CEA) 
CEA is a secreted glycoprotein and was identified in 1965 as the first human cancer-
associated antigen and serological tumour biomarker (Bieglmayer et al. 1991). Many 
studies have also shown that the concentration of CEA is increased in a variety of 
cancers including breast cancer (Gold and Freedman 1965). Therefore, it is an important 
tumour marker for the diagnosis and monitoring of the therapy of breast cancer (Ebeling 
et al. 1999, Sajid et al. 2008, Lee et al. 1991). CEA is elevated in about 50-60% of 
patients with metastatic breast cancer (Ebeling et al. 1999). Therefore similar to mucin 
family members, CEA cannot be recommended for screening or early diagnosis, but 
serial levels may be useful in the early diagnosis of distant metastases (Esteban et al. 
1994). However, the use of CA 15-3 and CA 27.29 with CEA could provide additional 
complementary information and for this reason the combination of at least one MUC1 
biomarker with CEA is the recommended serum biomarker panel in patients with breast 
cancer (Molina et al. 2005).   
 
1.4.2 Tissue Biomarkers 
While serum markers in breast cancer are mostly used for monitoring patients with 
diagnosed disease, tissue-based markers are primarily measured in order to determine 
prognosis and predict response to therapy. Clinically, the most useful tissue-based 
markers in breast cancer are estrogen receptor (ER), progesterone receptor (PR) and 
HER-2 (also known as c-erbB-2 or neu). Although not yet in widespread clinical use, 
urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) 
are potential markers for determining prognosis in lymph node-negative breast cancer 
patients. 
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1.4.2.1 Estrogens and Progesterone receptors (ER and PR) 
Estrogen and progesterone receptors (ER and PR) are transcriptional factors which 
mediate the actions of estrogens and progesterone, respectively. ER and PR are 
powerful mitogens for breast epithelium cells and breast cancer cells. ER and PR are 
measured on every primary invasive breast cancer (Molina et al. 2005). In both pre- and 
post-menopausal women, steroid hormone receptor status is used to identify patients 
most likely to benefit from endocrine forms of therapy in both early breast cancer and 
metastatic disease (Molina et al. 2005, Taucher et al. 2003, Allegra et al. 1980). ER and 
probably PR positivity are associated with a favourable diagnosis because in both early 
and advanced disease, hormone receptor-positive patients have a significantly greater 
probability of responding to hormone therapy than patients lacking receptors (Taucher 
et al. 2003, Osborne 1998). ER and PR also have prognostic value in breast cancer. 
Generally, ER-positive patients have a better outcome than ER-negative patients for the 
first 4–5 years after diagnosis (Molina et al. 2005, Taucher et al. 2003, Duffy 2005). 
Although less work has been carried out on the prognostic impact of PR, patients with 
tumours expressing PR also tend to have a better prognosis than those lacking this 
receptor (Hayes et al. 2001). Currently immunohistochemistry is the most widely used 
technique to measure ER and PR status of breast tumours, however this is semi-
quantitative technique and therefore limits the findings. 
 
1.4.2.2 HER-2 
HER-2 is a member of the epidermal growth factor receptor (EGFR) family. The HER-2 
gene is either amplified or over expressed in 15–30% of invasive breast cancers (Duffy 
2005). Amplification of the HER-2 gene means that instead of having only 2 copies of 
the gene per cell, there may be 50–100 gene copies per cell. The number of HER-2 
proteins per cell can then increase from 20,000–50,000 to as high as 2 million (Molina 
et al. 2005). HER-2 has a number of potential uses in breast cancer, including 
determining prognosis, predicting relative resistance to both hormone and adjuvant 
CMF therapy (combination of three drugs cyclophosphamide, methotrexate and 5-
fluorouracil), selecting for enhanced response to adjuvant anthracycline-based therapy 
and identifying patients for treatment with Herceptin (trastuzumab) (Slamon and 
Pegram 2001). Herceptin is a humanized MAb that binds with high affinity to the 
extracellular domain of HER-2, thereby blocking its role in signal transduction (Molina 
et al. 2005). HER-2 expression can be measured using a number of different ways; by 
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immunohistochemistry (IHC) on either frozen or paraffin embedded tissue sections 
using monoclonal or polyclonal antibodies, gene amplification by fluorescence in situ 
hybridization (FISH), and by Enzyme-linked immunosorbent assay (ELISA) or western 
blot of circulating HER-2 extracellular domain (ECD) levels. There are limitations to 
HER-2; over expression of HER-2 is not always associated with resistance to hormone 
and adjuvant CMF therapy and secondly a small number of patients have been 
considered for HER-2 investigations.  
 
1.4.2.3 Urokinase plasminogen activator (uPA) and plasminogen Activator 
Inhibitor 1 (PAI-1) 
uPA is a serine protease implicated in cancer growth, invasion and metastasis and PAI-1 
is an endogenous inhibitor of uPA, but paradoxically is also involved in tumour 
progression (Harries and Smith 2002). uPA and PAI-1 have been shown to be potent 
and independent prognostic factors in breast cancer (Andreasen et al. 1997). The main 
use of uPA and PAI-1 lies in selecting lymph node-negative patients, who do not need 
or are unlikely to benefit from adjuvant chemotherapy. However, over expression of 
uPA and/or PAI-1 has been consistently related to poor prognosis in early stage and 
node-negative breast cancer (Duffy et al. 1999, Duffy 2002, Schneider et al. 2003). The 
IHC and ELISA assays are commonly used to monitor the levels of uPA and PAI-1, 
however the outcomes do not always correlate with patient’s outcome.  
 
1.4.3 Others potential biomarkers 
There are number of biomarkers for breast cancer currently in the pipeline. The 
evaluation of these biomarkers could improve the efficiency of diagnosis and prognosis 
process. These novel biomarkers include BRCA1 and BRCA2, cyclin-E and p53. 
 
1.4.3.1 BRCA1 and BRCA2 
BRCA1 and BRCA2 are putative tumour suppressor genes located on chromosome 
17q21. Many tumours with germline BRCA1 and BRCA2 mutations display loss of 
heterozygosity at this locus, which uniformly involves loss of the wild-type alleles 
indicating the role of BRCA1 and BRCA2 as tumour suppressor gene (Grondahl-
Hansen et al. 1993). However, previous studies have also suggested that complete loss 
of the BRCA1 and BRCA2 proteins correlate with poor prognostic markers (Smith et 
al. 1992, Egawa et al. 2001) and their expression levels predict distant metastasis of 
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sporadic breast cancers (Lee et al. 1999, Egawa et al. 2002). Therefore, in depth 
investigation of these proteins could provide an additional prognostic parameter for 
breast cancer. 
 
1.4.3.2 Cyclin E  
Cyclin E is a regulator of the cell cycle transition in breast-cancer cells. In normal 
dividing cells, cyclin E regulates the transition from the G1 phase to the S phase (Egawa 
et al. 2001). A high level of the cyclin E protein accelerates the transition through the G1 
phase (Dou et al. 1993). The cyclin E gene is amplified and the cyclin E protein is often 
constitutively expressed in breast-cancer cell lines (Resnitzky et al. 1994). Some of 
these lines over express not only the full-length 50-kD cyclin E protein, but also up to 
five low-molecular-weight isoforms of cyclin E (ranging in size from 34 to 49 kD) 
(Keyomarsi and Pardee 1993, Keyomarsi et al. 1994, Buckley et al. 1993, Sgambato et 
al. 1997). These isoforms, which lack the amino terminus, are hyperactive, as compared 
with the full-length protein, in phosphorylating substrates and inducing progression 
from the G1 phase to the S phase (Keyomarsi and Pardee 1993, Keyomarsi et al. 2002, 
Keyomarsi and Herliczek 1997, Porter et al. 2001). Recently the levels of total cyclin E 
and low-molecular-weight cyclin E in tumour tissue were observed to correlate strongly 
with survival in patients with breast cancer (Porter et al. 2001). Cyclin E has been 
observed to be an independent prognostic marker for lymph node–negative breast cancer 
patients (Keyomarsi et al. 2002). Therefore these investigations indicate that cyclin E 
could serve as a potential biomarker for breast cancer diagnosis and prognosis. 
 
1.4.3.3 p53 
p53, a tumour suppressor, is involved in regulating cell proliferation, inducing 
apoptosis, and promoting chromosomal stability (Sieuwerts et al. 2006). Disruption of 
these functions has an important role in carcinogenesis (Toledo and Wahl 2006). The 
abrogation in the p53 gene is associated wtih breast cancer progression (Ho et al. 2001, 
Gasco et al. 2002). Mutations in the p53 gene (Malkin et al. 1990), changes in its 
upstream regulators (Bartek et al. 1990), changes in its transcriptional targets (Bell et al. 
1999), and modifications in its coactivators (Ferguson et al. 2000) have been 
extensively observed in breast cancer disease. The presence of p53 mutations has been 
observed to correlate with worse survival in aggressive breast cancer (Samuels-Lev et 
al. 2001). Similar results were observed in a comprehensive meta-analysis of the effect 
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of somatic p53 mutations on prognosis in breast cancer (Mazars et al. 1992). Although 
mutant p53 has been correlated with poor prognosis of breast cancer (Pharoah et al. 
1999, Norberg et al. 2001), the investigation of p53 and its associated proteins could 
enable the identification of improved biomarker and drug targets.  
 
In summary, CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, 
progesterone receptor, urokinase plasminogen activator and plasminogen activator 
inhibitor 1 are the breast cancer biomarkers that are being used clinically to some 
extent. However, other markers (BRCA1, BRCA2, Cyclin E and p53 and HER2) are 
being investigated for their clinical value. 
 
1.5. Proteomics and breast cancer    
The term 'proteome' refers to all the proteins in a cell, tissue, or organism and 
‘Proteomics’ refers to the study of the proteome. Because proteins are involved in 
almost all biological activities, the proteome is a rich source of biological information. 
Proteomic studies of mammary glands have progressed enormously in recent years and 
a number of potential biomarkers for breast cancer have been identified using 
proteomics tools (Table 1.3). 
 
1.5.1 Cell culture-based investigations 
Breast cancer cell lines have been the most widely used models to investigate how 
proliferation, apoptosis and migration become deregulated during the progression of 
breast cancer (Linderholm et al. 2001). The reason for this lies in the fact that the 
biological fluids and tissue represent a high degree of complexity and variability and 
limited number and amounts of samples. Cell line models are easy to maintain for 
longer times and are reproducible in terms of sample generation. Moreover it has been 
observed that different cell lines from same tissue origin may also represent a high 
degree of heterogeneity in expression of genes. Therefore, in the initial discovery phase 
for novel cancer biomarkers, a less complex sample, such as cell lines, is essential 
(Lacroix and Leclercq 2004). To gain more information regarding the cancer and 
invasion in breast, different fractions such as whole cell lysate, secreted proteins in 
conditioned media and membrane & membrane-associated proteins are being 
investigated using proteomics-based techniques. 
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A. Table 1.3 List of potential biomarkers identified using proteomics tools for cancer (A) and invasion (B) in breast cancer disease. 
 
Protein name Potential biomarkers for 
breast cancer (Regulation in 
cancer) 
Sample Reference 
Maspin   Down-regulated Conditioned media and 
tissue 
Lacroix and Leclercq 2004, Kulasingam and Diamandis 2008 
Cathepsin D Up-regulated  Conditioned media and 
tissue 
Vecchi et al. 2008, Maass et al. 2001a & b, Toillon et al. 2007 
14-3-3 protein  Down-regulated  Cell lysate and tissue Deng et al. 2006, Westley and Rochefort 1980 
HSP60 Up-regulated Tissue and serum Vercoutter-Edouart et al. 2001b, Umbricht et al. 2001, 
Hondermarck et al. 2001, Rui et al. 2003 
HSP27 Up-regulated Tissue and serum Desmetz et al. 2008, Fransson et al. 2006, Franzen et al. 1996 
MUC-1 Up-regulated Tissue and serum Rui et al. 2003, Gharbi et al. 2002, Song et al. 2005, Kabbage et 
al. 2008 
HSP70 and 
HSP90 
Up-regulated Cell lines and tissue Bieglmayer et al. 1991, Seuma et al. 2008 
Peroxiredoxin-2 Down-regulated Tissue and serum Hondermarck et al. 2001, Vercoutter-Edouart et al. 2001a, 
Somiari et al. 2003 
Tropomyosin-1 Up-regulated Tissue Somiari et al. 2003, Hamrita et al. 2008 
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eIF-4E  Up-regulated Tissue Bhattacharya et al. 1990, Ismail et al. 2008 
Annexin 1 Down-regulated Cell lines Hudelist et al. 2004, Anthony et al. 1996, DeFatta et al. 1999 
L-plastin Up-regulated Plasma Shen et al. 2006, Shen et al. 2005, Ou et al. 2008 
K5, K6, K7, K14 and 
K17 
Down-regulated Cell lines Pitteri et al. 2008, Lapillonne et al. 2000 
K8, K18 and K19 Up-regulated Cell lines Trask et al. 1990 
Prohibitin Up-regulated Cell lines and tissue Trask et al. 1990, Moll et al. 1982 
 
B. 
Protein name Potential biomarkers 
for invasion 
Sample Reference 
Nm23 Down-regulated Tissue Hamrita et al. 2008, Jupe et al. 1996, Dowling et al. 2007b 
Cathepsin D Up-regulated Cell lines and tissue Ismail et al. 2008, Peihong and Perry 2007, Niu et al. 2002 
Cofilin1 Up-regulated Cell lines Johnson et al. 1993, Hahnel et al. 1993, Bazel and Alhadeff 
1999 
Vimentin Up-regulated Cell lines and tissue Dowling et al. 2007b, Imai et al. 2008, Keshamouni et al. 2009 
Galectin-1 Down-regulated Cell lines Korsching et al. 2005, Thomas et al. 1999, Lin et al. 2005, 
Liang et al. 2009 
14-3-3 protein Down-regulated Cell lines and tissue  Imai et al. 2008 
Gelsolin Down-regulated Tissue Umbricht et al. 2001, Imai et al. 2008 
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1.5.1.1 Cell lysates 
Molecular analysis of cells in their native tissue environment provides the most accurate 
picture of the in vivo disease state. However, tissues are complicated three-dimensional 
structures, composed of large numbers of interacting cell populations therefore it can be 
complicated to prepare protein samples (Kim et al. 2008, Winston et al. 2001, Tanaka et 
al. 2006). Therefore a considerable part of research on breast carcinomas is based on in 
vitro studies performed with breast cancer cell (BCC) lines. The cell lysates from cell 
lines provide an unlimited source of homogenous, self-replicating material which is free 
of contaminating stromal cells, and often easily cultured in simple standard media 
(Liotta and Petricoin 2000) . Investigations using cell lysates provide an overall view of 
cellular alterations in cells in respose to specific conditions and therefore have been 
considered valuable reseach material for indentification of biomarkes and drug targets. 
In a study using two-dimensional PAGE and MALDI-ToF MS, the expression of 14-3-3 
sigma was observed to be down-regulated in primary breast carcinomas cell lines, 
MCF-7 and MDA-MB-231, and in primary breast carcinomas as compared with normal 
breast epithelial cells (Lacroix and Leclercq 2004). 14-3-3 has been shown to interact 
with cyclin-dependent kinases and to control the rate of entry into mitosis. 
Hypermethylation of 14-3-3 sigma was observed in early stage in breast cancer 
indicating that inactivation or depletion of 14-3-3 sigma is directly associated with 
carcinogenesis in breast cells (Vercoutter-Edouart et al. 2001b). Recently a study using 
a proteomic approach complemented by immunohistochemistry showed that the loss of 
14-3-3 sigma protein is a frequent event in breast cancer, as out of the 68 breast 
tumours, only 3 represented cross reactivity for 14-3-3 sigma during 
immunohistochemistry (Umbricht et al. 2001). Therefore 14-3-3 sigma could be an 
attractive biomarker for breast cancer diagnosis identified from breast cancer cell lines.  
An luminal epithelial cell line expressing ErbB-2 was investigated using 2D-gel 
electrophoresis as ErbB-2 has been observed over expressed in breast cancer and 
therefore the changes associated with ErbB-2-over expression could help to understand 
the process of transformation from a normal cell to a cancer cell (Moreira et al. 2005). 
Members of plastins (T and L plastin), HSPs (HSP27 and 70) and 14–3-3 (14–3-3b) 
family were observed to be differentially regulated indicating their potential role in 
breast cancer (Gharbi et al. 2002). Recently, four isogenic cell lines representing non-
metastatic, mild-metastatic, moderately metastatic and aggressive metastatic phenotypes 
were investigated using an isobaric peptide labeling approach (iTRAQ) coupled with 
 24 
NanoLC-MS/MS (Gharbi et al. 2002). SH3GLB1 was down regulated whereas SUB1, 
SND1 and TRIM28 were up regulated in the metastatic cell model compared to normal 
cell and similar expression patterns were confirmed using immunohistochemistry which 
suggests their potential role as potential drug targets and/or biomarkers for breast cancer 
metastasis (Ho et al. 2008). 
The protein profiles from seven breast-cancer cell lines (MDA-MB-231, HCC1428, 
AU565, MDA-MB-468, SK-BR-3, MCF7 and BT-474) and one normal cell (HMEC) 
generated using fluorogenic derivatization–liquid chromatography/tandem mass 
spectrometry (FD-LC-MS/MS) were compared to identify proteins that may be 
involved in cancer (Ho et al. 2008). Tropomyosin-1 was highly expressed only in the 
normal cell lines (HMEC), whereas it was undetectable in all seven breast cancer cell 
lines used in this investigation. Tropomysins are critical to stabilize the cytoskeletal 
filaments and therefore loss of tropomyosin-1 could be associated with the development 
of metastatic breast cancer (Imai et al. 2008). Annexin-2 and galectin-1 were highly 
expressed in the normal cell line (HMEC) compared to all seven breast cancer cell lines. 
This suggests that cytoskeletal proteins, such as tropomyosin-1, annexin-2 and galectin-
1, could serve as potential biomarkers for the breast cancer. On the other hand, Ran, 
thioredoxin-1 and RhoGDI were highly expressed in breast cancer cell lines compared 
to the normal cells. Thioredoxin-1 and RhoGDI have already been associated with 
cancer (Bhattacharya et al. 1990) while the role of Ran in cancer is still unknown. In 
another study, the comparison of genomic (microarray) and proteomic (2D-PAGE) 
expression profiles of breast cancer cell lines (MCF-7 and HCC-38) with normal breast 
cells (CCD-1059Sk) revealed that structural proteins including, annexin-1 (ANXA1) 
and α-basic-crystallin protein (CRAB), were down regulated while 6-
phosphogluconolactonase (6PGL) and F-actin capping protein α-2 subunit (CAZ2) were 
up regulated specifically in the breast cancer cell lines compared to normal cells (Zhang 
et al. 2005, Berggren et al. 2001). The expression patterns of ANXA1, CRAB, 6PGL 
and CAZ2 were confirmed by immunohistochemistry analysis and therefore suggested 
as potential biomarkers for breast cancer (Ou et al. 2008). 
Because phosphorylated cytoskeletal proteins and chaperones mediate cell motility and 
apoptotic resistance, phosphoproteomic changes in the MCF10AT model of breast 
cancer progression were studied using a combination of phosphotyrosyl affinity 
enrichment, iTRAQ technology, and LC-MS/MS (Ou et al. 2008). A number of tyrosine 
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kinases, phosphatases, and other signaling proteins including SLC4A7 were detected to 
undergo differential phosphorylation during disease progression. SLC4A7 is a 
bicarbonate transporter and was observed to be down-regulated in 64% of the 25 
matched normal and tumour clinical samples in further investigations (Chen et al. 
2007a). This demonstrates that starting with a cell culture based cellular proteome, 
which exhibits a lower level of complexity, facilitates the identification of relevant 
proteins that can be validated in tumours.  
 
1.5.1.2 Conditioned media 
Secreted proteins can act locally and systemically in the body and play important roles 
in the regulation of cell physiology (growth and apoptosis, etc) and pathophysiology 
(invasion and motility). Therefore, the secretome reflects the functionality of a cell in a 
given environment (Chen et al. 2007a). Biological fluids, such as serum, may contain 
the molecules of interest (biomarker or drug target) in too low concentrations which 
cannot be easily measured or purified, unless specific immunological reagents and 
highly sensitive ELISA methods are used (Hathout 2007). Moreover, the secretome in a 
tumour microenvironment contains the secreted proteins such as cytokines, chemokines, 
growth factors and proteases as well as the extracellular matrix, constituted by proteins, 
receptors and adhesion molecules, and this makes biological fluids a complex mixture 
to investigate and may mask the potential biomarkers (Kulasingam and Diamandis 
2008).  
Increased expression of a secreted cathepsin D was identified using 2D-gel 
electrophoresis in estrogen-receptor positive human breast cancer cell lines, MCF7, 
ZR75 and T47D (Chen et al. 2008b). Cathepsin D has been observed to be involved in 
the regulation of breast cancer and invasion phenotype (Westley and Rochefort 1980). 
Recently, an extensive comparative proteomic analysis of supernatants from 3 breast 
cancer cell lines, MCF-10A, BT474 and MDA-MB-468 was performed and a number of 
proteins, including proteases, receptors, protease inhibitors, cytokines and growth 
factors were identified using LC-MS/MS (Hahnel et al. 1993). Three kallikreins 
(KLK5, KLK6, and KLK10) and HER2 were observed to be differentially regulated in 
conditioned media from BT474 and MDA-MB-468 cells. KLK5 and KLK10 have 
already been used as prognostic markers for breast carcinoma (Kulasingam and 
Diamandis 2007).  
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The normal (HTB-125) and malignant (HTB-126) breast cell lines have also been 
investigated using ‘stable isotope labelling with amino acids in cell culture’ (SILAC) 
coupled with mass spectrometry (Luo et al. 2002, Yousef et al. 2002). A number of 
growth factors were observed to be differentially regulated between normal and 
malignant cell lines. In this study, approximately 37% of proteins identified were 
observed to belong to ECM and cytoskeletal proteins, including collagen, vimentin, 
laminin, fibronectin, ECM protein 1, annexin, filamin, lumican, perlican, and plectin. 
There is increasing evidence to suggest that the ECM proteins participate in the control 
of successive stages of breast tumors, from appearance to progression and metastasis 
(Liang et al. 2009). Tumour necrosis factor (TNF), pigment epithelial-differentiating 
factor (PEDF) and stem-cell growth factor precursor showed decreased expression in 
breast-cancer cell lines, whereas Inhibin-β and macrophage migration inhibitory factor 
show increased expression. Interestingly, protease inhibitors, including plasma protease 
(C1) inhibitor, PZP precursor, and SERPINE2 were significantly down-regulated in the 
cancer cell lines as were angiostatic factors from extracellular matrix (ECM) such as 
endorepillin. Members of the SERPIN family are already well known to have tumour 
suppressor activity (Lochter and Bissell 1995). Furthermore, the C-terminal fragment of 
type XVIII collagen, endostatin, a potent angiostatic factor, was reported to be down-
regulated as well whereas extracellular collagens and osteoblast-specific factor 2 (OSF-
2), were reported to be up-regulated in this investigation. This indicates that the tumour 
cells differ from normal cells significantly in their secretome. 
Another interesting study used tandem mass spectrometry to investigate the conditioned 
media from 4 isogenic breast cancer cell lines differing in aggressiveness includes non-
tumourigenic (MCF10A), pre-malignant/tumourigenic (MCF10AT), 
tumourigenic/locally invasive (MCF10 DCIS.com) and tumourigenic/metastatic (MCF 
10CA cl. D.) cells, and a number of differentially expressed proteins were identified in 
this investigation (Shi et al. 2001). The most apparent changes were observed for alpha-
1-antichymotrypsin and galectin-3-binding protein which were secreted extensively 
from MCF10 DCIS.com and MCF10CA cl. D. cells compared to MCF10A and 
MCF10AT cell lines. Galectin-3-binding protein has already been associated with 
aggressive prostate and colon cancer suggesting its importance in the regulation of 
aggressiveness of breast cells (Mbeunkui et al. 2007). More recently, another group 
created the secreted protein map by analyzing the conditioned media of human 
mammary epithelial cells (HMEC) and identified ~900 proteins using LC-MS/MS 
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(Mbeunkui et al. 2006, Ulmer et al. 2006). Of these identified proteins, ~150 have 
already been known to be extracellular in localization and were comprised from growth 
factors and MMPs.  
The MMPs could enable tumour cells to degrade basement membrane and thus to 
metastasize and therefore a number of small-molecule and peptidic MMP inhibitors 
were investigate for their therapeutic value (Jacobs et al. 2008). These inhibitors were 
unsuccessful in treating cancer disease in the phase III clinical trials because at that time 
only three MMPs were recognized to be involved in metastasis, however the full range 
of their substrates and other biological functions are unknown (Bissett et al. 2005, 
Coussens et al. 2002). Therefore a breast cell line expressing membrane type-1 MMP-
14 was treated with an anti-MMP-14 drug (prinomastat) and the membrane-associated 
and secreted proteins from both treated and non-treated cells were investigated for their 
differential expression using isotope-coded affinity tag (ICAT) labeling and tandem 
mass spectrometry (Overall and Kleifeld 2006). In this investigation, 12 unknown 
substrate molecules, including CD59 and uPAR, were identified to be the potential 
substrates for MMP-14, of which 7 proteins were specifically observed in the 
conditioned media and includes ALCAM and melanotransferrin. ALCAM, CD59 and 
uPAR are already well known for their involvement in the regulation of cancerous and 
invasive phenotypes in breast (Butler et al. 2008). 
 
1.5.1.3 Membrane and membrane-associated fraction 
Membrane and membrane-associated proteins in cancer have been observed to be 
targets of a number of new drug and antibody cancer therapeutics such as Gleevec (abl-
kinase), herceptin (her2neu), Panorex (Ep-CAM), and IRESSA (EGF1 receptor) 
(Cartwright et al. 1995, Andreasen et al. 1997). Furthermore many other membrane-
associated proteins such as small GTPases, kinases, and catenins are implicated in 
carcinogenesis (Brenner and Adams 1999, Abicht and Lochmuller 2000, Ranson et al. 
2002). Thus a comprehensive definition of cancer cell membrane-associated proteins 
can reveal further proteins involved in cancer biology which may themselves represent 
new therapeutic targets. However, a limited numbers of studies have been carried out to 
date to investigate the role of membrane and membrane-associated proteins in breast 
cancer. 
Recently a database of cancer membrane-associated proteins was created by identifying 
more than 500 proteins from multiple human breast carcinoma cell lines with different 
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molecular pathologies MDA-MB-468, T-47D, BT-474, and MCF-7 (Ranson et al. 2002, 
Adam et al. 2003, Liang et al. 2006). In this investigation, three novel breast cancer 
membrane proteins, BCMP11, BCMP84, and BCMP101, were specifically observed to 
be associated with the cancer cell membrane compared to normal breast epithelial cells. 
Similarly, in an another effort, more than 830 cancer membrane-associated proteins 
were identified from culturing normal and malignant breast cancer cells isolated from a 
74-year-old female with breast carcinoma using SILAC coupled with mass 
spectrometry (Adam et al. 2003). Among these, more than 40 proteins were found up-
regulated or down-regulated by greater than 3-fold. A number of proteins that are 
already known to be associated with carcinogenesis in breast cells such as cathepsins, 
integrins and annexins were observed to be differentially regulated (Liang et al. 2006).  
The protein profiles of cell surface proteins between the human breast cancer cell line 
MDA-MB-231 and its highly osteotropic B02 subclone have also been analysed using 
cell surface biotinylation and a mass spectrometric approach, and Class I HLAs were 
observed to be down-regulated, whereas αv-β3 integrins were up-regulated in B02 cells 
compared to MDA-MB-231 cells (Liang et al. 2006). The reduced HLAs class I 
expression has already been found in metastatic cells from the bone marrow of patients 
with squamous cell carcinoma of the head and neck region (Kischel et al. 2008). 
Similarly, αv-β3 integrins confer to breast tumor cells a greater propensity to 
metastasize to bone (Andratschke et al. 2003) and can even promote spontaneous 
metastasis of breast cancer cells to bone (Pecheur et al. 2002). This indicate that 
analysis of the cell surface proteome of parental cancerous cell lines and derived organ-
specific metastatic cell lines provides an effective approach for the identification of 
potential biomarkers of breast cancer disease. 
The investigation of membrane-associated and secreted proteins from MDA-MB-231 
expressing MMP-14 and cells (MMP-14 expressing) treated with an anti-MMP-14 drug 
(prinomastat) was carried out using ICAT labeling coupled with tandem mass 
spectrometry (Sloan et al. 2006). In this investigation, 16 unknown substrate molecules, 
including CD59 and uPAR, were identified to be the potential substrates for MMP-14, 
of which 7 proteins were specifically observed in the membrane fraction and includes 
integrin-α3. Integrins, CD59 and uPAR are already well known for their involvement in 
the regulation of the cancerous and invasive phenotypes in breast (Butler et al. 2008). 
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This suggests that the knowledge of MMP-14 target proteins localized in membrane 
could help to understand the cell signaling induced by MMP-14 to facilitate metastasis.  
 
1.5.2 Serum-based investigation 
It has been realized that an extensive, complex and functionally significant cross talk 
between different molecules in the microenvironment does occur and that these 
interactions determine to a large extent, the malignant phenotype of the cells 
(Andreasen et al. 1997, Felding-Habermann 2003, Han et al. 1999). Secreted proteins 
are an important part of microenvironment. These microenvironmental molecules could 
influence tumour progression by three major non-mutually exclusive mechanisms; by 
further increasing the genetic instability of tumour cells (Park et al. 2000, Liotta and 
Kohn 2001), by inducing signalling cascades in tumour cells via tumour-associated 
receptors thereby controlling gene expression in these cells (Yuan and Glazer 1998), 
and by exerting selective pressures on the cells. Microenvironmental factors exert, in 
many cases, opposing effects on tumour cells and on tumour progression. Therefore, 
investigations for alterations in the microenvironment due to secreted proteins could 
help us to understand the cancerous and invasive behaviour of breast cells (Bissell et al. 
1999).   
One of the sources to mine for potential secreted biomarkers is serum or plasma of 
breast cancer patients. In a proteomics study of breast cancer patient serum, two 
proteins were differentially regulated; HSP27 was observed to be increased while 14-3-
3 sigma protein was found to be decreased in cancer serum compared to normal serum 
using 2D-PAGE coupled with MALDI-ToF MS (Liotta and Kohn 2001). The 
comparison of the expression patterns of these two proteins correctly classified 97% of 
the controls as not cancer, and 100% of cancer samples as malignant. This result yielded 
100% sensitivity. The positive predictive value for this sample set was 98%. MALDI-
ToF MS profiles have also been used to discriminate diseased samples from normal 
samples (Rui et al. 2003). A total of 72 peaks identified from MALDI-ToF MS profiles 
of 48 breast cancer patients and 28 controls were observed to identify breast cancer 
patients with approximately 85% sensitivity and specificity (Callesen et al. 2008). In 
another study, 2D-DIGE analysis of serum samples obtained from 39 patients with 
breast cancer and 35 controls revealed that proapolipoprotein A-I, transferrin, and 
hemoglobin were up-regulated, and three proteins, apolipoprotein A-I, apolipoprotein 
C-III, and haptoglobin a2 were down-regulated in cancer patients (Callesen et al. 2008).  
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A serological proteomics-based approach (SERPA) has also been applied to identify the 
novel tumour antigens that may induce a humoral immune response in sera from 
patients with breast carcinomas (Huang et al. 2006). Tumor antigens elicit a humoral 
immune response in patients. In SERPA, cellular proteins from tumour (breast) cell 
lines are separated by 2-DE and transferred onto PVDF membranes. Using these 
membranes, sera from cancer (breast) patients and controls, as a source of primary 
antibody, are screened individually by western blot analysis for antibodies that react 
against separated tumour-derived proteins on PVDF membranes. An RNA-protein 
interaction protein, RS/DJ-1, was identified using cellular proteins from a breast cancer 
cell line (SUM-44), sera from 30 breast cancer patients, 116 patients with other cancer 
and 42 control individuals (Hamrita et al. 2008, Le Naour et al. 2001). Similarly, 26 
tumour antigenic proteins were identified using MCF-7 cellular proteins and sera from 
40 invasive breast cancer patients and 42 control individuals (Le Naour et al. 2001). 
Among these, HSP60, prohibitin, β-tubulin, peroxiredoxin-2, hnRNPK, Mn-SOD and 
F1-ATPase represented significant immunoreactivity in specifically with patients sera, 
whereas cytokeratins 8 and 18, and F1- actin were observed in both control and breast 
cancer patients sera (Hamrita et al. 2008). Many of these proteins such as HSP60, 
prohibitin and hnRNPK have already been correlated with breast cancer (Hamrita et al. 
2008). The autoantibodies for HSP60 has been observed in the 16/49 (31%) early stage 
breast cancer and 18/58 (32.6%) DCIS patients, compared to 4/93 (4.3%) healthy 
subjects (Desmetz et al. 2008, Jupe et al. 1996, Fink 1999, Bukau and Horwich 1998, 
Moumen et al. 2005). In particular, autoantibodies were present in 11/23 patients 
(47.8%) with high-grade DCIS, compared to 5/26 (19.2%) with low-grade DCIS and 
expression of HSP60 was also observed using immunohistochemisty to increase 
gradually from normal through DCIS to invasive tissues (Desmetz et al. 2008). Based 
on these findings, the SERPA approach offers great potential to discover novel 
biomarkers as well as drug targets for breast cancer disease.   
A pattern of three serum biomarkers (two up-regulated at 8.1 kDa and 8.9 kDa and one 
down-regulated at 4.3 kDa) were identified from the SELDI profiles of 169 serum 
samples from 103 breast cancer patients, 41 healthy women, and from 25 benign breast 
cancer patients that distinguished patients from controls (Desmetz et al. 2008). The 
sensitivity and specificity after cross-validation within the sample group 
(bootstrapping), using a random subset of the data to build the model and testing it with 
the remaining data were found to be 93% and 91%, respectively. However, a new set of 
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samples in a later study confirmed the up-regulation of the 8.1 kDa and 8.9 kDa 
biomarker species, and subsequently the 8.9 kDa species was identified to be a 
complement component of C3a (desArg) and the 8.1kDa species as a C-terminal-
truncated form of C3a (desArg) (Li et al. 2002). In a later study also using SELDI-ToF 
MS, the combination of an independent cancer biomarker Ca 15.3 with the serum 
biomarkers, 4.2 kDa and 4.3 kDa possibly corresponding to the 4.3 kDa peak identified 
by Li et al. (Li et al. 2005) and 8.9 kDa and 8.9 kDa possibly corresponding to the 8.9 
kDa peak also identified by Li et al. (Li et al. 2002), significantly improved breast 
cancer diagnosis. In another study, four peaks, CA1 (17.3 kDa), CA2 (26.2 kDa), CA3 
(5.7 kDa), and CA4 (8.9 kDa), were chosen as potential biomarkers from the SELDI 
profiles of 49 breast cancer patients, 51 patients with benign breast diseases, and 33 
healthy women to build a prediction model using artificial neural networks and 
discriminant analysis (Li et al. 2005). 100% sensitivity and specificity were observed in 
a training set while a blind test set showed 76.47% sensitivity and 90% specificity. 
Another study utilized this technology as a prognostic tool on a pool of 81 serum 
samples from high risk early breast cancer patients, collected in a retrospective way 
after primary surgical resection and before starting any adjuvant chemotherapy. Forty-
eight patients showed metastatic relapse while 33 were long-term metastasis-free 
survivors. SELDI-ToF MS analysis produced a pattern of 40 peaks which allowed the 
development of a multi protein index that was able to correctly predict outcome in 83% 
of patients with a sensitivity of 87% and a specificity of 76% (Hu et al. 2005).  
Glycosylation, one of the most abundant post-translational modifications required by 
proteins to perform its specific biological functions, has been associated with secreted 
proteins (Goncalves et al. 2006). However, very little information is available for the 
role of these secreted glycoproteins in cancer disease, as they are typically not detected 
due to their low concentration in biological fluids, such as serum. Recently, lectin-based 
and hydrophilic interaction chromatography (HILIC) using resin-based affinity 
techniques have been successfully applied to enrich the glycoproteins and glycopeptides 
in serum samples from breast cancer patients to identify these glycosylated proteins 
using MALDI and ESI mass spectrometry (Calvano et al. 2008). A total of 45 proteins 
were identified in this investigation and includes SERPINS, integrins and Kallikrein 
which are already well known for their role in the breast cancer.  
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1.5.3 Plasma-based investigations 
The plasma samples from mice bearing breast tumours have been compared with 
normal mice by combining isotopic labelling, extensive intact protein separation (2D-
HPLC) and mass spectrometry (LTQ-Orbitrap mass spectrometer coupled with a 
NanoLC-1D MS) (Calvano et al. 2008). A total of 133 proteins were observed to be 
increased in the plasma samples from the tumour bearing mice compared to the normal 
mice (Pitteri et al. 2008). Of these, 49 proteins including fibronectin, enolase 2, 
perlecan and L-plastin, were already known to be up regulated in breast cancer cell lines 
compared to normal cells (Pitteri et al. 2008). Osteopontin and fibulin-2 have been 
observed as a plasma biomarker for breast tumours, whereas osteopontin was observed 
to be capable of early disease detection in the mouse (Kulasingam and Diamandis 2007, 
Patwardhan et al. 2005, Hou et al. 2007). In another study, the plasma samples from 
MCF7-xenografted tumour model (mouse) and normal mice were investigated using 
multilectin affinity chromatography (M-LAC) to identify tumour-secreted glycoproteins 
(Whiteaker et al. 2007). A large set of known murine-secreted proteins was identified in 
this study, including several signalling molecules such as HER-2, interleukin-6 receptor, 
protein-kinase C, and phosphatidylinositol kinase which changed in plasma levels 
relative to tumour-free animals. Whereas, 17 human tumour-derived proteins, that were 
involved in wide variety of cellular functions such as cell signalling, immune response, 
and transcriptional regulation, were also identified in this investigation. This suggests 
that glycoproteins could be investigated using enrichment techniques and could enable 
us to identify potential drug targets and/or biomarker for cancer disease.  
 
1.5.4 Nipple aspirate fluid-based investigation 
Nipple aspirate fluid (NAF) has been identified as a potential source of biomarkers for 
early diagnosis of breast cancer (Orazine et al. 2008). Therefore NAF samples from 23 
women with stage I or II unilateral invasive breast carcinoma and five healthy female 
volunteers were investigated using SELDI Protein-chip arrays (WCX2 and IMAC3-
Cu++), and protein expression was analyzed using time-of-flight MS (Sauter et al. 
1997, Liu et al. 2000b). Two peaks (952.59 and 2310.87 m/z) that were over expressed 
in breast cancer patients and one peak (3284.74 m/z) that was down regulated in breast 
cancer patients showed a distinct expression pattern in normal, stage I and stage II 
samples and could be useful for breast cancer screening and diagnosis. NAF have also 
been investigated using 2D-gel electrophoresis. 52 NAF samples from breast cancer 
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patients and 53 NAF samples form normal were investigated using 2D-gel 
electrophoresis and a total of 41 different proteins were identified using MALDI-ToF 
MS (Pawlik et al. 2005), of which 25 proteins, including cystic disease fluid protein 
(GCDFP)-15 and α-1-acid glycoprotein (AAG), were known to be secretary in nature. 
The expression of GCDFP-15 and AAG was observed to correlate with presence and 
stage of breast cancer disease. The NAF protein profiles from 18 women with I or II 
unilateral invasive breast carcinoma and 4 healthy volunteers were analyzed using 
ICAT labeling, sodium dodecyl sulfate-polyacrylamide gel (SDSPAGE), liquid 
chromatography and MS (Alexander et al. 2004). Alpha2HS-glycoprotein was observed 
to be down regulated, while lipophilin B hemopexin and vitamin D-binding protein 
precursor were over expressed in NAF from tumor-bearing breast compared to healthy 
women in this investigation suggesting these proteins as potential plasma biomarkers 
for breast cancer disease. Recently, NAF proteomic profiles have been observed not to 
vary substantially during the menstrual cycle and therefore NAF proteomic profiles for 
different stages in the menstrual cycle could be compared to identify potential 
biomarkers and/or drug targets for breast cancer disease (Pawlik et al. 2006). 
 
1.5.6 Tissue based investigations 
Tissue biopsies are the ideal source for biomarkers and/or drug target discovery for 
breast cancer disease as they represent a similar state of disease as observed in vivo. 
However, their use is limited due to limited number (and amount) of available samples 
representing various stages (early or late) of disease and complexity of specific tissues. 
Tissue sample have been used to validate the potential drug targets and/or biomarkers as 
well as for their discovery. The proteomic analysis of ductal carcinoma in situ (DCIS) 
has revealed 57 proteins that show differential expression between normal cells and 
DCIS (Noble et al. 2007). Although the differential expression was predominantly due 
to differences in overall abundance, there was also evidence of posttranslational 
modification of the proteins. Proteins such as transgelin and the voltage-dependent 
anion channel protein (VDAC) showed evidence of posttranslational modification 
(Wulfkuhle et al. 2002). A subset of proteins including, Annexin V, profilin and HSP90 
showing differential expression on 2D gels have been confirmed by IHC, a further 
evidence that current proteomic strategies have sufficient sensitivity (qualitatively and 
quantitatively) to detect clinically relevant changes and therefore can be successfully 
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used to explore protein expression trends and discover novel clinically relevant protein 
expression portraits previously unconnected to breast cancer. The proteomic analysis of 
infiltrating ductal carcinoma (IDCA) of the breast from different stages (Stage I 
(normal), IIA, IIB and IIIA) by 2D-DIGE revealed a number of proteins that appeared 
to be differentially expressed between breast IDCA and matching normal tissue 
(Wulfkuhle et al. 2002). Approximately, 69–85% of the proteins detected were found 
not to be significantly different between the normal and diseased samples. A total of 27 
differentially expressed proteins were identified in this investigation using LC-MS/MS, 
however the functional role or how the majority of these identified proteins mediate the 
highly complex tumour processes are largely unknown. Examples of the proteins 
detected as differentially expressed were carbonic dehydratase, disulfide isomerase, 
gelsolin and fibrinogen beta (Somiari et al. 2003). The protein expression profile and 
observed trend for a number of the proteins is consistent with information in literature 
for some of the proteins. For example, fibrinogen gamma-chain and fibrinogen beta-
chain fragments have been identified in various solid tumour types at the protein level, 
and fibrinogen gamma-chain dimmer cross linked by transglutaminase were detected in 
tumour patients but not in controls (Somiari et al. 2003). It is suggested that the 
elevation of β-fibrinogen correlates with tumour-associated fibrin deposition. Carbonic 
dehydratase, disulfide isomerase, gelsolin and fibrinogen beta are over expressed in 
IDCA whereas gelsolin, which is known to bind to β-actin, is less abundant in IDCA 
compared to normal tissue (Jones et al. 2006). 
The investigation of protein profiles of primary epithelial cells from 7 metastatic breast 
cancer patients and 16 non-malignant breast cancer patients using 2D-DIGE coupled 
with LC-MS/MS revealed that the expression of nucleoplasmin was observed to be 
increased and the expression of glutathione peroxidise 1 and 2,3-trans-Enoyl-CoA 
isomerase were reduced in metastatic breast cancer patients compared to non-malignant 
breast cancer patients (Gerner et al. 2001). The nucleoplasmin and glutathione 
peroxidise 1 are already known to be involved in cancer whereas the roles of 2,3-trans-
Enoyl-CoA isomerise are still unknown (Vydra et al. 2008). 
In an another study, 8 ER+ and 8 ER- breast tumours were investigated using 2D-PAGE 
coupled with MALDI-ToF MS (Lei et al. 2007, Zhang 2004). Progesterone receptor 
membrane component 1 (PGRMC1) was identified to be differentially expressed at 
three different spots on the 2D-gel due to phosphorylation of this protein and of these 3 
spots, 2 spots were more abundant in ER- tumours compared to the ER+ tumours. 
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Abrogated activity of PGRMC1 was observed to result in reduced peroxide-induced cell 
death in MCF7 breast cancer cells. PGRMC1 abundance and phosphorylation was 
expected to be involved in the regulation of clinical consequences of tumours, 
potentially maintaining not only cell migration and tissue morphogenesis but also 
improved survival and tissue homeostasis. A pool of 4 differentially expressed peaks 
identified in the comparison of protein profiles from 61 ER+ breast tumours and 56 ER- 
breast tumours using laser capture microdissection and MALDI-ToF were observed to 
identify ER+ breast tumours compared to ER- breast tumours with 66.1% accuracy in 
the testing cohort with a sensitivity of 53% and a specificity of 87.5% (Neubauer et al. 
2008). The analysis of protein profiles from 122 invasive mammary carcinomas and 167 
normal mammary epithelium cells generated using laser capture microdissection and 
MALDI-ToF was also performed and this identified a set of 14 peaks that could be used 
to discriminate diseased samples from normal tissue (Sanders et al. 2008). These 14 
peaks were observed to identify breast cancer tissue with 94% accuracy from normal 
samples with a high sensitivity (89%) and specificity (98%). 
Some studies have been carried out to classify breast tumours on paraffin-embedded 
samples at the protein level. 166 breast cancer tissue samples were evaluated by 
immunohistochemistry, using 15 different antibodies (Sanders et al. 2008). Cytokeratin 
5/6 (Ck 5/6)-positive breast carcinomas were in general negative for estrogen receptor 
and progesterone receptor and were highly proliferating whereas Ck 5/6-negative breast 
carcinomas revealed a lower tumour proliferation rate (Korsching et al. 2002). Another 
study classified tumour in two distinct groups based on ER-negative and ER-positive 
status (Korsching et al. 2002). The ER- and ER+ groups were further divided into two 
subgroups based on the VEGF status, thus forming four subgroups, ER-/VEGF+, ER-
/VEGF-, ER+/VEGF+ and ER+/VEGF-. Interestingly, the ER-/VEGF-, ER+/VEGF+ and 
ER+/VEGF- phenotypes were either p53 positive or p53 negative, whereas the ER-
/VEGF+ tumours were distinguishable as either c-erbB2 positive or c-erbB2 negative 
(Zhang et al. 2003).  
In another effort, SELDI proteomic profiles were compared with a previous cDNA 
expression analysis using whole tissue lysates of 105 breast carcinomas (Zhang et al. 
2003). SELDI-ToF MS analysis provided similar clustering of tumours to those 
identified by the cDNA expression profiles (Brenton et al. 2005). The first subgroup 
was luminal subtypes (A and B), which makes up the hormone receptor-expressing 
breast cancer and has expression patterns reminiscent of the luminal epithelial 
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component of the breast (including luminal cytokeratin 8/18 and cyclin D1 genes). The 
second subgroup was called the HER2/neu subtype, but should not be confused with 
HER2/neu-positive tumours identified by immunohistochemistry or fluorescence in situ 
hybridization because not all clinically HER2/neu-positive tumours show the RNA 
expression changes that define this subtype (Brenton et al. 2005, Brozkova et al. 2008). 
SELDI-ToF MS analysis also identified differential protein peaks in primary breast 
cancers that predict the presence and number of axillary lymph node (ALN) metastases 
and non- sentinel lymph node (SLN) status (Brenton et al. 2005, Brozkova et al. 2008).  
Two metal-binding polypeptides at 4,871 and 8,596 Da were identified to be associated 
with significant risk factors for nodal metastasis in this investigation. Recently, SELDI-
ToF MS analysis of breast tissue has identified the carboxyl terminus-truncated 
ubiquitin as a marker for luminal-like and S1009 for basal type (Nakagawa et al. 2006).  
Therefore the investigation of cancer tissue using proteomics based approaches could 
reveal potential drug targets and/or biomarkers for breast cancer diagnosis and 
prognosis. 
 
1.5.7. Summary  
It is clear that there is a limited number of established biomarkers and/or drug targets 
for the diagnosis and prognosis of breast cancer in the early phase of disease. To date, 
only a few studies have investigated the expression of proteins that may have a role in 
the regulation of breast cancer and invasion. Therefore, investigation of differential 
expression of cellular, secreted and membrane & membrane-associated proteins in 
breast cancer cell models could enable us to identify proteins that could be potential 
biomarkers and/or drug targets for breast cancer disease.  
 
1.5.8 Selection of cell line models for this study 
Although cell line model based investigation has significantly contributed to develop 
new therapies for cancer disease, currently there are only few studies on breast cancer 
invasion using cell lines. Therefore four cell lines (HMEC, MCF-10A, MCF-7 and BT-
20) representing normal, cancerous, non-invasive and invasive phenotypes were 
investigated in this study to identify cancer and invasion-associated proteins. HMEC 
cells are normal human mammary epithelial cells that are derived from the basal 
subtype and are invasive. MCF-10A cells are basal subtype with intact p53 that were 
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derived by spontaneous immortalization of breast epithelial cells from a patient with 
fibrocystic disease (Goncalves et al. 2008). These cells do not survive when implanted 
subcutaneously into immuno-deficient mice (Soule et al. 1990). MCF-10A cells are 
therefore immortalized normal cells and have been used extensively as a non-invasive 
normal control in breast cancer studies. MCF-7 cells are ‘luminal epithelial-like’ 
subtype established from a pleural effusion obtained from a 69-year-old caucasian 
woman and express estrogen receptor (Soule et al. 1990). MCF-7 cells are the most 
common example of estrogen-responsive breast cancer cells and are non-invasive. The 
BT-20 cell lines are derived from an advanced invasive ductal carcinoma during a 
mastectomy in 1958 (Dickson et al. 1986, Charafe-Jauffret et al. 2006). These cells 
were obtained by slicing the primary tumour into thin sections and collecting the cells 
that had detached from the stroma. It is a basal subtype and expresses estrogen receptor 
and is invasive.  
A panel of breast cell lines including non-invasive (MCF-7, MCF-10A, T47D and 
UACC 812) and invasive (HMEC, SKBR-3, MDA-MB 231, HCC 1937, BT20 and 
Hs578T) were also included to screen identified protein targets which have potential 
role in invasion. This panel of cell lines covered a broad range of origin (basal, luminal 
and normal-like), i.e. basal (MCF-10A, MDA MB 231, HCC-1937 and Hs578T), 
luminal (MCF-7, T47D, UACC 812 and SKBR-3) and normal-like (MCF-10A). Thus, 
these cell lines represented heterogenity of samples which often occurs in in-vivo 
models and was therefore could lead to the identification of real targets associated with 
invasion in breast cells. 
 
1.6 Melanoma 
Melanoma is a malignant tumour originating from melanocytes, the cells that produce 
the pigment melanin. During the first trimester of fetal life, precursor melanocytes arise 
in the neural crest (ectoderm). As the fetus develops, these cells migrate to different 
body areas, such as the skin, uvea, leptomeninges and mucous membranes (e.g. upper 
esophagus, vulva, anus). Accordingly, melanoma can arise in all these sites, although 
cutaneous melanoma is by far the most frequent type of melanoma. Melanoma is the 
most lethal skin cancer and accounts for about 75% of all deaths from skin tumours 
(Lasfargues and Ozzello 1958). Melanoma originates from the melanocytes of the 
epidermis. Melanoma mostly occurs in skin but may occur in eye or other places where 
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melanocytes occurs. The etiologic factors leading to melanoma are unknown, although a 
few factors, i.e. nature of skin (caucasians or black), exposure to sun light and 
hereditary factors have been correlated with the development of melanoma (Liotta et al. 
2003). Over the past two decades, substantial preclinical advancements have been made 
in the understanding of melanoma molecular biology (development, progression, 
resistance to medical therapy). Nevertheless, the clinical implementation of molecular 
medicine principles (e.g. the use of melanoma-specific prognostic biomarkers and 
molecular therapies) is just in its infancy, and much work remains to be done in order to 
develop a tumour-targeted patient-tailored therapeutic approach to this disease. 
 
1.6.1 Types of Melanoma 
Four main morphological types of melanoma have been classically recognized: 
superficial spreading melanoma (SSM), nodular melanoma (NM), lentigo maligna 
melanoma (LMM), and acral lentiginous melanoma (ALM). Furthermore, several 
unusual variants of melanoma such as desmoplastic melanoma and nevoid melanoma 
have been recently characterized (Setlow 1999). 
 
1.6.1.1 Superficial Spreading Type  
This type of melanoma is more commonly found on the trunk, upper arms, and thighs, 
and is the most common form of melanoma in white races. It begins as a small 
pigmented macule that is asymmetric, has irregular borders, and has colour variations. 
This type of melanoma remains in the flat phase for a shorter period of time than the 
lentigo maligna type before it penetrates into the deeper levels of the skin.  
 
1.6.1.2 Nodular Type 
This type of melanoma can occur on any skin surface but is found more commonly on 
the trunk, upper arms, and thighs. The nodular type of melanoma has a very short flat 
phase before it forms a raised nodule and penetrates into the deeper levels of the skin. 
This type of melanoma may ulcerate and present as a non-healing skin ulcer. 
 
1.6.1.3 Lentigo maligna melanoma (LMM) 
LMM typically occurs in older people, on sun-exposed areas (mostly head and neck). 
LMM was considered to have a better prognosis than the other forms of melanoma, but 
recent studies have suggested that the different biologic behaviour may be related to an 
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inferior thickness at the time of diagnosis. This variant of melanoma is histologically 
characterized by a confluent growth of atypical melanocytes along the dermal-epidermal 
junction frequently extending downwards the cutaneous appendages. The invasive 
component may be composed of spindle cells or may be associated to a desmoplastic 
reaction. 
 
1.6.1.4 Acral-Lentiginous Type 
This type of melanoma is more commonly found on the hands, feet, and nail beds. It is 
seen in all races, but is most frequently found in dark-skinned races. It is similar to the 
lentigo maligna and superficial spreading type in that it has a relatively long flat phase 
before it penetrates into the deeper levels of the skin. 
 
1.7 Serum biomarkers for Melanoma 
Biomarkers enable the clinical diagnosis and prognostic classification of various types 
and stages of cancers. Biomarkers are usually proteins that may be produced by cancer 
cells or by normal cells (Magro et al. 2006). They may be intracellularly or on the 
surface membrane, from where they can be released in to body fluid. There are some 
promising serum markers for melanoma currently being studied: 
 
1.7.1 S100  
S100 was originally extracted from bovine brain and its name is derived from its 
solubility in 100% saturated ammonium sulphate at neutral pH. The S100 protein is a 
low molecular weight (21 kDa), acidic, thermolabile, calcium-binding protein. It is a 
dimer consisting of two subunits, α and/or β, with three combinations αα, α β and β β 
cells. The beta subunit is expressed in cells of the central nervous system as well as in 
cells of the melanocytic lineage (Liotta et al. 2003). In melanoma, the β-subunit is 
positively correlated with the invasiveness of the tumour and was considered as a 
prognostic marker in stage I to IV melanoma patients (Jackel et al. 1999, Moore 1965). 
 
1.7.2 Melanoma inhibitory activity 
Melanoma inhibitory activity (MIA) is an 11-kDa soluble protein identified as an 
autocrine-secreted tumour cell growth inhibitor (from which it derived its name) 
isolated from the supernatant of the human HTZ-19 melanoma cell line culture (Henze 
et al. 1997). This protein showed the reduction of melanoma cell attachment to the 
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extracellular matrix, because it binds to fibronectin and laminin, thereby preventing 
cell–matrix interaction (Bogdahn et al. 1989). MIA was shown to be useful prognostic 
marker in melanoma patients with metastatic malignant melanoma (Apfel et al. 1992). 
 
1.7.3 Lactate dehydrogenase 
The strongest prognostic serum biomarker in advanced metastatic melanoma is lactate 
dehydrogenase (LDH), an unspecific marker indicating high tumour load in a variety of 
tumour entities, including melanoma. Studies comparing LDH, S100-beta and MIA 
using multivariate data analysis showed LDH to be the strongest independent prognostic 
factor in stage IV melanoma patients (Deryugina and Quigley 2006). Due to its high 
prognostic significance, coupled with its easy, cost-efficient and widely distributed 
detection methodology, serum LDH is the only molecular marker that has been included 
in the current melanoma staging and classification system of the AJCC (Deichmann et 
al. 1999). 
 
1.7.4 Cytokines and cytokine receptors 
Cytokines are small and secreted proteins which mediate and regulate immunity, 
inflammation, and hematopoiesis. The cytokine family consists mainly of smaller, 
water-soluble proteins and glycoproteins with a mass between 8 and 30 kDa. Increased 
serum levels of IL-6 and IL-8 were found increased in the serum of stage IV patients 
and there was a correlation with tumour burden. Serum levels of IL-6 were also higher 
in patients who were non-responsive to therapy, regardless of tumour burden (Balch et 
al. 2001). IL -10 was also found increased in patients with metastatic malignant 
melanoma and correlated with poor survival (Mouawad et al. 1996, Scheibenbogen et 
al. 1995, Tartour et al. 1994). Elevated levels of sIL-2R have been reported in 
melanoma, even in early stage disease and a correlation between the sIL-2R level and 
melanoma progression has also been reported (Dummer et al. 1995, Nemunaitis et al. 
2001). Although these substances have been demonstrated in melanoma patients, the 
exact role in tumour immunology is not yet understood. 
 
1.7.5 Cell adhesion molecules 
Cell Adhesion Molecules (CAMs) are proteins located on the cell surface involved with 
the binding with other cells or with the extracellular matrix (ECM) in the process called 
cell adhesion. Increased intercellular adhesion molecule-1 (sICAM-1), and decresed L-
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selectin (sL-selectin) levels were generally associated with the progression of malignant 
melanoma (Ottaiano et al. 2006). Elevated levels of VCAM-1 in serum (sVCAM-1) 
have been observed in some, but not all of the previous reports on melanoma (Yamada 
et al. 2005). 
 
1.7.6 5-S-cysteinyldopa (5-S-CD) 
5-S-cysteinyldopa (5-S-CD) is a precursor of melanin. 5-S-CD is produced by 
melanocytes and melanoma cells, and is detectable in sera of patients. Elevated serum 
levels of 5-S-CD have been reported in melanoma patients and have correlated its 
expression with the prognosis of stage IV melanoma patients (Franzke et al. 1998, 
Miller et al. 1997).  
 
1.7.7 Glypican-3 (GPC3) and secreted protein acidic and rich in cysteine (SPARC) 
Glypican-3 is a cell surface heparan sulfate proteoglycans. GPC3 may be involved in 
the suppression/modulation of growth in the predominantly mesodermal tissues and 
organs. Secreted protein acidic and rich in cysteine (SPARC), also called osteonectin or 
BM-40, is a matricellular glycoprotein that modulates cellular interaction with the 
extracellular matrix during tissue remodeling. One study reported glypican-3 (GPC3) as 
a novel tumour marker but could diagnose only 40% of melanomas (Banfalvi et al. 
2002). They also detected SPARC in the sera of melanoma patients at higher 
concentrations than in healthy donors. Indeed, SPARC was detected in the sera of 33% 
of all melanoma patients, irrespective of the clinical stages and even in the sera of 
patients with stage 0 in situ melanoma. Moreover, the combined use of secreted protein 
acidic and rich in cysteine (SPARC) and GPC3 will thus make it possible to diagnose 
melanoma, especially in the early stages (0-II) (Nakatsura et al. 2004). 
 
1.7.8 Cytoplasmic melanoma-associated antigen (CYT-MAA) 
Cytoplasmic melanoma-associated antigen (CYT-MAA) is a cytoplasmic protein 
composed of 4 noncovalently associated polypeptides of 94, 75, 70 and 25 kDa 
molecular weight. While elevated levels of the marker do not correlate to the stage of 
the disease, being equally high at all AJCC stages (II–IV), elevated serum levels 
correlate significantly with disease recurrence and progression, and was found to be an 
accurate marker when used to monitor response to treatment in patients with AJCC 
stages IIb–IV. 90% of patients that were initially CYT-MAA positive, showed a 
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decrease in CYT-MAA serum levels during the treatment and those with elevated 
marker levels during the treatment were around three times more likely to recur or 
suffer disease progression (Ikuta et al. 2005). 
 
1.7.9 High-molecular-weight melanoma-associated antigen (HMW-MAA) 
A high-molecular weight melanoma-associated antigen (HMW-MAA), also known as 
melanoma-associated chondroitin sulphate proteoglycan (MSCP) is found expressed in 
high density on the surface of cultured melanoma cells. HMW -MAA is a serum marker 
for residual melanoma in patients with resected disease (Reynolds et al. 2006). 
 
1.7.10 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF-C, VEGF-D) are multifunctional, 
homodimeric peptide cytokines. Elevated levels of VEGF in sera of patients with 
melanoma have been correlated with progression of melanoma (Vergilis et al. 2005). 
One recent study reported that VEGF-C might be involved in the deep lymphatic 
dissemination and progression of melanoma metastasis (Ascierto et al. 2004). Another 
study reported significantly increased serum levels of VEGF, bFGF, interleukin-8 and 
angiogenin in melanoma patients with advanced stage disease and tumour burden 
(Vihinen et al. 2007). Elevated levels of endostatinin in serum of melanoma patients IV 
disease have also been reported (Ugurel et al. 2001a). 
 
1.7.11 L-Dopa/L-tyrosine and Tyrosinase 
The melanin biosynthetic pathway is critically regulated at the enzymatic level by 
tyrosinase in melanocyte-specific copper-containing organelles called melanosomes. 
Tyrosinase is a key factor in melanogenesis since it catalyzes the rate limiting step in 
melanin biosynthesis, i.e. L-tyrosine to L-DOPA, and subsequent oxidation to 
DOPAquinone. DOPAquinone is oxidized to DOPAchrome which gives 
dihydroxyindoles. These dihydroxyindoles are further oxidised to produce eumelanina 
(brown/black pigment) (Kurschat et al. 2007). A high level of serum L-dopa/L-tyrosine 
ratio (an index of tyrosinase functional activity) in melanoma patients correlates with 
the tumour burden and in some cases predicted disease progression in metastatic 
melanoma patients (Letellier et al. 1997). Very few studies showed high tyrosinase 
activity in serum from patients with malignant melanoma (Stoitchkov et al. 2002). 
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1.7.12 soluble HLA-DR (sHLA-DR) 
HLA-DR is a major histocompatibility complex, MHC class II, cell surface receptor 
encoded by the human leukocyte antigen complex. The complex of HLA-DR and its 
ligand, a peptide of 9 amino acids in length or longer, constitutes a ligand for the T-cell 
receptor (TCR). HLA-DR is also involved in several autoimmune conditions, disease 
susceptibility and disease resistance. Lower sHLA-DR levels in serum from melanoma 
patients have been reported and reduced amounts of sHLA-DR have been found 
associated with advanced disease stages and tumour burden (Agrup et al. 1989, Lugovic 
et al. 2007). 
 
1.7.13 CRP (C-reactive protein) 
C-reactive protein (CRP) is a plasma protein, an acute phase protein produced by the 
liver and by adipocytes. CRP is a member of the pentraxin family of proteins. Elevated 
levels of CRP in serum have been associated with shortened survival in metastatic 
melanoma patients and resistance to interleukin-2 therapy (Rebmann et al. 2002). High 
CRP levels to indicate progression of distant metastases during therapy could be useful 
serum markers for monitoring metastatic malignant melanoma (Tartour et al. 1996). 
 
1.7.14 sFas/CD95  
The membrane-bound type I protein Fas/CD95 and its ligand, FasL, play a key role in 
maintaining tissue homeostasis via induction of apoptosis. Besides regulation of 
lymphatic cells and tissues providing immunotolerance, limiting clonal expansion, and 
maintaining immunoprivileged sites of the organism, the Fas/CD95-FasL system has 
recently been described to exert important functions in the control of malignant 
proliferation. Elevated levels of serum sFas/CD95 had shown a prognostic relevance in 
melanoma patients (Deichmann et al. 2000). Limited studies on function and clinical 
significance of serum sFas/CD95 have been carried out to date. 
 
1.7.15 YKL-40 
YKL-40 is a growth factor for connective tissue cells and stimulates migration of 
endothelial cells. Cancer cells, macrophages, and neutrophils secrete YKL-40. Its 
function in cancer is unknown. Elevated serum levels of YKL-40 have been reported 
and could be an early biomarker of relapse and survival in patients with AJCC stage I 
and II melanoma (Ugurel et al. 2001b). 
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1.7.16 TA-90  
TA-90 has been found on the outer surface of melanoma cells. TA-90 is also found in 
the serum of melanoma patients as a free antigen and as an immune complex (IC) with 
IgG antibody. In addition, immunoglobulin-M (IgM) and IgG-mediated antibody 
responses to TA90 can be detected in the sera of patients with melanoma. The presence 
of TA90-IC in the serum of patients with melanoma has been shown to correlate with 
occult lymph node metastases and decreased overall survival (Schmidt et al. 2006, 
Schmidt et al. 2006). Both the presence of TA90-IC and the absence of IgM antibody 
against TA90 (anti-TA90) after surgical resection of distant melanoma metastases 
(AJCC stage IV) are inversely correlated with outcomes even in patients who receive 
postoperative adjuvant treatment with a polyvalent vaccine (Kelley et al. 1998). 
 
1.7.17 Matrix metalloproteinases (MMPs) 
Matrix metalloproteinases (MMP) are a family of zinc-dependent neutral 
endopeptidases characterized by their ability to degrade extracellular matrix components 
as described in section 1.2.2.2.1. The serum levels of MMP-2 in patients with advanced 
melanoma was studied and found that serum MMP-2 does not have any role as a 
prognostic marker (Hsueh et al. 2000). On the other hand, the serum levels of MMP-2 
were significantly higher in patients with metastatic melanoma than in patients with 
localized melanoma. In addition, somewhat higher MMP-2 levels were noted in patients 
with more advanced disease when MMP-2 levels were compared with different tumour 
stages. High serum levels of MMP-9 were found to be associated with poor overall 
survival. Elevated MMP-9 levels were found to correlate with multiple tumour sites. In 
some studies elevated levels of TIMP-1 and TIMP-2 were found that reflected the 
extent of metastatic melanoma lesions (Vuoristo et al. 2000). 
In summary, serum S100-beta has been shown to be superior compared to MIA, as an 
early indicator of tumour progression, relapse or metastasis, and its distribution as a 
serum biomarker of melanoma, therefore, is the broadest. Both markers have been 
shown to be useful prognostic markers in melanoma patients with distant metastases 
(stage IV, classification system of the American Joint Committee on Cancer, AJCC). 
The strongest prognostic serum biomarker in advanced metastatic melanoma is lactate 
dehydrogenase, an unspecific marker indicating high tumour load in a variety of tumour 
entities, including melanoma. Studies comparing LDH, S100β and MIA using 
multivariate data analysis showed LDH to be the strongest independent prognostic 
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factor in stage IV melanoma patients. Although LDH, S100β and MIA have been shown 
to be useful prognostic markers of malignant melanoma, they failed to be prognostic in 
early-stage of melanoma. None of the other markers could be confirmed to be superior 
to S100-beta or LDH in reflecting the prognosis of patients in advanced disease stages, 
nor could any marker be shown to be of strong prognostic relevance in early stage 
tumour-free patients. 
 
1.8 Proteomics and melanoma 
Currently no protein marker is available for surveillance of melanoma progression in 
early-stage melanoma (Yoshino et al. 2008). Only little work has been reported to date 
concerning the presence of abnormal proteins or peptides in patients bearing melanoma.  
The secretome of uveal malignant melanoma (UM) was investigated using 2D-gel 
electrophoresis coupled with LC-MS/MS spectrometer in an attempt to detect tumour 
specific proteins liberated into the tumour surroundings (Wilson et al. 2004, Caputo et 
al. 2005). Cathepsin D, melanoma-specific antigen gp100, and adapter protein mda-
9/syntenin 1 (melanoma differentiation-associated protein) were found to be positive in 
all the UM secretomes compared to normal cells indicating these proteins as potential 
biomarkers (Pardo et al. 2007). There are a few reports in the literature on profiling 
serum from melanoma patients using SELDI-ToF MS. Serum specimens of 49 early 
stage (American Joint Committee on Cancer (AJCC) stage I and II) patients including 
25 patients with melanoma recurrence and 24 without evidence of disease following 
resection were profiled using SELDI-ToF MS (Pardo et al. 2007). The differential 
patterns of peaks among patients with recurrence and without recurrence were used for 
predicting the chances of melanoma recurrence and it resulted in a sensitivity of 72% 
and a specificity of 75% that was significant (Wilson et al. 2004). Similarly 205 serum 
samples from 101 early-stage (AJCC stage I) and 104 advanced stage (AJCC stage IV) 
melanoma patients were analysed by SELDI-ToF and MALDI-ToF mass spectrometry 
(Wilson et al. 2004). SELDI profiles were used to train artificial neural networks 
(ANN). Based on these ANN algorithms, 88% of stage assignment was correctly 
predicted. Moreover, 80% of stage III samples could be correctly predicted as 
progressors and 82% of stage III progressors were correctly identified. The prediction 
accuracy was much improved compared to the cases predicted by the conventional 
marker S-100β (Mian et al. 2005) where only 21% of the stage III progressors were 
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detected. In other study, plasma peptide components (PPC) from ten melanoma (Mel) 
and healthy individuals were examined by a combination of RP-HPLC, SELDI-ToF MS 
and tandem mass spectrometry (Mian et al. 2005). They found that three peak patterns 
(2023, 2039, 2053.5 m/z) were primarily present, whereas fibrinogen alpha (2554.3 
m/z) and inter-α-trypsin inhibitor heavy chain H4 fragments (2272.0 m/z) were absent 
in melanoma tumour samples compared to normal samples (Caputo et al. 2005). In 
another attempt, 17 samples of sera from patients with malignant cutaneous melanoma 
at various stages and 14 samples from healthy subjects were analysed by matrix-assisted 
laser desorption/ionization (MALDI) mass spectrometry (Caputo et al. 2005). In 
samples from melanoma patients, the peaks for the low molecular weight proteins (m/z 
2500–3500) were observed whereas it was completely absent in spectra from healthy 
subjects. Moreover, the presence and abundance of low molecular weight proteins was 
increased as cells progressed from stage 1 to stage 2 of the disease indicating that these 
peaks could be used in the diagnosis of melanoma (Ferrari et al. 2000). 
Recently differential expression of proteins in the patient primary and metastatic 
melanoma cell lines WM-115 and WM-266-4, respectively, has been investigated using 
2DE to understand the processes regulating tumour progression (Ferrari et al. 2000). 
Increased expression of 131 proteins and down regulation of 15 proteins was observed 
in the metastatic compared to the primary melanoma cell line. These proteins included 
galectin-1 and 14-3-3 that are already known to be involved in cancer other than 
melanoma (Al-Ghoul et al. 2008) and therefore could be useful biomarkers for 
melanoma. Galectin-1 has also been reported to be abundant in the fraction of detergent-
resistant membrane proteins in early stage (radial growth phase) melanoma cells 
compared to those of metastatic cells (Rubinstein et al. 2004, Qi et al. 2005). A 
potentially novel protein, cyclophilin A, was observed to be expressed at higher levels 
in metastatic melanoma compared to the primary melanoma and normal fibroblasts 
suggesting it as potential drug target and biomarker for melanoma in this study 
(Baruthio et al. 2008). In an another effort, the proteome of two clear cell sarcoma 
(CCS) cell lines (soft tissue melanoma) from a patient were compared with the 
corresponding xenografts after xenotransplantation of those cells into the mice (Al-
Ghoul et al. 2008). A total of 124 proteins, including vimentin, nestin and S100, were 
reported common between the cell lines and the xenografts, whereas 249 proteins were 
specific to the cell lines and 178 proteins were specific to the xenografts. This 
knowledge could help to identify potential drug targets or biomarkers for melanoma. 
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The solid melanoma tumours from a mice (fresh and stored at -80 °C for one month) 
have also been investigated using phosphoproteomics approach coupled with high 
resolution mass spectrometry to understand the signalling mechanism in melanoma 
(Dimas et al. 2008). A detailed phosphoproteome map describing a total of 5600 
phosphorylation sites on 2250 proteins was created and it was also observed in this 
investigation that one month storage at -80 °C did not significantly decrease the number 
of identified phosphorylation sites in tumour samples. Of the identified proteins, 31 
proteins, such as ERK, Jun and AKT, have already been reported to be phosphorylated 
in cancer and kinase proteins were the most abundantly identified proteins in this 
investigation suggesting the dominance of kinases-induced signalling cascades in 
melanoma.   
It is clear that very limited investigations have focused their interests in investigating 
the proteins that may have role in regulation of cancer and invasion in melanoma 
disease and no established protein biomarker is available to date for diagnosis of 
melanoma cases in early stage of disease. Therefore, the investigation of secreted 
proteins from melanoma cell lines using proteomics based approaches could reveal 
potential biomarkers and/or drug targets for melanoma diagnosis and prognosis. 
 
1.9 Proteomics technologies 
Cancer is a complex disease that reflects the genetic as well as protein changes within a 
cell. Gene expression data gives us limited relevant information since proteins are the 
main functional units performing all biological process in the cell or organism and may 
have post-transcriptional event(s) and post-translational modification(s) that contribute 
towards biological activity of proteins. Protein expression patterns are also changed 
specifically and significantly in response to every disease (Zanivan et al. 2008). The 
first protein cancer marker, carcinoembryonic antigen (CEA), was identified in 1965 for 
the detection of colorectal cancer in patient serum (Banks et al. 2000).  Other 
biomarkers discovered in the 1970s and 1980s include prostate-specific antigen (PSA) 
for prostate cancer, CA-19 for colorectal and pancreatic cancer, CA-15-3 for breast 
cancer and CA-125 for ovarian cancer. However, not all biomarkers are effective in all 
clinical situations. For example, PSA is well established in clinical practice, but 
approximately one third of patients with an elevated PSA level often undergo 
unnecessary medical procedures because they do not have a malignant form of prostate 
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cancer (Gold and Freedman 1965). Identification of new tumour biomarkers with 
predictive value is needed to allow early detection and treatment of cancer. It is also 
necessary to distinguish between poor and good prognosis and being able to suggest 
patient-tailored therapy, thus improving treatment. The recent advances in mass 
spectrometry technology - a technique for separating and identifying molecules based 
on mass - have highlighted this possibility and it has become an important tool for 
proteomic studies. Several proteomics technologies including Two Dimensional 
Polyacrylamide Gel Electrophoresis (2D-PAGE), Surface Enhanced Laser 
Desorption/Ionisation Time of Flight Mass Spectrometry (SELDI-ToF MS), Protein 
Arrays, Isotope Coded Affinity Tags (ICAT), iTRAQ, Multidimensional Protein 
Identification Technology (MudPIT) and SILAC are the approaches being implemented 
in cancer research. 2D-PAGE and SELDI-ToF are the main technologies used to date in 
serum cancer research, however other technologies such as protein arrays, ICAT, 
iTRAQ and SILAC also offer great potential for future biomarker discovery in cancer. 
We used Two Dimensional differential Gel Electrophoresis (2D-DIGE) couples with 
MALDI-ToF and LC-MS/MS and Surface Enhanced Laser Desorption/Ionisation Time 
of Flight (SELDI-ToF) in this thesis. 
 
1.9.1 Two-dimensional Differential Gel Electrophoresis (2D-DIGE) 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) is the most widely 
used proteomics technique to study the proteome as well as cancer biomarkers (U.S. 
Preventive Services Task Force 2008).  2D-PAGE remains challenging mainly because 
of its low sensitivity and reproducibility. Modified 2D electrophoresis by fluorescent 
tagging to proteins, Differential gel electrophoresis (DIGE), offers increased 
throughput, ease of use, reproducibility, and accurate quantitation of protein expression 
differences (Gharbi et al. 2002, Somiari et al. 2003, Lilley et al. 2002, Yu et al. 2005).  
This system enables the separation of two or three fluorescently labelled protein 
samples (Cy2, Cy3 and Cy5) on the same gel. Differential analysis software identifies 
the differentially expressed protein targets that can be trypsin- digested and readily 
identified using mass spectrometry by generating peptide mass fingerprints (PMF) using 
Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry 
(MALDI-ToF MS), a technique that is both relatively easy to use and reasonably 
sensitive for identifying proteins. Additionally other mass spectrometry techniques such 
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as electrospray ionization (ESI-MS/MS) are capable of providing amino acid sequence 
information on peptide fragments of the parent protein (Unlu et al. 1997).  
 
Florescent dyes labelling 
Mixing labelled extracts
2-DE Separation 
Typhoon Variable Mode Imager
DeCyder Differential Analysis 
software 
Proteins sample
Cy5: Control Cy3: Test Cy2: internal 
standard
4 biological replicate of each
 
Figure 1.2: Work flow of 2D-DIGE experiment 
 
Although 2D-PAGE based techniques have a reasonable level of throughput, however 
there are a number of difficulties inherent to the technique such as separation of low 
abundant proteins as it is difficult to enrich for these proteins.  Membrane proteins are 
also difficult to separate due to poor solubility. Efforts have been made to overcome 
these limitations. For example, low abundant proteins can be identified using higher 
protein concentrations, and applying fractionation methods. Moreover, membrane 
proteins can be identified to some extent by using commercially available mild 
detergents such as oligooxyethylene, sulfobetaine, dodecyl maltoside, and decaethylene 
glycol mono hexadecyl, as the use of strong detergents like SDS, interfere with the 
isoelectric focusing of proteins (Mann et al. 2001). Additional problems with 2D 
electrophoresis include insufficient resolution to separate multiple species originating 
from a single protein with post-translational modifications, such as those with 
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carbohydrates, difficulties in detecting proteins with molecular masses >120000 Da and 
those with pI values <4 or >9, low visualisation of less-abundant proteins, and co-
migration of proteins to same spots (Luche et al. 2003). Conventional 2-D 
electrophoresis shows only protein expression and cannot detect protein-protein 
interactions and protein function without using particular methods such as affinity 
electrophoresis (Gygi et al. 2000).  
 
1.9.2 Matrix assisted Laser Desorption/Ionisation Time-of-flight Mass 
spectrometry (MALDI-ToF MS) 
Matrix assisted Laser Desorption/Ionisation Time-of-flight Mass Spectrometry 
(MALDI-ToF MS) involves the precipitation of sample molecules with an excess of 
matrix material (α-cyano-4-hydroxycinnamic acid or dihydroxybenzoic acid). The 
precipitant is then bombarded with laser pulses and imparts energy. The matrix 
materials have absorbances at the wavelength of the laser and are subject to desorption 
and ionisation accompanied by fragmentation. The MS measures the mass-to-charge 
ratio (m/z) of the protein, peptide or peptide fragments. The time-of-flight (ToF) 
analyzer separates ions according to their m/z ratios by measuring the time it takes for 
ions to travel through a field free region known as the flight or drift tube. The laser is set 
in such a way that it always generates single charged ions and therefore m/z represents 
the approximate molecular weight of the protein target. The smaller ions possess a 
higher velocity relative to larger/heavier ions. Separated ion fractions arriving at the end 
of the drift tube are detected by an appropriate recorder that produces a signal upon 
impact of each ion group. The ToF mass spectrum is a recording of the detector signal 
as a function of time. This peptide mass fingerprint can then be used to search databases 
using MASCOT and ProFound against SWISS-PROT and NCBI to identify the protein 
(Kameshita et al. 1998). 
 
1.9.3 Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-
MS/MS) 
LC-MS/MS combines the liquid chromatographic separation with mass spectrometric 
detection. The combination of these two powerful techniques enables us to analyze 
virtually any molecular species including thermally labile, non-volatile, and high 
molecular weight species. Most of the analyte species are amenable to separation with 
liquid chromatography. Tandem mass spectrometry (LC-MS/MS) is capable of 
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providing structure, molecular weight, empirical formula, and quantitative information 
about a specific analyte. Therefore LC-MS/MS has become a major tool for the study of 
biological processes. Biological samples are generally highly complex mixtures of 
biomolecule(s). The complexity of these samples is usually reduced in a series of 
separation steps in LC-MS/MS analysis. Whole proteins often first undergo an 
enzymatic digestion with trypsin. The resulting mixture of peptides and other 
compounds is transferred into a chromatographic column. The retention period of the 
individual components in the mixture depends on their interaction with the column 
material, and consequently, different peptides are likely to elute at different retention 
times. The separated substance zones are continuously transferred into a mass 
spectrometer, where they are ionized and separated by their mass/charge ratio. The mass 
spectrometric data from an LC-MS/MS experiment consists of a sequence of spectra (or 
scans). Each scan gives a snapshot of the peptides eluting from the column during a 
fixed interval. It consists of a series of data points, each described by m/z and ion count 
(intensity). The set of scans from one LC-MS/MS sample constitutes an LC-MS/MS 
data set (or LC-MS/MS map). The atoms contained in a peptide exist in different 
isotopic variants which occur in a fairly constant distribution in nature. This gives rise 
to a characteristic pattern of adjacent peaks in the mass spectrum. Analysis of distances 
between peaks could enable us to identify amino acids in the peptide. The LC-MS/MS 
maps can be searched in to the database of known proteins using SEQUEST and 
MASCOT against SWISS-PROT and NCBI to identify protein/peptide. Therefore LC-
MS/MS is so sensitive that it can generate the sequence information for the 
protein/peptide under investigation. 
 
1.9.4 Surface Enhanced Laser Desorption/Ionization time-of-flight mass 
spectrometry (SELDI –ToF MS)  
This technique allows proteins/peptides to be profiled from different biological samples, 
on a variety of chemically (anionic, cationic, hydrophobic, hydrophilic, metal affinity 
capture, etc.) or bio-chemically (immobilized antibody, receptor, DNA, enzyme, etc.) 
defined chromatographic surfaces. A small amount of sample of interest is loaded onto 
ProteinChipTM arrays that selectively bind different subset of proteins in crude samples 
by adsorption, partition, electrostatic interaction or affinity chromatography according 
to their surface chemistries.  After a short incubation period, unbound proteins and 
unspecific substances are washed away with an appropriate buffer and water. The ToF 
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reader records the time of flight and calculates the accurate molecular weight of 
proteins/peptides in the form of a spectral map containing mass to charge ratios (m/z) 
and intensities corresponding to each bound proteins/peptides. Biomarker wizard 
software analyses the spectral map and detects differentially expressed protein/peptides 
with statistical significance. SELDI –ToF MS produces a characteristic profile for the 
source material analysis of serum, plasma, intestinal fluid, urine, cell lysates and cellular 
secretions focusing on the discovery and identification of potential biomarkers for 
various diseases. SELDI-ToF MS utilizes the different chromatographic properties of 
ProteinChip® arrays to bind different subsets of peptides and proteins for subsequent 
analysis (Blackstock and Weir 1999). Further advantages of this MS -based technology 
is the small amount of sample required and its ability to detect low molecular weight 
proteins (<15 KDa) which are usually missed by other techniques (like, for example, 2–
D gel Electrophoresis) and on which there is an increasing interest of researchers 
(Merchant and Weinberger 2000). SELDI-ToF MS has been extensively used in the 
field of biomedical research including breast and melanoma cancer (section 1.5 and 
1.8). However, there is some controversy over this technology such as its 
reproducibility, the bioinformatics used, the possibility of over-fitting, the potential 
biasness in the samples as well as how this could possibly fit into a routine diagnostic 
lab (Petricoin and Liotta 2004). 
 
 
 
 
 
 
 
 
 
 53 
Aim of thesis 
The goals of this work were the identification of differentially expressed 
proteins/peptides between normal non-invasive, normal-invasive, cancerous-non-
invasive and cancerous-invasive cell lines using proteomic profiling techniques, which 
could possibly help to understand the molecular mechanisms of cancer invasion and 
lead to the discovery of biomarkers for melanoma and breast cancer. 
 
The specific aims of this work were 
 
• To identify key cellular proteins, followed by functional analysis using siRNA 
knockdown, in order to investigate the mechanisms of N+C invasion and 
proliferation in human breast cancer cell lines.  
 
• To investigate the changes in expression profiles of secreted proteins in the 
conditioned media from breast cell lines to identify cancer and N+C invasion- 
associated proteins. 
 
• To investigate differential protein expression mapping of the membrane fraction 
of breast cell lines to identify cancer-specific and N+C invasion-specific 
proteins and potential targets for cancer invasion.  
 
• To identify differentially expressed proteins/peptides in conditioned media from 
the melanoma cell line MDA-MB-435S-F and its drug resistant variants 
(paclitaxel-resistant cell line MDA-MB-435S-F/ Taxol10p4pSI and 
doxorubicin-resistant cell line MDA-MB-435S-F/Adr-10p10pSI) followed by 
further analysis to establish cancer specificity and/or role in invasion. 
 
•  To discover low molecular weight biomarkers for melanoma in conditioned 
media from melanocytes and melanoma cells. 
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Section 2 
 
 
 
 
 
 
 
Materials & Methods 
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2.1 Ultrapure water 
Ultrapure water was used in the preparation of all media and solutions. For ultra-
purification, the water was initially pre-treated which involved activated carbon, pre-
filtration and anti-scaling. This water was then purified by a reverse osmosis system 
(Elga USF Maxima Water Purification System) to a standard of 12 - 18 MΩ/cm 
resistance. 
 
2.2 Glassware 
All glassware and lids were soaked in a 2% (v/v) solution of RBS-25 (VWR 
International) for at least 1 hour (hr). This is a deproteinising agent, which removes 
proteineous material from the bottles. Glassware was scrubbed and rinsed several times 
in tap water. The bottles were then washed by machine using Neodisher detergent, an 
organic, phosphate-based acid detergent. The bottles were then rinsed twice with 
distilled water, once with ultrapure water and sterilised by autoclaving.  
 
2.3 Preparation of cell culture media 
Ultrapure water (UHP) and glassware were autoclaved before use in cell culture as 
described in Section 2.1 & 2.2. All 1X basal media were prepared in-house as follows: 
10X media were added to sterile UHP water, buffered with HEPES (N-(2-
Hydroxyethyl) piperazine-N-(2-ethanesulfonic acid) (Sigma, H-9136) and NaHCO3 
(BDH, 30151) as required and adjusted to pH 7.5 using sterile 1.5N NaOH or 1.5N HCl. 
The media was then filtered through sterile 0.22µm bell filters (Gelman, 12158) and 
stored in sterile 500mL bottles at 4°C. Sterility checks on all media bottles for bacterial, 
yeast and fungal contamination were made using Trypto Soya Broth (TSB, Oxoid, 
CM0129) and Thioglycolate broths (Oxoid, CM173). All samples for sterility checks 
were then incubated at both 25°C and 37°C. Basal media were stored at 4°C for up to 
three months in the dark.  
Complete media was then prepared by adding serum as required (Table 2.1). An aliquot 
of complete medium was kept in a T-25cm2 flask in an incubator over 5-7 days to 
ensure that the complete medium is free of contamination at the time of use. Complete 
media was also stored at 4°C for a maximum of one month in the dark. 
 
 
 56 
Table 2.1. Details of cell lines and complete growth media components 
Cell Lines  Growth media components 
 
HMEC 
 
MEGM basal media, plus growth factor kit (bovine pituitary 
extract (2mL/500mL), epithelial growth factor (0.5mL/500mL), 
insulin (0.5mL/500mL), hydrocortisone (0.5mL/500mL), 
transferrin (0.5mL/500mL) (Lonza, CC-3150) 
MCF10A 
 
MEGM basal media, plus growth factor kit (bovine pituitary 
extract (2mL/500mL), epithelial growth factor (0.5mL/500mL), 
insulin (0.5mL/500mL), hydrocortisone (0.5mL/500mL), 
transferrin (0.5mL/500mL) (Lonza, CC-3150), plus 50µg/mL 
cholera toxin (Sigma, C8052) 
MCF-7 
 
DMEM Media, 10% (v/v) fetal calf serum (Sigma, F7524) 
BT20 
 
RPMI-1640, 10% (v/v) fetal calf serum 
MDA-MB231 
 
RPMI-1640, 10% (v/v) fetal calf serum, 1% (v/v) Sodium pyruvate 
(Gibco, 11360-035) 
HCC1937 
 
RPMI-1640, 10% (v/v) fetal calf serum 
Hs578T 
 
DMEM, 10% (v/v) fetal calf serum,  10µg/mL bovine insulin 
(Sigma, 10516) 
SK-BR-3 
 
RPMI, 10% (v/v) fetal calf serum 
TD47D 
 
DMEM, 10% fetal calf serum 
UACC-182 
 
L15 media (Sigma, L-5520) , 15% (v/v) fetal calf serum 
NHEM 
 
Melanocyte growth medium M2 (487.7mL) + Supplement Mix 
(PromoCell, C-24300) (12.3mL) 
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SKMEL-5 RPMI 1640, 10% (v/v) fetal calf serum 
SKMEL-28 RPMI 1640, 10% (v/v) fetal calf serum 
Malme-3M RPMI 1640, 10% (v/v) fetal calf serum 
HT144 McCoy's 5a, 10% (v/v) fetal calf serum 
M14 RPMI 1640, 10% (v/v) fetal calf serum 
Lox-IMVI RPMI 1640, 10% (v/v) fetal calf serum 
DLKP ATCC (1:1 (v/v) mixture of DMEM and Hams F12), 5% 
(v/v) fetal calf serum 
H1299 RPMI 1640, 1mM sodium pyruvate (Gibco, 11360-035), 5% 
(v/v) fetal calf serum 
MDA-MB 435S RPMI 1640, 10% (v/v) fetal calf serum 
MDA-MB435S 
/taxol10p4p 
RPMI 1640, 10% (v/v) fetal calf serum 
MDA-MB435S 
/Adr10p10p 
RPMI 1640, 10% (v/v) fetal calf serum 
 
2.4    Routine management of cell lines  
2.4.1    Safety Precautions 
All cell culture work was carried out in a class II laminar air-flow (LF) cabinet (Holten). 
Before and after use, the LF cabinet was cleaned with 70% industrial methylated spirits 
(IMS) for 15 minutes. Any items brought into the cabinet were also swabbed down with 
IMS. At a time, only one cell line was used in the LF cabinet and upon completion of 
work with any given cell line, 15 minutes clearance was given to eliminate any 
possibilities of cross-contamination between the various cell lines. The cabinet was 
cleaned weekly with Virkon (Antech International, P0550) and IMS. 
 
2.4.2    Cell Lines 
The cell lines used during the course of this study, their sources and detailed 
information are listed in Table 2.2.  Cells were maintained in 25cm2 flasks (Costar, 
3050), 75cm2 flasks (Costar, 3075) or 175cm2 flasks (Nulge Nunc, 156502) at 37°C and 
were fed every 2nd or 3th day or as required in order to maintain active cell growth in 
culture.  
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Table 2.2 Details of cell lines used in this investigation.  
Cell Lines  Source  Detailed Information  
HMEC Lonza Normal mammary epithelial  
MCF10A ATCC# Non-tumorigenic mammary epithelial 
MCF-7 NICB* Breast adenocarcinoma  
BT20 NICB* Breast invasive ductal carcinoma 
MDA-MB231 NICB* Breast invasive ductal carcinoma 
HCC1937 NICB* Breast primary ductal carcinoma 
Hs578T NICB* Breast carcinosarcoma 
SK-BR-3 NICB* Breast invasive ductal carcinoma 
TD47D NICB* Breast invasive ductal carcinoma 
UACC-182 NICB* Breast invasive ductal carcinoma 
NHEM PromoCell Normal Epithelial Melanocytes 
SKMEL-5 NICB* Malignant melanoma 
SKMEL-28 NICB* Malignant melanoma 
Malme-3M NICB* Malignant melanoma 
HT144 NICB* Malignant melanoma 
M14 NICB* Malignant amelanotic melanoma 
Lox-IMVI NICB* Malignant amelanotic melanoma 
DLKP NICB* Poorly differentiated lung squamous carcinoma 
H1299 NICB* Large cell lung carcinoma 
MDA-MB 435S NICB* Metastatic carcinoma, melanoma 
MDA-MB435S 
/taxol10p4p 
NICB* Metastatic carcinoma, melanoma, paclitaxel-
resistant variant 
MDA-MB435S 
/Adr10p10p 
NICB* Metastatic carcinoma, melanoma, doxorubicin-
resistant variant  
# ATCC - American Type Tissue Culture Collection, * NICB- National Institute for 
Cellular Biotechnology 
2.4.3 Subculturing of cancer cell lines 
Exhausted cell culture medium was removed from the tissue culture flask and discarded 
into a sterile bottle. The flask was then rinsed out with 2mL of trypsin solution (0.25% 
(v/v) of trypsin (Gibco, 043-05090) and 0.01% (v/v) of EDTA (Sigma, E9884) solution 
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in PBS (Oxoid, BRI4a)) to ensure the removal of any residual media. Depending on the 
size of the flask, 2-5mL of trypsin was then added. Cells were then incubated at 37°C 
for approximately 2-5 minutes until all of the cells detached from the inside surface of 
the flask. This was monitored by microscopic observation. An equal volume of 
complete media was added to the flask to deactivate the trypsin. The cell suspension 
was removed from the flask and placed in a sterile universal container (Sterilin, 128a) 
and centrifuged at 250g for 5 minutes. The supernatant was then discarded from the 
universal and the pellet was suspended gently in fresh complete medium. A cell count 
was performed as described in section 2.4.6 and an aliquot of cells was used to seed a 
flask at the required density. All cell waste or media exposed to cells was autoclaved 
before disposal. 
 
2.4.4 Subculturing of normal cells (HMEC and Melanocytes) 
HMEC cells were subcultured using the subculture reagent kit supplied by Lonza (CC-
5002) and melanocytes were subcultured using the subculture reagent kit supplied by 
PromoCell (C-41210). For subculture, cells were rinsed with 5mL of room temperature 
HEPES Buffered Saline Solution from the kit. The cells were covered with 5mL of 
room temperature Trypsin/EDTA. The cells were monitored using an inverted 
microscope. The trypsinization process was allowed to continue until approximately 
90% of the cells had rounded up. The process takes about 2-6 minutes. At this point, the 
flask was rapped against the palm of hand to release the majority of the cells from the 
culture surface. If only a few cells detached, trypsinization was allowed to continue for 
a further 1-2 min. The flask was then given a further rap with the palm of the hand. This 
process was repeated until majority of cells had detached. The trypsin in the flask was 
immediately neutralized by addition of 5mL of room temperature Trypsin 
Neutralization Solution from the kit. The cell suspension was removed from the flask 
and placed in a sterile universal container (Sterilin, 128a) and centrifuged at 250g for 5 
minutes.  The supernatant was then discarded from the universal and the pellet was 
suspended gently in fresh complete medium. A cell count was performed as described 
in Section 2.4.6 and an aliquot of cells was used to seed a flask at the required density. 
All cell waste or media exposed to cells was autoclaved before disposal. 
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2.4.5 Subculture of MCF-10A 
Exhausted cell culture medium was removed from the tissue culture flask and discarded 
into a sterile bottle. The flask was then rinsed out with 2mL of trypsin solution to ensure 
the removal of any residual media. Depending on the size of the flask, 2-5mL of trypsin 
was then added to the flask, which was then incubated at 37°C, for approximately 5 
minutes, until all of the cells detached from the inside surface of the flask monitored by 
microscopic observation. Since the culture medium for MCF-10A does not contain 
serum (trypsin inhibitor), an equal volume of soybean trypsin inhibitor (1mg/mL) 
(Sigma, T6522) was added to the flask to deactivate the trypsin. The cell suspension 
was removed from the flask and placed in a sterile universal container (Sterilin, 128a) 
and centrifuged at 250g for 5 minutes. The supernatant was then discarded from the 
universal and the pellet was suspended gently in complete medium. A cell count was 
performed and an aliquot of cells was used to seed a flask at the required density. All 
cell waste or media exposed to cells was autoclaved before disposal. 
 
2.4.6 Assessment of cell number and viability 
Prior to cell counts, cells were prepared by subculturing as detailed in sections 2.4.3-5. 
An aliquot of the cell suspension was then added to trypan blue (Gibco, 525) at a ratio 
of 1:1 (v/v). The mixture was incubated for 2-3 minutes at room temperature. An 
aliquot (10µL) was then applied to the chamber of a glass coverslip-enclosed 
haemocytometer. For each of the four grids, cells in the 16 squares were counted. Non-
viable cells stained blue, while viable cells excluded the trypan blue dye as their 
membrane remained intact, and remained unstained. The average number of viable and 
dead cells per 16 squares was multiplied by a factor of 104 (volume of the grid) and the 
relevant dilution factor to determine the average cell number per mL in the original cell 
suspension. Using the data for viable and non-viable cells, percentage viability was 
calculated. 
 
2.4.7 Cryopreservation of cells 
Cells for cryopreservation were harvested in the mid-log phase of growth and counted 
as described in section 2.4.6. Cell pellets were resuspended in a suitable volume of cold 
serum. An equal volume of filter sterilized solution of 10% (v/v) DMSO in serum was 
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added dropwise with mixing into the cell suspension. 1mL of cell suspension was then 
aliqoted into the cryovials (Greiner, 122278) and immediately placed in the -20°C 
freezer for 1hr and then placed in a -80°C freezer for four hours or overnight. The 
cryovials were then transferred to liquid nitrogen tank for long term storage (-196°C). 
 
2.4.8 Thawing of cryopreserved cells  
A volume of 5mL of fresh complete culture medium was added to a sterile universal 
and into a T-25cm2 flask and incubated at 370C for ~1hr. The cryopreserved cells were 
removed from the liquid nitrogen and thawed at 37°C as quickly as possible. The cells 
were removed from the vials and transferred into the pre-warmed aliquoted media in the 
universal. The resulting cell suspension was centrifuged at 250g for 5 minutes. The 
supernatant was removed and the pellet was resuspended in the pre-warmed culture 
medium from T-25 cm2 flask. This cell suspension was then transferred to T-25 cm2 
flask and allowed to attach and grow overnight in incubator. The following day, the 
culture media was replaced with fresh complete culture medium to remove any non-
viable cells and floating cells. 
 
2.5 Mycoplasma analysis of cell lines 
Mycoplasma testing was carried out for all cell lines for possible Mycoplasma 
contamination in house by Ms. Shane and Mr. Michael Henry at the NICB following 
the protocols described in sections 2.5.1 and 2.5.2. All cell lines are found to be 
Mycoplasma free. 
 
2.5.1 Indirect staining procedure for Mycoplasma analysis 
Mycoplasma negative NRK (Normal rat kidney fibroblast) cells were used as indicator 
cells for this analysis. The cells were incubated with supernatant from the cell lines in 
question and then examined for Mycoplasma contamination. A fluorescent Hoechst 
stain was used in this analysis. This stain binds specifically to DNA (i.e. the nucleus of 
the cell and any Mycoplasma present). Mycoplasma infection was indicated by 
fluorescent bodies in the cytoplasm of the NRK cells. 
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2.5.2 Direct staining procedure for Mycoplasma analysis 
Direct staining for Mycoplasma analysis involved inoculating samples on to a 
Mycoplasma culture broth (Oxoid, CM403). This was supplemented with 16% (v/v) 
serum, 0.002% (v/v) DNA (BDH, 42026), 2µg/mL fungizone (Gibco, 042 05920), 
2x103 units penicillin (Sigma, Pen-3) and 10mL of a 25% yeast extract solution. 
Incubation was carried out at 37°C for a period of 48 hours. Samples of this broth were 
then streaked onto plates of Mycoplasma agar base (Oxoid, CM401) which had been 
supplemented as described above. The plates were incubated for three weeks at 37°C 
and examined microscopically every 7 days. The appearance of small oval shaped 
colonies indicated the presence of Mycoplasma infection. 
 
2.6    Invasion assay 
2.6.1    Preparation of invasion chambers 
Invasion assays were carried out using BD BioCoatTM MATRIGELTM Invasion 
Chambers (BD Biosciences, 354483). Inserts were rehydrated with serum-free basal 
media for 2 hours at 37oC in incubator containing 5% CO2 atmosphere. Cell 
suspensions were prepared in serum-free basal media at a concentration of 2x105 
cells/mL. A volume of 750µL of complete media was added to the lower chamber of the 
insert in BD FalconTM TC Companion Plate. A volume of 500µl of the cell suspension 
was then added into the insert. The invasion assays were then incubated for 48 hours at 
37oC in 5% CO2 atmosphere.  
 
2.6.2 Staining of invasive cells 
After 48 hours incubation, the non-invading cells were removed from the upper surface 
of the membrane. The inner side of the insert was wiped with a PBS-soaked swab while 
the outer side of the insert was stained with 0.25% crystal violet for 10 minutes and then 
rinsed in ultrapure water and allowed to dry. Inserts were then analyzed using the 
microscope.   
 
2.6.3 Counting of invading cells 
Cell counting was facilitated by photographing the insert-membrane using an inverted 
microscope. The cells were observed at 200X magnification. Cells in the central fields 
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of membranes were counted and an average count calculated from 5 counts per chamber 
within a grid at 20x objective. The average count was multiplied by the conversion 
factor 140 (growth area of membrane divided by field of viewed area  at 200 X 
magnification) to determine the total number of invading/migrating cells. All assays 
were performed in triplicate.   
 
2.7 Proteomic analysis  
2.7.1 Protein sample preparation 
2.7.1.1 Lysates 
Cells were seeded in four biological replicates in T-75cm2 flasks. Cells pellets were 
obtained by trypsinization as described in section 2.4.3-5, once culture reached 70-80% 
confluency. The cell pellets were dissolved in cold PBS and centrifuged at 250g for 
5min. This was repeated again to remove residual medium or trypsin from cell pellet. 
Cell pellets were then washed twice with sucrose buffer (10nM sucrose, 100mM Tris, 
pH 8.0). Cell pellets were then reconstituted with 0.5mL of the lysis buffer (Table 2.3).  
 
 
Table 2.3 Preparation of lysis buffer 
Contents Recipe Required weight/volume for making 
25mL of lysis buffer 
Urea  7M 10.5 g 
Thiourea 2M 3.8 g 
CHAPS  4%  1 g 
Tris  30mM 0.091 g 
Magnesium acetate  5mM 0.027 g 
Water Up to 25mL 
pH 8 – 9 
Aliquot in 1 mL/eppendorf and store at -200C   
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The lysate was then homogenised by passing though a 21-gauge needle 6 times using a 
1mL syringe. After incubation, lysates were centrifuged on a bench-top centrifuge at 
3500g for 15 minutes at 4°C. The middle layer of the supernatant containing extracted 
protein was transferred to a fresh chilled eppendorf tube and its pH was checked by 
spotting 3µL onto a pH indicator strip to ensure that it lies between pH 8.0-9.0. A small 
aliquot of sample was used for protein estimation. The sample was then divided into 
smaller aliquots and stored at –800C. 
 
2.7.1.2 Conditioned Media preparation 
Cells (3x106) were seeded in four biological replicates in T-175cm2 flasks. Cells were 
allowed to grow until 50-60% confluent. Cells were washed three times with 10mL of 
serum-free (SF) basal media and then incubated in 15mL of SF basal media for 60 min. 
After this time, cells were washed again twice with SF basal media. 15mL of SF basal 
media was added to the cells and incubated for 72hrs. After such time, conditioned 
media (CM) was collected, centrifuged for 15min at 250g, and stored at –800C. At the 
time of analysis conditioned media was concentrated using 5,000 dalton (Da) molecular 
weight cut-off concentrators (Millipore, UFC 900524). A volume of 15mL was 
concentrated to 500µL by centrifuging at 1000g at 40C. 
Before 2D-DIGE analysis proteins were precipitated using acetone precipitation 
method. 1:5 volumes of sample and cold acetone were incubated overnight and 
centrifuged at 1000g for 20 minutes. Samples were reconstituted with 100-500µL of the 
lysis buffer. The pH of samples was roughly maintained to pH 8-9 by addition of HCl 
(acidic pH) or NaOH (alkaline pH). A small aliquot of sample was used for protein 
estimation. The sample was then divided into smaller aliquots and stored at –800C. 
 
2.7.1.3 Membrane fractionation 
Cells were seeded in four biological replicates in T-175cm2 flasks. Cells pellets were 
obtained by trypsinization as described in section 2.4.3-5, once the culture reached 50-
60% confluency. The cell pellets were washed twice with cold PBS as described in 
section 2.7.1.1.  
The fractionation process for the isolation of hydrophobic proteins from the cell lines 
were carried out using ReadyPrepTM  Protein Extraction Kit (Membrane I) ( Biorad, 
163-2088). The kit separates the membrane proteins from other proteins using 
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temperature-dependent phase partitioning (Bordier 1981, Santoni and Kieffer 2000). For 
this, cells were lysed by incubating for 15 minutes in ice in a solution containing 2% 
precondensed Triton X-114 in TBS (150mM NaCl, 10mM Tris-HCl, pH 7.6). Samples 
were then vortex 4–5 times, 60 second each. The tubes were maintained in an ice for 
30–60 second between each vortexing step and the solution was collected and incubated 
at 370C for 30 minutes. The cloudy solution obtained was again centrifuged at 10,000x 
g for 10 minutes at room temperature. This caused the formation of two liquid phases. 
The lower liquid phase that is enriched in hydrophobic proteins was collected. Before 
2D-DIGE analysis proteins were precipitated using the acetone precipitation method as 
described in section 2.7.1.2. 
 
2.7.2 Protein quantification  
2mg/mL of bovine serum albumin (BSA) solution (Sigma, A9543) was used as a known 
standard. Dilutions of BSA stock for 0.125, 0.25, 0.5 and 1.0mg/mL was prepared and 
used for generating a protein standard curve. 240µL/well of thiourea-compatible 
Bradford protein assay reagent (Bio-Rad, 500-0205) was added to a 96-well plate. 10µL 
of protein standard dilution or sample (diluted 1:10) was added to the 96-well plate. All 
samples were assayed in triplicate. After 5 minutes incubation, the absorbance was 
assessed at 595nm. The concentration of the protein samples was determined from the 
plot of the absorbance at 595nm versus the concentration of the protein standard.  
 
2.7.3 Two-dimensional difference gel electrophoresis (2D-DIGE) 
2D-DIGE is an advanced version of classical two-dimensional gel electrophoresis (2D-
PAGE). In 2D-DIGE, protein samples are labeled with three different fluorescent dyes 
(Cy2, Cy3 and Cy5) and then separated by 2D-PAGE. Labeling of different protein 
samples with different fluorescent dyes and then mixing together allows samples to be 
separated on the same gel and this minimizes gel-to-gel variation. The following steps 
were carried out to perform 2D-DIGE experiment in this investigation. 
 
2.7.3.1 Labelling of proteins 
2.7.3.1.1 Preparation of CyDye dyes for minimal-DIGE protein labelling 
The three CyDye DIGE Fluor Minimal dyes (Cy3, Cy5 and Cy2 (GE Healthcare, 25-
8010-65) were thawed from –20oC to room temperature for 5 minutes. To each 
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microfuge tube dimethylformamide (DMF) (Sigma, 22,705-6) was added to a 
concentration of 1 nmol/µL. Each microfuge tube was vortexed vigorously for 30 
seconds to dissolve the dye. The tubes were then centrifuged for 30 seconds at 3500g in 
a microcentrifuge. The reconstituted dyes were stored at –20oC for up to 3 months. 
 
2.7.3.1.2 Preparation of 10 µL working dye solution (200 pmol/µL) 
On thawing, the dye stock solutions were centrifuged in a microcentrifuge for 30 
seconds. To make 10 µL of the three working dye solutions, 8 µL of DMF was added to 
three fresh eppendorfs labelled Cy2, Cy3 and Cy5 and 2 µL of Cy dye (1 pmol/µL). A 
200 pmol/µL volume of each of the reconstituted dye stock solutions was added to their 
respective tubes. The dyes were stored at -20oC in tinfoil in the dark for 3 months. 
 
2.7.3.2 Protein sample labeling 
The 2D-DIGE experiment was carried out using four biological replicate samples. The 
protein samples equivalent to 50µg (or 25µg for the membrane fraction study) was 
placed into eppendorf tubes and HMEC and MCF-7 samples were labeled with the Cy3 
and MCF-10A and BT20 samples with Cy5 minimal dyes. The Cy2 pool for each gel 
(50µg) (or 25µg for the membrane fraction study) contained an equal concentration 
aliquot of each of the protein samples from HMEC, MCF-7, MCF-10A and BT20. To 
this, 1µL of each dye (200 pmol/µL) was added 50µg (or 25µg for the membrane 
fraction study) of protein sample. Each tube was mixed by vortexing, centrifuged and 
then left on ice for 30 minutes in the dark. To stop the reaction, 1µL of 10 mM lysine 
(per 200pm of dye) was added. The tubes were mixed, centrifuged briefly and left on 
ice for 10 minutes in the dark. An equal volume of 2X sample buffer (rehydration buffer 
stock solution (7M urea, 2 M thiourea, 4% CHAPS, 2% IPG buffer pH 4-7 (GE 
Healthcare, 17-6000-86), 50mM DTT (Sigma, D9163)) was added to the labeled protein 
samples. The mixture was left on ice for at least 10 minutes then applied to Immobiline 
DryStrips for isoelectric focussing. The mixture was left on ice for at least 10 minutes 
and then applied to Immobiline DryStrips for isoelectric focussing. 
 
2.7.3.3 First dimension separation - isoelectric focussing  
2.7.3.3.1 Strip rehydration 
Isoelectric focussing of all samples was carried out using immobiline pH gradient (IPG) 
strips (18cm, 4-7pH) (GE Healthcare, 17-1233-01). The protective lid was removed 
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from the Immobiline Dry Strip Reswelling tray. The tray was levelled using the spirit 
level. 350µL of rehydration buffer was slowly pipetted into the centre of each slot. All 
air bubbles generated were removed. The cover film from the IPG strip (GE Healthcare) 
was removed and positioned with the gel side down and lowered. To ensure the entire 
strip was evenly coated with rehydration buffer, the strip was gently lifted and lowered 
onto the entire surface of the solution avoiding trapping air bubbles. Each strip was 
overlaid with about 3mL IPG Cover Fluid (GE Healthcare, 17-1335-01) starting on both 
ends of the strip and moving to the centre. The protective lid was then replaced and the 
strips were left at room temperature to rehydrate overnight (or at least 12 hours). 
 
2.7.3.3.2 Isoelectric focussing 
Following the rehydration procedure, the Manifold (GE Healthcare) was placed onto the 
IPGphor unit (GE Healthcare) by inserting the “T” shape into the hollow provided. A 9 
mL of Cover Fluid was placed into each of the twelve lanes in the tray in order to cover 
the surface. Two wicks (GE Healthcare, 80-6499-14) per strip were placed on tinfoil 
and 150 µL of UHP was pipetted onto each one to rehydrate them. The rehydrated strips 
were placed in the correct orientation (+ to anode) and aligned just below the indented 
mark, to allow for the wicks to overlap the strip. The rehydrated wicks were then placed 
over both the cathodic and anodic ends of all the strips. The wicks were checked to 
ensure they were positioned over the gel portion of the strip and avoiding the indent in 
the lane so as to guarantee a good contact with the electrodes. The sample cups (GE 
Healthcare, 80-6498-95) were then positioned approximately 1 cm from the cathodic 
end of the strip and an insertion tool was used to securely “click” the cups into place. 
The electrodes were then fitted with their “Cams” open and in direct contact with the 
wicks. The amount of protein loaded per strip was 150µg for DIGE or 400µg for spot 
picking. The protein samples were prepared by centrifuging to remove any insoluble 
material and the appropriate volume was loaded with a pipette tip placed just beneath 
the surface of the cover fluid. The cover of the IPGphor unit was closed and the desired 
programme selected. The temperature was set for 20oC with 50µA/strip. The IEF 
parameters are as follows: step 1: 300 volts for 3 hours (step-and-hold), step 2: 600 
volts for 3 hours (gradient), step 3: 1000 volts for 3 hours (gradient), step 4: 8000 volts 
for 3 hours (gradient). The IEF was hold at 500 volts until ready for SDS-PAGE step. 
step 5: IEF was refocused for 1 hour at 8000 volts, step 6: On completion of the IEF 
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run, the strips were drained of the cover fluid and stored in glass tubes at –80oC or used 
directly in the second dimension.  
 
2.7.3.4 Second Dimension – SDS polyacrylamide gel electrophoresis 
2.7.3.4.1 Casting gels in the ETTAN Dalt-12 gel caster 
The 12.5 % acrylamide gel solution was prepared in a glass beaker (acrylamide/bis 
30%, 1.5 M Tris pH 8.8, 10 % SDS). Prior to pouring, 10 % ammonium persulfate and 
neat TEMED were added.  
Two types of plates were used, low fluorescent for DIGE experiments and hinged for 
preparative and silver stained gels. All plates (both normal hinged and low fluorescent) 
and casting equipment were inspected to ensure they were clean. The gel caster frame 
was placed on a level bench leaning on its “legs” so that the back of the caster was open 
and facing the operator. The plates were assembled so that the front and back plates 
were evenly aligned and all seals and hinges in place. A thin spacer was placed in the 
gel caster unit followed by an assembled plate and then a thin spacer and then another 
plate. The plates were positioned in the caster unit so that the lower, front plate was the 
furthest away from the operator and the spacers packed with their curved edges to the 
top. This layering was repeated until all 14 plates and spacers were in place. All plates 
and spacers were checked to ensure they were packed tightly together so as to minimise 
any gaps and air pockets. When the desired amount of plates had been added, the 
thicker spacers were placed next to bring the level marginally over the edge of the back 
of the caster. The backing plate was then added to the caster frame and screwed into 
place with the 6 screws provided. The silicone tubing was added to the outlet of the 
glass beaker and the glass tube was inserted to the other end of the silicone tubing. The 
glass tube was inserted into the inlet of the reservoir and the glass beaker containing the 
gel solution was then clamped to a retort stand. The gel solution was held in place using 
arterial clamps on the top tube and the tube running down from the reservoir to the 
caster chamber. The top tube was unclamped and the gel solution was allowed to fill the 
tubing and the reservoir drain. Air bubbles that had been generated were dislodged by 
flicking the tube. When all air bubbles had been removed the bottom clamp was 
released allowing the gel solution into the gel caster. When the gel solution reached the 
indicator line across the top of the caster, the bottom and top tubes were reclamped. The 
displacement solution (0.375M Tris-Cl 1.5M pH8.8, 30% glycerol, UHP and 
bromophenol blue) was added to the reservoir and the glass tubing was slowly removed 
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from the reservoir inlet. The clamp was removed from the bottom tube allowing the 
displacement solution into the tube and forcing the remaining gel solution into the gel 
caster. The gels were overlaid with 1 mL of saturated butanol or sprayed with 0.1 % 
SDS solution. The gels were left to set for at least three hours at room temperature. 
Following this, the caster was gently unlocked and the gels removed and rinsed with 
distilled water. If the gels were not used immediately they were stored for up to four 
days in 1X running buffer at 4oC. 
If gels were to be used for “spot picking” the plates were silanised to stick the 
acrylamide gel to the plates. A volume of 2mL of working bind-silane solution (8mL 
ethanol, 200µL glacial acetic acid, 10µL bind-silane (GE Healthcare) and 1.8mL UHP) 
was pipetted over the glass plate and wiped over with a lint free cloth. This was left to 
air dry for 15 minutes, after which 2mL ethanol and 2 mL UHP were each pipetted over 
the plate and wiped off respectively. The plate was left to air dry for approximately 1 
hour 30 minutes.  
 
2.7.3.4.2 Preparing the ETTAN DALT-12 electrophoresis unit 
The electrophoresis chamber was prepared by adding 6.48 litres of UHP and 720 mL of 
10X SDS running buffer. The pump was then turned on to cool the system to 10oC.  
 
2.7.3.4.3 Equilibration of focussed Immobiline DryStrips 
The SDS equilibration buffer (30% glycerol, 6M urea, 50nm 1.5M Tris-Cl pH 8.8, 2% 
SDS, bromophenol blue and UHP) which had been prepared, aliquotted into 30 mL 
volumes and frozen at –20oC was allowed to thaw to room temperature. Two SDS 
equilibration buffer solutions with DTT (65 mM) or iodoacetamide (240 mM) (Sigma, 
I1149) were then prepared. Using a forceps, the IPG strips were removed from the 
IPGphor unit, the cover fluid was drained off by holding the strips at an angle and they 
were placed into individual glass tubes with the support film toward the wall. 
Equilibration buffer (10 mL containing DTT) was added to each tube and incubated for 
15 minutes with gentle agitation using an orbital shaker. During this equilibration step, 
the gel cassettes were rinsed with UHP and then the tops rinsed with 1X running buffer. 
After the first equilibration, DTT containing equilibration solution was removed and 5 
mL of the iodoacetamide containing equilibration buffer was added. The strips were 
incubated for 15 minutes with gentle agitation. During this equilibration step, the 
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agarose overlay solution (0.5% agarose in running buffer) was prepared and 50 mL of 
1X running buffer was placed in a glass tube. If the strips had been frozen at this stage 
they were left at room temperature to thaw before the DTT-containing equilibration 
solution was added. 
 
2.7.3.4.4 Loading the focussed Immobiline DryStrips 
Using a forceps and holding the anode end, the IPG strips were rinsed in 1X SDS 
electrophoresis running buffer and placed between the two glass plates of the gel. The 
strip was pushed down gently using a thin plastic spacer until it came in contact with the 
surface of the gel. Any air bubbles trapped between the gel surface and the strip were 
gently removed. Approximately 1mL of the 0.5 % agarose overlay solution was applied 
over the IPG strip to seal it in place. 
 
2.7.3.4.5 Loading gels into the Ettan DALT-12 electrophoresis unit 
When the running buffer reached the desired temperature (10oC) the loaded gel cassettes 
were wetted with UHP and inserted into the tank through the slots provided in the same 
orientation. When all 12 slots in the upper chamber were filled, 2X running buffer was 
added to the upper chamber until the mark on the side of the chamber was reached. The 
cover of the unit was replaced and the required running conditions selected. The unit 
was run for 18–24 hours at 1.5 Watts per gel at 10°C or until the bromophenol blue dye 
front reached the bottom of the gel. When the run was completed, the gel cassettes were 
removed from the tank one at a time using the DALT cassette removal tool and rinsed 
with UHP to remove the running buffer.  
 
2.7.3.5 Method for scanning DIGE labeled samples 
The Typhoon Variable Mode Imager (GE Healthcare) was turned on and left to warm 
up for 30 minutes prior to scanning. The scanning control software was opened and the 
fluorescence mode was selected. The appropriate emission filters and lasers were then 
selected for the separate dyes (Cy2 520 BP40 Blue (488), Cy3 580 BP30 Green (532) 
and Cy5 670 BP30 Red (633)). The first gel was placed in the scanner and pre-scanned 
at a 1000 pixel resolution in order to obtain the correct photo multiplier tube (PMT) 
value (to prevent saturation of the signal from high abundant spots). Once the correct 
PMT value was found (500-600), the gel was scanned at 100 pixel resolution, resulting 
in the generation of three images, one each for Cy2, Cy3 and Cy5. Once the scanning 
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was completed, the gel images were imported into the Image Quant software. All gels 
were cropped identically to facilitate spot matching in the Decyder BVA module. 
 
2.7.3.6  Analysis of gel images 
Scanned fluorescent gel images were analysed using the Biological Variation Analysis 
(BVA) module of DeCyder 6.5 software (GE Healthcare). Images were loaded into 
DeCyder software using the image loader function. The Batch Processor Module of 
DeCyder was used. The experiment design was set up to compare the cancerous cells 
(MCF-7+BT20) with normal cells (MCF-10A+HMEC), normal and cancer invasive 
cells (HMEC+BT20) with normal and cancer non-invasive cells (MCF-10A+MCF-7), 
cancer invasive (BT20) with normal invasive, normal non-invasive and cancer non-
invasive cells (HMEC+MCF-10A+MCF-7). The spots on the gels were then matched 
across all gels in the experiment. The software standardises the relative spot intensity of 
the Cy5 image and Cy3 image in the same or different gels using the intensity of the 
Cy2 image. The standardised spot intensity was then averaged across the four replicate 
gels. The BVA module calculates the degree of difference in the standardized protein 
abundance between 2 spots from different groups and expressed these differences as 
average ratio. The values by the software are displayed in the range of -∞ to -1 for a 
decrease in expression and +1 to +∞ for an increase in expression. For example, a two-
fold increase and decrease is represented by +2 and -2, respectively (not by 2 and 0.5). 
The ‘average ratio’ has been termed as ‘fold change’ in this thesis. The software also 
calculates the consistency of the differences between samples across all the gels and 
applies statistics to associate a level of confidence (p-value) for each of the differences. 
The spots with statistically significant changes in protein expression (±1.5 fold with p-
value ≤ 0.05) were considered as differentially expressed proteins. These differentially 
expressed proteins observed using DeCyder were designated “proteins of interest” and 
placed in a pick-list to pick with the ETTAN Spot Picker (GE Healthcare) for 
identification using MALDI-ToF MS (GE Healthcare).  
 
2.7.3.7  Staining Methods 
2.7.3.7.1 Silver staining  
This method is used to screen protein samples prior to labelling with the Cy Dyes. After 
2-DE, the gels were removed from the plates by very carefully placing a ruler between 
the two plates at the top right hand corner and the top plate removed gradually. Using 
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the ruler, the side borders of the gel were cut away in line with the ends of the IPG strip 
at the top of the gel. The strip and agarose were then removed and the gel was lifted 
gently and placed in a gel box containing fixing solution (50mL ethanol, 12.5 mL acetic 
acid (Lennox) and 62.5 mL UHP). The gel boxes were placed on an orbital shaker and 
fixed for at least 1 hour (usually overnight). After fixing, the solution was drained from 
the gels. The gels were then washed three times with 150 mL of UHP for 5 minutes 
each time and drained. The gels were next sensitised (60 mL ethanol, 13.6 g sodium 
acetate, 0.4 g sodium thiosulfate and UHP in 200 mL) for 30 minutes on the orbital 
shaker. 
The gels were then washed three times (for 10 minutes). Following the washes, 200 mL 
of silver staining solution (0.5 g silver nitrate, 80µL formaldehyde and 200mL UHP) 
was added and the boxes returned to the orbital shaker. After 20 minutes the silver 
solution was drained and the gels were washed twice for 5 minutes each with UHP. 
After the last wash, 200 ml of developer (5 g sodium carbonate, 40 µL formaldehyde 
and 200mL UHP) was added to each of the boxes. The gels were placed on the orbital 
shaker and allowed to develop. When the desired amount of spots appeared the 
developer was drained into the silver containing 5 L drum (this precipitated out the 
silver) and 200 mL of stopping solution (2.92g EDTA and 200 mL UHP) was added. 
The gels were left on the orbital shaker for at least 10 minutes. The gels were then 
scanned at 300dpi resolution. 
 
2.7.3.7.2 Brilliant blue G Colloidal Coomassie staining 
After electrophoresis, the smaller lower plates that are attached with preparative-gels 
were placed in the boxes containing fixing solution (7% glacial acetic acid in 40% (v/v) 
methanol) for at least one hour. During this step a 1X working solution of Brilliant Blue 
G colloidal coomassie (Sigma, B2025) was prepared by adding 800 mL UHP to the 
stock bottle. When the fixing step had nearly elapsed a solution containing 4 parts of 1X 
working colloidal coomassie solution and 1 part methanol was made, mixed by 
vortexing for 30 seconds and then placed on top of the gels. The gels were left to stain 
for 2 hours. To destain, a solution containing 10% acetic acid in 25% methanol was 
poured over the shaking gels for 60 seconds. The gels were then rinsed with 25% 
methanol for 30 seconds and then destained with 25% methanol for 24 hours. The glass 
surface was dried and two reference markers (GE Healthcare, 18-1143-34) were 
attached to the underside of the glass plate before scanning. The resulting image was 
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imported into the ImageMaster software (GE Healthcare) and the spots were detected, 
normalised and the reference markers selected. While keeping the shift key depressed, 
all spots of interest were manually selected. The resulting image was saved and 
exported into the Ettan Spot Picker software (GE Healthcare).  
 
2.7.3.7.3 Ruthenium (II) tris bathophenanthroline Bisulponate (RuPBS) staining 
For the synthesis of RuPBS, 0.5g of potassium pentachloro aquo ruthenate (Ru, 26.9%) 
was dissolved in 50mL of boiling water and resulting in deep red-brown solution. 3M of 
1, 10-phenthroline monohydrate was added. The solution turned to deep greenish 
brown. Meanwhile, a reducing solution containing 12mM of sodium hydroxide and 
8mM of phosphinic monohydrate was added to the refluxing mixture and refluxing was 
continued for another 20 min. The solution turned to a deep orange-brown. After 
cooling, the pH was adjusted to 7 with NaOH or HCL and the volume was adjusted to 
65mL with water. This gives a 20mM stock solution, which can be stored in the fridge 
for ~6 months.  
Low fluorescence plates were used for running preparative 2D-gels for RuPBS staining. 
After electrophoresis, the smaller lower plates that are attached with preparative-gels 
were placed in the boxes containing fixing solution (7% glacial acetic acid in 40% (v/v) 
methanol) for at least one hour. 600mL of RuPBS staining solution was prepared by 
adding 123mL of 0.2M acetic acid, 37mL of 0.2M sodium acetate, 120mL of ethanol, 
120mL of glycerol, 3mL of tween, 15µL of RuPBS stock and water. Staining solution 
was poured on to the gel and allowed to stain for at least 6hrs or overnight under gentle 
agitation. The destaining solution (600mL) was composed of 123mL of 0.2M acetic 
acid, 17mL of 0.2M sodium acetate, 120mL of ethanol and water. Destaining was 
performed using 2 washes with destaining solution for 4hrs and one for overnight. Two 
reference markers were fixed on the back of the low fluorescence plates and gels were 
scanned at excitation wavelength of 488nm and emission wavelength of 605nm using 
the Typoon 9400 scanner. Images were imported into ImageQuant software and cropped 
appropriately. A single gel DIA file was created for the detection of spots and reference 
marker location were assigned. Spot maps were exported and imported into the BVA 
file created for the DIGE experiment for which the preparative gel was part of. 
Matching mode was selected in the BVA experiment file and landmark mode was 
activated. Highly abundant spot patterns were matched manually in this mode across the 
gels as landmarks. The software was then instructed to match image to experiment 
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using these landmarks. Pick spots were displayed in matched mode gel images by 
alteration of image preferences. Matching of these proteins spots between DIGE images 
preparative 2D-gel images were also checked individually and proteins that were 
matched incorrectly were corrected. Where the correct spot could not be found the spot 
was left unmatched. The pick list was then exported to the Ettan Spot Picker (GE 
Healthcare) software.  
 
2.7.3.8 Spot picking 
Spots that showed differential protein expression in DeCyder analysis were picked with 
the ETTAN Spot Picker (GE Healthcare). The stained gel was placed in the tray of the 
Ettan Spot Picker with reference markers (GE Healthcare) aligned appropriately and 
covered with UHP. The imported pick list was opened, the syringe primed and the 
system was set up for picking the spots from the pick list. The spots were robotically 
picked and placed in 96-well plates, which was stored at 4oC until spot digestion. 
 
2.7.3.9 Spot digestion  
The 96-well plate was placed in the Ettan Digester (GE Healthcare, 18-1142-68) to 
digest the protein as follows: Step 1- the gel plugs were washed three times for 20 
minutes each with 50µL of 50mM ammonium bicarbonate (Sigma, A6141) in 50% 
methanol. Step 2- the gel plugs were washed twice for 15 minutes with 50µL of 70% 
acetonitrile (Sigma, 34967). The gel plugs were left to dry for at least 60 minutes. After 
drying, the individual gel pieces were rehydrated in 10µL digestion buffer (12.5ng 
sequence-grade trypsin (Promega, V5111) per µL of 10% acetonitrile, 40mM 
ammonium bicarbonate). Exhaustive digestion was carried out overnight at 37oC. After 
digestion, the samples were transferred as follows: Step 1 – A volume of 40µL of 0.1% 
trifluoroacetic acid (Sigma, 302031) in 50% acetonitrile was added to the wells, mixed 
and left for 20 minutes. A volume of 50µL of this solution was transferred to a fresh 96-
well plate. Step 2 - A volume of 40µL of 0.1% trifluoroacetic acid in 50% acetonitrile 
was added to the wells, mixed and left for 20 minutes. A volume of 40µL of this 
solution was transferred to a fresh 96-well plate. The liquid in the plate was dried using 
a Maxi-Dry-Plus vacuum-dryer (Medical Supply Co.). After drying, the 96-well plate 
was placed in the Ettan Spotter (GE Healthcare, 18-1142-67) for spotting the peptides 
onto the target plates. A volume of 3µL of 0.5% trifluoroacetic acid in 50% acetonitrile 
was added to the concentrated peptides and mixed 5 times. A volume of 0.3µL of this 
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mixture was spotted onto the target plate followed by a volume of 0.3µL matrix solution 
(7.5mg/mL a-cyano-4-hydroxycinnamic acid (LaserBio labs, 28166-41-8) in 0.1% 
trifluoroacetic acid in 50% acetonitrile). A sample mix, Pep4 (Laser Biolabs) was also 
spotted onto target slides and used as an external calibrant. 
 
2.7.3.10 Identification of proteins with MALDI-ToF 
Mass spectra were recorded in the positive ion, reflectron mode using the Ettan 
MALDI-ToF Pro mass spectrometer (GE Healthcare) equipped with delayed extraction 
and a standard nitrogen laser (337 nm). Mass spectra were recorded using the MALDI 
TOF instrument operating in the positive reflector mode at the following parameters: 
accelerating voltage 20 kV; and pulsed extraction: on (focus mass 2500). Spectra were 
acquired by selective accumulation of 250 individual laser shots and processed using 
Ettan MALDI evaluation software. The spectra were internally calibrated with trypsin 
enzyme autolysis peptide peaks at m/z 842.51 and m/z 2211.10, and externally 
calibrated with Pep4 mix with the five individual peaks covering the 500-3500 Da mass 
range and include bradykinin fragment 1-5 (573.315), angiotensin II human 
(1046.5424), neurotensin (1672.9176) and insulin B chain oxidised (3494.6514). 
Known contaminant peaks were removed from the resulting mass spectra and remaining 
sample-related peaks were used for database searching. The identification sequencing 
method were set for the mass range 0-300kDa, pI 1-14, missed cleavage 1. The artificial 
modifications of peptides (carbamidomethylation of cysteines and partial oxidation of 
methionines) were also considered. Protein identification was achieved using Ettan 
MALDI-ToF Pro evaluation software (GE Healthcare) incorporating the ProFound 
database search engine for peptide mass fingerprints. The sequence database searched 
was the NCBI-nr database (2007/12/02) using subset species Homo sapiens and 
NR_NICB_Human070308. Protein identifications were accepted if they could be 
established at greater than 99% probability and had at least 3 identified peptides. The 
unidentified protein spot that had promising spectrum to get identification were desalted 
and concentrated using C-18 Zip-Tips (Millipore) and were reanalysed by MALDI-ToF 
MS to get identification. For this, the mixtures of tryptic peptides from individual 
samples were desalted using Millipore C-18 Zip-Tips (Millipore) and eluted onto the 
sample plate with the matrix solution (5 mg/mL CHCA in 50% ACN/0.1% TFA v/v) 
and analysed with MALDI-ToF. 
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2.7.3.11 Identification of proteins with LC–MS/MS 
Tryptic digest of proteins (for those which were more than 3 fold differentially 
expressed) were also analysed  by 1-D LC-MS using the Ettan™ MDLC system (GE 
Healthcare) in high-throughput configuration directly connected to a Finnigan™ LTQ™ 
(Thermo Electron). Samples were concentrated and desalted on RPC trap columns 
(Zorbax™ 300SB C18, 0.3 mm65 mm, Agilent Technologies) and the peptides were 
separated on a nano-RPC column (Zorbax 300SB C18, 0.075 mm 6100 mm, Agilent 
Technologies) using a linear ACN gradient from 0 to 65% acetonitrile (Sigma, 34967) 
over 60 min. All buffers used for nano-LC separation contained 0.1% formic acid 
(Fluka, 94318) as the ion pairing reagent. Full scan mass spectra were recorded in 
profile mode and tandem mass spectra in centroid mode. A scan time of ~0.15 s (one 
microscan with a maximum ion injection time of 10ms) over an m/z range of 300-2000 
was used followed by MS/MS analysis of the 3 most abundant peaks from each scan 
which were then excluded for the next 60 seconds followed by MS/MS of the next next 
three abundant peaks which in turn were excluded for 60 seconds and so on. A 
“collision energy”setting of 35% was applied for ion fragmentation and dynamic 
exclusion was used to discriminate against previously analysed ions (data dependent 
analysis).  
Protein identification search was performed using the Turbo-SEQUEST algorithm in 
the BioWorks 3.1 software package (Thermo Electron) and the Swiss-Prot human 
database (Swiss Institute of Bioinformatics, Geneva, Switzerland). The identified 
peptides were further evaluated using charge state versus cross-correlation number 
(XCorr). The criteria for positive identification of peptides was XCorr > 1.5 for singly 
charged ions, XCorr > 2.0 for doubly charged ions, and XCorr > 2.5 for triply charged 
ions. The distinct peptides with p-value ≤0.05 were considered for protein identification 
and also had at least 2 peptides. 
 
2.8 Western blot Analysis 
2.8.1 Gel electrophoresis 
Proteins for analysis by Western blotting were resolved using 12% NuPAGE Bis-Tris 
Gels (Invitrogen, NP0341BOX) in XCell SureLock™ Mini-Cell (Invitrogen, EI0001) 
running instrument. Western blotting samples (2µg/µL) were prepared by diluting 
samples with water and then an equal volume of 2X loading buffer (Sigma, S3401). 10-
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40µg of protein and 5µL of molecular weight marker (ISIS, P7708S) were loaded onto 
gels. The samples were electrophoretically separated at 200V and 45mA using a 
MOPS/SDS buffer (MOPS 1M (Fluka, 69949), 1M Tris base (Sigma, T8404), 2% SDS 
(Sigma, 23771), 20mM EDTA, pH 7.7 (Fluka, 03609)), until the bromophenol blue dye 
reached the bottom of the gel. 
 
2.8.2 Western blotting 
Once electrophoresis had been completed, the gel was equilibrated in transfer buffer 
(25mM Tris (Sigma, T8404), 192mM glycine (Sigma, G-7126), pH 8.3-8.5) for 
approximately 30 minutes. Five sheets of Whatman 3mm filter paper (Whatman, 
1001824) were soaked in freshly prepared transfer buffer. These were then placed on 
the cathode plate of a semi-dry blotting apparatus (Bio-rad). Air pockets were then 
removed from between the filter paper. Nitrocellulose membrane (GE Healthcare, 
RPN3032D), which had been equilibrated in the same transfer buffer, was placed over 
the filter paper on the cathode plate. Air pockets were once again removed. The gels 
were then aligned onto the membrane. Five additional sheets of transfer buffer-soaked 
filter paper were placed on top of the gel, all air pockets removed and excess transfer 
buffer removed from the cathode plate. The proteins were transferred from the gel to the 
membrane at a current of 34mA at 15V for 30-40 minutes, until all colour markers had 
transferred. Following protein transfer, membranes were stained using Ponceau (Sigma, 
P7170) to ensure efficient protein transfer. The membranes were then blocked overnight 
using 1-5% Marvel (Cadburys; Marvel skimmed milk) in PBS at 4°C. The membranes 
were washed with PBS prior to the addition of the primary antibody.  Membranes were 
incubated with primary antibody overnight at 4°C. Antibodies were prepared in 1-5% 
Marvel in PBS. The antibody dilutions are illustrated in Tables 2.4 and 2.5. The 
membranes were then rinsed 3 times with PBS containing 0.5% Tween 20 (Sigma 
P1379) for a total of 15-30 minutes. Relevant secondary antibody (1/1000 dilution of 
anti-mouse (Dako Cytomation, P0260) or anti-rabbit (Dako Cytomation, P0448) or anti-
goat (Santa Cruz Biotechnology, Sc2098) IgG peroxidase conjugate in 2-5% Marvel-
TBS) was added for 1 hour at room temperature (Table 2.4). The membranes were again 
washed three times thoroughly in TBS containing 0.5% Tween for 15 minutes. 
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Table 2.4 Primary antibodies and dilutions 
No. Primary Antibody  Dilution Source Details 
1 3-PGDH 1/1000 Mouse Abcam, ab57030 
2 Vimentin  1/2000 Goat  Sigma, MMS-459S 
3 Erp29 1/2000 Rabbit Abcam, ab11420 
4 QPRT 1/1000 Mouse Abcam, ab57125 
5 Nucleobindin-1 precursour 1/1000 Rabbit Abcam, ab26093 
6 Alpha-tubulin 1/1000 Mouse Sigma, T6199 
7 GAPDH  1/10000 Mouse Abcam, ab8245 
8 TXNRD1 1/1000 Goat Santa Cruz 
Biotechnology,sc-
18220 
9 RAD23B 1/1000 Goat Abcam, ab3835 
10 Cathepsin B 1/1000 Mouse Abcam, ab58802 
11 Transaldolase-1 1/200 Goat Santa Cruz 
Biotechnology,sc-
51439 
12 Keratin 8 1/1000 Mouse Sigma, C5301 
13 Nm23 1/1000 Mouse Calbiochem, OP48 
14 Bip 1/1000 Rabbit Sigma, G8918 
15 Maspin (SERPINB5) 1/1000 Rabbit Abcam, ab22354 
16 STIP-1 1/200 Goat Santa Cruz 
Biotechnology,sc-
15276 
17 CLIC1 1/1000 Rabbit Abcam, ab28722 
18 PSME1 1/1000 Goat Abcam, ab60278 
19 CLP 1/1000 Mouse Abnova, H00023406 
20 Ubiquitin 1/500 Mouse Sigma, U0508 
21 Transferrin Receptor 1/1000 Mouse Abcam, ab1086 
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Table 2.5 Secondary antibodies and dilutions 
No. Secondary Antibody Dilution Details 
1 Anti-mouse 1/1000 DakoCytomation, P0260 
2 Anti-rabbit 1/1000 DakoCytomation, P0448 
3 Anti-goat 1/1000 DakoCytomation, E0466 
4 IRDye 800CW Goat Anti-
Mouse 
1/10000 LI-COR Bioscences, 926-32210 
5 IRDye 800CW Goat Anti-
Rabbit 
1/10000 LI-COR Bioscences, 926-32211 
 
 
2.8.3 Enhanced chemiluminescence detection using autoradiographic films 
Immunoblots were developed using an Enhanced Chemiluminescence kit (GE 
Healthcare, RPN2106), which facilitated the detection of bound peroxidase-conjugated 
secondary antibody. Following the final washing, membranes were subjected to ECL. A 
layer of parafilm was flattened over a glass plate and the membrane placed gently upon 
the plate.  A volume of 3 mL of a freshly prepared 1:1 (v/v) mixture of ECL reagent A 
and B was used to cover the membrane. The ECL reagent mixture was completely 
removed after a period of one minute and the membrane were covered with transparent 
film. All excess air bubbles were removed. The membrane was then exposed to 
autoradiographic film (Roche, 11666916001) for various times (from 10 seconds to 30 
minutes depending on the intensity of the signal). The exposed autoradiographic film 
was developed for 3 minutes in developer solution (Kodak, LX24, diluted 1:5 in water). 
The film was then washed in water for 15 seconds and transferred to a fixative solution 
(Kodak, FX-40, diluted 1:5 in water) for 5 minutes. The film was washed with water for 
5-10 minutes and left to dry at room temperature. 
 
2.8.4 Western blot signal detection using IRDye® infrared dyes conjugated 
secondary antibody 
After protein transfer, the membranes were incubated with 10mL of PBS containing 
odyssey blocking buffer (1:1 (v/v), PBS: odyssey blocking buffer (LI-COR Bioscences- 
N0012)). Membranes were the incubated with primary antibody overnight in PBS at 
4°C.  Antibodies were also prepared in 10mL of 1:1 (v/v) of PBS: odyssey blocking 
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buffer. The primary antibody dilutions are illustrated in Table 2.8.1. The expression of 
CLIC1, CLP and ubiquitin in samples were analyzed using IRDye® infrared dyes 
conjugated secondary antibody in western blotting. The membranes were then rinsed 3 
times with 10mL of 1:1 (v/v) of PBS: odyssey blocking buffer for 15-30 minutes each. 
Relevant secondary antibody (1/10000 dilution of anti-mouse or anti-rabbit conjugate 
with IRDye® infrared dyes in 10mL of 1:1 (v/v) of PBS: odyssey blocking buffer) was 
added on to the membrane for 1hrs at room temperature. The membranes were again 
washed three times thoroughly in 10mL of 1:1 (v/v) of PBS: odyssey blocking buffer 
for 15 minutes each. The membranes were then scanned by using infrared imaging 
system (LI-COR Bioscences, version 3) at resolution 80µm, intensity 5.0µm and 
wavelengths 800nm (for anti-mouse) and 700nm (for anti-rabbit).  
 
2.9 RNA interference (RNAi) 
RNAi using small interfering RNAs (siRNAs) was carried out to silence the expression 
of specific genes. The siRNAs used were purchased from Applied Biosystems. siRNAs 
were introduced into the cells using the transfection reagent, siPORTTM NeoFXTM 
(Applied Biosystems, AM4511).  
 
2.9.1 Transfection optimization 
The conditions for siRNA transfection into MCF-10A, MCF-7, SKBR-3 and BT20 cells 
were optimized in 96-well and 6-well plates. 
 
2.9.1.1 96-well plate optimization 
In order to determine the optimal conditions for siRNA transfection in 96-well plates, 
siRNAs for kinesin (Applied Biosystems, AM16704) were transfected into MCF-10A, 
MCF-7, SKBR-3 and BT20 cell lines using different cell densities and neoFX 
concentrations. Scrambled-treated cultures were considered as controls, however 
untreated cultures were also monitored. siRNAs for scrambled siRNA (Applied 
Biosystems, 17010) and kinesin siRNAs were incubated in 5µL of optiMEM (GibcoTM, 
31985) to achieve 30nM siRNA concentration in 100µL of volume. NeoFX solutions at 
a range of concentrations as described in Table 2.9.1 were also prepared in 5µL of 
optiMEM. siRNA and neoFX solutions were incubated at room temperature for 10 
minutes. After incubation, either scrambled siRNAs or kinesin siRNAs solution were 
added to respective neoFX solutions. siRNA/NeoFX solutions were mixed well and 
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incubated for a further 10 minutes at room temperature. For neoFX-treated wells, 5µL 
of optiMEM was added to the tube containing 5µL of neoFX and incubated for 10min. 
10µL of siRNA/neoFX or neoFX solution was added to respective each well. Cell 
suspension was added to each well to achieve the required cell density per well as 
described in table 2.6. This experiment was performed using biological triplicates. The 
plates were mixed gently and incubated at 37°C for 24 hours.  After 24 hours, medium 
was replaced and cells were allowed to grow. The plates were assayed for changes in 
proliferation at 72 hours after transfection using the acid phosphatase assay (Section 
2.9.3.1). Optimal conditions for transfection were determined as the combination of 
conditions that gave the greatest reduction in cell number after kinesin siRNA 
transfection and the least cell death in the presence of transfection reagent. 
 
Table 2.6. Three different concentrations of cell density and NeoFX were used for 
optimization of conditions for siRNA transfection of MCF-10A, MCF-7, SKBR-3 and 
BT20 cell lines. 
NeoFX (µL) Cell lines Cell density/well 
(100µL) 1 2 3 
5x103 
7.5x103 
MCF-10A 
1x104 
0.4  0.6 0.8 
5x103 
7.5x103 
MCF-7 
1x104 
0.4  0.6 0.8 
1x103 
2x103 
SKBR-3 
3x103 
0.2  0.3 0.4 
2x103 
5x103 
BT20 
7.5x103 
0.4  0.6 0.8 
 
 
2.9.1.2 6-well plate optimization 
After narrowing down the potential siRNA transfection conditions, optimization for 
siRNA transfection into MCF-10A, MCF-7, SKBR-3 and BT20 cell lines was 
performed in 6-well plate format using siRNA for GAPDH (Applied Biosystems, 
AM4605) to further ensure the efficiency of transfection conditions. Scrambled-treated 
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cultures were considered as controls, however untreated cultures were also monitored. 
Solutions of siRNAs for scrambled and kinesin at a final concentration of 30nM/mL 
were prepared in 50µL (per well) of optiMEM (GibcoTM, 31985) and incubated at room 
temperature for 10 min. NeoFX was added into 50µL (per well) of optiMEM in parallel 
to achieve required final concentrations as mentioned in Table 2.9.2 and incubated at 
room temperature for 10 minutes. 50µL of the siRNAs were added to the respective 
50µL of neoFX solution for another 10 min. For neoFX-treated wells, 50µL of 
optiMEM was topped up on the 50µL of neoFX and incubated for 10min. 100µL of 
siRNA/neoFX or neoFX solution was added to respective each well. Cells were added 
to achieve required cell density per well in 2mL of final working volume as mentioned 
in Table 2.7. The plates were mixed gently and incubated at 37°C for 24hrs.  After 
24hrs, the culture medium was replaced with fresh medium. After 72hrs (or after 96hrs 
in case of MCF-7), cells were collected for protein extraction as mentioned in section 
2.7.1.1. The inhibition was investigated using Western blot analysis as described in 
section 2.8.  
 
Table 2.7. Optimization of siRNA transfection conditions in 6-well plate format. 
NeoFX (µL) Cell lines Cell density/well 
(100µL) 1 2 3 
MCF-10A 5x105 4 6 8 
MCF-7 5x105 4 6 8 
SKBR-3 1x105 1 2 3 
BT20 5x105 4 5 6 
  
 
2.9.2 siRNA transfection of targets in MCF-10A, MCF-7, SKBR-3, BT20 and 
MDA-MB231 
Three pre-designed Silencer® Select siRNA were chosen for each of the gene targets 
and transfected into cells. Two independent siRNA molecules were used for TXNRD1 
and 3 independent siRNA molecules were used for 3-PGDH and RAD23B. The 
Silencer® Select siRNAs are chemically modified siRNAs that are meant to reduce 
overall off-target effects by up to 90% without compromising potency. For each set of 
siRNA transfections, scrambled siRNA treated cells were considered as control, 
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however un-treated cells (NT) and NeoFX treated cells were also monitored. Solutions 
of siRNAs for scrambled and kinesin at a final concentration of 30nM/mL were 
prepared in 50µL (per well) of optiMEM (GibcoTM, 31985) and incubated at room 
temperature for 10 min. NeoFX was added into 50µL (per well) of optiMEM in parallel 
to achieve the required final concentrations as mentioned in Table 2.8 and incubated at 
room temperature for 10 minutes. 50µL of the siRNAs were topped on the respective 
50µL of neoFX solution for another 10 min. For neoFX-treated wells, 50µL of 
optiMEM was topped up on the 50µL of neoFX and incubated for 10min. 100µL of 
siRNA/neoFX or neoFX solution was added to respective each well. Cells were added 
to achieve the required cell density per well in 2mL of final working volume as 
mentioned in Table 2.9.3. The plates were mixed gently and incubated at 37°C for 
24hrs.  After 24hrs, the culture medium was replaced with fresh medium. After 72hrs 
(or after 96hrs in case of MCF-7), cells were collected for protein extraction as 
mentioned in section 2.7.1.1. The inhibition was investigated using Western blot 
analysis as described in section 2.8. Table 2.9 outlines the list of siRNAs and IDs used 
in this thesis. 
 
 
Table 2.8 Transfection conditioned used for MCF-10A, MCF-7, SKBR-3, MDA-MB 
231 and BT20. 
Target Transfected in  Cell density siRNA (nM) NeoFX (µL) 
SKBR-3 1x105 30 3 TXNRD1 
MDA-MB 231 2x105 50 4 
MCF-10A 5x105 50 4 RAD23B 
MCF-7 5x105 50 4 
SKBR-3 1x105 30, 50 3 
MDA-MB 231 2x105 30, 125 4 
3-PGDH 
BT20 5x105 30 6 
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Table 2.9. List of siRNAs used and their Ambion ID. * denotes Silencer® Select 
siRNAs. 
Name  Ambion ID 
Scrambled AM16708 
Scrambled* AM4390843 
Kinesin 14851 
GAPDH  4300 
TXNDR1#1* s755 (Validated) 
TXNDR1#1* s756 (Validated) 
3-PGDH#1* s515 
3-PGDH#2* S223685 
3-PGDH#3* S223686 
RAD23B#1* s11731 
RAD23B#2* s11732 
RAD23B#3* s11733  
 
 
2.9.2.1 Invasion assays on siRNA transfected cells 
After 48hrs of siRNA transfections for targets in 6-well plates, cells were trypsinized 
and used to set the invasion assays for investigating the effects of target knockdown on 
invasion status of cells. Invasion assays were carried out for a further 48hrs for MCF-
10A, MDA-MB231 and SKBR-3 and for 72hrs for MCF-7as described in section 2.6. 
Scrambled treated cultures were considered as controls in this investigation. 
 
2.9.2.2 Proliferation effects of siRNA transfection 
Proliferation assay were carried out after 72hrs of transfection for each of the cell lines 
to see changes in proliferation of the cells due to inhibition of target genes. Kinesin was 
used as a negative control to assess the efficiency of the siRNA transfection. Kinesin 
plays an important role in cell division; facilitating cellular mitosis. Therefore, 
transfection of siRNA kinesin resulted in cell cycle arrest and confirmed efficient 
transfection. Scrambled treated cultures were considered as positive control in this 
investigation. The plates were assayed for changes in proliferation using the acid 
phosphatase assay (Section 2.9.3.2). 
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2.9.3 Assessment of cell number - Acid Phosphatase assay 
2.9.3.1 Acid Phosphatase in 96-well plate  
Following an incubation period of 72 hours, media was removed from the plates. Each 
well of the plate was washed with 100µL PBS. 100µL of freshly prepared phosphatase 
substrate (10mM p-nitrophenoln phosphate (Sigma 104-0) in 0.1M sodium acetate 
(Sigma, S8625), 0.1% triton X-100 (BDH, 30632) and pH 5.5) was added to each well. 
The plates were wrapped in tinfoil and incubated in the dark at 37°C for 1.5hrs. The 
enzymatic reaction was stopped by the addition of 50µL of 1M NaOH to each well. The 
OD of each was measured at 405nm. Low OD value indicates more cell death in 
culture. 
 
2.9.3.2 Acid Phosphatase in 6-well plate  
Following an incubation period of 72 hours, media was removed from the plates. Each 
well on the plate was washed with 1mL PBS. 2mL of freshly prepared phosphatase 
substrate was added to each well. The plates were wrapped in tinfoil and incubated in 
the dark at 37°C for 1-2hrs. The enzymatic reaction was stopped by the addition of 
500µL of 1M NaOH to each well. The OD of each was measured at 405nm. Low OD 
value indicates more cell death in culture. 
 
 2.10 SELDI-ToF MS 
SELDI-ToF MS is a highly sensitive proteomics tool being used to identify differential 
expression of proteins in a given sample. Protein samples from serum-free conditioned 
media of human cell lines were analyzed using SELDI-ToF MS to identify differentially 
expressed proteins. 
 
2.10.1 Collection of serum-free conditioned media 
Cells (3x106) were seeded in four biological replicates in T-175cm2 flasks. Cells were 
allowed to grow until 50-60% confluent. Cells were washed three times with 10mL of 
serum-free (SF) basal media and then incubated in 15mL of SF basal media for 60 min. 
After this time, cells were washed again two times with SF basal media. 10mL of SF 
basal media was added to the cells and incubated for 72hrs. After such time, 
conditioned media (CM) was collected, centrifuged for 15min at 250g, and stored at –
800C.  
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2.10.2 Preparation of IMAC30 chip surface 
IMAC30 array, 8-spot (Biorad, C730043) chip surface was activated by adding 5 µL of 
100mM CuSO4 (Sigma, 2091198) for a total of 30 minutes (2x15 minute applications) 
and then rinsed with high-performance liquid chromatography grade water (Sigma, 
39295). The copper ions were charged by applying 50µL of 100mM sodium acetate 
(Sigma, S8625) for 5 minutes. The chip was placed in a bioprocessor (Biorad) and 
washed twice with 300µL of 250mM sodium chloride containing 0.1% Triton X-100. 
The protein sample was diluted in 300µL of 250mM sodium chloride containing 0.1% 
Triton X-100 and samples were applied to the spots of the array. The array was placed 
on a shaker and gently agitated for 90 minutes to allow for interaction with the array 
surface. After removing the sample, the array was washed x2 with 300µl of 250mM 
sodium chloride for 5 minutes, followed by a brief high-performance liquid 
chromatography grade water wash. 5mg of Sinapinic acid (Biorad, C730078) solution 
was prepared by dissolving in 200µL of 50% acetonitrile (Sigma, 34967) containing 
0.5% trifluoroacetic acid (Sigma, 302031). After removing the array from the 
bioprocessor, a 0.8µL aliquot of saturated sinapinic acid was added to the spots, allowed 
to dry and repeated. 
 
2.10.3 Preparation Q10 chip surface 
Q10 array, 8-spot (Biorad, C730043) was placed in a bioprocessor and washed twice 
with 300µL of 50mM Tris (Sigma, T8404) pH 8.0. The protein sample was diluted in 
300µL of 50mM Tris pH 8.0 and samples were applied to the spots of the array. The 
array was placed on a shaker and gently agitated for 90 minutes to allow for interaction 
with the array surface. After removing the sample, the array was washed x2 with 300µL 
of 50mM Tris pH 8.0 for 5 minutes, followed by a brief high-performance liquid 
chromatography grade water wash. After removing the array from the bioprocessor, a 
0.8µL aliquot of saturated sinapinic acid was added to the spots, allowed to dry and 
repeated. 
 
2.10.4 Preparation CM10 chip surface 
CM10 array, 8-spot (Biorad, C530075) was placed in a bioprocessor and washed twice 
with 300µL of 20mM Tris pH 4.5. The protein sample was diluted in 300µL of 20mM 
Tris pH 4.5 and samples were applied to the spots of the array. The array was placed on 
a shaker and gently agitated for 90 minutes to allow for interaction with the array 
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surface. After removing the sample, the array was washed x2 with 300µL of 20mM Tris 
pH 4.5 for 5 minutes, followed by a brief high-performance liquid chromatography 
grade water wash. After removing the array from the bioprocessor, a 0.8µL aliquot of 
saturated sinapinic acid was added to the spots, allowed to dry and repeated. 
 
2.10.5 Preparation H50 chip surface 
H50 array, 8-spot (Biorad, C730065) was placed in a bioprocessor and washed twice 
with 10% acetonitrile/0.1% trifluoroacetic acid. The protein sample was diluted in 
300µL of 10% acetonitrile/0.1% trifluoroacetic acid and samples were applied to the 
spots of the array. The array was placed on a shaker and gently agitated for 90 minutes 
to allow for interaction with the array surface. After removing the sample, the array was 
washed x2 with 300µL of 10% acetonitrile/0.1% trifluoroacetic acid for 5 minutes, 
followed by a brief high-performance liquid chromatography grade water wash. After 
removing the array from the bioprocessor, a 0.8µL aliquot of saturated sinapinic acid 
was added to the spots, allowed to dry and repeated. 
 
2.10.6 Preparation NP20 chip surface 
NP20 array, 8-spot (Biorad, C5730043) was washed twice with 2µL of high-
performance liquid chromatography grade water. 1µL samples were applied to the spots 
of the array and incubated for 20 minutes to allow for interaction with the array surface. 
The array was washed x2 with high-performance liquid chromatography grade water. A 
0.8µL aliquot of saturated sinapinic acid was added to the spots, allowed to dry and 
repeated. 
 
2.10.7 Analysis of Protein chip array in ToF Reader 
The IMAC-Cu2+ ,Q10, CM10 and H50 ProteinChip arrays were analyzed in a Ciphergen 
Series PBS-IIC ProteinChip® System, and time-of-flight (ToF) data was generated by 
averaging a total of 220 laser shots collected at a laser intensity of 200, a detector 
sensitivity of 8 and molecular mass range from 5–20,000 Da for low molecular weight 
range and 20,000-100,000 Da for high molecular weight range. 
 
2.10.8 Analysis of differential expression of Proteins/peptides 
Molecular weights were calibrated externally using an all-in-1 protein standard (Biorad, 
N76006). All data was analyzed using Biomarker Wizards Software, version 3.1 (Bio-
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Rad). After automatic baseline noise correction, all of the spectra were normalized 
together by the ‘‘total ion content’’ method as described by the manufacturer, i.e. with 
an m/z between 5,000 and 100,000. The peaks with an m/z value < 3000 were excluded, 
as these peaks were mainly ion noise from the matrix (sinapinic acid). Peak clusters 
were generated by automatically detecting qualified mass peaks with a signal to noise 
ratio (S/N) >5 in the first pass, completed with a second-pass peak selection of S/N >3, 
with a 0.3% mass error for 5000-20,000 Da, and the same for 20,000-100,000 Da. 
Statistically significant peaks were considered to be those with p <0.05.   
 
2.10.9 Optimization of serum concentration 
MDA-MB 435S-F and MDA-MB 435S-F/Taxol10p4p cells (1x105 cells/mL) were 
seeded in T-25cm2 flask in 10% and 0.5% serum supplemented and serum-free media 
and incubated for 72 hours. Cells were grown in serum-free media using the same 
method as described in section 2.13.1. Conditioned media were collected and 
centrifuged at 250g for 15 minutes and then transferred to new universal. A volume of 
1mL of conditioned media was concentrated to 100µL using a Maxi-Dry-Plus vaccum-
dryer (Medical Supply Co.). Protein concentrations were estimated as described in 
section 2.7.2. 50µg of protein was analyzed on a Q10 chip surface as described in 
section 2.10.6. 
 
2.10.10 Selection of chip surface 
After 72 hours serum-free conditioned media from MDA-MB 435S-F and MDA-MB 
435S-F/Taxol10p4p were collected and concentrated using 5000 MW (Millipore, UFC9 
00524) and 10000 MW (Millipore, UFC901024) cut-off centrions to 500µL by 
centrifuging at 1000g at 40C. 10µg of protein sample was analyzed on IMAC30 
(immobilized Metal Affinity capture) coupled with Cu++ ion, Q10 (Strong anion-
exchange), CM10 (weak cation-exchange) and H50 (reversed-phage hydrophobic 
surface) protein chip arrays. 
 
2.11 Protein purification and identification  
2.11.1 Protein Purification  
Serum-free conditioned media from the MDA-MB-435S-F/Taxol10p4pSI and SKMEL-
28 were fractionated first using BioSepra IMAC-Cu2+ HyperCel spin columns 
(BioSepra, Cergy, C540-0027). Each of the fractions eluted from the spin columns 
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using 50 to 500 mmol/L imidazole in binding buffer containing 250mM sodium 
chloride was analyzed further on a hydrophilic NP20 ProteinChip Array (section 2.10.9) 
to monitor the elution and recovery of the protein of interest. The eluted fractions in 
which the marker was the most abundant were concentrated to 30µl using centricons.  
 
2.11.2 Separation of protein  
The 7.6kDa protein/peptide was separated on 12% NuPAGE Bis–Tris Gels (Invitrogen, 
NP0341BOX) and the 8.5kDa protein/peptide was separated on 16% Tricine gels 
(Invitrogen, EC6695BOX) as described in section 2.8.1. 
16% Tricine gels were placed in the XCell SureLock™ Mini-Cell (Invitrogen, EI0001) 
running instrument. Samples were diluted in 2X loading buffer (Sigma, S3401). 40µg of 
protein was loaded onto a gel and electrophoretically separated using a 1X Tricine SDS 
buffer (Invitrogen, LC1675). Molecular weight peptide markers (Invitrogen, 17-
501934) were loaded along side the samples in gels. The gels were run at 200V and 
45mA until the bromophenol blue dye front was found to have reached the end of the 
gel, at which time sufficient resolution of the molecular weight markers was achieved. 
 
2.12 Zymography 
Zymography was used to assess the level of proteolytic activity of different proteinases 
in cell culture supernatants. The choice of substrate incorporated into the resolving gel 
depends on substrate specificity of the species of enzyme to be detected (Johansson et 
al. 1986). Gelatin as a substrate for matrix metalloproteinases (MMPs), serine and 
cysteine proteinases, was used in these experiments.  
Serum-free conditioned media from MDA-MB 435S-F and MDA-MB 435S-
F/Taxol10p4p cells collected and concentrated as discussed in 2.10.1. Protein was 
quantified using a Bio-Rad protein assay kit as discussed in section 2.7.2. Samples were 
mixed 3:1 with 4X sample buffer (20% glycerol; 0.25M Tris-HCl, pH 6.8; 0.1% (w/v) 
bromophenol blue) and were loaded onto the gel. A 5µl aliquot of boiled broad size 
range protein marker (New England Biolabs, 7708S) was also loaded onto the gel. The 
gelatin gels (Invitrogen, EC6175BOX)  were run at 30 mA per gel in 1X running buffer 
(14.4g Glycine, 3.03g Tris and 1g SDS in 1L UHP) until the dye front reached the 
bottom of the gel. After electrophoresis, gels were soaked in 2.5% Triton X-100 at room 
temperature with gentle shaking for 30 min and incubated in substrate buffer (50mM 
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Tris-HCl, pH 8.0, 5mM CaCl2) with ±EDTA, ±Aprotinin, ±Pepstatin A, ±E-64 or 1,10 
Phenanthroline at 37°C for 18-24 hrs. Gels were then stained with 2.5 mg/ml Coomassie 
Blue for 2 hours and destained in a mixture of acetic acid: isopropanol: distilled water 
(1:3:6) until clear bands were visible. Gelatinase activity was determined as distinct, 
clear bands. 
 
2.13 Treatment with MMP inhibitors 
Cells were seeded at 2.0 105 cells/well in 6-well plates and grown to 50-60 % 
confluency in complete medium and then washed three times in serum-free medium. 
Cells were subsequently incubated in serum-free medium for 1 hour, washed two more 
times in serum-free medium, and incubated in 500µl of serum free media with 1µg of 
MMP2 and 1µM MMP9 inhibitor separately for 72 hours. Untreated cultures without 
MMP inhibitors were also maintained as controls for this experiment. Conditioned 
medium was collected, centrifuged at 250g for 15 min to remove cellular debris, 
decanted into clean eppendorffs. 200µl of conditioned media from each biological 
samples were then analysed on IMAC-Cu++ ProteinChip arrays as discussed in section 
2.10.5, 2.10.10 and 2.10.11. 
 
2.15 Statistical Analysis 
Significance of data presented in section 3.0 was determined using 2 tailed T-tests with 
2 unpaired samples with unequal varience. 
T-tests were performed on invasion, siRNA and in treatment with MMP inhibitors 
assays in order to determine if data was significant. 
 
A t-test > 0.05 was deemed not significant 
A t-test > 0.05 was deemed significant 
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3.1 Proteomic analysis of cell lysates from HMEC, MCF-10A, MCF-7 and BT20 
The transformation of a normal cell into a cancer cell and the process of tumour cell 
invasion are complicated multistage procedures that reflect well coordinated alterations 
in the expression of many genes and proteins within cells. The understanding of 
proteomic alterations may be helpful to a better understanding of the molecular as well as 
cellular mechanisms involved in the process transformation of cancerous and invasive 
phenotypes. Therefore, proteomics study of cell lysates from normal mammary epithelial 
cells (HMEC), non-tumorigenic immortalized epithelial (MCF-10A) and breast 
carcinoma cell lines (MCF-7 and BT20) were carried out (Table 3.1). 
 
Table 3.1.1: Description of the cells used in this investigation in respect of cell type and 
invasive phenotypes. 
Cells Cell Type Type Invasion Status 
HMEC Basal Normal-like Invasive 
MCF-10A Basal Normal Non-invasive 
MCF-7 Luminal Cancerous Non-invasive 
BT20 Basal Cancerous Invasive 
 
 
3.1.1 Invasion assay of HMEC, MCF-10A, MCF-7 and BT20 
The invasive capabilities of HMEC, MCF 10A, MCF-7 and BT20 were measured using 
pre-coated matrigel invasion chambers over the 48hrs of culture as described in section 
2.6 to ensure that the invasion status of cells reflects the phenotypes as described in the 
literature. The graph was plotted on the basis of total number of cells that crossed the 
matrigel membrane (Figure 3.1.1). The results indicated that the MCF-10A and MCF-7 
cell lines are non-invasive, whereas HMEC is low invasive and BT20 is highly invasive 
in this group (Figure 3.1.1B). However, why HMEC cells are invasive is not clear.  
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Figure 3.1.1 Investigation of invasion capabilities of cells from breast origin. (A) 
Images from invasion assay- (1) MCF-10A, (2) MCF-7, (3) HMEC, (4) BT20. (B) 
Graphical representation of the comparative levels of invasion in the cells tested. 
Magnification= 200x, Scale bar=200µm. Error bars represent the standard deviation 
calculated from data obtained from three biological samples. 
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3.1.2 Analysis of differential expression of proteins using 2D-DIGE 
Investigations were carried out to establish the differential expression of cellular 
proteins between normal, cancerous, non-invasive and invasive breast cell lines as 
described in section 2.7.3. For this, four biological replicate samples from normal 
mammary epithelial cells (HMEC), non-tumorigenic immortalized mammary epithelial 
cells (MCF 10A), non-invasive breast cancer cells (MCF7) and invasive breast cancer 
cells (BT20) were prepared separately. Samples from each cell line were differentially 
labelled with 2D-DIGE dyes (i.e. Cy3 and Cy5) as outlined in Table 3.1.2. A pooled 
internal control containing a mixture of all biological replicate samples in the 
experiment was labelled with Cy2 dye. 
2D-DIGE protein expression maps (PEMs) for normal mammary epithelial cells 
(HMEC), breast epithelial cells (MCF 10A), non-invasive breast cancer cells (MCF7) 
and invasive breast cancer cells (BT20) were created. The PEMs were then analysed 
using the Biological Variation Analysis (BVA) module of DeCyder 6.5 software as 
described in section 2.7.3.6. This was aided by the use of a pooled internal standard 
which facilitated spot matching and relative spot quantitation while minimizing gel-to-
gel variation. Spots originating from dust particles and gel impurities in each gel image 
were checked and removed manually to improve the quantitation and matching process. 
Landmarks, which aid the gel-to-gel spot matching process, were also defined in the gel 
to increase the accuracy of the matching algorithm. Manual checks were carried out to 
allow for cases where spots were detected more than once (due to spot splits by the spot 
detection algorithms). These spots were then merged back to improve spot matching. 
After spot matching and filtering a total of 883 protein spots were matched across all of 
the gels in the experiment (i.e, a total of 21 gels, 1 gel of Cy2, Cy3 and Cy5 labelled 
samples was taken out from the analysis as the quality of this gel was not good). 
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Table 3.1.2. 2D-DIGE experimental design used for the analysis of differential protein 
expression in normal mammary epithelial cells (HMEC), breast epithelial cells (MCF 
10A), non-invasive breast cancer cells (MCF7) and invasive breast cancer cells (BT20). 
Gel number Cy2 Cy3 Cy5 
1 Pooled internal 
standard  
HMEC Biological 1 MCF-10A 
Biological 1  
2 Pooled internal 
standard  
HMEC Biological 2 MCF-10A 
Biological 2 
3 Pooled internal 
standard  
HMEC Biological 3 MCF-10A 
Biological 3  
4 Pooled internal 
standard  
HMEC Biological 4 MCF-10A 
Biological 4  
5 Pooled internal 
standard  
MCF-7 Biological 1 BT20 Biological 1  
6 Pooled internal 
standard  
MCF-7  Biological 2 BT20 Biological 2 
7 Pooled internal 
standard  
MCF-7  Biological 3 BT20 Biological 3  
8 Pooled internal 
standard  
MCF-7  Biological 4 BT20 Biological 4  
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3.1.3 Creation of differentially expressed protein lists related to cancer and 
invasion 
The objective of this investigation was to identify the proteins that are being up-
regulated or down-regulated with the cancerous and invasion status of the cell lines. For 
this, PEMs of HMEC, MCF-10A, MCF-7 and BT20 were analysed in the following 
three comparison groups. Spots that were ±1.5 fold up or down-regulated with p-value ≤ 
0.05 were considered significantly differentially expressed (DE) in this investigation 
(section 2.7.3.6). The software calculates the degree of difference in the standardized 
protein abundance between 2 spots from different groups and expresses these 
differences as an average ratio. The values generated by the software are displayed in 
the range of -∞ to -1 for a decrease in expression and +1 to +∞ for an increase in 
expression. For simplicity, the ‘average ratio’ has been termed as ‘fold change’ in this 
thesis.  Hence, for example, a two-fold increase and decrease is represented by 2 and -2, 
respectively (not 2 and 0.5).  
 
3.1.3.1 Cancerous (MCF-7+ BT20) vs. Normal (HMEC+ BT20) 
To see which proteins are being differentially expressed between the cancer and normal 
cells, the PEMs of the cancerous cell lines (MCF-7+BT20) were compared with the 
PEMs of the normal cells (HMEC+MCF10A). The comparison revealed altered 
expression of 89 proteins; with 47 proteins up-regulated and 42 proteins down-regulated 
in the cancer cell lines (MCF-7+BT20) compared to the normal cells 
(HMEC+MCF10A).  
 
3.1.3.2 Invasive (HMEC+ BT20) vs. Non-invasive (MCF-10A + MCF-7)  
There is evidence in the literature that normal and malignant invasion use similar 
molecular mechanisms and the only difference between them is that malignant invasion 
can persist (Diamandis 2004, Baggerly et al. 2004). Therefore, grouping of cell lines by 
their invasion status, i.e. normal+cancer ((N+C) invasive (HMEC+ BT20) and 
normal+cancer ((N+C) non-invasive (MCF-10A + MCF-7), and comparing differential 
expression of proteins between the invasive and non-invasive cells could reveal 
potential targets that may have an important role in normal +cancer -related  invasion. 
31 proteins were found differentially expressed in this comparison with 11 proteins up-
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regulated and 20 proteins down-regulated in the non-invasive cells. We have used the 
term ‘normal + cancer-related invasion’ to describe this comparison in this thesis.  
 
3.1.3.3 Cancerous invasive (BT20) vs. Normal invasive+ normal non-invasive+ 
cancerous non-invasive (HMEC+MCF-10A+MCF-7) 
In another aspect to investigate alterations in the invasion-related protein expression, the 
proteins that are up-regulated or down-regulated only in the cancerous invasive cell line 
(BT20) compared to the normal invasive, normal non-invasive, cancerous non-invasive 
cells (HMEC+MCF-10A+MCF-7) could help to identify proteins that may have a 
potential role specifically in the cancer invasion. Therefore, the PEMs of BT20 were 
compared with the PEMs of HMEC+MCF-10A+MCF-7. This comparison also possibly 
eliminates protein changes that would be related to cell type rather than specifically to 
invasion as BT20, HMEC and MCF-10A are basal types, while MCF-7 is luminal type. 
In this comparison, 92 proteins were found differentially expressed, with 24 up-
regulated and 86 down-regulated in BT20 cells. We used the term ‘Cancer-related 
invasion’ to describe this comparison in this thesis. 
A number of differentially expressed protein spots were observed in these three groups 
(Table 3.1.3). 
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Table 3.1.3. List of the total number of differentially expressed proteins in the comparison of 
the cancerous (MCF-7+BT20) vs. Normal (HMEC+MCF-10A), invasive (HMEC+BT20) 
vs. non-invasive (MCF-10A+MCF-7) and cancerous invasive (BT20) vs. normal invasive + 
normal non-invasive + cancerous non-invasive (HMEC+MCF-10A+MCF-7), and which 
pass the fold change ≥ 1.5 fold up/down regulated with t-test score of ≤ 0.05. 
No. Comparison Groups No. of 
differentially 
expressed 
proteins 
Up- 
regulated  
Down-
regulated 
1 Cancerous (MCF-7+ BT20) vs. Normal 
(HMEC+ BT20) 
96 41 54 
2 Invasive (HMEC+ BT20) vs. Non-
invasive (MCF-10A + MCF-7) 
(Normal+ cancer-related invasion) 
31 20 11 
3 Cancerous invasive (BT20) vs. Normal 
invasive+ normal non-invasive+ 
cancerous non-invasive (HMEC+MCF-
10A+MCF-7) 
(Cancer-related invasion) 
92 24 68 
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3.1.4 Identification of differentially expressed proteins using mass-spectrometry 
For protein identification, preparative colloidal coomassie stained gels were used. One 
hundred and ninety three proteins spots were picked for identification using the Matrix 
Assisted Laser Desorption/ionization Time-of-Flight (MALDI ToF MS) mass-
spectrometry (section 2.7.3.10). The same spots were also picked from different cell lines 
to confirm the identifications from these spots. A few identifications were also confirmed 
from repeat preparative gels. All identified proteins by MALDI ToF MS had an 
expectation value of 0.01 or better (a value of 0 denotes 100% confidence in the database 
match and a value of 0.01 denotes a 1% or less chance that the identification is random). 
Expectation value for proteins was determined by Ettan MALDI-ToF Pro evaluation 
software using the ProFound database search engine for peptide mass fingerprints. The 
proteins that were ≥ ±3 fold up- or down-regulated were also analysed using Liquid 
Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) for identification 
or to confirm the identification obtained from MALDI ToF MS (section 2.7.3.12). The 
criteria for positive identification of peptides from LC-MS/MS were XCorr N1.5 for singly 
charged ions, XCorr N2.0 for doubly charged ions, and XCorr N2.5 for triply charged ions 
peptides containing a p-value ≤ 0.01. LC-MS/MS is a very sensitive technique and 
therefore in some cases more than one protein at the same molecular weight and isoelectric 
point (pI) were identified. The location of all identified proteins has been shown on a 
representative 2-D DIGE gel (Figure 3.1.2). Each protein has been denoted by its master 
number ID, which was generated by Decyder 6.5 BVA module during the analysis of 
differentially expressed spots (proteins). 
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Figure 3.1.2 Representative 2D-DIGE gel image of Cy2-labelled pool of HMEC, MCF-
10A, MCF-7 and BT20 cell lysate samples showing differentially expressed protein spots 
that have been successfully identified by MALDI-ToF MS and/or LC-MS/MS. Identified 
spots are represented on the gel using the Master Number ID generated by the Decyder 
software as a reference. 
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3.1.5 List of identified proteins differentially regulated in the cancerous vs. normal 
and invasive-related comparisons.   
As described in section 3.1.3, PEMs from HMEC, MCF-10A, MCF-7 and HMEC were 
compared in three comparison groups, cancer cell lines (MCF-7+BT20) vs. normal cells 
(MCF-10A+ HMEC), invasive cells (HMEC+BT20) vs. non-invasive cells (MCF-
10A+MCF-7) and cancer invasive cell line (BT20) vs. normal non-invasive, normal 
invasive and cancer non-invasive cell lines (MCF-10A+HMEC+MCF-7). A number of 
differentially expressed proteins were identified in each comparison group.  
 
3.1.5.1 Cancerous (MCF-7+BT20) vs. normal (MCF-10A+ HMEC) 
A total of 44 proteins were identified in the comparison of cancer cell lines (MCF-
7+BT20) vs. normal cells (MCF-10A+HMEC) comparison group (Table 3.1.4.) as 
described in section 2.7.3. Among these proteins, 27 were up-regulated and 17 were 
down-regulated in the cancer cell lines compared to the normal cells. The cell lines are 
compared from cancerous to normal. The proteins that are up-regulated are increased in 
their expression in the cancerous cell lines compared to normal cells and are represented 
as positive fold changes, whereas the proteins that are down-regulated are expressed at 
lower levels in the cancerous cell lines compared to the normal cell lines and have been 
denoted by negative fold change. These alterations in protein expression, i.e. up or 
down regulation, of these proteins could potentially be associated with breast cancer.  
 
A number of proteins that are already well known for their involvement in cancer were 
identified to be differentially expressed in the comparison, for example, Serpin B5, 
annexin A1 and KRT19 (Table 3.1.4.). 
 
• Serpin B5 (SERPINB5), also known as Maspin, is a serine protease inhibitor 
and is involved in proteolysis in cells (Liotta and Stetler-Stevenson 1991). 
SERPINB5 was showed the highest differentially expression in this comparison 
and was 98-fold down-regulated in the cancer cell lines compared to the normal 
cells. 
• Annexin A1 (ANXA1), also known as p35, is a cytoskeletal protein. Apart from 
cell motility, ANXA1 is a mediator of apoptosis and an inhibitor of cell 
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proliferation (Sheng et al. 1996). ANXA1 was found to be down-regulated (3.8-
fold and 26.8-fold) in the cancerous cell lines compared to the normal cells. 
 
• Keratin 19 (KRT19) was observed to be 37.8 fold up-regulated in the cancerous 
cell lines compared to the normal cells. KRT19 is an intermediate filament 
protein and is involved in maintenance of structural integrity of cells (Gerke and 
Moss 2002).  
 
A number of proteins including SERPINB5, ANXA1 and transaldolase 1 (TALDO1) 
were identified at more than one location on the 2D-gel possibly indicating some form 
of post-translational modifications (PTMs) (Table 3.1.4.). For example, ANXA1 was 
down-regulated in both spots (3.8-fold and 26.8-fold) and SERPINB5 was down-
regulated in both spots (98.6-fold and 20.6-fold) in the cancerous cell lines  compared to 
the normal cells. TALDO1 was up-regulated in both spots (2.2-fold and 2.7-fold) in the 
cancerous cell lines compared to the normal cells. Investigation of potential PTMs in 
these proteins could potentially reveal a mechanistic view of breast cancer.   
 
This comparison also revealed a number of potentially novel proteins, including 
EIF4A3, UQCRC1, DCI, SOD1 and SERPINB1 that have not been investigated 
extensively to date for their involvement in breast cancer and could have a significant 
role in regulation of the cancerous phenotype (Table 3.1.5.). Therefore, further study to 
establish the clinical relevance of these 5 proteins (EIF4A3, UQCRC1, DCI, SOD1 and 
SERPINB1) in breast tissue could be very helpful to understand the mechanisms of 
tumourigenesis in breast cells. 
 
• Ubiquinol-cytochrome-c reductase complex core protein 1(UQCRC1) is a 
nuclear-encoded protein and is localized to the inner mitochondrial membrane. 
UQCRC1 was found to be 8.1-fold up-regulated in the cancer cell lines  
compared to the normal cells.  
 
• Translation initiation factor 4A isoform 3 (EIF4A3) is an RNA helicase which 
participates in the unwinding of the 5' secondary structure in the mRNA and 
facilitates binding of the small ribosomal subunit during protein translation 
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(Tamai et al. 2000). The expression of EIF4A3 was 2.2-fold up-regulated in the 
cancer cell lines compared to the normal cells. 
 
• 3,2-trans-enoyl-CoA isomerase (DCI) is involved in the biochemical reactions 
of lipids and fatty acid and was 3.1-fold up-regulated in the cancer cell lines 
compared to the normal cells.  
 
• Chain J, Superoxide Dismutase Mutant With Lys 136 Replaced By Glu, Cys 6 
Replaced By Ala And Cys 111 Replaced By Ser (SOD1) is one of the main 
reactive oxygen species in the cell and serves a key antioxidant role (Li et al. 
1999). The SOD1 protein was 2.3-fold up-regulated in the cancer cell lines 
compared to the normal cells.  
 
• Leukocyte elastase inhibitor (SERPINB1) displays tumour suppressor activity in 
cancer (Noor et al. 2002) and was found to be 2.9-fold down-regulated in the 
cancer cell lines compared to the normal in this study.  
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Table 3.1.4. Cancer vs. normal list: Proteins identified from the comparison of cancerous (MCF-7+BT20) vs. normal (HMEC+MCF-10A) 
groups using MALDI ToF MS and/or LC-MS/MS. 2D-DIGE number refers to location of the identified protein on the gel shown in the Figure 
3.1.2. ‘+’ represents up-regulation and ‘-’ represent down-regulation of protein in terms of fold change in the given comparison. (Supplementary 
data containing additional information of proteins identified: Appendix 4). 
2D-DIGE No 
Gene 
Symbol Protein Name 
Cancerous vs. 
Normal (Fold  
Change) Biological function 
611 GSN Gelsolin precursor -2.21 Cell structure 
641 EIF4A3 Translation initiation factor 4A isoform 3  2.24 Protein translation 
773 LMNA Lamin-A/C -4.54 Cell structure 
789 LMNB1 Lamin B1  2.51 Cell structure 
818 G6PD 
Glucose-6-Phosphate Dehydrogenase (Deletion 
Variant) Complexed With Glucose-6-Phosphate 2.17 Monosaccharide Metabolism 
829 LMNA Lamin A protein 2.13 Cell structure 
884 HSPA 
Chain A, Heat-Shock 70kd Protein 42kd Atpase 
N-Terminal Domain 2.03 
Carbohydrate and amino acid 
metabolism 
958 ME3 
Chain C, Crystal Structure Of A Human Malic 
Enzyme 2.22 Cell adhesion  
996 STIP1 STIP1 protein 1.86 Stress response 
998 CBS Cystathionine beta-synthase 6.97 Amino acid biosynthesis 
1076 TXNRD1 Thioredoxin reductase 1, cytoplasmic precursor  3.31 Electron transport 
1079 ARCN1 Coatomer subunit delta  -2.59 Constitutive exocytosis 
1105 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2  -2.28 Cell cycle and Cell structure 
1146 KRT8 Keratin, type II cytoskeletal 8  5.52 Cell structure 
1174 ACTC1 Cardiac muscle alpha actin proprotein  3.49 Cytokinesis and cell structure 
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1191 VIM Vimentin -32.09 Cell structure 
1211 gi|31874087 Hypothetical protein  -5.98 Unclassified 
1221 KRT18 Keratin 18  3.44 Cell structure 
ACTB ACTB protein  Actin and actin related protein 1222 
  HNRPF Heterogeneous nuclear ribonucleoprotein F  
3.44 
  mRNA splicing 
1230 UQCRC1 
Ubiquinol-cytochrome-c reductase complex core 
protein 1, mitochondrial precursor  8.18 Electron transport 
1279 NDRG1 N-myc downstream-regulated gene 1 protein -2.82 
Cell proliferation and 
differentiation 
1292 NUDC Nuclear migration protein NudC 2.2 
Cell proliferation and 
differentiation 
1316 KRT19 Keratin, type I cytoskeletal 19 37.85 Cell structure 
1341 SERPINB1 Leukocyte elastase inhibitor (LEI) -2.94 Proteolysis 
1374 BTRC WD-40 repeat protein  2.28 
Proteolysis, Intracellular 
signaling cascade  
1397 SERPINB5 Serpin B5 precursor  -98.67 Proteolysis 
1399 SERPINB5 Serpin B5 precursor -20.14 Proteolysis 
1405 CAPG Macrophage-capping protein -11.98 
Cell proliferation and 
differentiation 
1411 SERPINB5 Serpin B5 precursor  -7.28 Proteolysis 
1468 ANXA1 Annexin I -3.81 Cell motility 
1469 ANXA1 Annexin I -26.8 Cell motility 
1488 TALDO1 Transaldolase 2.26 Pentose-phosphate shunt 
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1513 ANXA3 Annexin A3  -7.34 
Lipid and fatty acid 
metabolism 
1527 TALDO1 Transaldolase 2.77 Pentose-phosphate shunt 
1552 QPRT Quinolinate phosphoribosyl transferase 3.66 
NAD pyrophosphorylase 
activity 
1707 PSME1 Proteasome activator subunit 1 isoform 2  2.86 Proteolysis 
1722 DCI 
3,2-trans-enoyl-CoA isomerase, mitochondrial 
precursor  3.18 metabolism 
1734 PSME1 Proteasome activator subunit 1 isoform 2  2.79 Proteolysis 
1753 CTSD Cathepsin D At Ph 7.5 -2.07 Proteolysis 
1800 
 HSPB1 Heat-shock protein beta-1 
2.03 
 Stress response 
1971 SOD1 
Chain J, Superoxide Dismutase Mutant With Lys 
136 Replaced By Glu, Cys 6 Replaced By Ala 
And Cys 111 Replaced By Ser  2.34 Immunity and defense 
2139 NME1 Nm23 protein  3.02 Pyrimidine metabolism 
2477 LGALS1 Galectin-1 -2.94 Cell adhesion 
 
 
 107 
 
Table 3.1.5. The list of cellular protein targets either not previously associated with breast 
cancer or poorly known, identified from the comparison of cancerous cell lines (MCF-
7+BT20) vs. normal cells (HMEC+MCF-10A). 
2D-
DIGE 
No 
Gene 
Symbol 
 
 
  Protein Identification Name 
Cancerous vs. 
Normal  
Fold  change 
641 EIF4A3 Translation initiation factor 4A subunit 3 2.24 
1230 
 
UQCRC1 
 
Ubiquinol-cytochrome-c reductase 
complex core protein 1, mitochondrial 
precursor 8.18 
1341 SERPINB1 Leukocyte elastase inhibitor (LEI) -2.94 
 1722 DCI 
3,2-trans-enoyl-CoA isomerase, 
mitochondrial precursor 3.18 
 1971 
SOD1 
Chain J, Superoxide Dismutase Mutant 
With Lys 136 Replaced By Glu, Cys 6 
Replaced By Ala And Cys 111 Replaced 
By Ser 
2.34 
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3.1.5.2 Invasive (HMEC+BT20) vs. non-invasive (MCF-10A+MCF-7) (normal+cancer 
invasion related) 
Table 3.1.6. outlines the 15 identified proteins in the N+C invasive (HMEC+BT20) vs. N+C 
non-invasive (MCF-10A+MCF-7) comparison group. Among these proteins, 8 proteins were 
up-regulated and 7 proteins were down-regulated in the invasive cell lines compared to the 
non-invasive cells. The cell lines are compared from N+C invasive to N+C non-invasive 
therefore proteins that are up-regulated in the N+C invasive cell lines compared to the N+C 
non-invasive cells are represented as positive fold changes. The proteins that are down-
regulated have negative fold changes as these proteins are expressed at lower levels in the 
N+C invasive cell lines compared to the N+C non-invasive cells. 
A number of proteins, that are already known to be involved in the invasion of cancer cells 
were identified in this investigation (Table 3.1.6.). These include-   
 
• Keratin 8 (KRT8) and 18 (KRT18) both identified at one spot on the 2D gel were 
found to be 2.7-fold down-regulated in the N+C invasive cell lines compared to the 
N+C non-invasive cells KRT8 and KRT18, members of the intermediate filament 
family of proteins, have been observed co-expressed in many types of cancer and are 
associated with metastatic spread in breast cancer (Remold-O'Donnell 1985).  
 
• Nm23 protein (NME1) expression has been shown to be correlated with invasion and 
its up-regulation is suggested to interfere with PKC signalling pathways (Schaller et 
al. 1999). NME1 was found 2.4-fold up-regulated in the N+C non-invasive cells 
compared to the N+C invasive cells, indicating it may have an invasion-suppressing 
property.  
 
This comparison list also revealed a number of proteins that have not been investigated 
extensively to date for their involvement in normal+cancer related invasion including 
AKR1A1, RAD23B, CLIC1 and PSME1 (Table 3.1.6.).  
 
• RAD23B, a protein involved in the nucleotide excision repair (NER) (Ouatas et al. 
2003), was 2.0-fold up-regulated in the N+C non-invasive cells compared to the 
N+C invasive cells.  
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• Chloride intracellular channel 1 (CLIC1) is a member of the p64 family; the protein 
localizes principally to the cell nucleus and exhibits both nuclear and plasma 
membrane chloride ion channel activity (Watkins et al. 1993). CLIC1 was found 4.2-
fold up-regulated in the N+C non-invasive cells compared to N+C invasive cells.  
 
• Proteasome activator subunit 1 isoform 2 (PSME1) alpha subunit of 11 S regulator of 
proteasome (Chen et al. 2007) and was 3-fold up-regulated in the N+C non-invasive 
cells compared to N+C invasive cells.  
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Table 3.1.6. Invasive vs. Non-invasive (Normal + cancer-related invasion): Proteins identified from the comparison of invasive (HMEC+ BT20) 
vs. non-invasive (MCF-10A + MCF-7) comparison group using MALDI ToF MS and/or LC-MS/MS. 2D-DIGE number refers to the location of the 
identified protein on the gel shown in the Figure 3.1.2. ‘+’ represents up-regulation and ‘-’ represent down-regulation of protein in terms of fold 
change in the given comparison. (Supplementary data containing additional information of proteins identified: Appendix 4). 
2D-DIGE No 
Gene 
Symbol Protein Identification 
Invasive vs. non-
invasive (fold 
change) 
 Molecular 
function 
KT18 Keratin,  type I cytoskeletal 18  907 
  KT8 Keratin, type II cytoskeletal 8 
-2.71 
  Cell structure 
1019 PDIA3 Protein disulfide-isomeraseA3 precursor  4.03 
Protein disulfide 
isomerase reaction 
G6PD Glucose-6-phosphate 1-dehydrogenase (G6PD)  
Monosaccharide 
Metabolism 1050 
  CCT-beta T-complex protein 1 subunit beta  
3.84 
  Protein folding 
1098 3-PGDH 3-phosphoglycerate dehydrogenase  4.11 
Amino acid 
biosynthesis 
1105 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2 3.48 
Cell cycle and Cell 
structure 
1378 RAD23B RAD23B protein  -2.07 DNA repair 
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1450 TSSC1 
Tumor-suppressing subchromosomal 
transferable fragment candidate gene 1 protein -3.05 Protein binding 
1502 AKR1A1 Chain A, Apo R268a Human Aldose Reductase 5.27 
Oxidoreductase 
activity 
1732 PSME1 proteasome activator subunit 1 isoform 2 -3.07 Proteolysis 
1743 CLIC1 Chloride intracellular channel protein 1 -4.24 Anion transport 
1781 TPI1 
Chain B,  Triosephosphate Isomerase Of New 
Crystal Form 2.23 Glycolysis 
1798 Hsp27 Heat shock protein 27  -2.69 Stress response 
1800 HSPB1 Heat-shock protein beta-1 -2.5 Proteolysis 
2139 NME1 Nm23 protein  -2.47 
Pyrimidine 
metabolism 
2424 CLP 
Chain A, Three Crystal Structures Of Human 
Coactosin-Like Protein 3.36 Cell adhesion  
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3.1.5.3 Cancerous invasive (BT20) vs. Normal invasive+normal non-
invasive+cancerous non-invasive (MCF-10A+HMEC+MCF-7) (Cancer-related 
invasion) 
Table 3.1.7. outlines the 25 identified proteins in the Group 1 (cancer invasion (BT20)) vs. 
Group 2 (Normal invasive+normal non-invasive+cancerous non-invasive (HMEC+MCF-
10A+MCF-7)) comparison. Among these proteins, 16 proteins were up-regulated and 9 
proteins were down-regulated in group 1 compared group 2.  
 
A number of proteins identified in this comparison have already been shown to be involved 
in the invasion of cancer cells. Therefore our results indicate that the proteins which are up 
or down-regulated in the cancer invasive cells (BT20) could possibly have potential roles in 
breast cancer invasion.  
 
• Gelsolin is a calcium-binding protein which binds to and regulates actin filaments 
(Zhang et al. 2007). Gelsolin was observed to be 4.3-fold down-regulated in group 1 
compared to group 2. 
 
• Heterogeneous nuclear ribonucleoprotein (HNRPK) has been implicated in chromatin 
remodelling, transcription and translational process and can also interact with kinases 
(Kumar et al. 2004). HNRPK was 9.48-fold down-regulated in group 1 compared to 
the group 2.  
 
This comparison also revealed a number of proteins, including TXNRD1, ERp29, 3-PGDH, 
CLP, QPRT and TALDO1 that have not been investigated extensively to date for their 
involvement in cancer-related invasion (Table 3.1.7.).  
 
• Thioredoxin reductase 1 (TXNRD1) reduces thioredoxins as well as other substrates, 
and plays a role in selenium metabolism and protection against oxidative stress 
(Mandal et al. 2001). TXNRD1 was observed to be 4.6-fold up-regulated in group 1 
compared to group 2. 
 
• Endoplasmic reticulum protein 29 (ERp29), a molecular cheparone, was 10.4-fold 
down-regulated in group 1 compared to group 2.  
 113 
 
• 3-phosphoglycerate dehydrogenase (3-PGDH) involved in amino acid biosynthesis, 
was 5.2-fold up-regulated in group 1 compared to group 2. 
 
• Coactosin-Like protein (CLP), actin binding protein, was found 5.1-fold up-
regulated in group 1 compared to group 2. 
 
• Quinolinate phosphoribosyltransferase (QPRT) involved in de novo synthesis of 
nicotinamide adenine dinucleotide, was found 5.2-fold up-regulated in group 1 
compared to group 2. 
 
• Transaldolase 1, involved in the pentose-phosphate pathway, was found to be 2.7 and 
4.1-fold up-regulated in group 1 compared to group 2. This protein was identified at 
two locations on the 2D gel. 
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Table 3.1.7. Group 1 vs. Group 2 (Cancer-related invasion): Proteins identified from the Group 1 (cancer invasive cell line (BT20)) vs. 
Group 2 (Normal invasive+ normal non-invasive+ cancerous non-invasive (HMEC+MCF-10A+MCF-7)) using MALDI ToF MS and/or 
LC-MS/MS. 2D-DIGE number refers to location of the identified protein on the gel shown in the Figure 3.1.2. ‘+’ represents up-regulation 
and ‘-’ represent down-regulation of protein in terms of fold change in the given comparison. (Supplementary data containing additional 
information of proteins identified: Appendix 4). 
2D-DIGE 
No 
Gene 
Symbol Protein Identification 
Group1/ 
Group 2 Fold 
change Molecular function 
611 GSN Gelsolin precursor   -4.35 Cell structure 
HNRPK Heterogeneous nuclear  ribonucleoprotein K mRNA splicing 
897 HSP60 60 kDa heat shock protein 1.57 Stress response 
HNRPK heterogeneous nuclear ribonucleoprotein K mRNA splicing 901 
 TUBA6 Tubulin alpha-1C chain 
                           
9.48 
  Cell structure 
KT18 Keratin,  type I cytoskeletal 18  Cell structure 907 
  KT8 Keratin, type II cytoskeletal 8 
3.01 
  Cell structure 
998 CBS Cystathionine beta-synthase 3.12 Amino acid biosynthesis 
1019 PDIA3 Protein disulfide-isomeraseA3 precursor 3.38 
Protein disulfide-isomerase 
reaction 
1076 TXNRD1 Thioredoxin reductase 1, cytoplasmic precursor  4.6 Electron transport 
1098 3-PGDH 3-phosphoglycerate dehydrogenase  5.2 Amino acid biosynthesis 
1105 DYNC1LI2 
Cytoplasmic dynein 1 light intermediate chain 2 
(Dynein light intermediate chain 2, cytosolic) -2.8 
Cell cycle and Cell 
structure 
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1126 TBCE Tubulin-specific chaperone E  2.88 Cell structure 
1191 VIM Vimentin 20.39 Cell structure 
1279 NDRG1 N-myc downstream-regulated gene 1 protein  -3.49 
Cell proliferation and 
differentiation 
1405 CAPG 
Chain A, Ca2+-Binding mimicry In The Crystal 
Structure Of The Eu3+-Bound Mutant Human 
Macrophage Capping Protein Cap G -12.16 
Cell proliferation and 
differentiation 
1411 SERPINB5  Tumour Suppressing Serpin -9.27 Proteolysis 
1468 ANXA1 Annexin I -3.3 Cell motility 
1469 ANXA1 Annexin I -20.73 Cell motility 
1488 TALDO1 Transaldolase 2.7 Pentose-phosphate shunt 
1502 AKR1A1 Chain A, Apo R268a Human Aldose Reductase 7.48 Oxidoreductase activity 
1527 TALDO1 Transaldolase 4.12 Pentose-phosphate shunt 
1552 QPRT Qinolinate phosphoribosyl transferase 5.27 
NAD pyrophosphorylase 
activity 
1722 DCI 
3,2-trans-enoyl-CoA isomerase, mitochondrial 
precursor  2.06 Metabolism 
1752 ERP29 Endoplasmic reticulum protein ERp29 precursor  -10.45 Constitutive exocytosis 
1781 TPI 1 
Chain B, Human Triosephosphate Isomerase Of New 
Crystal Form 2.36 Glycolysis 
1798 Hsp27 Heat shock protein 27  -2.72 Stress response 
2424 CLP 
Chain A, Three Crystal Structures Of Human 
Coactosin-Like Protein 5.1 Cell adhesion 
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3.1.6 Identification of invasion-related proteins by overlapping differentially 
expressed proteins from the normal cells (MCF-10A vs. HMEC) with the 
cancerous cell lines (MCF-7 vs. BT20) 
The aim of this analysis was to identify proteins that are only differentially expressed in 
the invasive phenotypes or in the non-invasive phenotypes. Two lists of differentially 
expressed proteins between normal non-invasive vs. normal invasive cell lines (MCF-
10A vs. HMEC) and cancerous non-invasive vs. cancer invasive cell lines (MCF-7 and 
BT20) were generated (supplementary data: Appendix 1). The two generated 
differentially expressed protein lists were overlapped to determine unique and common 
differentially expressed proteins between these lists. A Venn diagram outlining the 
distribution of proteins between the lists of differentially expressed proteins in a 
comparison of cancerous non-invasive (MCF-7) vs. invasive (BT20) cell lines and 
normal non-invasive (MCF-10A) vs. normal invasive (HMEC) cells is shown in figure 
3.1.3.  
 
The overlapping of these lists identified 4 unique proteins, including SERPINB5 and 
ANXA1, in the normal comparison group (MCF-10A vs. HMEC). SERPINB5 and 
ANXA1 were up-regulated in the normal-non-invasive cells (MCF-10A) in comparison 
to the normal-invasive cells (HMEC). This indicates that inhibition of SERPINB5 and 
ANAXA1 could be associated with the development of the invasive phenotype in 
HMEC cells. 
 
27 proteins, including well known cancer and invasion-associated proteins (KRT8, 
KRT18 and NME1) as well as other proteins, which have not been linked with breast 
invasion (ERP29 and QPRT), were found unique in the cancer non-invasive vs. invasive 
(MCF-7 vs. BT20) comparison group. KRT8, KRT18 and QPRT were up-regulated 
whereas ERp29 was down-regulated in the cancerous invasive cells (BT20) in 
comparison to the cancerous non-invasive cells (MCF-7). Over expression of KRT8, 
KRT18 and QPRT, and inhibition of ERp29 in the cancerous-invasive cells (BT20) 
could contribute to the development of the invasive phenotype in BT20 cells.  
 
A total of 10 proteins were observed common in both comparison groups indicating the 
proteins involved in normal and cancer invasion. Alterations in the expression of these 
proteins could contribute to the development of invasive phenotypes. Of these 10 
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proteins, 7 proteins showed similar expression patterns in both comparison groups, 
normal-non-invasive vs. normal-invasive and cancer-non-invasive vs. cancer-invasive, 
while 3 protein spots, TALDO1 and NDRG1 (NDRG1 identified at 2 spots), were 
differentially expressed with opposite expression patterns. For example, TALDO1 and 
NDRG1 were over expressed in the normal-noninvasive cells (MCF-10A) in 
comparison to normal-invasive cells (HMEC), while they were down-regulated in the 
cancerous-non-invasive cells (MCF-7) in comparison to the cancerous-invasive cells 
(BT20). This suggests that inhibition of TALDO1 and NDRG1 could be involved in the 
development of the invasive phenotype in normal cells whereas over expression could 
be associated with invasion in cancerous cells.   
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Figure 3.1.3. Venn diagram of differentially expressed overlapping proteins identified from the comparison of the normal non-invasive 
vs. invasive (MCF-10A vs. HMEC) cells, and the cancer non-invasive vs. invasive (MCF-7 vs. BT20). Proteins are represented by the 
2D-DIGE number inside the circle and gene symbols outside the circle of protein. 
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3.1.7 Validation of proteomics data by Western blot analysis 
In order to validate the expression observed by 2D-DIGE analysis and identifications by 
MALDI-ToF and/or LC-MS/MS, Western blot analysis was carried out for selected target 
proteins (Keratin 8, Maspin (SERPINB5), vimentin, Nm23, transaldolase and STIP1) 
across the four cell lines (HMEC, MCF-10A, MCF-7 and BT20) as described in section 
2.8.  
 
Maspin (SERPINB5) was over expressed in the normal cells (HMEC+MCF-10A) 
compared to the cancerous cell lines (MCF-7+BT20), whereas transaldolase (TALDO1) 
was over expressed in the cancerous invasive cells (BT20) in comparison to normal 
non-invasive+normal invasive+cancerous-non-invasive cells (MCF-
10A+HMEC+MCF-7) (Table 3.1.4. and 3.1.7.). This was in agreement with the 
published literature as SERPINB5 has been found down-regulated in breast cancer and 
TALDO1 was found increased in breast cancer tissues (Hirota et al. 2000b). Therefore, 
SERPINB5 and TALDO1 were selected as protein targets for Western blot analysis. 
Four other differentially expressed proteins, keratin 8, Nm23, vimentin and STIP1, were 
also considered for Western blotting since antibodies against them were available in the 
lab.  
 
Biological duplicate samples from cell lysates were separated using 12% SDS gels and 
immunoblotted using appropriate antibodies (Section 2.8.2). Keratin 8, Maspin, 
vimentin, Nm23, transaldolase and STIP1 confirmed the trends observed in the 
proteomic analysis. Figures 3.1.4 to 3.1.6 show the expression pattern of these selected 
proteins observed using 2D-DIGE and Western blot analysis. Table 3.1.8 and 3.1.9 
summarize the expression patterns observed in 2D-DIGE and western blot analysis for 
the targets. Two bands were detected by the antibody in Western blot analysis of 
Transaldolase-1 (Figure 3.1.7.1 A). The upper band confirmed the expression pattern 
observed at 2D-DIGE No. 1488 whereas and lower band followed the expression 
pattern observed at 2D-DIGE No. 1527 (Table 3.1.4). 
 
Western blot analysis for GAPDH and BIP was also carried out as an internal loading 
control but both proteins were found differentially expressed across the four cell lines 
(Figure 3.1.7 A). Therefore commassie stained gels was used to demonstrate as best as 
possible equal loading between the samples (Figure 3.1.7 B). 
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Figure 3.1.4 Standardized log abundance graph view (Decyder BVA module) and 
Western blot images of Keratin 8 and Maspin protein expression from HMEC, MCF-
10A, MCF-7 and BT20. Biological duplicate samples were used in this investigation. 
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Vimentin 
 
 
 
Nm23 
 
 
Figure 3.1.5 Standardized log abundance graph view (Decyder BVA module) and 
Western blot images of vimentin and Nm23 protein expression from HMEC, MCF-10A, 
MCF-7 and BT20. Biological duplicate samples were used in this investigation. 
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Transaldolase-1  
 
 
 
STIP1  
 
 
Figure 3.1.6 Standardized log abundance graph view (Decyder BVA module) and 
Western blot images of Transaldolase-1 and STIP-1 protein expression from HMEC, 
MCF-10A, MCF-7 and BT20. Biological duplicate samples were used in this 
investigation. 
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The differential expression of proteins observed in 2D-DIGE and results observed in 
western blot analysis has been summarised in Table 3.1.8 and 3.1.9. 
 
Table 3.1.8. Expression pattern of keratin 8, Maspin and Vimentin observed in both 2D-
DIGE and WB analysis.   
 
Protein name 
2D-DIGE expression pattern 
(cancer vs. normal) 
WB expression pattern 
(cancer vs. normal) 
Keratin 8                 ↑                ↑ 
Maspin                 ↓                ↓ 
Vimentin                 ↓                ↓ 
 
 
Table 3.1.9. Expression patterns of Nm23, Transaldolase-1 and STIP-1 observed in 2D-
DIGE and WB analysis.  (↑) up-regulated, (↓) down-regulated, (NDE) not significantly 
differentially expressed. 
Protein name Analysis MCF-10A 
vs. MCF-7 
MCF-7 vs. 
BT20 
HMEC vs. 
BT20 
MCF-10A vs. 
HMEC 
2D-DIGE ↓ ↑ NDE NDE Nm23 
WB ↓ ↑ NDE NDE 
2D-DIGE ↓ ↓ ↓ NDE Transaldolase-
1 
 
WB ↓ ↓ ↓ NDE 
2D-DIGE ↓ ↑ NDE NDE STIP-1 
WB ↓ ↑ NDE NDE 
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Figure 3.1.7 A represents Western blot images for the expression of BIP and GAPDH 
proteins in cell lysate sample from HMEC, MCF-10A, MCF-7 and BT20. Biological 
duplicate samples were used in this investigation. B represents coomassie stained gel of 
cell lysates samples from HMEC, MCF-10A, MCF-7 and BT20 to demonstrate as best as 
possible even loading between the samples. 
 
 
 
 
 
 
 
 
 125 
3.1.8 Screening of potential invasion-specific protein targets for functional analysis 
To investigate the role of proteins identified in the process of invasion, a few potential 
protein targets were chosen based on the following criteria for further screening for their 
possible involvement in the regulation of the invasive phenotypes in breast cells using 
Western blot analysis.   
 
1. Proteins that have approximately similar expression patterns between normal and non-
invasive cells (HMEC, MCF-10A and MCF-7) and are highly up-regulated or down-
regulated in the cancerous invasive cell line (BT20) (Table 3.1.7). This criteria enables 
us to identify cancer invasion-related targets (Figure 3.1.8 A) 
2. Proteins that have approximately similar expression patterns between the non-
invasive cells (MCF-10A and MCF-7) and the invasive cells (HMEC and BT20) 
and are highly up-regulated or down-regulated in the invasive or non-invasive cell 
lines (Table 3.1.6). This analysis enables us to identify protein associated with invasion 
in both normal as well as cancer cells (Normal + Cancer- related invasion) (Figure 
3.1.8 B). 
3. All biological replicates are tightly clustered together statistically in their expression 
pattern from the analysis.  
4. From the literature, we chose proteins which either have not been investigated 
previously in this context or for which only limited information is available 
regarding their potential role in cancer and/or invasion. 
 
The following proteins have been found to pass the above selection criteria and 
therefore were selected for further western blot analysis in a panel of non-invasive and 
invasive breast cell lines in order to narrow down the protein list for functional 
validation using the siRNA knockdown technique. The selected protein targets were 
divided into two groups. 
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3.1.8.1 Cancer-related invasion (BT20 vs. HMEC+MCF-10A+MCF-7) 
Six protein targets, thioredoxin reductase 1 (TXNRD1), 3-phosphoglycerate 
dehydrogenase (3-PGDH), endoplasmic reticulum protein 29 precursor (ERp29), 
transaldolase (TALDO1), coactosin-like protein (CLP) and quinolinate 
phosphoribosyltransferase (QPRT), were selected in this comparison group (Figure 3.1.8 
A). TXNRD1, 3-PGDH, TALDO1, CLP and QPRT were observed to be up-regulated 
and ERp29 was found to be down-regulated in the cancerous invasive cell line (BT20) 
in comparison to the normal invasive+normal non-invasive+cancerous non-invasive 
cells (HMEC+MCF-10A+MCF-7). Investigation of these proteins in a panel of invasive 
and non-invasive breast cancer cell lines could further aid the selection of potential 
targets for cancer-related invasion in breast cancer. 
 
3.1.8.2 Normal +Cancer- related invasion (HMEC+BT20 vs. MCF-10A+MCF-7) 
Three proteins, proteasome activator subunit 1 isoform 2 (PSME1), nuclear chloride 
channel 1 (CLIC1) and RAD23B, were selected from this comparison group 
(HMEC+BT20 vs. MCF-10A+MCF-7) since these proteins were specifically down-
regulated in the normal-invasive and cancer-invasive cells (HMEC+BT20) in 
comparison to the normal-non-invasive and cancer-non-invasive cells (MCF-
10A+MCF-7) (Figure 3.1.8.B). Analysis of the expression of these protein targets in a 
panel of invasive and non-invasive breast cancer cell lines could help to improve the 
efficiency of potential target selection for normal + cancer- related invasion in breast cells.   
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Figure 3.1.8. Standardised log abundance for each of the selected protein targets from 2D-DIGE analysis.( A) Cancer- related invasion (1), 
TXNRD1, (2) 3-PGDH, (3) ERp29, (4) TALDO1, (5) TALDO1 (6) CLP and (7) QPART. (B) Normal + Cancer- related invasion (1) PSME1 
(2) CLIC1 and (3) RAD23B.
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3.1.8.3 Invasion assay 
A panel of breast cell lines including MCF-10A, MCF-7, T47D, UACC 812, HMEC, 
SKBR-3, MDA-MB 231, HCC 1937, BT20 and Hs578T were chosen on the basis of 
availability at the NICB culture collection. These cell lines covered a broad range of 
origin (basal, luminal and normal-like) and invasion status (low, medium and highly 
invasive) and therefore represent heterogenity of samples which often occurs in in-
vivo models (Table 3.1.10). Thus it provided an appropriate model to identify real 
targets associated with invasion. The invasion assays, as described in section 2.6, 
were performed to confirm the invasion status of each cell line as outlined in the 
literature. Table 3.1.10. summarises the invasion status of the cell lines observed in 
the 48hrs invasion assay and as described in the literature. The invasive capabilities 
of normal mammary epithelial cells (HMEC), non-tumorigenic immortalized 
mammary epithelial (MCF-10A) and breast carcinoma cell lines (MCF-7, BT20, 
HCC1937, MDA-MB-231, Hs578T, T-47D, UACC-812 and SKBR-3) were 
measured using pre-coated matrigel invasion chambers over 48hrs of culture. The 
graph was plotted on the basis of the total number of cells that crossed the matrigel 
membrane (Figure 3.1.9 B). The results indicated that the MCF-10A, MCF-7, T-47D 
and UACC-812 cells were non-invasive, and HMEC, SKBR-3, BT20, HCC1937, 
MDA-MB-231 and Hs578T were invasive (Figure 3.1.9). HMEC and SKBR-3 were 
low invasive and HCC1937, MDA-MB-231 and BT20 were more invasive than 
HMEC and SKBR-3.  Hs578T cells were found highly invasive in this assay.  
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Table 3.1.10. Summarised Invasion status of cell lines observed in 48hr invasion 
assay and described in the literature. 
Cell line Cell Type Phenotype Invasion assay  Information from 
literature 
MCF-10A Basal Normal-like Non-invasive Non-invasive (Jung et 
al. 2007, Streuli 2002) 
MCF-7 Luminal Cancerous Non-invasive Non-invasive (Nagaraja 
et al. 2006) 
T47D Luminal Cancerous Non-invasive Non-invasive (Nagaraja 
et al. 2006) 
UACC-
812 
Luminal Cancerous Non-invasive Non-invasive (Tong et 
al. 1999) 
SKBR-3 Luminal Cancerous Low invasive Low Invasive (Tong et 
al. 1999) 
HMEC Basal Normal Low invasive Invasive (Feltes et al. 
2002) 
MDA-MB 
231 
Basal Cancerous Invasive Invasive (Tong et al. 
1999) 
HCC-1937 Basal Cancerous Invasive Invasive (Nagaraja et al. 
2006) 
BT20 Basal Cancerous Invasive Invasive (Tong et al. 
1999) 
Hs578T Basal 
 
Cancerous Invasive Invasive (Tong et al. 
1999) 
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Figure 3.1.9. Investigation of the invasion capabilities of cells from breast origin. (A) Images from invasion assay- (1) MCF-10A, (2) 
MCF-7, (3) T47D, (4) UACC-812, (5) SKBR-3, (6) HMEC, (7) MDA-MB 231, (8) HCC-1937, (9) BT20 and (10) Hs578T. (B) 
Graphical representation of comparative levels of invasion in the cells tested. Magnification= 200x, Scale bar=200µm. Error bars 
represent standard deviation calculated from data obtained from three biological samples. 
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3.1.8.4 Western blot analysis 
Western blot analysis was carried out to investigate the expression pattern for 
TXNRD1, 3-PGDH, ERp29, TALDO1, CLP, QPART, PSME1, CLIC1 and RAD23B 
targets in a panel of normal, non-invasive and invasive cell lines (MCF-10A, MCF-7, 
T47D, UACC-812, SKBR-3, HMEC, MDA-MB 231, HCC-1937, BT20 and  Hs578T) 
(Figure 3.1.10 A). 
 
The western blot data of the nine target proteins across the four cell lines used in the 
2D-DIGE analysis (HMEC, MCF-10A, MCF-7 and BT20) were matched with the 
results from the biological variant analysis (BVA module) of DeCyder (3.1.6 and 3.1.7). 
All of the proteins confirmed the trends observed in the proteomic analysis except 
ERp29 (Figure 3.1.10 A and Table 3.1.7). The expression pattern of ERp29 did not fully 
correspond to the trend of expression identified in the proteomic analysis of the cell 
lines. This discrepancy could possibly be due to the presence of other isoforms caused 
by post-translational modifications of the protein. Additionally this protein could also 
be present in other spots in the gel which we did not identify. Table 3.1.11 summarises 
the expression pattern of the nine proteins including TXNRD1, 3-PGDH, ERp29, 
TALDO1, CLP, QPART, PSME1, CLIC1 and RAD23B observed in 2D-DIGE of the 4 
four cell lines (MCF-10A, HMEC, MCF-7 and BT20) and western blot analysis, again 
demonstrating the validation of the 2D-DIGE results. 
 
Figure 3.1.10 A shows the images from the western blot analyses of the nine proteins, 
TXNRD1, 3 PGDH, ERp29, TALDO1, CLP, QPART, PSME1, CLIC1 and RAD23B 
from the ten cell lines (MCF-10A, MCF-7, T47D, UACC-812, SKBR-3, HMEC, MDA-
MB 231, HCC-1937, BT20 and Hs578T). Coomassie stained gels was used to 
demonstrate as best as possible equal loading between the samples (Figure 3.1.10 B). 
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Table 3.1.11. Representation of the expression pattern of the nine proteins, including TXNRD1, 3-PGDH, ERp29, TALDO1, CLP, 
QPART, PSME1, CLIC1 and RAD23B, observed from 2D-DIGE analysis of the 4 four cell lines ( MCF-10A, HMEC, MCF-7 and BT20) 
and WB analysis. (↑) up-regulated, (↓) down-regulated, (NDE) not significantly differentially expressed. 
Protein name Analysis MCF-10A vs. 
MCF-7 
MCF-7 vs.  
BT20 
MCF-10A+MCF-7 
vs. HMEC+BT20 
HMEC vs.  
BT20 
MCF-10A vs. 
HMEC 
2D-DIGE NDE ↓ NDE ↓ NDE TXNRD1 
WB NDE ↓ NDE ↓ NDE 
2D-DIGE ↑ ↓ ↓ ↓ NDE 3-PGDH 
WB ↑ ↓ ↓ ↓ NDE 
2D-DIGE ↑ ↑ NDE ↑ NDE ERp29 
WB ↓ NDE NDE NDE NDE 
2D-DIGE ↓ ↓ NDE ↓ NDE TALDO1 
(upper band) WB ↑ ↓ NDE ↓ NDE 
2D-DIGE NDE ↓ NDE ↓ ↑ TALDO1 
(lower band) WB NDE ↓ NDE ↓ ↑ 
2D-DIGE NDE ↑ ↑ NDE ↑ CLP 
WB NDE ↑ ↑ NDE ↑ 
2D-DIGE NDE ↓ NDE ↓ NDE QPART 
WB NDE ↓ NDE ↓ NDE 
2D-DIGE NDE ↑ ↑ NDE ↑ PSME1 
WB NDE ↑ ↑ NDE ↑ 
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2D-DIGE ↑ ↓ ↓ ↓ NDE CLIC1 
WB ↑ ↓ ↓ ↓ NDE 
2D-DIGE NDE ↑ ↑ NDE NDE RAD23B 
WB NDE ↑ ↑ NDE NDE 
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Figure 3.1.10. Analysis of the expression of the selected protein targets in a panel of 
breast cancer cell lines including non-invasive (MCF-10A, MCF-7, T47D and UACC 
812), low invasive (HMEC and SKBR-3) and invasive (MDA-MB 231, HCC 1937, 
BT20 and Hs578T) using Western blot analysis. (A) represents Western blot images of 
PSME1, TXNRD1, CLIC1, 3-PGDH, ERp29, TALDO1, CLP, QAPRT and RAD23B in 
the cell lysate samples. Western blot images are representative of two biological samples. 
(N+NI) represents normal non-invasive, (C+NI) cancer non invasive, (N+I) normal 
invasive, (C+I) cancer invasive. (B) represents coomassie stained gel of cell lysate samples 
demonstrating as best as possible even loading between the samples.  
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After western blot analysis of 2 biological samples from each cell line, densitometry 
was carried out to calculate the intensity of the expressed protein. Average relative 
intensities were used to plot graphs from the two groups as mentioned below. 
 
3.1.8.4.1 Cancer invasion- related targets  
• TXNRD1 was found to be expressed in all cancerous invasive cell lines 
(SKBR-3, MDA-MB 231, HCC 1937, BT20 and Hs578T), whereas it was 
absent in the normal non-invasive and invasive cell lines (HMEC and MCF-
10A) and in the cancerous non-invasive cell lines (MCF-7 and T47D), 
except UACC 812 (Figure 3.1.10A and 3.1.11).  
 
• 3-PGDH was found to be expressed in all cancerous invasive cell lines 
(SKBR-3, MDA-MB 231, HCC 1937, BT20 and Hs578T) and was absent in 
the cancerous non-invasive cell lines (MCF-7 and T47D), except UACC 
812 (Figure 3.1.10A and 3.1.11).. This protein was present at low levels in 
the normal non-invasive and invasive cell lines (HMEC and MCF-10A) 
compared to the cancer invasive cell lines. 
 
• ERp29 was found to have similar levels of expression in the normal non-
invasive (MCF-10A), normal invasive (HMEC), cancerous non-invasive 
(MCF-7, T47D and UACC 812) and cancerous invasive cell lines (SKBR-3, 
MDA-MB 231, HCC 1937, BT20 and Hs578T) (Figure 3.1.10A and 
3.1.11A). 
• TALDO1 showed a mixed expression pattern among normal, cancer non-
invasive and cancer non-invasive cell lines. It was higly expressed in one 
cancerous non-invasive (UACC-812) and four cancerous invasive (SKBR-3, 
MDA-MB 231, HCC 1937 and BT20) cell lines. TALDO1 was expressed at 
low levels in one cancer invasive (Hs578T), two cancerous non-invasive 
cell lines (MCF-7 and T47D), normal invasive (HMEC), and normal non-
invasive (MCF-10A) cell lines (Figure 3.1.10A and 3.1.11A). 
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• QPRT was found highly expressed in two cancerous non-invasive cell lines 
(T47D and UACC 812) and was expressed at low levels in one cancerous 
non-invasive cell line (MCF-7) (Figure 3.1.10A and 3.1.11A). This protein 
was absent in normal non-invasive and invasive cell lines (HMEC and 
MCF-10A).  This protein was also found to be expressed in two cancer 
invasive cell line (SKBR-3 and BT20).  
 
• Low levels of expression of CLP were observed in the normal non-invasive 
(MCF-10A), normal invasive (HMEC), and cancerous non-invasive cells 
(MCF-7 and T47D), except UACC 812 which has a slightly higher level of 
expression (Figure 3.1.10.A and 3.1.11A). Higher levels of CLP were found 
in the cancer invasive cell lines (MDA-MB 231, HCC 1937 and BT20) but 
not in Hs578T. 
 
Out of the six proteins (TXNRD1, 3-PGDH, ERp29, TALDO1, CLP and QPRT) 
analysed in this comparison, only TXNRD1 and 3-PGDH were up-regulated in the 
cancerous invasive cell lines compared to the normal invasive+ normal non-invasive+ 
cancerous non-invasive cell lines, except UACC-812, as shown in figure 3.1.11B with 
the coloured lines. However, the other four proteins showed no real expression trends 
between the normal invasive+ normal non-invasive+ cancerous non-invasive vs. 
invasive cell lines. Therefore, ERp29, transaldose-1, QPRT and CLP were not observed 
to be associated with the invasion phenotype in breast cells in this investigation and 
were not selected for further siRNA studies. The proteins, TXNRD1 and 3-PGDH, were 
highly expressed in the invasive cells and therefore were selected for siRNA 
knockdown studies to investigate their potential involvement in the invasion process in 
breast cells (Figure 3.1.11B).  
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Figure 3.1.11. Graphical representation of average relative intensities calculated 
densitometry data from Western blotting analysis as shown in Figure 3.1.10 of selected 
cancer-invasion-related protein targets observed in a panel of cell lines. Average relative 
intensities represent the relative intensities obtained from 2 biological replicate samples. 
(A) TXNRD1, 3-PGDH, ERp29, TALDO1, TALDO1, CLP and QPART. (B) TXNRD1 
and 3-PGDH  
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3.1.8.4.2 Normal + Cancer invasion-related targets 
 
• PSME1 was found to be over expressed in three cell lines (MCF-10A, MCF-7 
and T47D) but was expressed at low levels in one non-invasive cell line (UACC 
812) (Figure 3.1.10A and 3.1.12A). In the invasive cells lines, it was also over 
expressed in 3 cell lines (HMEC, MDA-MB 231 and Hs578T), expressed at low 
levels in the remaining 2 invasive cell lines (HCC 1937 and BT20) and absent in 
the invasive cell line, SKBR-3.  
 
• CLIC1 was found to have similar levels of expression in four non-invasive cell 
lines (MCF-10A, MCF-7, T47D and UACC 812) and two invasive cell lines 
(MDA-MB 231 and HCC 1937) whereas it was expressed at low levels in 3 
invasive cell lines (HMEC, BT20 and Hs578T) (Figure 3.1.10A and 3.1.12A). 
 
• RAD23B was found to be up-regulated in the normal + cancer non-invasive cell 
lines (MCF-10A, MCF-7, T47D and UACC 812) compared to the normal + 
cancer invasive cell lines (SKBR-3, HMEC, MDA-MB 231, HCC 1937, BT20 
and Hs578T) (Figure 3.1.10A and 3.1.12A). 
 
Of the three proteins (PSME1, CLIC1 and RAD23B), only RAD23B was highly 
expressed in the normal + cancerous non-invasive cell lines compared to normal + 
cancerous invasive cell lines as denoted by the coloured line in Figure 3.1.12. PSME1 
and CLIC1 did not show this trend i.e. highly expressed in all non-invasive cell lines 
compared to the invasive cell lines (Figure 3.1.12A) and therefore were not selected for 
further functional studies. RAD23B was chosen for a further siRNA knockdown study 
to investigate potential involvement in the in vitro invasion process in normal and 
cancer cell lines (Figure 3.1.12B). 
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Figure 3.1.12. Graphical representation of average relative intensities calculated 
densitometry data from Western blotting analysis as shown in Figure 3.1.10 of selected 
normal+cancer invasion-related protein targets observed in a panel of cell lines. 
Average relative intensities represent the relative intensities obtained from 2 biological 
replicate samples. (A) PSME1, CLIC1 and RAD23B. (B) RAD23B  
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3.1.9 Optimization of transfection conditions of MCF-10A, MCF-7, SKBR-3 and 
BT20  
TXNRD1 and 3-PGDH were up-regulated in the invasive cell lines and therefore 
knockdown of these targets was expected to reduce the level of invasion. RAD23B was 
up-regulated in the non-invasive cell lines and therefore knockdown of RAD23B was 
expected to induce the level of invasion. For TXNRD1 and 3-PGDH siRNA knockdown, 
two invasive cell lines (SKBR-3 and BT20) were chosen for optimization. For RAD23B 
siRNA knockdown, one normal non-invasive (MCF-10A) and one cancer non-invasive 
(MCF-7) cell line were chosen for optimization.  
siRNAs can inhibit the expression of selected target proteins by hindering the 
transcription of specific genes. siRNA delivery through transfection can result in 
temporary changes in the cell, and in some cases cells may become resistant to 
conditions of delivery. To further ensure optimal target knockdown, siPORT™ 
NeoFX™, a lipid-based transfection reagent was used. The duration of gene silencing 
also varies greatly between cells, i.e. slow growing cells can show the effects of siRNA 
up to several weeks, whereas rapidly dividing cells can not show effects of siRNA for 
longer than 1 week (Tong et al. 1999). Therefore to achieve maximum effectiveness of 
exogenously introduced siRNA transfection optimization experiments were carried out 
as described in section 2.9.1.1. 
Optimisation of siRNA transfection conditions, using kinesin siRNA and scrambled 
siRNA, was carried out for MCF-10A, MCF-7, SKBR-3 and BT20 in 96 well plates. 
Three different cell densities and siRNA/NeoFX reagent concentrations were used. 
Scrambled treated cultures were considered as control. The plates were assayed for 
changes in proliferation at 72 hours using the acid phosphatase assay as mentioned in 
section 2.9.1.1. Optimal conditions for transfection were determined as the combination of 
conditions which gave the greatest reduction in cell number after kinesin siRNA 
transfection and the least cell death in scrambled siRNA transfected cells. Figure 3.1.13. 
shows the proliferation assay results obtained for MCF-10A, MCF-7, SKBR-3 and BT20, 
and table 3.1.12 summarises the optimal conditions for siRNA transfection in 96 well 
plates.  
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Table 3.1.12. The optimal conditions for siRNA transfection in MCF-10A, MCF-7, 
SKBR-3 and BT20 in 96 well plate. 
   Cell lines Seeding density/ well Volume of NeoFX reagent(µl) 
MCF 10A 1x 104 0.4 
MCF-7 7.5x 103 0.6 
SKBR-3 3x 103 0.4 
BT20  5x 103 0.8 
 
GAPDH, often used as an endogenous control, has been found to be an ‘easy target’ for 
siRNA, with efficient silencing observed in many different systems 
(www.Ambion.com). Optimisation of siRNA against GAPDH was also carried out in 
MCF-10A, MCF-7, SKBR-3 and BT20 cell lines to determine transfection knock down 
conditions at the protein level in 6 well plates using three different concentrations of 
NeoFX and cell density as mentioned in Table 3.1.13. Western blot analysis was carried 
out to establish the optimal conditions for siRNA transfection as described in section 
2.8. Alpha tubulin was used as a loading control. Figure 3.1.14 shows the western blots 
of GAPDH siRNA transfected cells for MCF-10A, MCF-7, SKBR-3 and BT20. The 
same conditions of siRNA transfection in MDA-MB 231 were used as recommended by 
Ambion and also used by Timoshenko et al (2006). Table 3.1.13 shows the optimized 
conditions for the cell lines in 6 well plates.  
 
Table 3.1.13. The optimal conditions for siRNA transfection in MCF-10A, MCF-7, 
SKBR-3 and BT20 in 6 well plate. 
   Cell lines Seeding density/ well Volume of NeoFX reagent(µl) 
MCF 10A    5x 105        4 
MCF-7    5x 105    4, 6, 8 
SKBR-3   1x 105      3 
BT20     5x 105      6 
MDA-MB 231    2x 105     4 
 
 143 
0
20
40
60
80
100
120
Control NFX0-
SCR
NFX0-
KNS
NFX0.4-
SCR
NFX0.4-
KNS
NFX0.6-
SCR
NFX0.6-
KNS
NFX0.8-
SCR
NFX0.8-
KNS
Conditions
%
 
G
r
o
w
t
h
5.00E+03 7.50E+03 1.00E+04
0
20
40
60
80
100
120
140
160
Control NFX0-SCR NFX0-KNS NFX0.4-SCR NFX0.4-KNS NFX0.6-SCR NFX0.6-KNS NFX0.8-SCR NFX0.8-KNS
Conditions
%
 
G
r
o
w
t
h
5.00E+03 7.50E+03 1.00E+04
0
20
40
60
80
100
120
Control NFX0-
SCR
NFX0-
KNS
NFX0.2-
SCR
NFX0.2-
KNS
NFX0.3-
SCR
NFX0.3-
KNS
NFX0.4-
SCR
NFX0.4-
KNS
Conditions
%
 
G
r
o
w
t
h
1.00E+03 2.00E+03 3.00E+03
0
20
40
60
80
100
120
140
Contol NFX0-SCR NFX0-
KNS
NFX0.4-
SCR
NFX0.4-
KNS
NFX0.6-
SCR
NFX0.6-
KNS
NFX0.8-
SCR
NFX0.8-
KNS
Conditions
%
 
G
r
o
w
t
h
2.00E+03 5.00E+03 7.50E+03
A B
C D
Cells/well Cells/well
Cells/well Cells/well
%
 
G
r
o
w
t
h
%
 
G
r
o
w
t
h
%
 
G
r
o
w
t
h
%
 
G
r
o
w
t
h
 
Figure 3.1.13. Proliferation assay of cell lines transfected with three different cell densities, three different concentrations of Kinesin siRNA and 
scrambled siRNA and three concentrations of NeoFX. (A) MCF-10A (B) MCF-7 (C) SKBR-3 (D) BT20. Control denotes untreated cultures. 
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Figure 3.1.14. Western blot analysis of cell lines transfected with GAPDH siRNA with 
three concentrations of NeoFX, and optimal cell densities as described in Table 3.1.9.2   
(A) MCF-10A (B) MCF-7 (C) SKBR-3 (D) BT20 
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3.1.10 Functional analysis of final targets 
Of the 9 targets from section 3.1.8.4, 3 protein targets were chosen for further siRNA 
knockdown to investigate their functional role in invasion. The levels of silencing can 
vary between species, cells and tissues due to differences in the efficiency with which 
the siRNAs are taken up by target cells. Due to this problem the conditions for siRNA 
transfection in each cell line were optimised in 96- and 6-well plates using GAPDH and 
kinesin as positive controls, and scrambled siRNA as an siRNA transfection control. 2-3 
siRNAs were chosen for each target for transfection into the cells as appropriate. For 
each set of siRNA transfections, untreated, NeoFX without siRNA and scrambled 
siRNA transfected culture were used as a control. Kinesin was also used as positive 
control to show efficient transfection as inhibition of kinesin reduces proliferation in 
culture.  
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3.1.10.1 Investigation into the role of TXNRD1 (cancer invasion related target) in 
invasion in breast cancer cells 
TXNRD1 was identified as a protein potentially involved in invasion in our in vitro 
breast cancer cell line models. This protein was 4.6 fold up-regulated in the cancerous 
invasive cell line (BT20) compared to normal invasive (HMEC) + normal non-invasive 
(MCF-10A) + cancerous non-invasive (MCF-7) cell lines in 2D DIGE analysis (Table 
3.1.7). Western blot analysis also showed that TXNRD1 was highly expressed in the 
invasive cell lines compared to the normal and non invasive cell lines. However, UACC-
812 is a non-invasive cell line but is expressing TXNRD1 and is possibly an outlier in this 
comparison (Figure 3.1.12A and 3.1.13B). The invasive cell line (MDA-MB 231) and 
the low invasive cell line (SKBR-3) were used to investigate the effects of inhibition of 
the expression of TXNRD1 on cell proliferation and invasion using siRNA transfection. 
The endogenous levels of TXNRD1 were higher in the invasive cell line, BT20, 
compared to MDA MB 231, therefore MDA MB 231 was chosen for siRNA 
knockdown, as the effect of knock down may be more difficult to see in BT20 cells.  
 
3.1.10.1.1 Effect of TXNRD1 siRNA transfection on MDA-MB 231 and SKBR-3  
2 independent siRNA molecules were used to inhibit the expression of TXNRD1 in this 
investigation and the inhibition was confirmed for biological duplicate samples using 
Western blotting after 72hrs of transfection. 30nM of siRNA in SKBR-3 and 50nM 
siRNA in MDA-MB 231 were used. Figure 3.1.15A and B show Western blot analysis 
of siRNA transfection of TXNRD1 in MDA-MB 231 and SKBR-3 cells compared to 
untreated, NeoFX without siRNA, and siRNA scrambled transfected control cultures. 
Results indicate that the expression of TXNRD1 was reduced following siRNA 
transfection for both siRNA molecules in comparison to scrambled treated control 
cultures. 
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Figure 3.1.15. Western blot analysis of the inhibition of expression of TXNRD1 using 
siRNA knockdown in MDA-MB 231 (A) and SKBR-3 (B) cells. Two independent siRNA 
molecules of TXNRD1 were transfected into the cells. Protein was harvested 72 hrs post-
transfection and used to determine the TXNRD1-siRNA specific decrease at the protein 
level using Western blot. Expression of GAPDH was used to demonstrate even loading 
between the samples in this investigation. 
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3.1.10.1.2 Investigation of the effects of inhibition of expression of TXNRD1 on the 
invasion status of cells 
After 48hrs of siRNA transfection, invasion assays were performed to investigate the 
effects of the inhibition of expression of TXNRD1 in MDA-MB 231 and SKBR-3 cells 
using precoated matrigel invasion chambers for a further 48hrs as described in section 
2.6. The total number of cells invading the membrane of the invasion chamber was 
reduced following siRNA transfection (Figure 3.1.16 and 3.1.17). The reduction in the 
invasion was 1.4-fold (p-value=0.00033) with siRNA TXNRD1 (1) and 1.3-fold (p-
value=0.00035) with siRNA TXNRD1 (2) after transfection in MDA-MB 231 (Figure 
3.1.16). Invasion was reduced by 3.1-fold (p-value=0.0015) with siRNA TXNRD1 (1) and 
2.2-fold (p-value=0.00041) with siRNA TXNRD1 (2) after transfection in SKBR-3 
(Figure 3.1.17). 
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Figure 3.1.16. Investigation of the effects of inhibition of expression of TXNRD1 on the 
invasion status of MDA-MB 231 cells. (A) Images of invasion assays- (i) un-treated, (ii) 
NeoFX without siRNA, (iii) transfected with scrambled, (iv) transfected with TXNRD1 
siRNA (1), and (v) transfected with TXNRD1 siRNA (2). Magnification= 200x, Scale 
bar=200µm. (B) Total number of cells invading through the membrane of invasion 
chambers after siRNA transfection. Error bars represent standard deviation calculated from 
data obtained from three biological samples. * P-value =0.0015 and ** P-value =0.00041. 
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Figure 3.1.17. Investigation of the effects of inhibition of expression of TXNRD1 on 
invasion status of SKBR-3 cells. (A) Images of invasion assays- (i) un-treated, (ii) NeoFX 
without siRNA, (iii) transfected with scrambled, (iv) transfected with TXNRD1 siRNA 
(1), and (v) transfected with TXNRD1 siRNA (2). Magnification= 200x, Scale 
bar=200µm. (B) Total number of cells invading through the membrane of invasion 
chambers after siRNA transfection. Error bars represent standard deviation calculated from 
data obtained from three biological samples. * P-value =0.00033 and ** P-value =0.00035. 
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3.1.10.2 Effect of TXNRD1 siRNA on proliferation 
Proliferation assays were carried out after 72hrs of transfection of TXNRD1 siRNAs 
into MDA-MB 231 and SKBR-3 cells to measure changes in growth. Figure 3.3.18 
displays the percentage survival of transfected cells relative to untreated control 
(Section 2.9.2.2). Kinesin was used as a positive control to represent the efficiency of 
transfection. No significant difference in proliferation of TXNRD1-siRNAs treated cells 
compared to scrambled cells was observed which indicates that the loss of expression of 
TXNRD1 did not affect proliferation in MDA-MB 231 cells (Figure 3.3.18A). Similar 
results were observed in the case of TXNRD1-siRNA transfection in SKBR-3 cells 
(Figure 3.3.18B)  
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Figure 3.3.18. Percentage survival of MDA-MB 231 (A) and SKBR-3 (B) transfected 
with TXNRD1-siRNAs relative to untreated, NeoFX without siRNA, and Scrambled 
siRNA transfected control cultures. Error bars represent standard deviation calculated 
from data obtained from three biological replicate samples. 
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3.1.10.3 Investigation of the role of RAD23B (normal+ cancer invasion-related target) 
in invasion in breast cells 
RAD23B was identified as a protein potentially involved in suppressing invasion in our 
in vitro breast cell line models. This protein was 2.07 fold up-regulated in non-invasive 
(MCF-10-A+ MCF-7) compared to invasive (HMEC+ BT20) cell lines from the 2D 
DIGE analysis (Table 3.1.6). Western blot analysis showed that RAD23B was highly 
expressed in the non-invasive cell lines (MCF-7, MCF-10 and T47D) compared to the 
invasive cell lines. However, UACC-812, which is a non-invasive cell line was found to 
express low levels of this protein and is a possible outlier in this experiment (Figure 
3.1.10A and 3.1.11B). Low levels of expression of RAD23B were also found in HMEC, 
SKBR-3 and BT20 cells (Figure 3.1.10A). Therefore the non-invasive cell line (MCF-
10A and MCF-7) were used to investigate the effects of inhibition of the expression of 
RAD23B on cell proliferation and invasion using siRNA transfection. 
 
3.1.11.3.1 Effect of RAD23B siRNA transfection on MCF-7 and MCF-10A   
3 independent siRNA molecules were used to inhibit the expression of RAD23B in this 
investigation and the inhibition was confirmed for biological duplicate samples using 
Western blotting after 72hrs of transfection. Figure 3.1.18A and 3.1.18B show Western 
blot analysis of siRNA transfection of RAD23B in MCF-7 and MCF-10A cells 
compared to un-treated, NeoFX without siRNA and siRNA scrambled transfected 
control cultures. The results indicate that the expression of RAD23B was significantly 
reduced following siRNA transfection for both siRNA molecules in comparison to 
scrambled treated control cultures. 
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Figure 3.1.19. Western blot analysis of the inhibition of expression of RAD23B using 
siRNA knockdown in MCF-7 (A) and MCF-10A (B) cells. 3 independent siRNA 
molecules of RAD23B were transfected into the cells. Protein was harvested at 72 hrs for 
MCF-10A and 96 hrs for MCF-7 post-transfection and used to determine the RAD23-
siRNA specific decrease at the protein level using Western blot. Expression of GAPDH 
was used to demonstrate even loading between the samples in this investigation. 
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3.1.10.3.2 Effect of RAD23B siRNA on invasion 
After 48hrs of siRNA transfection, invasion assays were performed to investigate the 
effects of inhibition of expression of RAD23B in MCF-7 and MCF-10A cells using pre-
coated matrigel invasion chambers for a further 72 and 48hrs respectively (section 
2.9.2.1). The total incubation time for transfection was 96 hrs for MCF-7 and 72 hrs for 
MCF-10A. The choice of a longer incubation period (72hrs) for MCF-7 in invasion 
chambers was driven by the previous observations in this laboratory that it is difficult to 
induce invasion of MCF-7 cells. The total number of cells invading the membrane of the 
invasion chamber was increased following siRNA transfection (Figure 3.1.20 and 3.1.21). 
The increase in the invasion was 1.9-fold (p=0.020) with siRNA RAD23B (1), 2.6-fold 
(p=0.00025) with siRNA RAD23B (2) and 2.9-fold (p=0.00018) with siRNA RAD23B (3) 
after transfection in MCF-7 cells (Figure 3.1.20). Invasion was increased by 2.7-fold 
(p=0.015) with siRNA RAD23B (1), 3.5-fold (p=0.0029) with siRNA RAD23B (2) and 
4.0-fold (p=0.0025) with siRNA RAD23B (3) following transfection in MCF-10A (Figure 
3.1.21). A few cells in control (neoFX, scrambled and non-transfected cells) were 
observed in MCF-7 in invasion assays which could be an artefact of longer incubation 
(72hrs) of cells in invasion chambers. 
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Figure 3.1.20. Investigation of effects of the inhibition of expression of RAD23B on the 
invasion status of MCF-7 cells. (A) Images of invasion assays- (i) un-treated, (ii) NeoFX 
without siRNA, (iii) transfected with scrambled, (iv) transfected with RAD23B siRNA (1), 
(v) transfected with RAD23B siRNA (2) and (vi) transfected with RAD23B siRNA (3). 
Magnification= 200x, Scale bar=200µm. (B) Total number of cells invading through the 
membrane of invasion chambers after siRNA transfection. Error bars represent standard 
deviation calculated from data obtained from three biological samples. * P-value =0.020, 
** P-value =0.00025 and *** P-value =0.00018. 
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Figure 3.1.21. Investigation of effects of the inhibition of expression of RAD23B on the 
invasion status of MCF-10A cells. (A) Images of invasion assays- (i) un-treated, (ii) 
NeoFX without siRNA, (iii) transfected with scrambled, (iv) transfected with RAD23B 
siRNA (1), and (v) transfected with RAD23B siRNA (2), (vi) transfected with RAD23B 
siRNA (3). Magnification= 200x, Scale bar=200µm. (B) Total number of cells invading 
through the membrane of invasion chambers after siRNA transfection. Error bars represent 
standard deviation calculated from data obtained from three biological samples. * P-value 
=0.015, ** P-value =0.0029 and *** P-value =0..0025. 
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3.1.10.4 Effect of RAD23B siRNA on proliferation 
Proliferation assays were carried out after 72hrs of transfection of RAD23B siRNAs 
into MCF-7 and MCF-10A cells to measure the changes in growth. Figure 3.1.22 
displays the percentage survival of transfected cells relative to untreated control (section 
2.9.2.1). Kinesin was used as a positive control to represent the efficiency of 
transfection. No significant difference in proliferation of RAD23B-siRNA treated cells 
compared to scrambled siRNA treated cells was observed which indicates that the loss 
of expression of RAD23B did not affect proliferation in MCF-7 cells (Figure 3.1.22A). 
Similar results were observed in the case of RAD23B-siRNA transfection in MCF-10A 
(Figure 3.1.22B). 
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Figure 3.1.22. Percentage survival of MCF-7 (A) and MDA-10A (B) transfected with 
RAD23B-siRNAs relative to untreated, NeoFX without siRNA, and Scrambled siRNA 
transfected control cultures. Error bars represent standard deviation calculated from data 
obtained from three biological samples. 
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3.1.10.5 Investigation of the role of 3-PGDH (cancer invasion-related target) in breast 
cancer cell invasion 
3-PGDH was identified as a protein potentially involved in invasion in the in vitro 
breast cancer cell lines used in this study. This protein was 4.6 fold up-regulated in the 
cancerous invasive cell line (BT20) compared to the normal invasive (HMEC)+ normal 
non-invasive (MCF-10A) + cancerous non-invasive (MCF-7) cell lines from 2D-DIGE 
analysis (Table 3.1.7). Western blot analysis showed 3-PGDH to be highly expressed in 
the invasive cell lines compared to the normal and non invasive cell lines, with the 
exception of UACC-812 cells (Figure 3.1.10A and 3.1.11A). Therefore, the invasive cell 
lines (MDA-MB 231 and SKBR3) were used to investigate the effects of inhibition of 
the expression of 3-PGDH on cell proliferation and invasion using siRNA transfection. 
 
3.1.10.5.1 Effect of 3-PGDH siRNA transfection on MDA-MB 231 and SKBR-3  
3 independent siRNA molecules (30nM) were used to inhibit the expression of 3-
PGDH in this investigation and no inhibition was observed for biological duplicate 
samples using Western blotting after transfection. Figure 3.1.23 show western blot 
analysis of siRNA transfection of 3-PGDH in MDA-MB 231 and SKBR-3 cells 
compared to un-treated, NeoFX and scrambled siRNA transfected control cultures. 
The results indicate that the expression of 3-PGDH was not inhibited following 
siRNA transfection for all of the siRNA molecules in comparison to scrambled treated 
control cultures. siRNAs were then transfected into another invasive cell line (BT20) 
and the protein samples were analyzed using Western blotting. No difference in 
siRNA treated vs. control samples was observed. Therefore increased concentrations 
of siRNA molecules (50nM for SKBR-3 and 125nM for MDA-MB 231 cells) were 
transfected into the cell lines and protein samples were collected after 72hrs of 
transfection from SKBR-3 and MDA-MB 231 cells and were analysed using western 
blotting.  
 
Higher concentrations of siRNA (100nM) have been recommended by Ambion 
(www.ambion.com) and a concentration of 125nM siRNA concentration on MDA-
MB 231 has been used by Timoshenko et al, (2006). No knockdown in the expression 
of siRNA treated vs. control samples was observed. This indicates that the siRNA 
molecules are not able to inhibit the expression of 3-PGDH. Two reasons for this 
could be possible that 3-PGDH may have slow turn over in the cells and confirmation 
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of knockdown at the mRNA level using qRT-PCR might be useful. The siRNA 
molecules used in this investigation are ‘not-validated-siRNAs’ (no experimental 
proof for efficiency of siRNAs) and therefore inhibition of 3-PGDH using validated-
siRNA from other providers could help to investigate the effects of 3-PGDH on 
invasion process in breast cancer.  
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Figure 3.1.23. Western blot analysis of the inhibition of expression of 3-PGDH using 
siRNA knockdown technique in MDA-MB 231, SKBR-3 and BT20 cells. (A) transfected 
with 3-PGDH 30nM siRNAs in MDA-MB 231, (B) transfected with 3-PGDH 30nM 
siRNAs in SKBR-3, (C) transfected with 3-PGDH 30nM siRNAs in BT20, (D) transfected 
with 3-PGDH 50nM siRNAs in SKBR-3, (E) transfected with 3-PGDH 125nM siRNAs in 
MDA-MB 231. Expression of GAPDH was used to demonstrate even loading between the 
samples in this investigation. 
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3.1.10.6 Effect of 3-PGDH siRNA on cell proliferation 
Proliferation assays were carried out after 72hrs of transfection of 3-PGDH siRNAs into 
MDA-MB 231, SKBR-3 and BT20 cell lines to measure changes in growth. Figure 
3.1.24 displays the percentage survival of transfected cells relative to untreated control. 
Kinesin was used as a positive control to represent efficient transfection. The reduction 
in expression of 3-PGDH was not achieved following siRNA tranfection resulting 
insignificant difference in proliferation of siRNA treated cells compared to scrambled 
siRNA treated cells. However, kinesin treated culture showed a significant reduction in 
cell growth demonstrating efficient transfection (Figure 3.1.24).  
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Figure 3.1.24. Percentage survival of MDA-MB 231 (A), SKBR-3 (B) and BT20 (C) 
transfected with 3-PGDH-siRNAs relative to untreated, NeoFX without siRNA, and 
Scrambled siRNA transfected control cultures. Error bars represent standard deviation 
calculated from data obtained from three biological samples. 
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3.2 Proteomic analysis of conditioned media from HMEC, MCF-10A, MCF-7 and 
BT20 
The proteins released by cells or shedding proteins are a record of its physiological 
status and are commonly associated with diseases including cancer. Invasion occurs 
within the tumour-host microecology, where stroma and tumour cells exchange 
enzymes and cytokines that modify the local extracellular matrix, stimulate migration 
and promote proliferation. Therefore, either the tumour itself or its microenvironment 
could be sources for biomarkers that would ultimately be shed into the serum proteome 
and possibly be important for early detection, monitoring therapeutic efficacy or 
understanding the biology of cancer.  
 
In vitro cell culture model systems, in which serum-free conditioned media are collected 
from cells, are being used to understand biological processes and functions (Ryther et 
al. 2005). Therefore, investigation of protein expression changes in breast cell lines 
representative of normal, non-invasive and invasive phenotypes might be helpful in 
understanding the biological mechanisms leading to breast cancer and early detection of 
breast cancer and invasion. For this, differential proteomics study of conditioned media 
from HMEC, MCF-10A, MCF-7 and BT20 were carried out. 
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3.2.1 Analysis of viability of cells in serum-free medium 
MCF-10A, MCF-7 and BT20 cells were grown in serum free medium (SFM) to ensure 
that the conditioned media contained as few as possible other exogenous proteins (such as 
serum proteins). To minimise cell death and maximize the concentration of secreted 
protein in the conditioned media, cells were grown in complete media until 60% 
confluency and then media was replaced with serum-free media.  The viability of MCF-
10A, MCF-7 and BT20 cells were measured at the time of sample collection as 
described in sections 2.4.6 and 2.7.1.2. The 10% serum-supplemented cells were used 
as a control in this study. Figure 3.2.1 shows the viability of cells cultured in serum and 
serum-free medium at 24, 48 and 96 hrs of MCF-10A, MCF-7 and BT20. The results 
indicate that the viability of MCF-10A, MCF-7 and BT20 after 96 hrs of culture in 
serum supplemented medium was 99%, 97% and 99% respectively. The viability of 
cells grown in serum-free was 95%, 96% and 97% which is comparable to the control 
culture and therefore represents the healthy state of cell at time of conditioned medium 
harvesting. HMEC grows in specialised media and has a short life-time, therefore the 
same conditions as optimized using MCF-10A, MCF-7 and BT20 were applied for 
HMEC for further investigations. 
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Figure 3.2.1: (A) Percentage viability of MCF10A, (B) Percentage viability of MCF-7, 
(C) Percentage viability of BT20 grown over 96 hours of culture. (■) represents the 
cells viability in serum supplemented medium; (▲) represents the cells viability in 
serum-free media. Error bars represents the standard deviation calculated from data 
obtained from the experiment (n=3) 
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3.2.2 Experimental outline  
Investigations were carried out to establish differential expression of secreted proteins 
as described in section 3.1.3. For this, four biological samples from normal mammary 
epithelial cells (HMEC), non-tumorigenic immortalized mammary epithelial cells 
(MCF-10A) non-invasive breast cancer cells (MCF-7) and invasive breast cancer cells 
(BT20) were prepared separately. Each cell line sample was labelled with 2-D DIGE 
dyes (i.e. Cy3 and Cy5) as outlined in Table 3.1.2. A pooled internal control containing 
a mixture of all biological replicate samples in the experiment was labelled with Cy2 
dye.  
 
3.2.3 Analysis of differential expression of proteins using DeCyder 
2D-DIGE protein expression maps (PEMs) for conditioned media from HMEC, MCF-
10AMCF-7 and BT20 were created. Analysis was carried out as described in section 
3.1.3. After spot matching and filtering a total of 305 protein spots were matched across 
all of the gels in the experiment, i.e. 24 gels in total. 
The objective of this investigation was to identify the proteins that are up-regulated or 
down-regulated with the cancerous and invasion status of the cell lines. For this, 
analyses of the following three comparison group were performed from the 2D-DIGE 
PEMs.  Spots that were ±1.5 fold up or down-regulated with p-value ≤ 0.05 were 
considered significantly differentially expressed (DE).  
 
3.2.3.1 Cancerous (MCF-7+ BT20) vs. Normal (HMEC+ BT20) 
To see which proteins are being differentially expressed between the cancer and normal 
cells, the PEMs for the cancerous cells (MCF-7+BT20) were compared with the PEMs 
for the normal cells (HMEC+MCF10A). The comparison revealed altered expression of 
81 proteins, of which 56 proteins up-regulated and 23 proteins down-regulated in the 
cancerous cell lines compared to the normal cells. 
 
3.2.3.2 Invasive (HMEC+BT20) vs. Non-invasive (MCF-10A+MCF-7) 
Proteins that are up-regulated or down-regulated in the normal+cancer ((N+C) invasive 
cells (HMEC+BT20) compared to normal+cancer (N+C) non-invasive cells (MCF-10A 
+ MCF-7) were investigated to identify invasion-specific targets. 33 proteins were 
found differentially expressed in this comparison, of which 4 proteins were up-regulated 
and 29 proteins were down-regulated in the invasive cells compared to non-invasive 
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cells. We have used ‘normal + cancer related invasion’ term for this comparison in 
this thesis.  
 
3.2.3.3 Cancerous invasive (BT20) vs. Normal invasive+ normal non-invasive+ 
cancerous non-invasive (HMEC+MCF-10A+MCF-7) 
To identify protein alterations in the cancer invasive cell lines, the PEMs of the 
cancerous invasive cell line (BT20) were compared with the PEMs of the normal 
invasive + normal non-invasive + cancerous non-invasive cells (HMEC+MCF-
10A+MCF-7). In this comparison, 52 proteins were found differentially expressed, of 
which 35 proteins were up-regulated and 17 proteins were down-regulated in BT20 
compared to HMEC+MCF-10A+MCF-7. We used ‘Cancer-related invasion’ term for 
this comparison in this thesis. 
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Table 3.2.1: List of total number of differentially expressed proteins in the comparison of 
cancerous (MCF-7+BT20) vs. Normal (HMEC+MCF-10A), Invasive (HMEC+BT20) vs. 
non-invasive (MCF-10A+MCF-7), and cancerous invasive (BT20) vs. normal invasive + 
normal non-invasive + cancerous non-invasive (HMEC+MCF-10A+MCF-7) and which 
pass the fold change ≥ 1.5 fold up/down regulated with  t-test score of ≤ 0.05. 
No. Comparison Groups No. of 
differentially 
expressed 
proteins 
Up- 
regulated  
Down-
regulated 
1 Cancerous (MCF-7+ BT20) vs. Normal 
(HMEC+ BT20) 
81 56 25 
2 Invasive (HMEC+ BT20) vs. Non-
invasive (MCF-10A + MCF-7) 
(Normal+ cancer-related invasion) 
33 29 4 
3 Cancerous invasive (BT20) vs. Normal 
invasive+ normal non-invasive+ 
cancerous non-invasive (HMEC+MCF-
10A+MCF-7) 
(Cancer-related invasion) 
52 35 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 171 
3.2.4 Identification of differentially expressed proteins using mass-spectrometry 
225 protein spots were picked for identification using MALDI ToF MS and/or LC-
MS/MS. The proteins that were ≥ 3 fold up or down-regulated were analysed using LC-
MS/MS for identification or to confirm identification from MALDI ToF MS. The criteria 
for positive identification of peptides were same as mentioned in 3.1.4. The location of 
identified proteins on a representative 2D-DIGE gel is shown in Figure 3.2.2. The gel 
showed the master number ID generated by Decyder 6.5 BVA module and refers to the 
specific protein IDs obtained for that particular protein spot. 
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Figure: 3.2.2. Representative 2D-DIGE gel image of the Cy2-labelled pool of HMEC, 
MCF-10A, MCF-7 and BT20 conditioned media samples showing differentially expressed 
protein spots that have been successfully identified by MALDI-ToF MS and/or LC-
MS/MS. Identified spots are represented on the gel using the Master Number ID generated 
by the Decyder software as a reference. 
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3.2.5 List of identified differentially regulated proteins in the cancerous vs. normal 
and invasive-related comparisons.   
3.2.5.1 Cancerous (MCF-7+BT20) vs. normal (HMEC+MCF-10A) 
A total of 42 proteins were identified in the comparison of cancerous (MCF-7+BT20) 
vs. normal (HMEC+MCF-10A) group (Table 3.2.2). Among these proteins, 25 proteins 
were up-regulated and 17 proteins were down-regulated in the cancer cell lines 
compared to the normal cells. The cell lines are compared from cancerous to normal and 
therefore proteins that are up-regulated are increased in the cancerous cell lines and are 
represented as positive fold changes. The proteins that are down-regulated have 
negative fold changes, as these proteins are expressed at lower levels in the cancerous 
cell lines compared to the normal cells. The identified secreted proteins are outlined in 
table 3.2.2 showing that dysfunction of these proteins/peptides could be associated with 
the cancerous phenotype.  
 
• The comparison interestingly revealed a range of serine proteases inhibitors 
including SERPINA1, SERPINB1, SERPINB5, SERPINB7 and SERPINF1, 
which were 12.5-fold, 7.9-fold, 41.7-fold, 3.8-fold and 3.2-fold down-regulated 
in the cancer cell lines compared to the normal cells respectively. The secreted 
SERPINB5 has been reported as tumour suppressor in breast cancer (Dowling et 
al. 2007b, Kulasingam and Diamandis 2007).  
 
• Three members of pro-cathepsins, which are cysteine proteinase proteases 
(Nakashima et al. 2004), were identified as differentially regulated. Pro-
cathepsin A (CTSA), pro-cathepsin B (CTSB) and pro-cathepsin D (CTSD) 
were 2.1-fold, 31.2-fold and 2.4-fold down-regulated in the cancer cell lines 
compared to the normal cells respectively.  
 
• Nucleobindin 1 precursor (NUCB1), involved in DNA binding and protein to 
protein interactions (Erickson 1989), were differentially regulated. NUCB1 was 
identified at 3 different spots, which could be due to post-translational 
modification, and were 12.5-fold, 12.5 and 14-fold up-regulated in the cancer 
cell lines compared to the normal cells.  
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• Ferritin, heavy polypeptide 1 (FHC), an iron-containing protein chain, was 3.6-
fold down-regulated in the cancer cell lines compared to the normal cells. 
 
• Protein disulfide isomerase family A, member 4 precursor (PDIA4) was found 
to be 37.8-fold up-regulated in the cancer cell lines compared to the normal 
cells.  
 
On the basis of limited information in the literature regarding their potential role in 
cancer, this study demonstrates that PDIA4, SERPINB1, SERPINB7, NUCB1, CTSA 
and FHC are high potential protein targets that could have important roles in breast 
cancer and also could be potential biomarkers for breast cancer. Table 3.2.3 summarises 
the fold changes of these protein in the cancerous cell lines (MCF-7+BT20) compared to 
the normal cells (HMEC+MCF-10A). 
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Table-3.2.2. Proteins identified from the conditioned media from the comparison of cancerous (MCF-7+BT20) vs. normal (HMEC+MCF-
10A) groups using MALDI ToF MS and/or LC-MS/MS. 2D-DIGE number refers to location of the identified protein on the gel shown in 
the Figure 3.2.2. ‘+’ represents up-regulation and ‘-’ represent down-regulation of protein in terms of fold change in the given comparison. 
(Supplementary data containing additional information of proteins identified: Appendix 5). 
DIGE 
No. 
Gene 
Symbol Protein Identification 
Cancer vs. 
normal  
Fold Change Biological function 
            
231 LAMC2 Laminin, gamma 2 isoform a precursor 
-4.45 
 Cell adhesion 
GSN 
Gelsolin precursor  
 Cell structure 232 
  
  C1R 
Complement C1r subcomponent precursor  
 
-2.53 
  
  Complement-mediated immunity 
326 TPTE2 
Phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase TPTE2  2.92 Phospholipid metabolism 
346 BF  Complement Factor B  3.46 
Complement-mediated immunity 
 
BF 
 Complement factor B precursor  
 
Complement-mediated  
Immunity 
350 
  
  
  RDX 
 Radixin  
 
3.44 
  
  
  Cell structure 
392 
  VIL2 
 Ezrin  
 
5.86 
  Cell structure 
431 
  
  PGM2  Phosphoglucomutase 2  
9.3 
  
  Monosaccharide metabolism 
 PLS3 Plastin-3   Cell structure 
 176 
 
437 RNPEP 
 Aminopeptidase B  
 19.48 Fatty acid biosynthesis Proteolysis 
451 PDIA4 
Protein disulfide-isomerase A4 precursor 
  37.88 
Protein disulfide-isomerase 
Reaction 
480 SERPINB1 
Serine (or cysteine) proteinase inhibitor, 
clade A member 1  8.31 Proteolysis 
483 NUCB1 
Nucleobindin 1 precursor 
 12.55 Calcium ion homeostasis 
484 NUCB1 
Nucleobindin 1 precursor 
  12.56 Calcium ion homeostasis 
486 NUCB1 
Nucleobindin 1 precursor 
 14.04 Calcium ion homeostasis 
497 
  HSPA6 
Heat shock 70 kDa protein 6  
 
8.47 
  Stress response 
590 PDIA3 
Protein disulfide-isomerase A3 precursor 
 3.82 
Protein disulfide-isomerase 
 reaction 
628 TUBB 
Tubulin beta 
 3.15 
Cell structure 
Cell motility 
629 NUCB2 
Nucleobindin-2 precursor  
 3.66 Calcium ion homeostasis 
661 CTSA 
Lysosomal protective protein precursor 
(Cathepsin A)  
 -2.11 
Cell surface receptor  
mediated signal  
transduction 
691 SERPINF1 
Pigment epithelium-derived factor 
precursor 
  -3.29 Proteolysis 
697 
  CTSD 
Cathepsin D preproprotein  
 
-2.41 
  Proteolysis 
 177 
731 
 SERPINB7 
Serpin B7  
 
-3.8 
 Proteolysis 
790 
  ACTB 
 Beta actin  
 
5.34 
  
Cytokinesis 
Cell structure 
791 
  gi58082049 
Hypothetical protein LOC123876  
 
3.5 
   
795 INHBA 
Inhibin beta A precursor 
  -2.86 
Cell proliferation and 
 differentiation 
NUDC 
Nuclear migration protein nudC 
 Cell proliferation and differentiation 799 
  
 KRT18 Keratin, type I cytoskeletal 18  
3.58 
 
Cell structure 
 
807 GLUL 
Chain A, Glutamine Synthetase  
 1.68 
Amino acid biosynthesis 
Nitrogen metabolism 
ACTG1 
Actin, gamma 1 propeptide  
 Cytokinesis, Cell structure 
809 
  
  
  KRT10 
Keratin, type I cytoskeletal 10  
 
4.9 
  
  
  Cell structure 
818 VIM 
Vimentin  
 -6.02 Cell structure 
854 
  SERPINB1 
Serine (or cysteine) proteinase inhibitor, 
clade B, member 1  
-7.98 
  Proteolysis 
855 SERPINB5 
Serpin B5 precursor (Maspin)  
 -41.75 Proteolysis 
869 CTSB 
Procathepsin B  
 -31.23 Proteolysis, Other oncogenesis 
930 DDAH1 
DDAH1 protein 
 2.59 Cell proliferation and differentiation 
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972 
  APOE 
Apolipoprotein E precursor  
 
-6.12 
  Lipid and fatty acid transport 
1070 
 TSP 
Thrombospondin-1 precursor  
 
-1.7 
 Developmental process 
1109 
  
  CAPZB 
F-actin-capping protein subunit beta 
 
1.72 
  
  Cell structure 
1118 NP 
Nucleoside phosphorylase  
 1.51 
mRNA transcription 
regulation 
1252 
  PRDX6 
Peroxiredoxin 6  
 
1.68 
  
Antioxidation and free  
radical removal 
1309 
  GSTP1 
Glutathione S-transferase P 
 
-21.77 
  Sulfur redox metabolism 
1318 
  
  SERPINA1 
Alpha-1-antitrypsin precursor 
 
-12.58 
  
  Proteolysis 
1328 
  HSPG2 
Basement membrane-specific heparan 
sulfate proteoglycan core protein precursor  
(fragment) 
-5.05 
  
Cell adhesion 
 
1395 FHC 
Ferritin, heavy polypeptide 1 
 -3.63 Oogenesis 
1580 SOD1 
Superoxide dismutase 
 2.62 Immunity and defense 
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Table 3.2.3: High priority secreted protein targets from the comparison of cancerous 
(MCF-7+BT20) vs. normal (HMEC+MCF-10A) group that might have a significant role 
in cancer. 
2D-
DIGE 
No. 
Gene 
Symbol Protein Identification 
Fold 
Change 
451 PDIA4 Protein disulfide-isomerase A4 precursor  37.88 
486 NUCB1 Nucleobindin 1 precursor 
14.04, 
12.55 and 
12.56 
661 CTSA 
Lysosomal protective protein precursor 
(Cathepsin A) -2.11 
691 SERPINB7 
Serpin B7  
 
-3.8 
 
854 SERPINB1 
Serine (or cysteine) proteinase inhibitor, 
clade B, member 1 
-7.98 and 
8.31 
1395 FHC Ferritin, heavy polypeptide 1 -3.63 
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3.2.5.2 Invasive (HMEC+BT20) vs Non-invasive (MCF-10A+MCF-7) (Normal + 
cancer-related invasion) 
Table 3.2.4 lists the proteins that have been identified in the N+C invasive 
(HMEC+BT20) vs. N+C non-invasive (MCF-10A+MCF-7) comparison. A total of 15 
proteins were identified, of which 14 proteins were up-regulated and 1 protein was 
down-regulated in the N+C invasive cells compared to the N+C non-invasive cells 
(Table 3.1.4). The N+C invasive cells were compared to N+C non-invasive and 
therefore up-regulated proteins in the N+C invasive cells have been denoted by positive 
fold changes. The proteins that are down-regulated have negative fold changes as these 
proteins are expressed at lower levels in the N+C invasive cells compared to the N+C 
non-invasive cells. The proteins identified in this comparison may have a role in the 
invasion of normal and cancer cells.  
 
Some well known proteins, like heat shock proteins (HSP90 and HSP5) and disulfide 
isomerase family A, member 3 precursor (PDIA3), that have been already correlated 
with invasion, were observed to be differentially expressed in this comparison. 
 
• Heat shock proteins (HSP90 and HSP5), that are induced stress were found 
differentially expressed in this comparison. The heat shock protein 90-beta 
(HSP90) and heat shock 70kDa protein 5 (HSP5) were up-regulated in the N+C 
invasive cells compared to the N+C non-invasive cells by 3.1-fold and 2.9-fold, 
respectively. 
 
• Protein disulfide isomerase-associated 3 precursor (PDIA3) is a soluble ER 
luminal protein that belongs to protein disulfide isomerase family. It was 
identified at 3 different spots in the gel and this could be due to post-
translational modifications. PDIA3 was found to be 1.8-fold, 2-fold and 2.2-fold 
up-regulated in the N+C invasive cells compared to the N+C non-invasive cells.  
 
Some proteins, like TALDO1 and GSS, were also identified from this comparison. The 
role of these proteins in breast cell invasion is poorly known.  
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• Transaldolase (TALDO1), involved in the pentose-phosphate pathway, was 
found to be 2.5-fold up-regulated in the N+C invasive cells compared to the 
N+C non-invasive cells.  
 
• Glutathione synthetase (GSS), involved in synthesis of glutathione, was found to 
be 1.8-fold up-regulated in the N+C invasive cells compared to the N+C non-
invasive cells.  
 
On the basis of limited information in the literature regarding their potential role in 
breast invasion, TALDO1 and GSS proteins are potentially novel findings that could 
have important roles in the normal and cancer breast invasion. 
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Table 3.2.4. Invasive vs. non-invasive (Normal + cancer-related invasion): Proteins identified from the comparison of Non-invasive 
(MCF-10A + MCF-7) vs. Invasive (HMEC+ BT20) group using MALDI ToF MS and/or LC-MS/MS. 2D-DIGE number refers to 
location of the identified protein on the gel shown in the Figure 3.2.2. ‘+’ represents up-regulation and ‘-’ represent down-regulation of 
protein in terms of fold change in the given comparison. (Supplementary data containing additional information of proteins identified: 
Appendix 5). 
2D-
DIGE 
No Gene symbol Protein Identification 
Invasive vs. 
Non-invasive Biological function 
380 HSPA5 Heat shock 70kDa protein 5  2.92 Stress response 
384 HSP90 Heat shock protein HSP 90-beta  3.11 Stress response 
PDIA3 Protein disulfide-isomerase A3 precursor 
Protein disulfide-isomerase 
reaction 
BAT1 Spliceosome RNA helicase BAT1  Nucleic acid metabolism 
557 FKBP4 FK506-binding protein 4  2.21 Protein folding 
558 PDIA3 
 Protein disulfide isomerase-associated 3 
precursor  1.84 
Protein disulfide-isomerase 
reaction 
561 PDIA3 
Protein disulfide isomerase-associated 3 
precursor 2.05 
Protein disulfide-isomerase 
reaction 
563 PDIA3 Protein disulfide isomerase-associated 3 2.29 Protein disulfide-isomerase 
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precursor reaction 
677 GSS Glutathione synthetase  1.82 Sulfur redox metabolism 
705 CTSD Cathepsin D preproprotein  -2.01 Proteolysis 
GDI2 Rab GDP dissociation inhibitor beta  Intracellular signaling cascade 
SSB Lupus La protein  tRNA metabolism 
711 AHCY Adenosylhomocysteinase  2.43 Purine metabolism 
726 PA2G4 Proliferation-associated protein 2G4 3.18 
Cell proliferation and 
differentiation 
HSPA5 Heat shock 70kDa protein 5  Stress response 
736 EIF4A Eukaryotic initiation factor 4A-I  3.35 Translational regulation 
748 CPA4 Chain A, Procarboxypeptidase A4  2.1 Proteolysis 
916 TALDO1 Transaldolase 1  2.07 Pentose phosphate pathway 
969 CAPZA F-actin capping protein alpha-1 subunit  1.93 Cell structure 
1060 ANXA3 Annexin A3 2.73 
Lipid, fatty acid and steroid 
metabolism 
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3.2.5.3 Cancerous invasive (BT20) vs. Normal invasive+ normal non-invasive+ 
cancerous non-invasive (HMEC+MCF-10A+MCF-7) (Cancer-related invasion) 
Table 3.2.5 outlines the identified proteins in the Group 1 (cancer invasive cell line 
(BT20)) vs. Group 2 (Normal invasive+ normal non-invasive+ cancerous non-invasive 
cells (HMEC+MCF-10A+MCF-7)) comparison. A total of 28 proteins were identified in 
this comparison group (Table 3.1.5). Among these proteins, 19 proteins were up-regulated 
and 9 proteins were down regulated in group 1 compared to group 2. The cell lines are 
compared from Group 1 vs.  Group 2 and therefore proteins that are up-regulated in 
Group 1 are represented as positive fold change. The proteins that are down-regulated in 
group 1 compared to group 2 have negative fold change.  
 
Some well known proteins, like plastin-2 (LCP1) and PDIA3 that have already been 
correlated with cancer invasion were differentially expressed in this comparison. 
 
• Plastin-2 (LCP1), an actin filament binding protein, was identified at 2 different 
spots which could possibly due to post-translational modification of this protein. 
LCP1 was found to be 9.8 and 7.9-fold up-regulated in group 1 compared to group 
2.  
 
• Protein disulfide isomerase-associated 3 precursor (PDIA3) was observed to be 1.8-
fold up-regulated in group 1 compared to the group 2.  
 
NUCB2, DDAH1 and HSPG2 were also identified in this comparison of the cancer 
invasive cell line (BT20) vs. normal invasive+ normal non-invasive+ cancerous non-
invasive cells (HMEC+MCF-10A+MCF-7). The role of these proteins in breast cancer cell 
invasion is poorly known.  
 
• Dimethylarginine dimethylaminohydrolase 1 (DDAH1) plays a role in nitric oxide 
generation by regulating cellular concentrations of methylarginines, which in turn 
inhibit nitric oxide synthase activity (Miura et al. 1992, Lin et al. 1998). DDAH1 
was 2.93 fold up-regulated in group 1 compared to group 2. 
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• Nucleobindin 2 precursor (NUCB2), which is involved in DNA binding and protein 
to protein interactions (Cartwright et al. 1999), was found to be 5.2-fold up-
regulated in group 1  compared to group 2.  
 
• Fragment of Heparan sulfate proteoglycan 2 precursor (HSPG2), a basement protein 
involved in cell adhesion (Miura et al. 1992, Lin et al. 1998), was found to be 5.3-
fold down-regulated group 1  compared to group 2.  
 
On the basis of limited information in the literature regarding their potential role in breast 
cancer invasion DDAH1, HSPG2 and NUCB2 proteins are potentially novel findings that 
could have important role in breast cancer invasion. 
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Table 3.2.5. Group 1 (BT20) vs. Group 2 (MCF-10A+HMEC+MCF-7) (Cancer-related invasion): Proteins identified from the Group 
1 vs. Group 2  using MALDI ToF MS and/or LC-MS/MS. 2D-DIGE number refers to location of the identified protein on the gel shown 
in the Figure 3.2.2. ‘+’ represents up-regulation and ‘-’ represent down-regulation of protein in terms of fold change in the given 
comparison. (Supplementary data containing additional information of proteins identified: Appendix 5). 
2D-DIGE 
No. 
Gene symbol 
 Protein Identification 
Group 1 vs.  
Group 2 Biological function 
GSN Gelsolin precursor  Cell structure 
232 C1R Complement C1r subcomponent precursor  -3.22 
Complement-mediated  
Immunity 
326 TPTE2 
Phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase TPTE2 2.46 Phospholipid metabolism 
411 HSPA8 Heat shock 70kDa protein 8 isoform 1  2.36 Stress response 
429 HSPA1B Heat shock 70kDa protein 1B  3.01 Stress response 
PGM2 Phosphoglucomutase 2  
Monosaccharide  
metabolism 
431 PLS3 Plastin-3 4.37 Cell structure 
437 RNPEP Aminopeptidase B  5.37 
Fatty acid biosynthesis 
Proteolysis 
440 LCP1 Plastin-2 9.81 Cell structure 
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443 LCP1 Plastin-2  7.99 Cell structure 
451 PDIA4 Protein disulfide-isomerase A4 precursor 5.74 
Protein disulfide-isomerase 
 Reaction 
509 CCT8 T-complex protein 1 subunit theta  2.78 Protein folding 
558 PDIA3 
Protein disulfide isomerase-associated 3 
precursor 1.85 
Protein disulfide-isomerase 
 Reaction 
628 TUBB Tubulin beta 3.02 Cell structure, Cell motility 
629 N UCB2 
Nucleobindin-2 precursor  
 
 Calcium ion homeostasis 
677 GSS Glutathione synthetase  1.72 Sulfur redox metabolism 
691 SERPINF1 Pigment epithelium-derived factor precursor  -3.3 Proteolysis 
697 CTSD Cathepsin D preproprotein  -2.26 Proteolysis 
705 CTSD Cathepsin D preproprotein  -2.19 Proteolysis 
HSPA5 Heat shock 70kDa protein 5  Stress response 
736 EIF4A Eukaryotic initiation factor 4A-I  3.75 Translational regulation 
763 CBS Chain A, Recombinant Procathepsin B -6.58 Proteolysis 
807 GLUL Chain A, Glutamine Synthetase  1.7 Sulfur redox metabolism 
854 SERPINB1 
Serine (or cysteine) proteinase inhibitor, clade 
B, member 1 -9.95 Proteolysis 
916 TALDO1 Transaldolase 1  2.5 Pentose-phosphate shunt 
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930  DDAH1 DDAH1 protein 2.93 
Cell proliferation and  
differentiation 
972 APOE Apolipoprotein E precursor  -5.69 
Lipid and fatty acid  
Transport 
1131 TPI1  Triosephosphate isomerase  5.15 Glycolysis 
1140 CLIC1 Chloride intracellular channel 1  1.83 Anion transport 
1318 SERPINA1 Alpha-1-antitrypsin precursor  -11.21 Proteolysis 
1328 HSPG2 
Basement membrane-specific heparan sulfate 
proteoglycan core protein precursor (fragment) -5.33 
Cell adhesion 
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3.2.6 Identification of invasion-related proteins by overlapping differentially 
expressed proteins from normal cells with cancerous cells 
The aim of this analysis was to identify secreted proteins that are only differentially expressed 
in the invasive phenotypes or in the non-invasive phenotypes. Two lists of differentially 
expressed proteins from the comparison of the normal non-invasive vs. normal invasive 
cells (MCF-10A vs. HMEC) and the cancerous non-invasive vs. cancer invasive cell lines 
(MCF-7 and BT20) were generated (supplementary data: Appendix 2). The two generated 
differentially expressed protein lists were overlapped, determining the unique and common 
expressing proteins between the lists. A venn diagram outlining the distribution of proteins 
between the lists of differentially expressed protein in a comparison of cancerous non-
invasive (MCF-7) vs. invasive (BT20) cell lines and normal-non-invasive (MCF-10A) vs. 
invasive (HMEC) cells is shown in figure 3.2.3.  
 
The overlapping identified 9 unique proteins, including PRDX6, SOD1, ARP3, ANXA3, 
VIM, HC8, THBS1 and SERPINA1 in the normal comparison group (MCF-10A vs. 
HMEC) and alterations in the expression of these proteins could potentially be associated 
with normal-invasion in cells. Out of these 9 proteins PRDX6 and SOD1 were up-regulated 
in the normal non-invasive cells (MCF-10A) compared to the normal invasive cells 
(HMEC). 4 proteins (VIM, HC8, THBS1 and SERPINA1) were found down-regulated in 
the normal non-invasive cells (MCF-10A) compared to the normal invasive cells (HMEC).  
 
A total of 27 proteins, including well known cancer and invasion-associated proteins 
(HSPA5, GNS, ACTB and HSP90) as well as other proteins (DDAH1, NUCB2 and 
SERPINB7) which are poorly known for their role in invasion, were found to be 
differentially expressed only in the cancer cell line comparison group (MCF-7 vs. BT20) 
and these proteins are possibly involved in the regulation of the invasive phenotype in 
breast cancer cells.  
 
5 proteins were common in both lists of differentially expressed proteins (MCF-10A vs. 
HMEC and MCF-7 vs. BT20). One of these proteins, LAMC2 was down-regulated in both 
comparisons. The second protein spot contained 3 identifications (PDIA3/BAT1/ FKBP4) 
 190 
so it is unclear at this stage which of these proteins is down-regulated in this comparison. 
The remaining 3 proteins include HSP60, CTSB and SERPINB1. HSP60 was up-regulated 
whereas CTSB and SERPINB1 were down-regulated in the cancer-invasive cell line 
(BT20) compared to the cancer-non-invasive cell line (MCF-7). HSP60 was down-
regulated while CTSB and SERPINB1 were up-regulated in the normal-invasive cells 
(HMEC) compared to the normal-non-invasive cells (MCF-10A).  
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Figure 3.2.3. Venn diagram of differentially expressed overlapping secreted proteins of comparison in normal non-invasive (MCF-10A) 
vs. invasive (HMEC) cells and in cancer non-invasive (MCF-7) vs. Invasive (BT20). Proteins are represented by the 2D-DIGE number 
inside the circle and gene symbols outside the circle of protein. 
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3.2.7 Validation of Proteomics data by Western blot analysis 
In order to validate the expression pattern as observed in 2D-DIGE analysis and 
identifications by MALDI-ToF and/or LC-MS/MS, Western blot analysis was carried out 
for selected proteins targets (Bip, Procathepsin B, Maspin, Nucleobindin 1 Precursor and 
Transaldolase-1) on conditioned media samples from the four breast cell lines (HMEC, 
MCF-10A, MCF-7 and BT20). Proteins from the conditioned media of biological 
duplicate samples were separated using 10% SDS gels and were blotted with antibodies 
as described in section 2.8.  
 
Maspin (SERPINB5) and Procathepsin B were highly up-regulated in the normal cells 
(MCF-10A+HMEC) compared to the cancer cell lines (MCF-7+BT20). Nucleobindin 1 
Precursor was also chosen for validation as it was highly down-regulated in this study in 
normal cell lines (HMEC+MCF-10A) compared to the cancer cell lines (MCF-
7+BT20). Heat shock protein 70 protein 5 (BIP) and transaldolase-1 were chosen on the 
basis of antibody availability for them in the laboratory. Transaldolase-1 was also 
identified from 2D-DIGE of cell lysates from HMEC, MCF-10A, MCF-7 and BT20, and 
was validated by Western blotting (Figure 3.2.4-3.2.6), but in the conditioned media 
study, it showed a different expression pattern compared to the cell lysates study and 
therefore was chosen to validate its pattern in conditioned media samples using Western 
blot analysis. 
 
Bip, Procathepsin B, Maspin, Nucleobindin 1 Precursor and Transaldolase-1 confirmed 
the trends observed in the proteomic analysis. Figures 3.2.4 to 3.2.6 show the 
expression pattern of these selected proteins observed using 2D-DIGE and Western blot 
analysis. Table 3.2.6 and 3.2.7 summarize the expression patterns observed in 2D-DIGE 
and western blot analysis for the targets.  
 
Commassie stained gels was used to demonstrate as best as possible equal loading 
between the samples (Figure 3.2.7). 
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Heat shock protein 5 (BIP) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Procathepsin B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.4. Standardized log abundance graph view (Decyder BVA module) and 
Western blot images of BIP and Procathepsin B protein expression from HMEC, MCF-
10A, MCF-7 and BT20. Biological duplicate samples were used in this investigation. 
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Maspin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nucleobindin 1 Precursor 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.5. Standardized log abundance graph view (Decyder BVA module) and 
Western blot images of Maspin (SERPINB5) and Nucleobindin 1 Precursor protein 
expression from HMEC, MCF-10A, MCF-7 and BT20. Biological duplicate samples were 
used in this investigation. 
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Figure 3.2.6. Standardized log abundance graph view (Decyder BVA module) and 
Western blot images of Transaldolase-1 protein expression from HMEC, MCF-10A, 
MCF-7 and BT20. Biological duplicate samples were used in this investigation. 
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Figure 3.2.7. represents coomassie stained gel of conditioned media samples from HMEC, 
MCF-10A, MCF-7 and BT20 to demonstrate even loading between the samples. 
 
 
 
 
 
 
 
 
 
 
 
 
HMEC MCF-10A MCF-7 BT-20
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The differential expression of proteins observed in 2D-DIGE and results observed in 
western blot analysis has been summarised in Table 3.2.7.1 and 3.2.7.2. 
 
Table 3.2.6. Expression pattern of Procathepsin B, Maspin and Nucleobindin 1 Precursor 
observed in 2D-DIGE and WB analysis.  (↑) up-regulated, (↓) down-regulated, (NDE) not 
significantly differentially expressed. 
 
Protein name 
2D-DIGE expression pattern 
(cancer vs. normal) 
WB expression pattern 
(cancer vs. normal) 
Procathepsin B                 ↓                ↓ 
Maspin                 ↓                ↓ 
Nucleobindin 1 Precursor                 ↑                ↑ 
 
 
 
Table 3.2.7. Expression pattern of Nm23, Transaldolase-1 and STIP-1 observed in 2D-DIGE 
and WB analysis.  (↑) up-regulated, (↓) down-regulated, (NDE) not significantly 
differentially expressed. 
Protein name Analysis MCF-10A 
vs. MCF-7 
MCF-7 
vs. BT20 
HMEC vs. 
BT20 
MCF-10A 
vs. HMEC 
2D-DIGE ↓ ↓ ↑ ↓ BIP 
WB ↓ ↓ ↑ ↓ 
2D-DIGE NDE ↓ ↓ NDE Transaldolase-1 
 WB NDE ↓ ↓ NDE 
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3.3 Proteomic analysis of isolated membrane fraction from HMEC, MCF-10A, 
MCF-7 and BT20 
Membranes serve as a barrier between cells and the external environment. Invasive 
cancer cells have the ability to break signalling contact with neighbouring cells, degrade 
and penetrate the basement membrane. This process can disturb the normal function of a 
range of membrane and membrane-associated proteins such as adhesion molecules, 
transduction receptors and transport proteins. Therefore, investigation of protein 
expression changes in breast cell lines representative of normal, non-invasive and 
invasive phenotypes might be helpful to understand biological mechanisms leading to 
breast cancer. For this, differential proteomics study of isolated membrane fractions from 
HMEC, MCF-10A, MCF-7 and BT20 cells were carried out. 
 
3.3.1 Experimental outline  
Investigations were carried out to establish differential protein expression of membrane 
and membrane-associated proteins as previously discribed in section 3.1.2. For this, four 
biological samples from HMEC, MCF 10A, MCF-7 and BT20 were prepared 
separately. Each cell line sample was labelled with 2D-DIGE dyes (i.e. Cy3 and Cy5) as 
outlined in Table 3.1.2. A pooled internal control containing a mixture of all biological 
replicate samples in the experiment was labelled with Cy2 dye as discribed in section 
2.7.3.2.  
 
3.3.2 Analysis of differential expression of proteins using DeCyder 
2D-DIGE protein expression maps (PEMs) for isolated membrane fractions from 
HMEC, MCF 10A, MCF-7 and BT20 were created. Analysis was carried out as 
described in section 3.1.3. After spot matching and filtering, a total of 614 protein spots 
were matched across all of the gels in the experiment (24 gels in total). Spots that were 
±1.5 fold up or down-regulated with p-value ≤ 0.05 were considered significantly 
differentially expressed (DE).  
 
3.3.2.1 Cancerous (MCF-7+ BT20) vs. Normal (HMEC+ BT20) 
The objective was same for this analysis as previously described in sections 3.1.3.1 and 
3.2.3.1 to identify membrane and membrane-associated proteins altered in the cancerous 
cell lines (MCF-7+BT20) in comparison to the normal cells (HMEC+ BT20). This 
comparison revealed altered expression of 78 proteins, of which 30 proteins were up-
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regulated and 48 proteins were down-regulated in the cancerous cell lines (MCF-
7+BT20) compared to the normal cells (HMEC+ BT20). 
 
3.3.2.2 Invasive (HMEC+BT20) vs. Non-invasive (MCF-10A+MCF-7) 
The objective was same for this analysis as previously described in section 3.1.3.2 and 
3.2.3.2 to identify changes in membrane and its associated proteins from cell lines 
representing invasive (normal+cancerous (N+C)) and non-invasive 
(normal+cancerous(N+C)) phenotypes. 73 proteins were found differentially expressed 
in this comparison with 59 up-regulated and 14 down-regulated in the invasive cells 
(HMEC+BT20) compared to the non-invasive cells (MCF-10A+MCF-7). We have used 
‘normal + cancer related invasion’ term for this comparison in this thesis.  
 
3.3.2.3 Cancerous invasive (BT20) vs. Normal invasive+ normal non-invasive+ 
cancerous non-invasive (HMEC+MCF-10A+MCF-7) 
The objective was same for this analysis as previously described in section 3.1.3.3 and 
3.2.3.3 to investigate membrane and membrane-associated protein changes in the 
cancerous invasive cell line (BT20) compared to the normal invasive+ normal non-
invasive+ cancerous non-invasive (HMEC+MCF-10A+MCF-7). In this comparison, 83 
proteins were found differentially expressed, of which 66 proteins were up-regulated 
and 17 proteins were down-regulated in BT20 compared to HMEC+MCF-10A+MCF-7. 
We used the ‘Cancer-related invasion’ term for this comparison in this thesis. 
 
Table 3.3.2 summaries the total number of differentially expressed proteins observed in the 
comparison of cancerous (MCF-7+BT20) vs. normal (HMEC+MCF-10A), invasive 
(HMEC+BT20) vs. non-invasive (MCF-10A+MCF-7) and cancerous invasive (BT20) vs. 
normal invasive + normal non-invasive + cancerous non-invasive (HMEC+MCF-
10A+MCF-7) cells. 
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Table 3.3.1: List of total number of differentially expressed proteins in the comparison of 
cancerous (MCF-7+BT20) vs. normal (HMEC+MCF-10A), invasive (HMEC+BT20) vs. 
non-invasive (MCF-10A+MCF-7) and cancerous invasive (BT20) vs. normal invasive + 
normal non-invasive + cancerous non-invasive (HMEC+MCF-10A+MCF-7) groups and 
which pass the fold change ≥ 1.5 fold up/down regulated with t-test score of ≤ 0.05. 
No. Comparison Groups No. of 
differentially 
expressed 
proteins 
Up- 
regulated  
Down-
regulated 
1 Cancerous (MCF-7+ BT20) vs. 
Normal (HMEC+ BT20) 
95 41 54 
2 Non-invasive (MCF-10A + 
MCF-7) vs. Invasive (HMEC+ 
BT20) 
(Normal+cancer-related 
invasion) 
85 63 22 
3 Cancerous invasive (BT20) vs. 
Normal invasive+ normal non-
invasive+ cancerous non-
invasive (HMEC+MCF-
10A+MCF-7) 
(Cancer-related invasion) 
109 87 22 
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3.3.3 Identification of differentially expressed proteins using mass-spectrometry 
328 protein spots were picked from all four cell lines for identification using MALDI ToF 
MS and/or LC-MS/MS. The proteins that were ≥ 3 fold up or down-regulated were 
analysed using LC-MS/MS for identification or to confirm identification from MALDI 
ToF MS. The criteria for positive identification of peptides were same as discribed in 
section 3.1.4. The location of identified proteins on a representative 2D-DIGE gel is shown 
in Figure 3.3.1. The gel represents the master number ID generated by Decyder 6.5 BVA 
module which refers to the specific protein IDs obtained for that particular protein spot. 
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Figure: 3.3.1. Representative 2D-DIGE gel image of the Cy2-labelled pool of HMEC, 
MCF-10A, MCF-7 and BT20 membrane fraction samples showing differentially expressed 
protein spots that have been successfully identified by MALDI-ToF MS and/or LC-
MS/MS. Identified spots are represented on the gel using the Master Number ID generated 
by the Decyder software as a reference. 
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3.3.4 List of identified proteins differentially regulated in the cancerous vs. normal 
and invasive-related comparisons.   
3.3.4.1 Cancerous (MCF-7+BT20) vs. normal (HMEC+MCF-10A) 
We identified 41 proteins which were found to be altered in the cancerous cell lines 
(MCF-7+BT20) in comparison to the normal cells (HMEC+MCF-10A) (Table 3.3.2). 
Among these proteins, 11 proteins were up-regulated and 30 proteins were down-
regulated in the cancerous cell lines compared to the normal cells. The cells are 
compared from cancerous to normal and therefore proteins that are up-regulated are 
increased in the cancerous cell lines compared to the normal cells and are represented as 
positive fold changes. The proteins that are down-regulated have negative fold changes, 
as these proteins are expressed at lower levels in the cancerous cell lines compared to 
the normal cells.  
 
• Interestingly, a number of mitochondrial membrane and membrane-associated 
proteins (mitochondrial Rho GTPases 2 (RHOT2), prohibitin (PHB), mitofilin 
(IMMT) and ATP synthase subunit beta, mitochondrial precursor (ATP5B) were 
observed to be altered in expression in the cancer cell lines compared to the 
normal cells. For examples, RHOT2 is a member of the novel subgroup of the 
Rho GTPases which are structurally different from Rho GTPases. The role of 
RHOT2 is in mitochondrial homeostasis and in apoptosis (Iozzo 1984). RHOT2 
was found 4.2-fold down-regulated in the cancerous cell lines compared to the 
normal cells. Another protein, PHB, localized to the inner mitochondrial 
membrane which helps in the maintenance of mitochondrial function (Fransson 
et al. 2006), was found 2.7-fold up-regulated cancerous cell lines compared to 
the normal cells and it has been previously reported to be over-expressed in 
breast cancer cells (Mishra et al. 2005).  
 
• A number of plasma membrane and membrane-associated S100 proteins were 
found to be down-regulated in the cancerous cell lines compared to the normal 
cells in this study. S100A2, which is well known to be associated with breast 
cancer (Jupe et al. 1996), was found to be 182.9-fold down-regulated in the 
cancerous cell lines compared to the normal cells. Other members of the S100 
protein family including S100A6, S100A9, S100A14 and S100A16 were also 
found 18-fold, 1.5-fold, 3.3-fold and 2.2-fold down-regulated in the cancerous 
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cell lines compared to the normal cells, respectively. The roles of S100A6, 
S100A9, S100A14 and S100A16 in breast cancer are poorly known. 
 
• SERPINB5 (maspin) was found to be 100.8-fold highly down-regulated in the 
cancerous cell lines compared to the normal cells. SERPINB5 was also found 
down regulated in the cancerous cell lines compared to the normal cells in the 
2D-DIGE studies of cell lysates and conditioned media as described in sections 
3.1.5 and 3.2.5.  
 
A number of other proteins, for which very little information is available for the role of 
these proteins in breast cancer, were observed to be differentially expressed in this 
comparison. For example- 
• FK506 binding protein 5 (FKBP5), also named as FKBP51, was observed to be 
4.22 fold down regulated in the cancerous cell lines compared to the normal 
cells.  
 
• Alpha-soluble NSF attachment protein (ASNAP1) a plasma membrane protein 
involved in intracellular protein traffic, was found to be 1.85-fold up-regulated 
in the cancerous cell lines compared to the normal cells. 
 
On the basis of limited information in the literature regarding their potential role in 
breast cancer, RHOT2, IMMT, FKBP5, ASNAP1 and S100A14 proteins are potentially 
novel findings that could have important roles in breast cancer and also could serve as 
potential biomarkers for breast cancer. Table 3.3.3 summarises the fold changes of these 
protein in the cancerous cell lines compared to the normal cells. 
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Table-3.3.2. Proteins identified from the isolated membrane fraction for the comparison of cancerous (MCF-7+BT20) vs. normal 
(HMEC+MCF-10A) groups using MALDI ToF MS and/or LC-MS/MS. 2D-DIGE number refers to location of the identified protein on the 
gel shown in the Figure 3.3.1. ‘+’ represents up-regulation and ‘-’ represent down-regulation of protein in terms of fold change in the given 
comparison. (Supplementary data containing additional information of proteins identified: Appendix 6). 
DIGE 
no 
 Gene 
Symbols Identification 
Cancer vs. 
Normal 
Fold Change Biological function 
229 RHOT2 Mitochondrial Rho GTPase 2  -4.2 Apoptosis, Cell adhesion 
243 IMMT  Mitofilin -4.2 
Mitochondrial cristae 
maintaince  
272 JUP Junction plakoglobin  -1.87 
Cell adhesion-mediated 
signalling 
334 NT5E  5'-nucleotidase precursor  -4.38 Nucleic acid metabolism 
367 ATP5B 
 ATP synthase subunit beta, mitochondrial 
precursor  -1.67 Electron transport 
386 HSPA9 Stress-70 protein, mitochondrial precursor  -1.84 Stress response 
393 HSPA9 Stress-70 protein, mitochondrial precursor  -2.03 Stress response 
LMNB1  Lamin-B1  Cell structure 431 
  HSPA8 Heat shock 70kDa protein 8 isoform 1  
2.05 
  Stress response 
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436 LMNB1 Lamin-B1  1.98 Cell structure 
527 CES1  Liver Carboxylesterase 1 precursor 33.25 Detoxification 
606 G6PD 
 Structure Of A Deletion Variant Of Human 
Glucose 6- Phosphate Dehydrogenase 
Complexed With Structural And Coenzyme 
Nadp  5.36 Monosaccharide metabolism 
619 FKBP5  FK506-binding protein 5  -4.22 
Protein folding, Calcium 
mediated signalling 
628 FKBP5 FK506-binding protein 5  -2.37 
Protein folding, Calcium 
mediated signalling 
649 KRT8  keratin 8  3.34 Cell structure 
695 ATP5B 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta subunit 
precursor  -1.77 Electron transport 
746 GCN1L1 Translational activator GCN1 1.52 Protein biosynthesis 
812 UQCRC1 
Ubiquinol-cytochrome c reductase core 
protein I -10.49 Electron transport 
848 A2M Alpha-2-macroglobulin precursor  -4.71 Ligand-mediated signalling 
866 ACTA1  Actin, alpha skeletal muscle (Alpha-actin-1) -5.13 Cytokinesis, Cell structure 
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867 ACTA1 Actin, alpha skeletal muscle (Alpha-actin-1) -4.21 Cytokinesis, Cell structure 
877 ACTB Beta actin  -1.66 Cytokinesis, Cell structure 
929 CAPG Macrophage-capping protein  -7.09 
Cell proliferation and 
differentiation 
934 CAPG Macrophage-capping protein -4.69 
Cell proliferation and 
differentiation 
950 SERPINB5 Serpin B5 precursor  -9.68 Proteolysis 
955 SERPINB5  Serpin B5 precursor -100.88 Proteolysis 
1029 NPM1  Nucleophosmin  -3.24 rRNA metabolism 
1050 TALDO1  Transaldolase 1 2.84 Pentose-phosphate shunt 
1153 ANXA3 Annexin A3  -3.51 
Fatty acid and steroid 
metabolism 
1181 ASNAP1 Alpha-soluble NSF attachment protein  1.85 Intracellular protein traffic 
1195 ANXA5 Annexin A5 -2.16 
Fatty acid and steroid 
metabolism 
1277 PHB  Prohibitin  2.76 
Cell proliferation and 
differentiation 
1303 PSME1 Proteasome activator complex subunit 1  2.72 Proteolysis 
1336 YWHAB Chain A, 14-3-3 Protein Beta In Complex -159 Signal transduction 
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With Exoenzyme S Peptide 
1469 GSTP1 
Glutathione S-Transferase P1- 1[v104] 
Complexed With (9r,10r)-9-(S-
Glutathionyl)-10- Hydroxy-9,10-
Dihydrophenanthrene 
-20.69 
 Detoxification 
1472 SAR1B SAR1a gene homolog 2  1.82 General vesicle transport 
1714 DIABLO Diablo homolog, mitochondrial precursor  2.36 Apoptosis 
2353 S100A9 S100-A9 -1.51 Cell communication 
2482 S100A16 S100-A16  -2.24 Calcium ion binding 
2509 S100A14 S100-A14  -3.37 Calcium ion binding 
2659 S100A6 S100-A6  -18.04 
Cell proliferation and 
differentiation 
2668 S100A2 S100-A2  -182.99 
Cell proliferation and 
differentiation 
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Table 3.3.3: High priority membrane and membrane-associated protein targets from the 
comparison of cancerous (MCF-7+BT20) vs. normal (HMEC+MCF-10A) that might have 
a significant role in breast cancer. 
DIGE 
no 
 Gene 
Symbols Identification 
Cancer vs. 
Normal 
Fold Change 
229 RHOT2 Mitochondrial Rho GTPase 2  -4.2 
243 IMMT  Mitofilin -4.2 
367 ATP5B 
ATP synthase subunit beta, 
mitochondrial precursor -1.67 
619 FKBP5  FK506-binding protein 5  -4.22, -2.37 
1181 ASNAP1 
Alpha-soluble NSF attachment 
protein 1.85 
812 UQCRC1 
Ubiquinol-cytochrome c reductase 
core protein I -10.49 
2509 S100A14  S100-A14  -3.37 
2659 S100A6 S100-A6  -18.04 
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3.3.4.2 Invasive (HMEC+BT20) vs. non-invasive (MCF-10A+MCF-7) (Normal + 
cancer-related invasion) 
Table 3.3.4 lists the proteins that have been identified in the N+C invasive (HMEC+ 
BT20) vs. N+C non-invasive (MCF-10A+MCF-7) comparisons. 27 proteins were 
identified in the invasive vs. non-invasive comparison group, of which 21 proteins were 
up-regulated and 6 proteins were down-regulated in the N+C invasive cells compared to 
the N+C non-invasive cells (Table 3.3.4). The invasive cells were compared to non-
invasive cells and therefore up-regulated proteins in the invasive cells have been 
denoted by positive fold change. The proteins that are down-regulated have negative 
fold change as these proteins are expressed at lower levels in the N+C invasive cells 
compared to the N+C non-invasive cells.  
 
This comparison revealed three mitochondrial membrane and membrane- associated 
proteins as being differentially expressed, include 60 kDa heat shock protein 1, 
mitochondrial precursor (HSPD1); NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
precursor (NDUFS1); ATP synthase, H+ transporting, mitochondrial F1 complex, beta 
subunit precursor (ATP5B).  
 
• ATP5B, involved in the glycolytic pathway, was found to be 1.52-fold down-
regulated in the normal and cancer invasive cells (HMEC+BT20) compared to 
the normal and cancer non-invasive cells (MCF-10A+MCF-7). 
 
• NDUFS1 which transfers electrons from NADH to the respiratory chain (Liu et 
al. 2000a), was 1.61 fold down-regulated in the N+C invasive cells compared to 
the N+C non-invasive cells.  
 
• HSPD1, also known as heat shock 60 protein, has been reported over- expressed 
in invasive breast tissues and this protein was found to be down-regulated (1.5 
and 2.2-fold) at two different locations on the gel in the N+C invasive cells 
compared to the normal and cancer N+C non-invasive cells.  
 
Two S100 proteins, S100A9 and S100A16 were differentially expressed in this 
comparison. S100A9 was found 1.8 fold down-regulated while S100A16 was up-
 211 
regulated in the N+C invasive cells compared to the normal and cancer N+C non-
invasive cells. 
 
Some well known proteins, like Non-metastatic cells 1 (NME1), involved in pyrimidine 
metabolism, is known to be correlated with invasion. NME1 was found 2.6-fold down-
regulated in the N+C invasive cells compared to the N+C non-invasive cells.  
 
Some other proteins like RuvB-like-2 and Neutral alpha-glucosidase AB precursor were 
also identified from this comparison. The role of these proteins in breast cell invasion is 
not yet known.  
• WD repeat protein 1 (WDR1), involved in protein-protein interactions and cell 
motility (Ricci et al. 2004), was found to be 2.4-fold up-regulated in  the N+C 
invasive cells compared to the N+C non-invasive cells . 
• RuvB-like 2 (RUVBL2) involved in ATPase and DNA helicase activities 
(Verma et al. 2004), was found to be 4.0-fold up-regulated in the N+C invasive 
cells compared to the N+C non-invasive cells. 
• Adipocyte plasma membrane-associated protein (C20ORF3), involved in 
adipocyte differentiation, was found to be 1.9-fold up-regulated in the N+C 
invasive cells compared to the N+C non-invasive cells. 
• Neutral alpha-glucosidase AB precursor (GANAB), involved in protein 
modification (Bal et al. 2005), was found to be down-regulated (2.3, 2.2 and 2.6-
fold) at three different locations on the gel in the N+C invasive cells compared 
to the N+C non-invasive cells. 
 
On the basis of limited information in the literature regarding their potential roles in 
breast invasion, GANAB, RUVBL2, WDR1 and C20ORF3 proteins are potentially 
novel findings that could have important roles in invasion process of normal and cancer 
breast cells. 
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Table 3.3.4: Invasive vs. Non-invasive (Normal + cancer-related invasion): Proteins identified from the comparison of Non-invasive 
(MCF-10A + MCF-7) vs. Invasive (HMEC+ BT20) group using MALDI ToF MS and/or LC-MS/MS. 2D-DIGE number refers to 
location of the identified protein on the gel shown in the Figure 3.3.1. ‘+’ represents up-regulation and ‘-’ represent down-regulation of 
protein in terms of fold change in the given comparison. (Supplementary data containing additional information of proteins identified: 
Appendix 6). 
DIGE no 
 Gene 
Symbol Identification 
Invasive vs. non-invasive 
Fold Change Biological function 
84 GANAB   Neutral alpha-glucosidase AB precursor  2.37 Protein modification 
177 GANAB   Neutral alpha-glucosidase AB precursor  2.69 Protein modification 
209 HSPD1  
60 kDa heat shock protein 1, mitochondrial 
precursor 2.27 Protein folding 
351 NDUFS1 
 NADH dehydrogenase (ubiquinone) Fe-S 
protein 1, precursor  -1.61 Electron transport 
370 HSPA5  Heat shock 70kDa protein 5  1.57 Stress response 
LMNB1 
 Lamin-B1  
 Cell structure 431 
  HSPA8 Heat shock 70kDa protein 8 isoform 1  
-1.52 
  Stress response 
434 RUVBL2 RuvB-like 2 4.06 
mRNA transcription 
regulation 
441 WDR1  WD repeat-containing protein 1  2.47 Cell motility 
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481 CCT6A T-complex protein 1 subunit zeta  1.83 Protein folding 
499 TCP1 T-complex protein 1 subunit alpha  1.78 Protein folding 
546 HSPD1 
60 kDa heat shock protein 1, mitochondrial 
precursor  1.59 Protein folding 
558 PDIA3 Protein disulfide-isomerase A3 precursor  2.92 
Protein disulfide-
isomerase reaction 
600 PDIA3 Protein disulfide-isomerase A3 precursor  1.96 
Protein disulfide-
isomerase reaction 
669 TUBA1C Tubulin alpha 6 1.51 Cell structure 
671 RUVBL1 RuvB-like 1 1.65 
mRNA transcription 
regulation 
695 ATP5B 
ATP synthase, H+ transporting, mitochondrial 
F1 complex, beta subunit precursor  -1.52 Electron transport 
726 C20ORF3 Adipocyte plasma membrane-associated protein  -1.71 
Other carbohydrate 
metabolism 
827 AHCY Adenosylhomocysteinase  2.02 Purine metabolism 
876 ACTB Actin, gamma 1 propeptide  1.72 
Cytokinesis, Cell 
structure 
884 ACTB Actin, gamma 1 propeptide 1.57 Cytokinesis, Cell 
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structure 
1053 ANXA3 Annexin A3  1.54 
Fatty acid and steroid 
metabolism 
1270 CLIC4 Chloride intracellular channel protein 4  1.62 Anion transport 
1336 YWHAB 
 Chain A, 14-3-3 Protein Beta In Complex With 
Exoenzyme S Peptide 1.94 Signal transduction 
1359 HSPB1  Heat shock protein beta-1 4.64 Stress response 
2353 S100A9  S100-A9 1.8 Cell communication 
1786 NME1  Non-metastatic cells 1, protein -2.65 
Pyrimidine 
metabolism 
2482 S100A16 S100-A16  -2.32 Calcium ion binding 
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3.3.4.3 Cancerous invasive (BT20) vs. Normal invasive+ normal non-invasive+ 
cancerous non-invasive (HMEC+MCF-10A+MCF-7) (Cancer-related invasion) 
Table 3.3.4.4 outlines the 35 identified proteins in the Group 1 (cancer invasive cell 
line (BT20)) vs. Group 2 (Normal invasive+ normal non-invasive+ cancerous non-
invasive cells (HMEC+MCF-10A+MCF-7)) comparison. Among these proteins, 25 
proteins were up-regulated and 10 proteins were down regulated in the group 1 
compared to the group 2. The cell lines are compared from Group 1 vs.  Group 2 and 
therefore proteins that are up-regulated in Group 1 are represented as positive fold 
change. The proteins that are down-regulated in group1 have negative fold change. 
These proteins could be involved in breast cancer invasion. 
 
This analysis showed that six mitochondrial membrane and membrane-associated 
protein were found altered in group 1 compared to group 2. HSPD1, UQCRC1 and 
NDUFS1 were 2.13, 3.39 and 2.67-fold down-regulated in group 1 compared to group 
2, respectively. HSPD1 was identified from two spots and was 1.82-fold and 1.67-fold 
up-regulated in group 1 compared to group 2. Prohibitin, ATP5B and DIALBO were 
found to be up-regulated in group 1 compared to group 2 by 1.85 fold, 2.13 and 2.23 
fold, respectively. 
 
From the S100 protein family, S100A2, S100A14 and S100A16 were found to be 155-
fold, 3.5-fold and 4-fold down-regulated in group 1 compared to group 2 respectively. 
 
This comparison list also revealed some other proteins that have not been investigated 
extensively to date for their involvement in cancer invasion and could have a significant 
role in breast cancer disease  
 
• Liver Carboxylesterase 1 precursor (CES1), involved in detoxification, was 
found to be 45.2-fold over-expressed in group 1 compared to group 2.  
 
• Adenosylhomocysteinase (AHCY), is an enzyme which converts S-
adenosylhomocysteine to homocysteine, was found to be 2.7-fold up-regulated 
in group 1 compared to group 2. 
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• RuvB-like 2 (RUVBL2) involved in ATPase and DNA helicase activities 
(Totani et al. 2006), was found to be up-regulated (5.57 and 2.0-fold) at two 
different locations on the gel in group 1 compared to group 2. 
 
• Transaldolase 1, involved in the pentose-phosphate pathway, was found to be 
4.2-fold up-regulated in group 1 compared to group 2. 
 
On the basis of limited information in the literature regarding their potential role in 
breast cancer invasion, ATP5B, CES1, AHCY, RUVBL2 and TALDO1 proteins are 
intersting findings as they have not been previously linked with breast cancer invasion 
and could be associated with the breast cancer invasive phenotype. 
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Table 3.3.5: Group 1/Group 2 (Cancer-related invasion): Proteins identified from the Group 1 vs. Group 2  using MALDI ToF MS 
and/or LC-MS/MS. 2D-DIGE number refers to location of the identified protein on the gel shown in the Figure 3.3.1. ‘+’ represents up-
regulation and ‘-’ represent down-regulation of protein in terms of fold change in the given comparison. (Supplementary data containing 
additional information of proteins identified: Appendix 6). 
DIGE 
no 
Gene 
symbol Identification 
Group 1 vs. 
group 2  
Fold change Biological function 
84 GANAB  Neutral alpha-glucosidase AB precursor 2.66 Protein modification 
177 GANAB   Neutral alpha-glucosidase AB precursor  2.71 Protein modification 
149 GANAB   Neutral alpha-glucosidase AB precursor  1.59 Protein modification 
209 HSPD1   60 kDa heat shock protein, mitochondrial precursor  2.67 Protein folding 
351 NDUFS1 
 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
precursor  -1.61 Electron transport 
370 HSPA5  Heat shock 70kDa protein 5  1.62 Stress response 
434 RUVBL2 RuvB-like 2 5.57 
mRNA transcription 
regulation 
441 WDR1  WD repeat-containing protein 1  2.11 Cell motility 
499 TCP1 T-complex protein 1 subunit alpha  2.03 Protein folding 
527 CES1  Liver Carboxylesterase 1 precursor 45.2 Detoxification 
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546 HSPD1  60 kDa heat shock protein, mitochondrial precursor  1.82 Protein folding 
550 HSPD1  60 kDa heat shock protein, mitochondrial precursor  1.67 Protein folding 
558 PDIA3 Protein disulfide-isomerase A3 precursor  3.91 
Protein disulfide-isomerase 
reaction 
600 PDIA3 Protein disulfide-isomerase A3 precursor  2.33 
Protein disulfide-isomerase 
reaction 
606 G6PD 
 Structure Of A Deletion Variant Of Human Glucose 6- 
Phosphate Dehydrogenase Complexed With Structural 
And Coenzyme Nadp  3.73 
Monosaccharide 
metabolism 
669 TUBA1C Tubulin alpha 6 1.6 Cell structure 
688 RUVBL2 RuvB-like 2  2.05 
mRNA transcription 
regulation 
695 ATP5B 
ATP synthase, H+ transporting, mitochondrial F1 
complex, beta subunit precursor  -2.13 Electron transport 
726 C20ORF3 Adipocyte plasma membrane-associated protein  -1.97 
Other carbohydrate 
metabolism 
746 GCN1L1 Translational activator GCN1 1.9 Protein biosynthesis 
812 UQCRC1 Ubiquinol-cytochrome c reductase core protein I -3.39 Electron transport 
827 AHCY Adenosylhomocysteinase  2.78 Purine metabolism 
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866 ACTA1  Actin, alpha skeletal muscle  2.47 Cytokinesis, Cell structure 
929 CAPG Macrophage-capping protein  -3.36 
Cell proliferation and 
differentiation 
934 CAPG Macrophage-capping protein -4.79 
Cell proliferation and 
differentiation 
1050 TALDO1  Transaldolase-1 4.29 Pentose-phosphate shunt 
1225 PSME2  Proteasome activator complex subunit 2  3.61 Proteolysis 
1270 CLIC4 Chloride intracellular channel protein 4  1.8 Anion transport 
1277 PHB  Prohibitin  1.85 
Cell proliferation and 
differentiation 
1408 HSPB1 Heat shock protein beta-1 -4.81 Stress response 
1714 DIABLO Diablo homolog, mitochondrial precursor  2.23 Apopotosis 
1786 NME1  Non-metastatic cells 1, protein -1.78 Pyrimidine metabolism 
2482 S100A16 S100-A16  -4.02 Calcium ion binding 
2509 S100A14  S100-A14  -3.53 Calcium ion binding 
2668 S100A2 S100-A2  -155.42 
Cell proliferation and 
differentiation 
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3.3.5 Identification of invasion-related proteins by overlapping differentially 
expressed proteins from normal cells with cancerous cells 
The objective of overlapping two lists was to identify membrane and membrane-associated 
proteins that are only differentially expressed in the invasive phenotypes or in the non-invasive 
phenotypes. Two lists of differentially expressed proteins between normal non-invasive vs. 
normal invasive cell lines (MCF-10A vs. HMEC) and cancerous non-invasive vs. cancer 
invasive (MCF-7 and BT20) cell lines were generated (supplementary data: Appendix 3). 
The two generated differentially expressed protein lists were overlapped determining 
unique and common expressing proteins between the lists. A venn diagram outlining the 
distribution of proteins between lists of differentially expressed proteins in a comparison of 
cancerous non-invasive (MCF-7) vs. invasive (BT20) cells, and normal-non-invasive 
(MCF-10A) vs. invasive (HMEC) cells.  
 
The overlapping identified 29 proteins, including GANAB, LANB1, ITGA3, KRT8, 
SERPINB5, S100A14 and ANXA3, in the normal comparison group and alterations in the 
expression of these proteins could potentially be associated with normal-invasion in cells. 
Out of these 29 proteins, 24 proteins were up-regulated in the normal non-invasive cell line 
(MCF-10A) suggesting reduced levels of thse poteins in the normal invasive cells (HMEC). 
5 proteins were found down-regulated in the non-invasive cell line (MCF-10A).  
 
28 proteins were found differentially expressed in the cancer non-invasive and invasive cell 
lines and these proteins are possibly involved in the invasive phenotype of breast cancer 
cells. Only 3 proteins (PNPO, HSPB1 and hypothetical protein) were found to be up-
regulated in the cancer non-invasive cell line (MCF-7), however 25 proteins were found to 
be down-regulated including TCP, TALDO1, ALDH1A3, S100A9 and S100A6.  
 
A total of 7 proteins were observed common in both comparison groups indicating the 
proteins involved in normal and cancer invasion.  Dysfunction of these proteins could be 
involved in the development of the invasive phenotype of normal cells as well as cancer 
cells. Out of these 7 proteins, 2 proteins (C20ORF3 and SA100A16) were up-regulated and 
2 were down-regulated (GANAB, RUVBL2) in both the non-invasive cell lines compared 
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to the normal and cancer invasive cell lines. 3 proteins were observed differentially 
expressed with the opposite expression pattern. PHB, HSPB1 and DIABLO proteins have 
been reported up-regulated in many types of cancer but the role of GANAB, RUVBL2, 
C20ORF3 and SA100A16 proteins in invasion especially in breast cancer are not clear yet.  
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Figure 3.3.2. Venn diagram of differentially expressed overlapping membrane and membrane-associated proteins of comparison in 
normal non-invasive (MCF-10A) vs. invasive (HMEC) cells and in cancer non-invasive (MCF-7) vs. Invasive (BT20). Proteins are 
represented by the 2D-DIGE number inside the circle and gene symbols outside the circle of protein. 
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3.4 Investigation of low molecular weight secreted proteins from human cell lines 
using Surface-enhanced laser desorption/ionization (SELDI-ToF MS) 
Melanoma is among the most serious cancers and originates from the melanocytes of 
the epidermis. Invasion and metastasis are intimately involved in the pathology of 
melanoma, but the biological and molecular natures of these phenomena remain poorly 
understood. Our objective of this study was to identify potential biomarker (s) for either 
melanoma or melanoma invasion. There have been various reports linking the 
development of resistance to chemotherapeutic drugs, such as doxorubicin, 
methotrexate and melphalan resulting in an increase in the invasive properties of cell 
lines. This indicates that a possible association exists between multiple drug resistance 
and the invasive potential of carcinoma cells. Previously in this laboratory, selection of 
the human drug sensitive and invasive melanoma cell line (MDA-MB-435S-F) with the 
chemotherapeutic agents paclitaxel and doxorubicin, resulted in the development of 
drug-resistant cell lines displaying enhanced invasion. Therefore, the identification of 
proteins/peptides which are differentially regulated in drug-sensitive and drug-resistance 
cells could be helpful to identify altered proteins/peptides that are associated with 
invasion (Bal et al. 2005). We used SELDI-ToF MS to monitor differential expression 
patterns from the melanoma cell lines MDA-MB-435S-F and its paclitaxel-resistant 
variant, MDA-MB-435S-F/Taxol-10p4p which display a greater invasive potential 
compared to the parental cell line (Glynn et al. 2004). 
 
3.4.1 Serum concentration   
To optimize the serum concentration that is suitable to ensure maximum binding of 
proteins/peptides to the chip surface, conditioned media from MDA-MB-435S-F and 
MDA-MB-435S-F/Taxol1p4pSI cells grown in 10% FCS, 0.5% FCS and serum-free 
conditioned media were analysed on Q10 (strong anion-exchange) chip surface using 50 
mM Tris pH 8.0 binding buffer as described in section 2.10.9. Figure 3.4.1 A & B 
shows the comparative map of conditioned media from MDA-MB-435S-F and MDA-
MB-435S-F/Taxol1p4pSI cultured in 10% and 0.5% FCS supplemented culture 
medium. The results indicate that the peaks between m/z 1010 to 1050 were possibly 
inhibited by the binding of other proteins/peptides from serum in conditioned media. 
However conditioned media from cells grown in serum-free media showed separate 
binding of all the proteins/peptides between m/z 1010 to 1200 as shown in Figure 
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3.4.1C. Therefore serum-free culture was considered as the optimal condition for further 
investigation.  
 
 
 
 
Figure 3.4.1: Comparative peak maps on Q10 chip surface of conditioned media from 
MDA-MB-435S-F and MDA-MB-435S-F/Taxol1p4pSI cells. (A) grown in 10% FCS, 
(B) grown in 0.5% FCS, (C) grown in serum-free conditions.  
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3.4.2 Selection of chip surface 
Prior to full profiling analysis, optimization studies were performed using 10 µg of 
extracted protein from serum-free conditioned media samples representing 72hrs of 
culture, on four different chromatographic surfaces to see which surface of Protein Chip 
array gives optimal results as described in section 2.10. Conditioned media samples 
from melanoma cell lines, MDA-MB 435S-F and MDA-MB 435S-F/Taxol10p4p, were 
concentrated using 5000 MW and 10000MW cut-off centricons (Millipore). The 
following Protein Chip arrays were selected, an IMAC30 (immobilized metal affinity 
capture) activated with copper ions, CM10 (weak cation-exchange) with 20 mM Tris 
pH 4.5, Q10 (strong anion-exchange) with 50 mM Tris pH 8.0 and H50 (reversed-phase 
hydrophobic surface) with 10% acetonitrile/0.1% trifluoroacetic acid. The IMAC30 
ProteinChip 8-spot arrays and 5000MW centricon fractionation provided better profiles 
under these conditions in terms of number and resolution of peaks and therefore was 
selected for the final profiling studies. Table 3.4.1 summarises the number of peaks 
discovered by profiling conditioned media on the four different ProteinChip arrays 
(CM10, Q10, H50 and IMAC). 
 
Table 3.4.1: The number of peaks observed by profiling serum-free conditioned media 
from MDA-MB 435S-F and MDA-MB 435S-F/Taxol10p4p on four chromatographic 
chip surfaces. ( * ) Peaks had signal to noise ratio ≥ 3.5 in the first pass; signal to noise 
ratio ≥ 2.0 in the second pass. 
 
 
Array type 
 
Total peaks discovered * 
using 5000MW 
centricons  with mass 
range 5-20000kDa  
Total peaks discovered * 
using 10000MW 
centricons  with mass 
range 20-60000kDa 
IMAC30 41 19 
Q10 pH 8.0 24 23 
CM10 pH 4.5 37 29 
H50 36 22 
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3.4.3 SELDI ToF MS analysis of conditioned media from MDA-MB-435S-F and 
MDA-MB-435S-F/Taxol10p4pSI 
Conditioned media from MDA-MB-435S-F and MDA-MB-435S-F/Taxol10p4pSI were 
analysed in triplicate using IMAC-Cu2+ chip surface. Results were cross-checked for 
their reproducibility by using different biological sample and replicates on different chip 
batches as described in section 2.10. Figure 3.4.2 (A) shows the comparative 
chromatographs of mass signals and Figure 3.4.2 (B) shows the one-dimensional gel 
view from the conditioned media samples analyzed on IMAC-Cu2+ ProteinChip arrays. 
A total of 166 peaks were detected and the most prominent differentially expressed peak 
identified was at m/z 7653. The peak intensity of the m/z 7653 was 4-fold greater in the 
MDA-MB-435S-F/Taxol10p4pSI cell line with a statistically significant p-value of < 
0.04. To further investigate m/z 7653, conditioned media samples representing 24, 48 
and 72 hrs of culture in serum-free media were profiled and the results indicated that the 
intensity of the peak gradually decreased with time (Figure 3.4.3).  
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Figure 3.4.2 (A) Chromatographic view of the conditioned media from the human 
cancer drug-sensitive phenotype MDA-MB-435-S-F (MDA-F) and its paclitaxel-
resistant MDA-MB-435S-F/Taxol10p4pSI (TAXOL SI) run in triplicate on IMAC-Cu2+ 
ProteinChip Arrays. The arrow indicates the position of a differentially expressed peak 
of m/z 7653, (B) 1D Gel view of the corresponding chromatographs.  
 
 
 
 
 228 
 
 
 
 
MDA-F -24hrs
MDA-F-48hrs
MDA-F-72hrs
TAXOL SI-24hrs
TAXOL SI-48hrs
TAXOL SI-72hrs
 
Figure 3.4.3: Chromatographic view of the conditioned media from the human cancer 
drug-sensitive phenotype MDA-MB-435-S-F (MDA-F) and its paclitaxel-resistant 
variant MDA-MB-435S-F/Taxol10p4pSI (TAXOL SI) collected at 24hrs, 48hrs and 
72hrs. Conditioned media from the different time intervals were analysed on IMAC-
Cu2+ ProteinChip Arrays. The arrow indicates the position of a differentially expressed 
peak of m/z 7653. 
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3.4.4 SELDI-ToF MS analysis of conditioned media from MDA-MB-435S-F, 
MDA-MB-435S-F/Taxol10p4pSI and MDA-MB-435S-F/Adr-10p10pSI 
The conditioned media from the drug resistance variant (Doxorubicin) were also 
analysed to see measure the levels of the m/z 7653 peak. For this, conditioned media 
from MDA-MB-435S-F, MDA-MB-435S-F/Taxol10p4pSI and MDA-MB-435S-F/Adr-
10p10pSI were analysed in duplicate on IMAC-Cu2+ chip surface using SELDI-ToF 
MS. The conditioned media from the doxorubicin-resistant variant of MDA-MB-435S-
F (MDA-MB-435S-F/Adr-10p10pSI) also showed a 2.6-fold greater peak intensity of 
m/z 7653 in comparison to the MDA-MB-435S-F parental cell line (Figure 3.4.4).  
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Figure 3.4.4: Chromatographic view of the conditioned media from the human cancer 
drug-sensitive and invasive phenotype MDA-MB-435-S-F (MDA-F), its paclitaxel-
resistant superinvasive variant MDA-MB-435S-F/Taxol10p4pSI (TAXOL SI) and its 
doxorubicin-resistant superinvasive variant MDA-MB-435S-F/Adr-10p10pSI (ADR SI) 
run in duplicate on IMAC-Cu2+ ProteinChip Arrays. The arrow indicates the position of 
a differentially expressed peak at m/z 7653. 
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3.4.5 Purification of the m/z 7653 marker candidate 
The IMAC HyperCel sorbent has the same binding capacity as an IMAC ProteinChip 
Array and is used for the enrichment of the target protein. The conditioned media from 
MDA-MB-435S-F/Taxol-10p4pSI cells was fractionated using BioSepra IMAC-Cu2+ 
HyperCel spin columns as described in section 2.11. All seven fractions collected from 
unbound peptides/proteins through to 500 mM Imidazole were analysed on NP20 
ProteinChip Arrays. Figure 3.4.5 A shows the chromatograph of all seven fractions 
collected from unbound peptides/proteins through to 500 mM Imidazole indicating that 
the greatest concentration of the m/z 7653 peak elutes in the 250 mM fraction with the 
majority of the contaminating proteins removed in earlier fractions. The 250mM 
fraction was run on a 4-12% NuPAGE Bis-Tris 1D gels using a MES/SDS running 
buffer (as described in section 2.11.2). The MES/SDS running buffer is specially 
formulated for greater resolution in the lower molecular weight range. Silver staining of 
the gel allowed a band at m/z 7653 to be excised (Figure 3.4.5 B).  
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Figure 3.4.5: Chromatograph on NP20 ProteinChip surface from all seven fractions 
collected from unbound peptides/proteins through to 500 mM Imidazole by IMAC-Cu2+ 
Hypercel fractionation of MDA-MB-435S-F/Taxol10p4pSI using increasing 
concentrations of Imidazole. The arrow indicates the position of the m/z 7653 peak. (B) 
location of the 7.6kDa band in the gel. 
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3.4.6 Identification of the m/z 7653 marker candidate 
In-gel digestion of proteins was carried out using a modified version of Schevchenko et 
al, 1996 (Glynn et al. 2004). Tryptic digests of the m/z 7653 band were subject to 
MALDI ToF/ToF analysis (as described in section 2.11.3). All MS and MS/MS 
experiments were carried out in positive reflectron mode. Five precursor ions for 
MS/MS were selected automatically on the basis of intensity from the MS spectra. The 
MS and MS/MS data were combined and searched against a number of databases and 
identified m/z 7653 as a bovine transferrin protein. The molecular weight of the 
identified transferrin protein was 79.8kDa suggesting that the m/z 7653 peak is a 
fragment of transferrin protein. The accession number of the protein was gi|29135265 
and its pI was 6.75. Figure 3.4.6 shows the spectra generated from MALDI ToF/ToF 
MS. 
 
 
 
Figure 3.4.6: MALDI-ToF/ToF generated spectrum from tryptic digest of the m/z 7653 
peak. Two matched peptides were at m/z 1466.6434 and m/z 1594.7573 and m/z 7653 
peak was positively identified as a possible protein fragment of bovine transferrin. 
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3.4.7 Gelatin Zymography analysis 
The increased levels of m/z 7653 in the conditioned media of MDA-MB-435S-
F/Taxol10p4pSI possibly indicates that bovine transferrin protein was being cleaved by 
proteases. Zymography was used to assess the levels of proteolytic activity of different 
proteinase enzymes in the conditioned medium from the melanoma cells as described in 
section 2.12. Gelatin is a substrate for matrix metalloproteinases (MMPs), serine and 
cysteine proteinases. Gelatin zymography analysis of the conditioned media from MDA-
MB-435S-F and MDA-MB-435S-F/Taxol10p4pSI showed increased protease activity in 
the MDA-MB-435S-F/Taxol10p4pSI cells compared to MDA-MB-435S-F. Using a panel 
of protease inhibitors the protease type was narrowed down to metalloproteinases. The 
panel included EDTA, Aprotinin, Pepstatin A, E-64 and 1,10 Phenanthroline. EDTA and 
1,10 Phenanthroline are metalloproteinase inhibitors and addition of EDTA and 1,10 
Phenanthroline to the substrate buffer eliminates expression of all protease bands, 
indicating the gelatin degrading proteases secreted by MDA-MB-435S-F/Taxol10p4pSI 
cells  are probably members of the matrix metalloproteinase family. Aprotinin, Pepstatin A 
and E-64 are protease inhibitors that cover cysteine and serine proteases and were found to 
have no effect on activity. Figure 3.4.7 shows the gelatin zymogram of secreted proteases of 
MDA-MB-435S-F (MDA-F) and MDA-MB-435S-F/Taxol10p4pSI (TAXOL SI) in the 
presence or absence of protease inhibitors (EDTA, 1,10 Phenanthroline, Aprotinin, 
Pepstatin A and E-64). The results indicate that EDTA and 1,10 Phenanthroline were able 
to inhibit the activity of the MMPs. The two secreted bands are possibly MMP-2 and MMP-
9 due to the approximate molecular weight of the bands; MMP-2 has a molecular weight of 
approximately 62kDa while MMP-9 has a molecular weight of 92kDa. 
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Figure 3.4.7: Gelatin zymograms of secreted proteases of MDA-MB-435S-F (MDA-F) and MDA-MB-435S-F/Taxol10p4pSI (TAXOL SI) in the 
presence or absence of protease inhibitors (EDTA, 1,10 Phenanthroline, Aprotinin, Pepstatin A and E-64). These gels are representative of 
repeated experiments.  
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3.4.8 Treatment with MMP inhibitors 
Three biological samples of conditioned media from cells treated with MMP 2 and 
MMP 9 inhibitors and untreated control cultures were profiled using SELDI-ToF MS to 
investigate the effect of MMP inhibitors (as described in section 2.13) on the peak at 
m/z 7653. Figure 3.4.8 (A) shows the chromatograph of conditioned media on IMAC-
Cu++ ProteinChip arrays from MDA-MB-435S-F/Taxol10p4pSI cultured untreated and 
treated with MMP 2 or MMP 9 inhibitors. Figure 3.4.8 (B) shows the relative intensity 
graphs of the m/z 7653 and m/z 8579 peaks. The m/z 7653 peak was 2.18 fold (p= 
0.00016) down-regulated in cells treated with the MMP 9 inhibitor and 3.97 fold (p= 
0.00010) down-regulated in cells treated with the MMP 2 inhibitor as compared to 
untreated cells. The expression of the m/z 8579 peak served as a control for this 
experiment and the expression level were found unaltered following treatment with the 
MMP inhibitors. The mean intensities of the m/z 8579 peak was similar in samples from 
MDA-MB-435S-F/Taxol10p4pSI treated with MMP 2 and MMP 9 inhibitors and 
untreated samples. This suggests that the decrease observed in the intensity of the m/z 
7653 peak intensity is specifically due to effects of MMP 2 and MMP 9 inhibition.  
 
 237 
 
Figure 3.4.8 (A) SELDI-ToF MS spectra of conditioned media on IMAC-Cu++ 
ProteinChip arrays from MDA-MB-435S-F/Taxol10p4pSI cultured with MMP 2 or 
MMP 9 inhibitors. The arrow indicates the position of the m/z 7653 (7.6kDa) and m/z 
8579 (8.5kDa) peak species. (B) Graph showing the comparison of the average peak 
intensities for the m/z 7653 peak from MDA-MB-435S-F/Taxol10p4pSI cultured with 
MMP 2 or MMP 9 inhibitors. The error bars represent the standard deviation calculated 
from the three independent biological replicate samples. 
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3.4.9 Prediction of possible cleavage sites for MMPs in transferrin 
The transferrin protein was scanned for the presence of potential MMP cleavage sites 
using the bioinformatics tool ProfileDB (http://protease.burnham.org/www/tools/cgi-
bin/specdb/specdb_home.html). The predicted cleavage sites for MMP 2 were P-X-X-
[Hy], [IL]-X-X-[Hy], [Hy]-S-X-L, H-X-X-[Hy] and for MMP 9 were P-X-X-[Hy]-[ST], 
P-R-[ST]-[Hy]-[ST], G-L-[KR], R-R-[Hy]-L, R-X-L. No MMP cleavage sites were 
predicted in the full transferrin sequence by this software. The identified fragment was 
also overlapped with the full transferrin protein sequence in an effort to identify 
potential MMP cleavage sites. The identified peptide was observed to be lying towards 
the C-terminus of transferrin (Figure 3.4.9). The fragment of transferrin was observed at 
m/z 7653 in SELDI analysis therefore it could be suspected that MMPs might be 
cleaving transferrin at ~69 amino acids from the C-terminus resulting in the 7.6kDa 
fragment.   
 
Figure 3.4.9. Investigation for possible cleavage site for MMP 2 and MMP 9 in 
transferrin. Red denotes the peptide identified by MALDI ToF/ToF for the transferrin 
fragment and the arrow indicates a possible cleavage site for these MMPs calculated 
based on molecular weight (7.6kDa). 
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The amino acid sequence of bovine transferrin was also aligned with the sequence of 
human transferrin using ClustalW (Figure 3.4.9 B). The results indicated that bovine 
transferrin shares 81% sequence homology with human transferrin. The similarity 
around the predicted MMP2 and MMP9 cleavage site was nearly similar. At 635 amino 
acid, K (Lysine) was replaced with S (Serine) in human transferrin, whereas 2 amino 
acids on each side of K were conserved. This is important because MMP2 and MMP9 
have cleavage site motifs comprised of ~4-6 amino acids with conserved boundary 
amino acids suggesting that human transferrin could possibly also be target for MMP2 
and MMP9, although human transferrin does not show significant sequence similarity at 
C-terminus region. Thus there is possibility that the expression of 7.6 kDa could be 
detected in human clinical samples (e.g. serum) from melanoma. 
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Figure 3.4.9 B: Sequence alignment of bovine and human transferrin using ClustalW. 
The box shows conserved boundary amino acids around the predicted cleavage site (K) 
for MMP2 and MMP9 in bovine transferrin. 
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3.4.10 Investigation of m/z 7653 peak in conditioned media from sixteen cell lines 
with different tissues origin by SELDI-ToF MS 
This analysis of the profiles was aimed to investigate the levels of the transferrin 
fragment (m/z 7653) as a potential biomarker in melanoma or if it can be related to 
melanoma invasion. SELDI-ToF MS was used to profile protein/peptides in the 
conditioned media of 16 cell lines including melanocytes (NHEM), 9 melanoma (M14, 
HT144, SKMEL-28, SKMEL-5, Malme-3M, Lox-IMVI, MDA-MB-435S-F, MDA-
MB-435S-F/ Taxol10p4pSI and MDA-MB-435S-F/ Adr-10p10pSI), 2 normal 
mammary epithelial (HMEC and MCF-10A), 2 breast cancer (MCF-7 and BT20) and 2 
lung cancer (DLKP and H1299) cell lines with different invasive phenotypes. For this 
purpose, four biological replicate samples of conditioned media from all 16 cell lines 
were profiled on IMAC30 Cu++ ProteinChip arrays.  Figure 3.4.10 (A) shows a 
representative SELDI-ToF MS spectra in a mass/charge (m/z) range from 7500 to 7900. 
Figure 3.4.10 B is a graphical representation of the m/z 7653 peak and also includes the 
statistical analysis of the expression of the m/z 7653 peak. Figure 3.6.10 (A) clearly 
indicates that the m/z 7653 peak is detected in all melanoma cell lines (M14, SKMEL-
28, SKMEL-5, Malme-3M, Lox-IMVI, MDA-MB-435S-F, MDA-MB-435S-F/ 
Taxol10p4pSI and MDA-MB-435S-F/ Adr-10p10pSI) except HT144 with statistical 
significance (p= 3x10-5). However the m/z 7653 was absent in melanocytes (NHEM), 
normal mammary epithelial (HMEC and MCF-10A), breast cancer (MCF-7 and BT20) 
and lung cancer (DLKP and H1299) cell lines. The m/z 7653 peak was 8.5-fold higher 
in MDA-MB-435S-F, 34.2-fold in MDA-MB-435S-F/ Taxol10p4pSI, 17.8 fold in 
MDA-MB-435S-F/ Adr-10p10pSI, 15.8-fold in SKMEL-28, 22.9-fold in SKMEL-5, 
12.6-fold in Lox-IMVI, 30.2-fold  in M14 and 1.68-fold in Malme 3M cells compared 
to melanocytes. This analysis clearly indicates that the m/z 7653 is detected in all 
melanoma cell lines analysed, except HT144. 
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Figure 3.4.10 (A) SELDI-ToF MS spectra of the m/z 7653 peak on IMAC-Cu++ 
ProteinChip Arrays from conditioned media from melanocytes (NHEM), melanoma 
(MDA-MB-435S-F, MDA-MB-435S-F/Taxol10p4pSI, MDA-MB-435S-F/Adr-
10p10pSI, M14, HT144, SKMEL-28, SKMEL-5, Malme-3M and Lox-IMVI), normal 
mammary cells (HMEC and MCF-10A), lung (DLKP and H1299) and breast (MCF-7 
and BT20) cancer cell lines. The arrow indicates the position of the m/z 7653 peak. (B) 
Graph showing the comparison of the average peak intensities for the m/z 7653 peak on 
the IMAC-Cu++ array in different cell lines. The error bars represent the standard 
deviation calculated from the four independent biological replicates from each cell lines.  
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3.4.11 Reproducibility of the experiment  
The reproducibility of the SELDI-ToF MS spectra for the m/z 7653 peak, i.e., mass and 
intensity intra-experiment and inter-experiment, was also determined. For this analysis 
four biological replicate samples of conditioned media from 6 melanoma cell lines 
(M14, HT144, SKMEL-28, SKMEL-5, Malme-3M and Lox-IMVI) were profiled 
independently on IMAC-Cu++ chip surfaces. The intra and inter-experiment mean CV 
for the mass of the m/z 7653 peak were 0.03% and 0.05% respectively, whereas the 
intra and inter experiment mean CV for the normalized intensity of the peak were 11% 
and 22% respectively, demonstrating the reproducibility of the technique. 
 
3.4.12 Invasion assay of melanocytes and melanoma cell lines 
The invasion status of melanocytes and all of the melanoma cell lines was analysed to 
determine if the expression of the m/z 7653 could be correlated with the invasion status 
of the cell lines. The invasion assays were performed for melanocytes (NHEM) and 
melanoma cell lines (MDA-MB-435S-F, MDA-MB-435S-F/Taxol10p4pSI, MDA-MB-
435S-F/Adr10p10pSI, HT144, M14, SKMEL-5, Lox-IMVI, Malme-3M and SKMEL-
28) over 48hrs of culture (section 2.6). The graph was plotted on the basis of the total 
number of cells that cross the matrigel membrane (Figure 3.4.11). In this investigation 
SKMEL-5 was found to be non-invasive and other melanoma cell lines (HT144, 
Malme-3M, M14, Lox-IMVI, MDA-MB-435S-F/Adr10p10pSI, MDA-MB-435S-F, 
MDA-MB-435S-F/Taxol10p4pSI and SKMEL-28) including melanocytes were 
invasive (Figure 3.4.11). SKMEL-28, MDA-MB-435S-F, MDA-MB-435S-
F/Taxol10p4pSI and melanocytes (normal cells) cells were highly invasive compared to 
Lox-IMVI, MDA-MB-435S-F/Adr10p10pSI. However HT144, Malme-3M and M14 
were low invasive compared to SKMEL-28, MDA-MB-435S-F, MDA-MB-435S-
F/Taxol10p4pSI.  
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Figure 3.4.11: Investigation of the invasion capabilities of melanocytes and melanoma cells. A. Images from the  invasion assay- (1) 
SKMEL-5, (2) Malme-3M, (3) HT144, (4) M14, (5) LovIMVI, (6) MDA-MB-435S-F/Adr10p10pSI, (7) MDA-MB-435S-F, (8) MDA-
MB-435S-F/Taxol10p4pSI, (9) NHEM and (10) SKMEL-28. (B) Graphical representation of comparative levels of invasion in the cells 
tested. Magnification= 200x, Scale bar=200µm. Error bars represent the standard deviation calculated from data obtained from three 
biological samples.
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3.4.13 Relation to invasion status 
Figure 3.4.12 shows the images from a 48 hour invasion assay of melanocytes (NHEM) 
and all melanoma cell lines (MDA-MB-435S-F, MDA-MB-435S-F/Taxol10p4pSI, 
MDA-MB-435S-F/Adr-10p10pSI, M14, HT144, SKMEL-28, SKMEL-5, Malme-3M 
and Lox-IMVI) and from the figure it is clear there is no correlation in the levels of 
expression of the transferrin fragment with the levels of invasion as SKMEL-5 is non-
invasive and expresses high levels of the m/z 7653 species. Malme 3M is invasive but 
expresses low levels of the the m/z 7653 species. Also melanocytes are invasive and 
there was no expression of the m/z 7653 species. Therefore, our results concluded that 
the m/z 7653 species could possibly be a biomarker for melanoma. Table 3.4.2 
summarises the invasion status and m/z 7653 expression in all of the melanoma cell 
lines. 
 
Table 3.4.2: Relation of invasion status with the levels of m/z 7653 peak in melenocytes 
and melanoma cell lines. 
Cell lines Invasion status Levels of m/z 7653 Peak 
(Fold change compared to 
melanocytes) 
NHEM Invasive Not detected 
MDA-MB-435S-F Invasive 8.5 
MDA-MB-435S-F/Taxol10p4pSI Invasive 34.2 
MDA-MB-435S-F/Adr-10p10pSI Invasive 17.8 
M14 Low invasive 30.2 
HT144 Low invasive Not detected 
SKMEL-28 Invasive 15.8 
SKMEL-5 Non-invasive 22.9 
Malme-3M Invasive  1.68 
Lox-IMVI Invasive  12.6 
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3.4.14 Western blot analysis of NHEM and MDA-MB-435S-F/Taxol10p4pSI cells 
There is no commercially available bovine transferrin antibody which can recognize the 
transferrin fragment from conditioned media. Transferrin receptor is a carrier protein for 
transferrin protein therefore it could be possible that transferrin receptor expression is 
also altered between melanocytes and melanoma cell lines. Thus western blot analysis 
of whole cell lysates from melanocytes (NHEM) and one melanoma cell line (MDA-
MB-435S-F/Taxol10p4pSI), which has the highest level of truncated transferrin, using 
an antibody against the transferrin receptor was carried out. Figure 3.4.12A shows that 
the transferrin receptor at approximately 190kDa was found to be increased in the 
MDA-MB-435S-F/Taxol10p4pSI cell line compared to the melanocytes. The 
expression of the internal control protein α-tubulin was un-changed. Densitometry 
analysis showed that the transferrin receptor was 35.9 fold up-regulated in the 
melanoma cell line (MDA-MB-435S-F/Taxol10p4pSI) compared to melanocytes. This 
35.9-fold increase in the expression of transferrin receptor possibly corresponds to the 
34.2-fold increase in the level of truncated transferrin identified by SELDI-ToF MS 
analysis in the MDA-MB-435S-F/Taxol10p4pSI conditioned media (Figure 3.4.13B).  
 
The expression of transferrin receptor also showed a marked increase in abundance 
MDA-MB-435S-F/Taxol10p4pSI cell line compared to its parental cell line MDA-MB-
435S-F. The transferrin receptor was found to be approximately 3.5-fold increased in 
the MDA-MB-435S-F/Taxol10p4pSI compared to the parental cell line (Figures 
3.4.14B). This 3.5-fold increase in the receptor possibly corresponds to a 4-fold increase 
in the transferrin fragment identified by SELDI analysis found in the MDA-MB-435S-
F/Taxol10p4pSI conditioned media (Figure 3.4.14C). The commassie stained gels was 
used to demonstrate as best as possible equal loading between the samples (Figures 
3.4.14A). 
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Figure 3.4.12 (A): Western blot analysis of transferrin receptor in melanocytes and the 
melanoma cell line, MDA-MB-435S-F/Taxol10p4pSI. Cell lysates from NHEM and 
MDA-MB-435S-F/Taxol10p4pSI (TAXOL SI) in duplicate were separated on an SDS-
PAGE gel, transferred on to nitrocellulose membranes, probed with anti-transferrin 
receptor and anti-α-tubulin antibody. An increase in the expression of transferrin 
receptor in melanoma cell lines compared to melanocytes was observed. α-tubulin was 
used as a loading control and no significant change in expression of  α-tubulin was 
observed. 
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Figure 3.4.13(B) Upper panel- Statistical analysis of the transferrin receptor protein 
levels from melanocytes (NHEM) and the melanoma cell line MDA-MB-435S-
F/Taxol10p4pSI. Lower panel- Statistical analysis for the intensity levels of the m/z 
7653 peak from SELDI-ToF MS found secreted in conditioned media by the melanoma 
cell line MDA-MB-435S-F/Taxol10p4pSI. 
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Figure 3.4.14 (A) Coomassie blue stained gel showing equal protein loading from both 
MDA-MB-435S-F and its paclitaxel-resistant superinvasive variant MDA-MB-435S-
F/Taxol10p4pSI. (B) Western blot analysis of MDA-MB-435S-F and MDA-MB-435S-
F/Taxol10p4pSI probed with a transferrin receptor antibody showing the increase in 
abundance of the 190kDa protein in the MDA-MB-435S-F/Taxol10p4pSI phenotype. 
This Western blot is representative of repeat experiments. 
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Figure 3.4.14 (C) Upper panel- Statistical analysis of the transferrin receptor from 
melanoma cell line MDA-MB-435S-F and MDA-MB-435S-F/Taxol10p4pSI. Lower 
panel- Statistical analysis for the intensity levels of the m/z 7653 peak from SELDI-ToF 
MS found secreted in conditioned media by melanoma cell lines MDA-MB-435S-
F/Taxol10p4pSI and MDA-MB-435S-F. 
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3.5 Differential expression of proteins/peptides from media conditioned by 
melanocytes and melanoma cell lines 
3.5.1 SELDI-ToF analysis analysis 
This study aimed to investigate differential expression profiling of melanocytes and 
melanoma cell lines to discover potential biomarkers for melanoma that could be 
helpful to understand the process of transformation of melanocytes cells into melanoma. 
For this, conditioned media from melanocytes (NHEM) and six melanoma cell lines 
(HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5 and SKMEL-28) were analysed by 
SELDI-ToF MS. For this purpose, four biological replicate samples of conditioned 
media from melanocytes and melanoma cell lines were profiled on IMAC30 Cu++ 
ProteinChip arrays.  Four peaks at m/z 7406, 8584, 11959 and 12081 were found 
differentially expressed. 
Figure 3.5.1 A shows a representative SELDI-ToF MS spectra of m/z 7406. Figure 
3.5.1 B is a graphical representation of intensities of the m/z 7406 peak and also 
includes the statistical analysis of the peak. The m/z 7406 peak is dominantly expressed 
in all melanoma cell lines (HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5 and 
SKMEL-28) with statistical significance (p= 3.5x10-7) (Figure 3.7.1B). The m/z 7406 
peak was up-regulated by 15.2-fold in HT144, 19.2-fold in Lox-IMVI, 35.6-fold  in 
M14, 21-fold in Malme 3M, 35.5-fold in SKMEL-5, and 37.5-fold in SKMEL-28 cells 
compared to melanocytes. 
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Figure 3.5.1 (A) SELDI-ToF MS spectra of the m/z 7406 peak on IMAC-Cu++ 
ProteinChip Arrays from conditioned media from the melanocytes (NHEM), melanoma 
(HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5 and SKMEL-28) cell lines. (B) 
Graph showing the comparison of the average peak on the IMAC-Cu++ array in 
different cell lines. The error bars represent the standard deviation calculated from the 
four independent biological replicates from each cell line. 
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Figure 3.5.2 A shows a representative SELDI-ToF MS spectra of m/z 8584 peak. Figure 
3.5.2 B is a graphical representation of the intensities of m/z 8584 and also includes the 
statistical analysis of the peak. The m/z 8584 peak is dominantly expressed in all 
melanoma cell lines (HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5 and SKMEL-28) 
with statistical significance (p= 9.3x10-7) (Figure 3.7.2B). The m/z 8584 peak was up-
regulated by 5-fold in HT144, 10.6-fold in Lox-IMVI, 8.6-fold  in M14, 10.4-fold in 
Malme 3M, 7.2-fold in SKMEL-5, and 7.9-fold in SKMEL-28 cells compared to 
melanocytes. 
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Figure 3.5.2 (A) SELDI-ToF MS spectra of the m/z 8584 peak on IMAC-Cu++ 
ProteinChip Arrays from conditioned media from the melanocytes (NHEM), melanoma 
(HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5and SKMEL-28) cell lines. The arrow 
indicates the position of a differentially expressed peak at m/z 8584. (B) Graph showing 
the comparison of the average peak intensities for the m/z 8584 peak on the IMAC-Cu++ 
array in different cell lines. The error bars represent the standard deviation calculated 
from the four independent biological replicates from each cell line. 
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Figure 3.5.3 A shows a representative SELDI-ToF MS spectra of the m/z 11959 and 
12081 peaks. Figure 3.5.3 B is a graphical representation of the intensities of m/z 11959 
and 12081 peaks and also includes the statistical analysis of the peaks. Figure 3.5.3 B1 
clearly indicates that the m/z 11959 peak is dominantly expressed in all melanoma cell 
lines (HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5 and SKMEL-28) with statistical 
significance (p= 2.2x10-6). The m/z 11959 peak was up-regulated by 4.9 fold in HT144, 
7.4-fold in Lox-IMVI, 13.8-fold in M14, 13.7-fold in Malme 3M, 12.3-fold in SKMEL-
5 and 9.7-fold in SKMEL-28 cells compared to melanocytes. Figure 3.5.3 B2 clearly 
indicates that the m/z 12081 peak is dominantly expressed in all melanoma cell lines 
(HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5 and SKMEL-28) with statistical 
significance (p= 1.0x10-8). The m/z 12081 peak was up-regulated by 11.3-fold in 
HT144, 3.5-fold in Lox-IMVI, 4.8-fold in M14, 13.9-fold in Malme 3M, 4.9-fold in 
SKMEL-5 and 22.1-fold in SKMEL-28 cells compared to melanocytes. 
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Figure 3.5.3 (A) SELDI-ToF MS spectra of the m/z 11959 and 12081 peaks on IMAC-
Cu++ ProteinChip Arrays from conditioned media from melanocytes (NHEM), 
melanoma (HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5and SKMEL-28) cell lines. 
The arrow indicates the position of differentially expressed peaks at m/z 11959 and 
12081. 
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Figure 3.5.3 (B1 and B2) Graph showing the comparison of the average peak intensities 
for the m/z 11959 and 12081 peak respectively on the IMAC-Cu++ array in different cell 
lines. The error bars represent the standard deviation calculated from the four 
independent biological replicates from each cell line. 
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3.5.2 Reproducibility of the experiment  
The reproducibility of the SELDI-ToF MS spectra for m/z 7404, 8584, 11959 and 
12081 peak, i.e., mass and intensity was also determined. For this analysis four 
biological replicate samples of conditioned media from melanocytes and 6 melanoma 
cell lines (M14, HT144, SKMEL-28, SKMEL-5, Malme-3M and Lox-IMVI) were 
profiled independently on IMAC-Cu++ chip surfaces. The inter-experimental mean CV 
for the mass of the m/z 7404, 8584, 11959 and 12081 peaks were 0.04, 0.03, 0.009 and 
0.03 % respectively, whereas the inter-experimental mean CV for the normalized 
intensity were 12.7, 15.2, 12.8 and 20.2% respectively, demonstrating the 
reproducibility of the technique. 
 
3.5.3 Relation to invasion status 
We were also interested to see if the expression of the m/z 7404, 8584, 11959 and 
12081 peaks have any correlation with the invasion status of the cell lines. To determine 
correlation with the invasion status, the expression levels of the m/z 7404, 8584, 11959 
and 12081 peaks were compared with the invasion assay results from the melanocytes 
and melanoma cell lines as outlined in result section 3.4.12. No correlation was seen as 
SKMEL-5 is non-invasive cell line expression and all of four peaks (m/z 7404, 8584, 
11959 and 12081 peaks) were observed to be expressed in the conditioned media of this 
cell line. Table 3.5.3.1 summarises the invasion status and expression of the m/z 7404, 
8584, 11959 and 12081 peaks in the conditioned media of melanocytes and melanoma 
cell lines. 
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Table 3.5.1 : Relation of invasion status with the levels of the m/z 7406, 8584, 11959 and 12081 peaks expression in melanocytes and 
melanoma cell lines. 
Cell lines Invasion 
status 
Levels of m/z 7406 
(Fold change 
compared to 
melanocytes) 
Levels of m/z 8584 
(Fold change compared 
to melanocytes) 
Levels of m/z 11959 
(Fold change compared 
to melanocytes) 
Levels of m/z 12081 
(Fold change compared 
to melanocytes) 
NHEM Invasive 
 
- - - - 
HT144 Low invasive 15.2 5 4.9 11.3 
Lox-IMVI Invasive  
 
19.2 10.6 7.4 3.5 
M14 Invasive 
 
35.6 8.6 13.8 4.8 
Malme-3M Low invasive 21 10.5 13.7 13.9 
SKMEL-5 Non-invasive 35.5 7.2 12.3 4.9 
SKMEL-28 Invasive 
 
37.5 7.9 9.7 22.1 
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3.5.4 Purification of the Potential marker candidate 
Although the m/z 7404, 8584, 11959 and 12081 peaks did not show any correlation with 
invasion but was highly expressed in melanoma cell lines therefore attempts were made to 
identify these proteins as they could play an important role in the transformation of 
melanocytes to melanoma. To identify differentially expressed peaks, conditioned media 
from SKMEL-28 cells was fractionated using BioSepra IMAC-Cu2+ HyperCel spin 
columns. The 150mM imidazole fraction showed the highest concentration of the 8.5kDa 
protein along with the least amount of contaminating peaks (section 2.11.1). We tried to 
fractionate the m/z 7404, 11959 and 12081 peaks but we were not able to purify them. This 
possibly needs more advanced fractionation methods to be applied to purify them from the 
complex mixture of proteins from the conditioned media. Figure 3.5.4 shows the 
chromatograph from all of the seven fractions collected from unbound peptides/proteins 
through to 500 mM Imidazole. All fractions were run on a 16% Tricine 1D-gel. Coomassie 
staining of the gel allowed a band at approximately 8.5kDa to be excised. Figure 3.5.4 B 
shows the coomassie stained gel and the position of the 8.5kDa protein. 
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Figure 3.5.4 (A): IMAC-Cu2+ Hypercel fractionation of SKMEL-28 using increasing 
concentrations of imidazole. All seven fractions were collected from unbound 
peptides/proteins through to 500 mM imidazole and were analysed on NP20 ProteinChip 
Arrays. (B) Coomassie stained gel and the arrow indicates the approximately position of the 
8.5kDa protein/peptide. 
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3.5.5 Identification of the 8.5kDa marker candidate 
In-gel digestion was carried out for the gel plug of that equivalent to the 8.5kDa 
protein/peptide band. Tryptic digests of the proteins were subject to MALDI ToF analysis. 
The expectation value for the protein was determined by Ettan MALDI-ToF Pro evaluation 
software (GE Healthcare) using the ProFound database search engine for peptide mass 
fingerprints (Section 2.7.3.10). The identified proteins by MALDI ToF MS had an expectation 
value of 0.09 (a value of 0 denotes 100% confidence in the database match, a value of, 0.09 
denotes a 9% or less chance that the identification is random) with 61.8% coverage of the 
sequence of the identified protein. The MS data were combined and searched against a 
number of databases and identified as ubiquitin protein. A total of 11 peptides were 
generated by MALDI ToF MS after tryptic digestion and 5 peptides matched for ubiquitin 
protein (gi|51703339). The molecular weight of identified ubiquitin was 8.55 and pI was 
6.6. Figure 3.5.5 shows the spectra generated from MALDI ToF MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.5: MALDI-ToF generated spectrum from a tryptic digest of the 8.5kDa peak. 
The 8.5kDa peak was positively identified as ubiquitin protein. 
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3.5.6 Validation of ubiquitin protein in conditioned media by western blot 
In order to the validate the expression pattern and the identification of the 8.5kDa peak 
observed by SELDI ToF MS, western blot analysis was carried out. Immunoblot analysis of 
conditioned media from melanocytes (NHEM) and one melanoma cell line (SKMEL-28), 
which has the highest expression of ubiquitin, using an antibody against ubiquitin showed a 
marked increase in the abundance levels of the ubiquitin protein in SKMEL-28 at 8.5kDa. 
Figure 3.5.6 shows ubiquitin was found to be increased in the melanoma cell line compared 
to the melanocytes.  
 
 
 
 
Figure 3.5.6. Western blot images for the expression of ubiquitin protein in the conditioned 
media from NHEM and SKMEL-28. Biological duplicate samples were used in this 
investigation.  
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Section 4 
 
 
 
 
 
 
 
Discussion 
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4.1 Breast Cancer 
Breast cancer is a leading cause of death among women. It is a disease of the middle and 
late ages of life as 75% of breast cancer is diagnosed in women over the age of 50. 
Although breast cancer is less common at a young age, younger women tend to have a more 
aggressive form of the disease than older women. The 5-year survival rate is close to 97% 
when the cancer is confined to the breast (Shevchenko et al. 1996). Currently 
mammography is the most commonly employed method for breast cancer screening despite 
its disadvantages such as high false positive and negative rates, hazardous exposure, and 
patient discomfort (Jemal et al. 2004). 
Breast cancer is a complex disease that reflects the genetic as well as protein changes 
within a cell. Gene expression data gives us limited relevant information since proteins are 
the main functional units performing all biological process in the cell or organism and may 
have post-transcriptional event(s) and post-translational modification(s) that contribute 
towards biological activity of proteins. Proteomic technologies allow for identification of 
the protein changes caused by the disease process in a relatively accurate manner. The 
inherent advantage afforded to proteomics is that the identified protein is itself the 
biological endpoint. At the protein level, distinct changes occur during the transformation of 
a healthy cell into a neoplastic cell, including altered expression, differential protein 
modification, changes in specific activity and aberrant localization, and all of which may 
affect cellular function. Therefore, we used 2D-DIGE followed by MALDI-ToF MS and 
LC-MS/MS mass spectrometry in this investigation to identify the changes in protein 
expression in breast cell lines with normal and cancerous, non-invasive and invasive 
phenotypes.  
Proteins redistribute in response to a variety of physiological stimuli. Activation of many 
cellular regulatory pathways is accompanied by the translocation of key proteins from one 
region of the cell to another such as membrane and extracellular regions. The main 
objective of this part of the work was to establish differential protein profiling followed by 
identification of differently expressed proteins from three fractions (cell lysates, 
conditioned media and membrane fraction) of four breast cell lines.  
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4.1.1 Differential Analysis of protein profiles of total cell lysates from 
HMEC, MCF-10A, MCF-7 and BT20 cells 
Protein expression maps (PEMs) were created for total cell lysates from normal-invasive 
(HMEC), normal-non-invasive (MCF-10A), cancer-invasive (BT20) and cancer-non-
invasive (MCF-7) cells. Since the cellular proteins could play an essential role in cancer 
and invasion in breast cells, PEMs were compared using DeCyder 6.5 software to identify 
cancer, normal+cancer-related invasion and cancer-related invasion-associated changes in 
protein expression in the cell lysates. The data was compared in three groups (Box 1) 
 
Box 1: To identify cancer and invasion-associated proteins, protein profiles were created for 
HMEC, MCF-10A, MCF-7 and BT20 cells and three lists of differentially expressed proteins 
were generated;  
• Cancer associated differentially expressed proteins from the comparison of cancer (MCF-
7+BT20) vs. normal (HMEC+MCF-10A),  
• Normal+cancer invasion-related differentially expressed proteins from the comparison of 
the invasive (HMEC+BT20) vs. non-invasive (MCF-10A+MCF-7)   
• Cancer invasion-related differentially expressed proteins from the comparison of cancer 
invasive (BT20) vs. normal invasive+ normal non-invasive+ cancerous non-invasive 
(HMEC+MCF-10A+MCF-7) (Group1 vs. group 2).  
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4.1.1.1 Cancer (MCF-7+BT20) vs. Normal (HMEC+MCF-10A) 
Investigation of the alterations of protein expression in breast cancer cells (MCF-7 and 
BT20) compared to normal cells (HMEC+MCF-10A) can be very useful in understanding 
the changes in the functional pathways and thus the fundamental mechanisms of cancer 
development. A total of 89 protein spots were observed differentially expressed in this 
comparison group, of which 42 were up-regulated and 47 were down-regulated in the 
cancerous cell lines in comparison to the normal cells (Table 3.1.3). A total of 44 protein 
spots were identified using MALDI-ToF MS and/or LC-MS/MS from this comparison, 
among these 27 proteins were up-regulated while 17 protein spots were down-regulated in 
the cancer cell lines (Table 3.1.4). In some cases, multiple protein identities were also 
observed for single protein spots for a number of differentially expressed protein spots, 
which could be due to the poor resolution of proteins that have the similar pI and molecular 
weight using 2D-gel electrophoresis-based investigations. For example, G6PD and CCT-β 
were identified at DIGE No. 1050 (Table 3.1.6, Appendix 4).   
This cancer vs. normal comparison study revealed some proteins which are well established 
in the literature as having a potential role in breast cancer; for example, ANXA1 and 
SERPINB5. We also identified five interesting proteins whose role in breast cancer is not 
yet clear. These include eIF4AIII, UQCRC1, SERPINB1, SOD1 and DCI as mentioned in 
Tables 3.1.4 and 3.1.5. 
 
4.1.1.1.1 Annexin 1 (ANXA1) 
ANXA1 was identified at two different locations on the 2D-gels and was observed to be 
down-regulated by 3.8-fold and 26.8-fold in the cancer cells compared to the normal cells. 
ANXA1 participates in the regulation of membrane trafficking and cellular adhesion and 
alteration of these processes could result in the development of cancer (Leitch 1995, 
Esserman et al. 2002). Down-regulation of ANXA1 was also reported in many types of 
cancers, including head and neck (Gerke and Moss 2002), esophageal (Garcia Pedrero et al. 
2004), gastric (Paweletz et al. 2000), breast (Hippo et al. 2001) and prostate (Ou et al. 
2008). The down-regulation of ANXA1 expression in multiple types of cancers suggests 
that ANXA1 may be a negative regulator of cancer cell growth (Xin et al. 2003). However, 
a few reports have suggested that ANXA1 is actually over expressed in some malignancies 
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including breast cancer (Gerke and Moss 2002). The reduction of ANXA1 protein 
expression has been suggested to occur at an early stage of malignant transformation (Ahn 
et al. 1997).  
 
4.1.1.1.2 SERPINB5 
SERPINB5, also called maspin, is a non-classical serine protease inhibitor (serpin) with 
tumour suppressive activity. This protein was identified at 3 locations on the 2D-gel and 
found to be 98.7, 20.1 and 7.3-fold down-regulated in the the cancer cells compared to 
normal cells. SERPINB5 could be cytosolic, secretory or membrane in localization (Shen et 
al. 2005). SERPINB5 is strongly down-regulated in various cancers (Toillon et al. 2007, 
Khalkhali-Ellis et al. 2008, Pemberton et al. 1997) and the level of SERPINB5 has been 
inversely correlated with the stage of malignancy during breast cancer progression 
(Khalkhali-Ellis et al. 2008, Machtens et al. 2001). Four different variants of SERPINB5 
possibly due to post-translation modifications (phosphorylation) have been already 
observed in fibroblast cells (Vecchi et al. 2008, Maass et al. 2001a & b). This suggests 
SERPINB5 as an important transduction molecule in cancer. A recent study showed that 
inhibition of miR-21 can increase the expression of SERPINB5 in MDA-MB-231 cells 
(Horswill et al. 2008, Odero-Marah et al. 2002). miR-21 has been observed to exert anti-
apoptotic effects and is over expressed in cancers (Zhu et al. 2008). Therefore, down-
regulation of SERPINB5 in the cancer cells in this investigation is in agreement with the 
published literature.  
 
4.1.1.1.3 Translation initiation factor 4A subunit 3 (eIF4AIII) 
eIF4AIII was 2.2-fold up-regulated in the cancer cells compared to the normal cells. 
Eukaryotic initiation factor 4A (eIF4A) is an ATP-dependent RNA helicase that facilitates 
translation with other initiation factors (eIF4F, eIF4E and eIF4G) (Chan et al. 2005). eIF4A 
has  3 isoforms, eIF4AI, eIF4AII and eIF4AIII. eIF4AI and eIF4AII are known to regulate 
translation, but the role of eIF4AIII in translation has not been characterized yet (Li et al. 
1999). eIF4AIII has been shown to inhibit translation in a rabbit reticulocyte lysate when 
added in large amounts (Li et al. 1999). eIF4AIII has been suggested to facilitate ribosomal 
entry site (IRES)-dependent translation of XIAP mRNA that codes for an inhibitor of 
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apoptosis (Li et al. 1999) which could be facilitating survival of the cancer cells. It has also 
been found up-regulated in gastric cancer (Marissen and Lloyd 1998, Clemens et al. 1998, 
Pestova et al. 1996, Holcik et al. 1999).  
             
4.1.1.1.4 Ubiquinol-cytochrome-c reductase complex core protein 1 (UQCRC1) 
UQCRC1 is a nuclear-encoded protein localized to the inner mitochondrial membrane. 
UQCRC1 was 18-fold up-regulated in the cancer compared to the normal cells. UQCRC1 
plays a key role in mitochondria-to-nucleus retrograde response and has been observed to 
be highly expressed in breast and ovarian tumours (Karam et al. 2008). However the 
mechanisms of UQCRC1 in breast cancer are not clear. 
 
4.1.1.1.5 SERPINB1 
SERPINB1, also known as monocyte/neutrophil elastase inhibitor, is a member of the 
serpin superfamily and was 2.9-fold up-regulated the cancer cells compared to the normal 
cells. SERPINB1 was characterized initially as a fast-acting inhibitor of neutrophil elastase 
(Kulawiec et al. 2006). SERPINB1 functions as a physiological inhibitor of the serine 
proteases of neutrophil azurophil (primary) granules, enzymes that are important in 
antimicrobial defense (Remold-O'Donnell 1985). SERPINB1 has overlapping target 
protease specificity with SERPINA1 but it is a member of the intracellular serpin family 
and is located in the cytoplasm. It is therefore more likely to be involved in the control of 
proteases that inadvertently leak from granules. The role of SERPINB1 in the regulation of 
cell growth is still unclear, however it has been observed at relatively high levels in early 
haemopoietic progenitor cells compared to mature cells (Cooley et al. 2001). 
 
4.1.1.1.6 Chain J, Superoxide Dismutase Mutant With Lys 136 Replaced By Glu, Cys 
6 Replaced By Ala and Cys 111 Replaced By Ser (SOD1) 
This SOD1 mutant was 2.3-fold up-regulated in the cancer cells compared to the normal 
cells. More than 20 mutants of SOD1 have been observed to date and many of which have 
been associated with various phenotypes including cytoskeleton maintenance, cell death 
and growth (Missen et al. 2006). The superoxide dismutases (SOD’s) constitute a family of 
antioxidant enzymes that catalyze the conversion of superoxide anions to oxygen and 
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hydrogen peroxide (Rosen et al. 1993, Juarez et al. 2008, Vigilanza et al. 2008). They 
include the manganese-containing SOD (SOD2) in the mitochondria, and the copper-zinc-
containing SOD (SOD1) in the cytoplasm (Noor et al. 2002), with a small fraction in the 
mitochondria intermembrane space (Gregory et al. 1974). The over expression of SOD1 
has been observed to be associated with alterations in the ubiquitin-proteasome system 
which may lead to accumulation of ubiquitinated proteins and various diseases including 
cancer and amyotrophic lateral sclerosis (Sturtz et al. 2001). Inhibition of SOD1 has been 
observed to inhibit EGF-, IGF-1- and FGF-2-mediated phosphorylation of ERK1/2 which 
results in reduced cell proliferation (Cheroni et al. 2009). The down regulation of SOD1 
has also been associated with a decrease in actin and beta-tubulin content leading to altered 
cell morphology and induced cell death (Juarez et al. 2008). This suggests that SOD1 may 
be associated with increased growth and reduced death in breast cancer cells. However, the 
role of a mutant form of SOD1, which was identified by mass-spectrometry in our study, in 
cancer is unknown.  
 
4.1.1.1.7  3,2-trans-enoyl-CoA isomerase (DCI) 
3,2-trans-enoyl-CoA isomerase (DCI) was observed to be 3.1-fold up-regulated in the 
cancer cell lines compared to the normal cells in our study. DCI is also known 
as dodecenoyl-CoA isomerase or Delta(3),Delta(2)-enoyl-CoA isomerase or D3,D2-enoyl-
CoA isomerase. DCI has been reported to be involved in the biochemical reactions of lipids 
and fatty acid and localized in the mitochondrion (Vigilanza et al. 2008). 2,3-trans-Enoyl-
CoA isomerase was found reduced in metastatic breast cancer patients compared to non-
malignant breast cancer patients (Janssen and Stoffel 2002). The role for DCI in breast 
cancer is not yet known.   
 
4.1.1.1.8 Summary 
The fact that ANXA1 and SERPINB5 are differentially expressed in our study and also in 
the published literature validates our experimental approach and techniques used. This 
approach also enabled us to identify eIF4AIII, UQCRC1, SERPINB1, SOD1 and DCI 
which have not previously been associated with breast cancer as they were found altered in 
breast cancer vs. breast normal cells in-vitro in our study. 
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4.1.1.2 Invasive (HMEC+BT20) vs. non-invasive (MCF-10A+MCF-7)  
A total of 31 protein spots were observed differentially expressed in this comparison group, 
of which 20 were up-regulated and 11 were down-regulated in the normal+cancer (N+C) 
invasive cells (HMEC+BT20) compared to N+C non-invasive cells (MCF-10A+MCF-7) 
(Table 3.1.3). From these, 15 proteins were identified out of which 8 were up-regulated and 
7 were down-regulated in the invasive cells (Table 3.1.6). A number of N+C invasion-
related proteins were identified in this study. This comparison also revealed a number of 
known invasion-associated proteins such as NME1 as well as three proteins, PSME1, CLIC1 
and RAD23B, which have not been previously associated with the normal+cancer-invasion 
and therefore may be involved in the regulation of invasion process in normal and cancer 
breast cells.  
4.1.1.2.1 Non-metastatic protein 1 (NME1) 
NME1, a metastasis-suppressor, was 2.4-fold down-regulated in N+C invasive vs. N+C 
non-invasive cells. NME1 is a heterodimeric protein and acts as a nucleoside diphosphate 
(NDP) kinase which is involved in the synthesis of nucleoside triphosphates. NME1 is well 
known for its involvement in cancer and invasion of breast (Vydra et al. 2008). The 
reduced expression of NME1 has been correlated with high tumour metastatic potential in 
several human breast carcinomas (Ouatas et al. 2003). An in vitro study showed that when 
a metastatic breast cancer cell line MDA-MB-435 (which is now considered as a melanoma 
cell line, see section 4.2.1) with low endogenous NME1 expression was transfected with 
NME1, the cells recovered their normal morphology and patterns of growth (Stahl et al. 
1991, Heimann et al. 1998). The mechanisms of action of NME1 are still unknown; 
however it has been shown that the histidine protein-kinase activity correlates tightly with 
the ability of NME1 to suppress cell motility (Howlett et al. 1994).  
 
4.1.1.2.2 Proteosome activator subunit 1 (PSME1)  
PSME1 was 3-fold down-regulated in the N+C invasive vs. N+C non-invasive cells. The 
proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave 
peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway (Hartsough 
and Steeg 1998). An essential function of a modified proteasome, the immunoproteasome, 
is the processing of class I MHC peptides (Mattsson et al. 2001). PSME1 is an alpha 
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isoform of PA28 unit of a proteasome. PA28 is reduced in hepatocarcinoa tumours 
compared to the non-tumour tissues (Rivett and Hearn 2004). PA28 selectively up-regulates 
the presentation of viral MHC class I epitopes in tumour cells and this results in impaired 
presentation of a human TRP2 tumour antigen and ultimately in tumourigenesis (Zhang et 
al. 2007). Impaired expression of proteasome subunits has also been observed to be 
involved in the loss of HLA class I expression in human colon cancer cells (Sijts et al. 
2002). However the involvement of PSME1 (PA28 alpha) in breast cancer is unclear.  
 
4.1.1.2.3 Nuclear choride channel 1 (CLIC1) 
CLIC1 is also known as nuclear chloride ion channel 27 or regulatory nuclear chloride 
channel protein. CLIC1 was 4.4-fold downregulated in N+C invasive vs. N+C non-invasive 
cells. CLIC1 is a member of the p64 protein family. This protein localizes principally to the 
cell nucleus and exhibits both nuclear and plasma membrane chloride ion channel activity. 
CLIC1 has been found over expressed in gastric cancer and hepatocellular carcinoma 
(Miyagi et al. 2003). The expression of CLIC1 has been found to be strongly correlated 
with lymph node metastasis, lymphatic invasion, perineural invasion, and pathological 
staging in gastric cancer (Chen et al. 2007). However its involvement in breast cancer and 
invasion is still not established.  
 
4.1.1.2.4 RAD23B 
RAD23B is one of two human homologs of the Saccharomyces cerevisiae nucleotide 
excision repair (NER) gene product RAD23 and a component of a protein complex that 
specifically complements the NER defect (Huang et al. 2004a). RAD23B was 2-fold up-
regulated in N+C non-invasive vs. N+C invasive cells. This protein contains an N-terminal 
ubiquitin-like domain, which was reported to interact with 26S proteasome, and thus this 
protein may be involved in the ubiquitin-mediated proteolytic pathway in cells (Huang et 
al. 2004b). RAD23B was shown to interact with and elevate the nucleotide excision 
activity of 3-methyladenine-DNA glycosylase (MPG), which suggests a role in DNA 
damage recognition in base excision repair. Genetic variants in genes involved in the NER 
pathway may increase the risk to many types of cancers including lung, bladder and breast 
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(van Laar et al. 2002). However, a role for RAD23B in invasion has not been previously 
reported.  
 
4.1.1.2.5 Summary 
Thus this data suggests an important role of PSME1, CLIC1 and RAD23B in normal and 
cancer invasion of breast cells, however the exact role they play is unclear. Our study 
indicates that alterations in the expression levels of PSME1, CLIC1 and RAD23B could 
possibly contribute to the invasive phenotype.  
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4.1.1.3 Cancer invasive (BT20) vs. normal invasive +normal non-invasive 
+cancer-non-invasive (HMEC+MCF-10A+MCF-7)  
This comparison enabled us to identify proteins that may have a role in cancer invasion. A 
total of 92 proteins were differentially regulated with 24 proteins up-regulated and 68 
down-regulated in group 1 (cancer invasive cell line (BT20)) compared to group 2 (normal 
invasive+normal non-invasive+cancer-non-invasive cells (HMEC+MCF-10A+MCF-7)) as 
mentioned in Box 1. A total of 25 proteins were identified, of which 15 proteins were up-
regulated and 10 were down-regulated in group 1 compared to group 2 (Table 3.1.7). This 
analysis identified a number of known proteins such as gelsolin as well as other proteins 
that have not been previously linked to breast cancer invasion such as TXNRD1, ERP29, 3-
PGDH, TALDO1, CLP and QPRT. These proteins may have roles in the regulation of 
breast cancer invasion and therefore could be potential targets for further study (Table 
3.1.7).  
 
4.1.1.3.1 Gelsolin (GSN) 
Gelsolin (GSN) is a calcium-binding protein which binds to and regulates actin filaments 
(Garcia-Pedrero et al. 2004, Shen et al. 2005, Mechanic et al. 2006, Chen and Madura 
2006). In our study, GSN was found to be 4.2-fold down-regulated in group 1 compared to 
group 2. Decreased expression of cytoplasmic GSN has been shown in several types of 
human cancers, including bladder cancer (Kumar et al. 2004), non-small cell lung cancer 
(Tanaka et al. 2006), prostatic adenocarcinoma (Dosaka-Akita et al. 1998) and breast 
cancer (Lee et al. 1999) suggesting its possible role as a tumour suppressor. GSN 
expression suppresses the activation of phospholipases C (PLC)/protein kinase C (PKCs) 
that are involved in phospholipid signalling pathways, thus inhibiting cell proliferation and 
tumourigenicity (Winston et al. 2001). Severing and capping of actin filaments due to 
reduced GSN levels enhances the rate of cell migration (Sagawa et al. 2003) and invasion 
(Cunningham et al. 1991). Therefore, loss of GSN could possibly contribute to the 
development of the invasive phenotype in breast cancer. 
 
4.1.1.3.2 Thioredoxin reductase 1 (TXNRD1) 
TXNRD1 is a cytosolic enzyme that plays a central role in controlling cellular redox 
homeostasis and was 4.6-fold over-expressed in group 1 compared to group 2. Tumour 
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cells often show increased glycolytic metabolism associated with rapid cell division. It has 
been suggested that TXNRD1 may have a possible role in cellular defence against 
oxidative damage (Tanaka et al. 2006). 
TXNRD1 has been investigated for its role in cell proliferation and therefore has been 
suggested as a potential anti-cancer molecular target. A few studies have shown that 
TXNRD1 enhances tumour proliferation (Hirota et al. 2000b, Hirota et al. 2000a, Wei et al. 
2000, Karimpour et al. 2002). TXNRD1 has been observed elevated in various cancers 
including breast (Smart et al. 2004), colon cancer (Kirkpatrick et al. 1998, Choi et al. 
2002), prostate (Gladyshev et al. 1998), hepatic (Gladyshev et al. 1998) and pancreatic 
cancer (Kirkpatrick et al. 1998, Choi et al. 2002). The inhibition of TXNRD1 expression 
has been shown to inhibit cell proliferation due to G1 cell cycle arrest (Han et al. 1999). 
Moreover, TXNRD1 has also been observed to inhibit the activity of thioredoxin-dependent 
TIMPs and could increase invasion (Engman et al. 2003, Wipf et al. 2001). Over-
expression of TXNRD1 has been also correlated with aggressive tumour growth, poorer 
prognosis and decreased patient survival (Farina et al. 2001).  
 
4.1.1.3.3 Endoplasmic reticulum protein 29 (ERp29) 
ERp29 was 10.4-fold down-regulated in group 1 compared to group 2. ERp29 is expressed 
ubiquitously and abundantly in metazoan cells, implying it has a general ‘housekeeping’ 
function. ERp29 is thought to facilitate the transport of secretory proteins in the early 
secretory pathway (Kakolyris et al. 2001, Raffel et al. 2003). Distinctively, ERp29 lacks 
classical chaperone, disulfide-editing, calcium-buffer, and stress-response properties 
(Cheretis et al. 2006). ERp29 has been found highly expressed in a variety of tumours and 
cancer cell lines including hepatocellular carcinoma (Demmer et al. 1997, Sargsyan et al. 
2002), SK-N-SH (bone marrow neuroblastoma), HeLa (cervix carcinoma), MCF-7 (breast 
carcinoma), A-375 (malignant melanoma) & A549 (lung carcinoma) (Seow et al. 2000), 
ovarian tissue (Myung et al. 2004) and  in basal-cell carcinoma of the skin (Bengtsson et al. 
2007). On the other hand, ERp29 has been shown to be down-regulated in pancreatic 
adenocarcinoma tissue compared to normal pancreatic tissue (Cheretis et al. 2006). The 
roles of ERp29 in breast cancer and invasion are still unclear.  
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4.1.1.3.4 3-phosphoglycerate dehydrogenase (3-PGDH) 
3-PGDH was 5.2-fold over-expressed in group 1 compared to group 2. 3-PGDH catalyzes 
the transition, using NAD+/NADH as a cofactor, of 3-phosphoglycerate into 3-
phosphohydroxy pyruvate, which is the first and rate-limiting step in the serine biosynthesis 
pathway (phosphorylated) (Lu et al. 2004). The serine is not only required for protein 
synthesis; it also serves as a precursor for the biosynthesis of glycine, cysteine, tryptophan, 
and phospholipids. High expression of 3-PGDH, which contributes towards energy 
metabolism, has been noticed in developing cells (Jun et al. 2008). Expression of 3-PGDH 
was also reported to be increased in colon cancer (Yamasaki et al. 2001) implicating its 
associated with the increased glycolytic metabolism of the cancer cells. The up-regulation 
of 3-PGDH in the cancer invasive cell line suggests that 3-PGDH could be involved in 
breast cancer invasion. 
 
4.1.1.3.5 Transaldolase (TALDO1) 
TALDO1 regulates the balance of metabolites in the pentose-phosphate pathway.  
TALDO1 was identified at two different locations on the 2D-gel and was 4.1-fold and 2.7-
fold over-expressed in group 1 compared to group 2. Up to 20 genetic variants of TALDO1 
have been reported and a few variants have been positively associated with the regulation 
of mitochondrial homoeostasis and apoptosis (Snell et al. 1988) and with increased risk of 
squamous cell carcinoma of the head and neck (SCCHN) (Qian et al. 2008). TALDO1 has 
previously been identified at 7 spots in 2D-gels due to phosphorylation of this protein 
(Basta et al. 2008). The activity of TALDO1 has also been observed to be improved due to 
these PTMs in transformed Xeroderma Pigmentosum (XP) diploid fibroblasts and SV40-
tranformed cells compared to normal cells as transcription of TALDO1 mRNA was 
unchanged in these cells (Lachaise et al. 2001). Therefore, the presence of TALDO1 at two 
locations on the 2D-gel in this investigation could be possibly due to either genetic 
variation of TALDO1 or PTMs in TALDO1 which may occur during the process of 
development of cancerous and invasive phenotype in breast cells. The expression of 
TALDO1 has been observed increased in breast carcinoma tissues (Lachaise et al. 2001). 
However, no specific role of TALDO1 in breast cancer invasion has yet been reported. The 
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up-regulation of TALDO1 in the cancer invasive cells suggests that TALDO1 could be 
involved in facilitating invasion of breast cancer. 
 
4.1.1.3.6 Coactosin-Like Protein (CLP) 
CLP was 5.1-fold over-expressed in group 1 compared to group 2. It is an actin-binding 
protein and is involved in the regulation of the actin cytoskeleton. CLP has been reported 
over-expressed in tumour tissue and cell lines as a tumour antigen and can be recognized by 
cellular and humoral immune systems (Jung et al. 2007). CLP is also reported as a human 
pancreatic cancer antigen (Li et al. 2004). CLP can up-regulate the expression of 5-
lipoxygenase (5LO), which is the first committed enzyme in leukotriene biosynthesis and 
also modulate 5LO activity (Nakatsura et al. 2002). The increased expression of 5LO has 
been associated with improved survival of prostate cancer cells (Rakonjac et al. 2006). 
However, the involvement of CLP in breast cancer and invasion is still unreported.  
 
4.1.1.3.7 Quinolinate phosphoribosyltransferase (QPRT)  
QPRT was 5.2-fold over-expressed in group 1 compared to group 2. QPRT, also known as 
nicotinate-nucleotide pyrophosphorylase, is involved in the de novo synthesis of 
Nicotinamide adenine dinucleotide (NAD). NAD acts as a coenzyme in redox reactions and 
therefore has essential roles in cellular metabolism. Inhibition of NAD has been associated 
with induced apoptosis in cancer cells (Ghosh 2004). The observed increased expression of 
QPRT in this study is in keeping with the fact that cancer cells show increased metabolic 
activity compared to normal cells. The role of QPRT in the regulation of the invasive 
phenotype in cancer has not been previously reported.  
 
4.1.1.3.8  Summary 
Therefore the data presented here indicate that increased expression of TXNRD1, TALDO1, 
3-PGDH, QPRT and CLP could be contributing towards enhancing invasion in breast cancer, 
whereas loss of ERp29 could contribute to the invasion by breast cells. 
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4.1.1.4 Identification of invasion-specific proteins by overlapping lists of 
differentially expressed proteins  
The list of differentially expressed identified proteins for the comparison of the cancer non-
invasive vs. cancer invasive cells (MCF-7 vs. BT20) was overlapped with the list of 
differentially expressed identified proteins for the comparison of the normal non-invasive 
vs. normal invasive cells (MCF-10A vs. HMEC) (supplementary data: appendix 1). This 
comparison enabled us to identify normal+cancer invasion-specific differentially expressed 
proteins.  
 
Four proteins, ANXA1, SERPINB5, ARCN1 and a hypothetical protein, were found 
differentially expressed only in the normal cell comparison group (MCF10A vs. HMEC). 
Of these ANXA1 and SERPINB5 are well known to be involved in cancer and invasion.  
• ANXA1 was up-regulated in the normal noninvasive cells (MCF-10A) compared to 
the normal invasive cells (HMEC) in this investigation (Figure 3.1.3). The role of 
this protein in cancer has been described in 4.1.1.1.1. The loss of ANXA1 could 
lead to the cancer phenotype. However, its role in the regulation of invasion in 
normal cells is unknown. 
• SERPINB5 was up-regulated in the normal noninvasive cells (MCF-10A) compared 
to the normal invasive cells (HMEC) (Figure 3.1.3). The role of this protein in 
cancer has been described in 4.1.1.1.2. SERPINB5 could be involved in maintaining 
the normal phenotype in breast cells. However, its role in the regulation of invasion 
in these normal cells remains unclear. 
 
A total of 27 proteins, including keratin 8 and 18 (KRT8 and KRT18) and heterogeneous 
ribonucleoprotein K (HNRPK), were specifically differentially expressed in the cancer cell 
comparison group (MCF-7 vs. BT20). 
• KRT8 and KRT18 were down-regulated in MCF-7 compared to BT20 (Figure 
3.1.3). KT8 and KT18 are the most common and characteristic members of the 
large intermediate filament gene family expressed in 'simple' or single layer 
epithelial tissues of the body. KT8 and KT18 have already been observed up-
regulated in cancerous cell lines (Muruganandham et al. 2005). The higher 
expression of KT8 and KT18 has been associated with increased invasion (Oshima 
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et al. 1996, Kralovich et al. 1998, Putz et al. 1999). Therefore differential 
expression of KRT8 and KRT18 could be associated with the regulation of cancer 
and invasion in breast cells. 
• HNRPK has been shown to be associated with cancer (Matthias et al. 2008, 
Hendrix et al. 1997) and is a member of the p53 MDM2 pathway. HNRPK has also 
been shown to be involved in cell migration (a process necessary for cancer 
metastasis) (Moumen et al. 2005). The over expression of HNRPK in breast cancer 
invasive cells significantly increased the expression of c-Myc protein and enhanced 
breast cancer cell proliferation (de Hoog et al. 2004). HNRPK was observed down-
regulated in MCF-7 compared to BT20 in this study supporting its role in tumour 
growth and invasion in breast cells (Figure 3.1.3).  
 
10 proteins including high-mobility group box 1 (HMGB1) were overlapped in the normal 
(MCF-10A vs. HMEC) and cancer (MCF-7 vs. BT20) comparison groups indicating that 
these proteins could be involved in both cancer and normal invasion as these proteins were 
differentially expressed between the normal non-invasive and the normal invasive cells 
(MCF-10A vs. HMEC) as well as between the cancer non-invasive cell line and cancer 
invasive cell line (MCF-7 vs. BT20) (Figure 3.1.3). This overlapping also identified 
invasion-associated differentially expressed proteins including some proteins that have not 
been previously reported to be associated with breast cancer invasion such as RAD23B, 
PSME1, CLIC1 and TALDO1 (section 4.1.1.2 & 4.1.1.3).  
HMGB1 is a cytokine-like nuclear protein, which is an important mediator of the body’s 
inflammation, ischemia, and injury. HMGB1 was observed abundantly expressed in breast 
cancer tissues compared to normal breast tissues (Mandal et al. 2001). However, the roles 
of HMGB1 in the regulation of invasion in breast cells still need to be explored.  
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4.1.1.5 Screening for invasion-specific proteins for siRNA functional analysis 
A total of 9 invasion-associated protein targets were selected based on the expression 
patterns observed using 2D-DIGE and limited information available in the published 
literature for their potential role in the regulation of invasion in breast cells.  
 
 
  
The expression of these 9 proteins was investigated using Western blotting in a panel of 
breast cell lines representing invasive and non-invasive phenotypes to further ensure the 
invasion-specific expression. Of the 6 cancer invasion-related proteins, only TXNRD1 and 3-
PGDH showed a cancer-related invasion pattern across all cell lines, except UACC-812. 
Briefly in this investigation, TXNRD1 and 3-PGDH were observed to be up-regulated in the 
invasive cell lines (SKBR-3, MDA-MB-231, Hs578T, HCC1937 and BT20) compared to the 
normal cells (HMEC and MCF-10A) and cancerous non-invasive cell lines (T47D and MCF-
7) (Figure 3.1.10A and 3.1.11B). However, in contrast to T47D and MCF-7 cells, both of 
these proteins were also expressed in a cancerous non-invasive cells line, UACC-812. The 
reason why the remaining four targets did not show a cancer invasion-related expression 
pattern could be that similar types of cell lines may also differ in the expression of certain 
proteins due to their genetic heterogeneity (Brezniceanu et al. 2003). For example, two breast 
cell lines, T47D and MCF-7, have been observed to express drastically differing levels of 
MUC1 protein (Lacroix and Leclercq 2004, Walsh et al. 1999), although both of these cell 
lines are similar in their origin (luminal type ductal carcinoma cells and were isolated from 
metastatic tumours) (Walsh et al. 1999). The possible explanations for UACC-812 as an 
outlier could be that although T47D, MCF-7 and  UACC-812 are luminal type, UACC-812 
could be different in the expression of certain proteins compared to T47D and MCF-7, as it is 
an ER and PR negative cell line that was isolated from a primary tumour (Lacroix and 
Leclercq 2004). T47D and MCF-7 are ER and PR positive cell lines and were isolated from 
metastatic tumours (Lacroix and Leclercq 2004).  
 
 
Cancer invasion-related proteins- TXNRD1, TALDO1, ERp29, 3-PGDH, QPRT and CLP 
 Normal+cancer invasion-related proteins- RAD23B, PSME1 and CLIC1 
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Of the 3 normal+cancer invasion-related proteins, only RAD23B showed the 
normal+cancer-related invasion pattern across all cell lines as it was highly expressed in the 
non-invasive cells (MCF-10A, MCF-7, UACC-812 and T47D) compared to the invasive 
cells (MDA-MB-231, Hs578T, HCC1937, BT20, HMEC and SKBR-3) (Figure 3.1.10A 
and 3.1.12B). 
 
Therefore 3 proteins, TXNRD1, 3-PGDH and RAD23B, were chosen to investigate their 
involvement in invasion and cell proliferation using siRNA knockdown technique. 
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4.1.1.6 Analysis of knock down of expression of protein targets using siRNAs 
4.1.1.6.1 TXNRD1 
Two independent siRNA molecules were transfected into the two invasive cell lines, i.e. 
MDA-MB 231 which is highly invasive and SKBR-3 which is low invasive, to inhibit the 
expression of TXNRD1 for investigating its potential effects on cell proliferation and 
invasion. Following the inhibition of TXNRD1 expression in both cell lines, MDA-MB 231 
and SKBR-3, the invasion status of TXNRD1 siRNA treated cultures was decreased in both 
cell lines in comparison to the scrambled siRNA treated control cultures (Figure 3.1.16 & 
3.1.17). However this decrease was greater in the case of SKBR-3 (3.1 fold) compared to 
MDA-MB 231 (1.4-fold). Therefore, these results suggest that TXNRD1 could have a role 
in the regulation of breast cancer invasion. 
 
4.1.1.6.1.1 Possible role of TXNRD1 in breast cancer invasion 
The gelatinases, MMP-2 and MMP-9 are over-expressed by many tumours and have been 
implicated in the induction and maintenance of the malignant phenotype, tumour invasion 
and tumour-associated angiogenesis (Lacroix and Leclercq 2004). MMPs are believed to be 
crucial to facilitate invasion by degrading extracellular matrix macro-molecules such as 
type IV collagen (Deryugina and Quigley 2006, Ray and Stetler-Stevenson 1994, 
Deryugina et al. 1997, Ballin et al. 1988). The MMPs activation and inhibition are 
regulated by members of the family of tissue inhibitors of MMPs (TIMPs). The 
MMP/TIMP balance is therefore a critical determinant of net proteolytic activity and its 
imbalance is generally considered a prerequisite for MMP involvement in tumour 
pathology (Tryggvason et al. 1993). TXNRD1 protein catalyses the reduction thioredoxins 
as well as other substrates that play a role in selenium metabolism and protection against 
oxidative stress (Liotta and Stetler-Stevenson 1991, Nagase 1997). Thioredoxins have been 
reported as inhibitors of TIMP-1, TIMP-2 and MMP-2 and can alter the MMP/TIMP 
balance in favour of MMP activity stimulating the SK-N-SH neuroblastoma cell invasion 
(Hirota et al. 2000a & b, Wei et al. 2000, Karimpour et al. 2002). TXNRD1 promotes 
alterations in the thioredoxin-dependent MMP/TIMP balance (Farina et al. 2001). Our 
study showed that knockdown of TXNRD1 in the invasive cells (SKBR-3 and MDA-MB 
231) was able to reduce in vitro invasion of these low and highly invasive cell lines. It 
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could be possible that silencing of TXNRD1 protein could reduce thioredoxin dependent 
inhibition of TIMP-1, TIMP-2, MMP-2 and MMP-9 and finally suppressing the MMPs 
activity thus reducing invasion in breast cancer cells. However, further studies are required 
to confirm this hypothesis. 
 
4.1.1.6.1.2 Possible role of TXNRD1 in cell proliferation 
Proliferation assays of TXNRD1 siRNA transfected cells, MDA-MB 231 and SKBR-3 
were performed after 3 days of transfection (Figure 3.1.18). No significant differences in 
the growth of TXNRD1 siRNA-treated cultures were observed in comparison to the control 
culture (Scrambled-treated culture) and this indicates that the loss of TXNRD1 does not 
affect cell growth in MDA-MB 231 and SKBR-3 cells. Thus the results indicate that 
TXNRD1 has no obvious effect on cell proliferation.  
 
The data presented here showed that TXNRD1 is an excellent target to reduce the invasion 
potential in breast cancer. However, further functional studies such as siRNA knockdown 
in a panel of invasive cell lines and over-expression in low and non-invasive cells lines will 
be beneficial to confirm its involvement in the regulation of invasion in breast cells. 
 
4.1.1.6.2 RAD23B 
Three independent siRNA molecules were transfected into the normal non-invasive cells 
(MCF-10A) and cancer non-invasive cell line (MCF-7) to inhibit the expression of 
RAD23B in order to investigate its effects on cell proliferation and invasion in breast cells.  
Following the down regulation of RAD23B expression in both non-invasive cells, MCF-
10A and MCF-7, the invasion status of RAD23B siRNA-treated cultures was increased in 
both cell lines in comparison to the scrambled siRNA-treated control cultures (Figure 
3.1.20 & 3.1.21). Cancerous non-invasive cells (MCF-7) and normal non-invasive cells 
(MCF-10A) showed a 4-fold and 2.9-fold increase in their invasion status, respectively. 
Therefore our results suggest that RAD23B could play a significant role in normal breast 
invasion and cancerous breast invasion. 
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4.1.1.6.2.1 Possible role of RAD23B in breast invasion 
The role of RAD23B in invasion is unknown. RAD23B is involved in the nucleotide 
excision repair (NER) pathways of mammalian cells. NER is a particularly important 
mechanism by which the cell can prevent unwanted mutations by removing DNA damage 
(mostly in the form of thymine dimers and photoproducts). NER can be categorized into 
two classes- global genome NER (GG-NER) and transcription-coupled NER (TC-NER). 
RAD23B has roles in GC-NER where it forms a complex (XPC-RAD23B) with xeroderma 
pigmentosum group C protein (XPC) which is responsible for distortion recognition, open 
complex formation, and repair protein complex formation (Farina et al. 2001). XPC-
RAD23B has been observed to be necessary to recruit the general transcription factor IIH 
(TFIIH) to the damaged DNA for global genome repair (Yokoi et al. 2000), however the 
exact functions of RAD23B remain unclear. Genetic variations in genes due to defects in 
NER pathway have been associated with increased risk of many types of cancer including 
lung, bladder and breast (Yokoi et al. 2000). The mutation in a homolog of RAD23B, 
RAD23, has been observed to result in reduced proficiency in excision repair in 
Saccharomyces cerevisiae (Garcia Pedrero et al. 2004, Shen et al. 2005, Mechanic et al. 
2006, Chen and Madura 2006). RAD23B has also been observed to be involved in the 
regulation of ubiquitin-dependent proteolysis (Watkins et al. 1993). Moreover, RAD23B 
has been observed to be reduced due to over expression of miR-373 during hypoxic stress 
conditions, where genomic stability is reduced (Huang et al. 2004b). The increased 
invasion in both normal and cancerous non-invasive cells (MCF-10A and MCF-7) 
following siRNA-mediated down regulation of RAD23B expression suggests that RAD23B 
could be one of the proteins that can regulate invasion (normal and cancerous). Normal and 
cancer invasion use similar molecular mechanisms and the only difference them is that 
malignant invasion can persist (Crosby et al. 2009). Therefore, it is possible that RAD23B 
could be modulated by other unknown regulators to start/stop invasion in normal breast 
cells, whereas the tumour cells might have lost these unknown regulators during 
development of cancerous and/or invasive phenotypes in breast cells (Liotta and Stetler-
Stevenson 1991). However, the exact mechanism needs to be elucidated through further 
studies. To our knowledge, this is the first study showing that RAD23B could possibly play 
a significant role in the invasion of normal breast cells and cancerous breast cells.  
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4.1.1.6.2.2 Possible role of RAD23B in cell proliferation  
Proliferation assays of RAD23B siRNA transfected cells, MCF-10A and MCF-7, were 
performed after 3 days of transfection (Figure 3.1.22). No significant differences in the 
growth of RAD23B siRNA treated cultures were observed in comparison to the control 
culture (Scrambled-treated culture). This indicates that the loss of RAD23B does not affect 
cell growth in MCF-10A and MCF-7 cells.  
 
4.1.1.6.3 3-PGDH 
Increased expression of 3-PGDH was observed in the invasive cells (MDA-MB-231, 
Hs578T, HCC1937, BT20, HMEC and SKBR-3) compared to the non-invasive cells 
(MCF-10A, MCF-7 and T47D), except UACC-812 (Section 4.1.2.6) indicating its potential 
involvement in the invasion in breast cells. Following optimized transfection conditions, 
30nM of three independent siRNA molecules for 3-PGDH was transfected into MDA-MB 
231 and SKBR-3 cells. The Western blot analysis for the protein samples harvested after 72 
hrs of transfection revealed no inhibition of 3-PGDH expression for both cell lines (Figure 
3.1.23). However as expected a significant reduction in cellular growth for the positive 
control cultures (kinesin siRNA-treated) was observed in both cell lines for the same 
experiment (Figure 3.1.24).  
Since cell lines can behave differently for particular siRNA molecules and protein targets, 
transfection was performed in another cell line (BT20). No effect on the expression of 3-
PGDH in siRNA treated samples compared to controls was again observed in Western 
blotting, although the positive control worked as expected. Increased concentrations of 3-
PGDH siRNA (50 and 125nM) were then used for SKBR-3 and MDA-MB 231. The 
samples collected at 96 hrs after transfection again showed no inhibition of 3-PGDH 
expression. These results indicated that the expression of 3-PGDH at the protein level was 
unaffected in all transfection conditions tested in this investigation. The possible 
explanation for this includes that 3-PGDH may have a slow turn over in cells and therefore 
investigation of knockdown at the mRNA level could help to understand the efficiency of 
transfection reactions since the proteins already translated and present in the cytoplasm can 
not be altered by siRNA molecules. Moreover the siRNA molecules used in this 
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investigation have not been validated by the supplier to date and we can not be sure about 
the efficiency of siRNA molecules. In this condition, the use of siRNAs designed using 
improved algorithms and/or validated siRNAs from other suppliers could inhibit the 
expression of 3-PGDH. The potential role of 3-PGDH in the regulation of cancer has been 
described in section 4.1.1.3.4.  
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4.1.2 Proteomic analysis of conditioned media from HMEC, MCF-10A, 
MCF-7 and BT20  
The term "secretome" was first proposed by a genome-based global survey on secreted 
proteins of Bacillus subtilis (Liotta and Stetler-Stevenson 1991). In a broader sense, the 
secretome harbours proteins released by a cell, tissue or organism through classical and 
nonclassical secretion pathways (Tjalsma et al. 2000). These secreted proteins could be 
stimulatory growth factors, proteases and cytokines (Volmer et al. 2005) and could be 
essential in the processes of differentiation, invasion, metastasis and angiogenesis of 
cancers by regulating cell-to-cell and cell-to-extracellular matrix interactions (Ariztia et al. 
2006). More importantly, these cancer-secreted proteins always enter body fluids such as 
blood or urine and can be measured by quantitative assays. Thus, the cancer secretome 
analysis is a promising tool supporting the identification of cancer biomarkers and drug 
targets.  
Cells are commonly cultivated in rich media supplemented with fetal bovine serum (FBS) 
medium. The use of serum-free media is preferred in order to guarantee the successful 
analysis of the cancer secretome in vitro. The reason lies in the fact that the highly 
abundant serum proteins such as albumin may mask and dilute the secretome. Therefore, in 
this investigation cells were initially cultured in serum-supplemented medium to achieve 
growth and then medium was replaced with serum-free medium to perform proteomic 
analysis. This enabled us to maintain highly viable cells at the time of sample collection 
and reduced the risk of getting proteins from autolysis of cells. Similar methods have 
already been used to analyse secreted proteins (Kulasingam and Diamandis 2007).  
In this investigation, protein profiles for serum-free conditioned media from four cell lines 
were investigated using 2D-DIGE coupled with mass-spectrometry to identify proteins that 
may be involved in cancer and invasion in breast cells. For this, data was analysed in 3 
main groups (Box 1). 
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4.1.2.1 Cancer (MCF-7+BT20) vs. Normal (HMEC+MCF-10A)  
This comparison revealed 81 secreted protein spots differentially expressed, of which 56 
were up-regulated and 25 were down-regulated in the cancerous cells (BT20 +MCF-7) 
compared to the normal cells (HMEC+MCF-10A). Of the 81 differentially expressed 
protein spots, 43 proteins were successfully identified and from them 25 were up-regulated 
and 18 were down-regulated in the cancer cells. A number of well-known and other 
proteins which have very limited information for their role in breast cancer were identified 
in this investigation. These proteins includes-  
• Serine protease inhibitors (SERPINA1, SERPINB1, SERPINB5, SERPINB7 and 
SERPINF1) 
• Cathepsin proteases (CTSA, CTSB and CTSD) 
• Other proteins, such as NUCB1, FHC and PDIA4 
4.1.2.1.1 Protease inhibitors (Serine protease inhibitors)  
Serine protease inhibitors, serpins, are a group of structurally similar proteins that can 
inhibit proteases in cells. About 36 serpins have been identified in humans to date and of 
which, approximately two thirds have been proven to perform extracellular roles 
(Kulasingam and Diamandis 2007, Mbeunkui et al. 2006). Five types of serpins, 
SERPINA1, SERPINB1, SERPINB5, SERPINB7 and SERPINF1, were observed to be 
down-regulated in this investigation, of which SERPINA1, SERPINB5 and SERPINF1 are 
well known (Box 2), and SERPINB1 and SERPINB7 are poorly known for their roles in 
breast cancer. 
 
4.1.2.1.1.1 SERPINB1  
SERPINB1, also known as monocyte/neutrophil elastase inhibitor, was identified at two 
different locations on the 2D-gel. It was observed to be up-regulated by 8.31 fold at one 
spot and 7.98 fold down-regulated at another spot in the cancer compared to the normal 
cells (Table 3.2.2). This protein has been discussed in section 4.1.1.1.5 Moreover two 
isoforms of SERPINB1 have been observed in the chronic myelogeneous leukemia (CML) 
patients, however the role of these isoforms is not known yet (Rawlings et al. 2004).  
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Box 2: Known serpins identified from 2D-DIGE study 
Serine 
Protease 
inhibitors 
Cancer vs. 
normal 
(Fold 
change) 
Function Regulation in cancer 
SERPINA1 -12.58 Negative regulator of cell 
growth (Grigoryev 2007) 
Down in breast cancer 
(Yavelow et al. 1997), 
anaplastic large cell 
lymphoma (ALCL) (Yavelow 
et al. 1997, Wozniak et al. 
2005) and pancreatic cancer 
(Duplantier et al. 2006) 
SERPINB5 -41.75 Inhibits tumour growth 
and metastasis (Thakur et 
al. 2008), induces 
apoptosis (Shi et al. 2001)  
Down in breast cancer 
(Toillon et al. 2007) 
SERPINF1 -3.2 Apoptosis and anti-
angiogenic apoptosis 
(Vecchi et al. 2008, 
Maass et al. 2001b, 
Toillon et al. 2007) 
Down in breast cancer (Chen 
and Madura 2006, Volpert et 
al. 2002, Ho et al. 2007)  and 
hepatocellular carcinoma (Cai 
et al. 2006) 
 
  
4.1.2.1.1.2 SERPINB7 
SERPINB7, also known as Megsin, was found to be 3.8-fold down-regulated in the cancer 
cells compared to the normal cells. Over expression of SERPINB7 has been observed to 
induce progressive mesangial cell proliferation (Barnstable and Tombran-Tink 2004, 
Matsumoto et al. 2004). It was over expressed in primary lung tumours compared to 
normal tissue (Miyata et al. 2002, Smith et al. 2003). The role of SERPINB7 in breast 
cancer is unclear.  
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4.1.2.1.2 Cathepsin proteases 
Cathepsins are cysteine and aspartic proteases, a type of protein that breaks apart other 
proteins, found in cells. Most of the members become activated at the low pH found in 
lysosomes (Miyata et al. 2002, Smith et al. 2003). Thus, the activity of this family lies 
almost entirely within those organelles. In this investigation, we identified three pro forms 
of cathepsin (CTSA, CTSB and CTSD) down-regulated in the cancer cell lines compared to 
normal cells, and of these procathepsin B and procathepsin D are well known (Box 3) 
whereas procathepsin A is poorly known for its association with breast cancer.  
 
Box-3: Known procathepsins identified from 2D-DIGE study 
Cathepsins  
proteases 
Cancer vs. 
normal (Fold 
change) 
Function Regulation in cancer 
Procathepsin B -31.23 
Metastasis and 
invasion 
(Erickson 1989) 
Up in breast (Mai et al. 2000), 
squamous cell carcinomas (Sloane et 
al. 1981) and prostrate tumours 
(Kawada et al. 1997)  
Procathepsin 
D 
-2.41 
Tumour growth, 
metastasis and 
invasion (Sinha 
et al. 1998)  
Up in breast cancer (Ohri et al. 
2008, Shi et al. 2001), 
nongynecological solid tumours 
(Ohri et al. 2008, Briozzo et al. 
1988, Vetvicka et al. 2002) and 
ovarian cancer (Leto et al. 2004)  
 
Procathepsin A (CTSA) 
Procathepsin A, also known as lyososomal carboxypeptidase A or lysosomal protective 
protein precursor, was found to be 2.1-fold down-regulated in the cancer vs. normal 
comparison. Cathepsin A is a multifunctional enzyme that expresses deaminidase and 
esterase activities at neutral pH and carboxypeptidase activity at acidic pH. The role of 
cathepsin A in breast cancer is still not known. Activity of lysosomal enzymes has been 
observed to be increased in patients with gynecologic cancers compared to normal (Bazzett 
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et al. 1999). The down regulation of procathepsin A in cancer cell lines could be associated 
with the abrogated conversion of procathepsin A into cathepsin A and as a result we 
observed reduction in procathepsin A levels. The observed reduction in procathepsin A in 
this study suggests that it could be involved in breast cancer.  
 
4.1.2.1.3 Other proteins such as NUCB1, PDIA4 and FHC 
4.1.2.1.3.1 Nucleobindin 1 precursor (NUCB1) 
NUCB1 was identified at 3 different spots and was found to be 14, 12.55 and 12.56-fold 
up-regulated at all three spots in the cancer vs. normal cells. Exogenous administration of 
recombinant NUCB1 to MRL/n mice has been found to induce an autoimmune phenomena 
and thymic apoptosis, indicating that NUCB1 plays an important role in inducing 
autoimmunity and apoptosis (Beratis et al. 2005). NUCB1 can be cleaved by caspase 
activity which could be involved in the initiation of apoptosis (Kanai et al. 1995). 
Accumulating evidence suggests that NUCB1 performs multiple functions through its 
Ca2+-binding, DNA-binding and EF-hand-mediated interactions with other proteins 
(Valencia et al. 2008). NUCB1 has up to 10 potential sites for phosphorylation including 
three protein kinase C sites which may well impact on its conformation and activity (Miura 
et al. 1992, Lin et al. 1998) and suggest it as an important signal transduction molecule. 
Higher expression of NUCB1 was observed in colon, gastric and lymphatic cancers 
(Wendel et al. 1995). A study on gastric adenocarcinoma has demonstrated that in 50 
gastric adenocarcinomas with lymph node metastasis, 56% of cases showed an increased 
level of NUCB1 (Chen et al. 2007b, Wang et al. 1993, Kubota et al. 1998). The subcellular 
distribution analysis of NUCB1 examined by subcellular fractionation and 
immunofluorescence revealed that NUCB1 is a membrane-associated protein and mostly 
distributed in Golgi (Wang et al. 1993). The role of NUCB1 in breast cancer is unclear.  
 
4.1.2.1.3.2 Protein disulfide isomerase family A, member 4 (PDIA4) 
Protein disulfide isomerase family A, member 4 (PDIA4), a member of the PDI family, was 
found to be 37-fold up-regulated in the cancer vs. normal cells. PDIA4 is responsible for 
forming disulfide bonds between polypeptide(s) during protein folding and ensures the 
proper folding that is required to perform defined biological functions in cells (Chen et al. 
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2007b). Increased levels of PDIA4 have been observed in differentiating mouse F9 
teratocarcinoma cells (Bulleid and Freedman 1988). Over-expression of PDIA4 was also 
reported in hepatocellular carcinoma cell lines and in metastasized HCC patient’s sera 
(Miyaishi et al. 1998). Although, the exact function of PDIA4 is not known yet; it is one of 
the critical factors for a normal growth rate as well as for calcium homeostasis (Chen et al. 
2008a).  
 
4.1.2.1.3.3 Ferritin heavy chain (FHC) 
Ferritin is a ubiquitous and highly conserved iron binding protein and has two chains, 
ferritin light chain (FLC) and ferritin heavy chain (FHC). FHC was found to be 3.6-fold 
down-regulated in the cancer vs. normal cells. Ferritin is localized predominantly 
intracellular; however it is also actively secreted by cells (Li and Lee 1991). A study based 
on 42 breast cancer patients showed that high levels of FHC mRNA was directly related to 
lymph-node status, presence of metastatic disease, and clinical stage (Addison et al. 1972). 
FHC mRNA was also found to be high in the immortalized human breast epithelial cell line 
MCF-10F but not in the mortal line S-130, from which MCF-10F cells were derived (Yang 
et al. 2002). An in vitro study showed that antisense FHC oligodeoxynucleotides 
specifically inhibited the growth of MCF-7 cells (Higgy et al. 1997). Ferritin promotes 
programmed cell death with low ratios of Bcl-2 to Bax mRNA and protein expression 
providing evidence that they specifically inhibited MCF-7 cell growth through increased 
apoptosis (Torti et al. 1988). However FHC was observed down-regulated in the cancer 
cells in our study and the reason remains unclear. 
 
4.1.2.1.4 Summary 
This analysis identified a number of interesting secreted protein targets that have not been 
previously associated with breast cancer and could be associated with breast cancer. These 
include PDIA4, NUCB1, CTSA, SERPINB1, SERPINB7, and FHC. Investigation of these 
targets in the serum or plasma samples from breast cancer patients and normal people may 
enable us to identify potential biomarkers for early diagnosis and prognosis of breast 
cancer. 
 295 
4.1.2.2 Invasive (HMEC+BT20) vs. Non-invasive (MCF-10A+MCF-7) 
A total of 33 protein spots were observed differentially expressed in this comparison group, 
of which 29 were up-regulated and 4 were down-regulated in the nornal+cancer (N+C) 
invasive cells (HMEC+BT20) in comparison to N+C non-invasive cells (MCF-10A+MCF-
7) (Table 3.2.1 and 3.2.4). A total of 15 secreted proteins were identified, out of which 14 
proteins were up-regulated and 1 protein was down-regulated in the N+C invasive cells. 
This analysis identified some secreted proteins that are already known to be involved in the 
development of cancerous and invasive phenotypes in breast cells. For example, 
• Disulfide isomerase family A, member 3 precursor (PDIA3) 
• Heat shock 90 (HSP 90) 
 
Some secreted proteins which are still unknown to be involved in the development of 
cancerous and invasive phenotypes in breast cells were also identified. For example, 
• Transaldolase-1 (TALDO1) 
• Glutathione synthetase (GSS) 
 
4.1.2.2.1 Disulfide isomerase family A, member 3 precursor (PDIA3) 
PDIA3 is a soluble ER luminal protein that belongs to the protein disulfide isomerase 
family. PDIA3 was identified at four different locations on 2D-gels and was 2.1, 1.8, 2.0 
and 2.2-fold up-regulated in the N+C invasive cells compared to N+C non-invasive cells. 
PDIA3 has also been found in the cytosol and nucleus and has been predicted to be secreted 
by cells (Torti et al. 1988). Three phosphorylated variants of PDIA3 have already been 
identified on the 2D-gel containing protein samples from human coronary artery smooth 
muscle cells (SMCs) (Hirano et al. 1995).  
PDIA3 has been observed to be up-regulated in hepatocarcinoma (Tokutomi et al. 2007). 
The over-expression of PDIA3 was reported in the more aggressive phenotype of a 
melanoma cell line (Chen et al. 2008a). The loss of PDIA3 was positively correlated with 
invasion, advanced stage of disease, and poor survival of gastric cancer (Dowling et al. 
2007b). However, PDIA3 has also been reported expressed in the larvae of Schistosoma 
mansoni, a parasite of humans, where it facilitates the penetration and migration processes 
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by the parasite (Leys et al. 2007). This suggests that the protein could be involved in the 
regulation of cell migration and the invasive phenotype of breast cells. Moreover 
investigation of potential PTMs in PDIA3 could improve our understanding of invasion in 
breast cells and could help to identify potential drug targets and/or biomarkers for breast 
cancer. 
 
4.1.2.2.2 Heat shock 90 (HSP 90) 
HSP90, a member of heat shock protein family, was found to be 3.1-fold up-regulated in 
the N+C invasive vs. N+C non-invasive. HSP90 was initially identified as a tumour-
specific transplantation antigen in mice (Wippersteg et al. 2002). Recently, HSP90 
expression was reported to be dramatically up-regulated in malignant melanoma cells when 
compared to benign melanocytic lesions, and HSP90 was expressed on the surface of seven 
of eight melanoma metastases (Ullrich et al. 1986). In many cases, HSP90 client proteins 
are mutated or activated in cancer cells (Becker et al. 2004). For example, HSP90 had been 
found in complex with the oncogenic tyrosine kinase v-Src, the mutated oncogene Bcr/Abl, 
and the serine/threonine kinase Raf-1 (Neckers 2002). HSP90 is constitutively expressed at 
2-10-fold higher levels in tumour cells compared with their normal counterparts suggesting 
that it could be crucially important for the growth and/or survival of tumour cells (Neckers 
2002). Indeed, HSP90 over-expression in breast cancer cells has been correlated with 
acquired resistance to some forms of chemotherapy (Ferrarini et al. 1992). This suggests 
that the chaperone activity of Hsp90 may be crucial for signalling proteins that contribute to 
invasion in breast cells. 
 
4.1.2.2.3 Transaldolase-1 (TALDO1) 
Transaldolase-1 (TALDO1), a key enzyme of the pentose phosphate pathway, was found to 
be 2-fold up-regulated N+C invasive cells compared to N+C non-invasive cells. The 
potential involvement of intracellular TALDO1 in cancer has been discussed in section 
4.1.1.3.5, however the role of secreted TALDO1 in the invasion of breast cells is not clear.  
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4.1.2.2.4 Glutathione synthetase (GSS) 
Glutathione synthetase (GSS), a member of the glutathione synthetase ATP binding 
domain-like superfamily, was found to be 1.8-fold up-regulated in the N+C invasive vs. 
N+C non-invasive cells. GSS catalyzes the second step in the biosynthesis of glutathione 
(tripeptide of l-glutamine, l-cysteine and glycine) (Dinescu et al. 2004). Glutathione 
protects cells from damage caused by unstable oxygen-containing molecules, which are 
byproducts of energy production. High levels of glutathione in cancer cells may detoxify 
endogenous and exogenous toxic compounds, which are thought to contribute to resistance 
of cancer cells to chemotherapeutic agents (Dinescu et al. 2004). The increased level of 
glutathione synthetase has been observed in a human hepatoma cell line (HepG2) compared 
to a normal hepatic cell line (Chang) (Burg and Mulder 2002). The increased expression of 
mRNA for GSS was also shown in cancerous liver tissue from patients compared to normal 
controls (Lee et al. 2002). This suggests that the defense-related enzymes are largely 
modulated in tumour cells, which might be linked to their uncontrolled growth and 
maintenance. GSS expression has been observed to positively correlate with survival in 
early stage adenocarcinoma of the lung (Huang et al. 2001). The role of GSS in invasion of 
breast cells is unclear. 
 
4.1.2.2.5 Summary 
This analysis identified some proteins that are well known such as PDIA3 and HSP90 and 
some other proteins that are poorly known, such as TALDO1 and GSS, for their 
involvement in regulation of invasion in breast cells. The investigation of these proteins in 
the secreted fractions (plasma, serum etc.,) from breast cancer patients compared to 
normal individuals could enable us to identify potential biomarkers as well as drug targets 
for early detection and treatment of breast cancer disease.  
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4.1.2.3 Cancer-invasive (BT20) vs. normal invasive +normal non-invasive 
+cancer-non-invasive (HMEC+MCF-10A+MCF-7)  
This comparison revealed 52 proteins differentially regulated in the cancer invasion-
specific manner with 35 proteins up-regulated and 17 down-regulated in group 1 (cancer 
invasive cell line (BT20)) compared to group 2 (normal and cancer-non-invasive cells 
(HMEC+MCF-10A+MCF-7)). A total of 28 proteins were identified, of which 19 proteins 
were up-regulated and 9 were down-regulated in group 1 (Table 3.2.5).  
These include some secreted proteins that are already known to be involved in regulation of 
invasion in breast cells. For example, 
• Disulfide isomerase family A, precursor (PDIA3) 
• Plastin-2 (LCP1) 
 
A number of interesting secreted proteins were also found to be differentially expressed and 
could possibly have a role in breast cancer invasion. These include - 
• Dimethylarginine dimethylaminohydrolase 1 (DDAH1) 
• Fragment of Heparan sulfate proteoglycan 2 (HSPD2) 
• Nucleobindin 2 precursor (NUCB2) 
 
4.1.2.3.1 Disulfide isomerase family A, precursors (PDIA3) 
PDIA3 is involved in protein folding and was observed to be 1.8-fold up-regulated in group 
1 compared to group 2. The involvement of PDIA3 in cancer and invasion has been 
discussed in section 4.1.2.2.1.  
 
4.1.2.3.2 Plastin-2 (LCP1) 
LCP1 was identified at two different locations on the 2D-gels possibly due to post-
translational modification and was found to be 9.8-fold and 8-fold up-regulated in group 1 
compared to group 2. LCP1 is an actin-binding protein and has been proposed to be 
involved in the control of cell adhesion and motility leading to invasion and metastasis in 
cancer (Allen et al. 2007). LCP1 was reported to be up-regulated in many types of cancer 
including breast (Jones et al. 1998, Foran et al. 2006, Samstag and Klemke 2007, 
Lapillonne et al. 2000), prostate (Ostergaard et al. 1997) and colorectal cancers (Zheng et 
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al. 1997). In breast carcinoma, LCP1 was only observed in malignant epithelial cells in 
around 14% of the tumours analyzed (Otsuka et al. 2001, Lapillonne et al. 2000). LCP1 
could be phosphorylated in melanoma cells, either by signaling events from the tumour cell 
environment, or by constant activation of signal transduction pathways in the course of 
transformation into cancerous or a cancer invasive (Ostergaard et al. 1997). The 
phosphorylation of LCP1 was observed to facilitate metastasis and invasion cells (Samstag 
and Klemke 2007). Thus LCP1 and its variants could be facilitating the invasive property 
of breast cancer cell lines.  
 
4.1.2.3.4 Dimethylarginine dimethylaminohydrolase 1 (DDAH1)  
DDAH1 plays a role in nitric oxide generation by regulating cellular concentrations of 
methylarginines, which in turn inhibit nitric oxide (NO) synthase activity. DDAH1 was 
observed 2.9-fold up-regulated in group 1 compared to group 2. Inhibition of DDAH1 
activity results in the accumulation of asymmetric dimethylarginine (ADMA), which 
reduces the production of NO by inhibiting NO synthases (NOS). NO is involved in a 
diverse range of physiological processes including motility and invasion (Samstag and 
Klemke 2007). Increased DDAH1 activity could lead to significantly increased cell motility 
and invasion (Cartwright et al. 1999, Ayling et al. 2006). The role of DDAH1 in invasion 
in breast cancer is still unknown. 
 
4.1.2.3.5 Nucleobindin 2 precursor (NUCB2) 
Nucleobindin 2 precursor (NUCB2) was found to be 5.2-fold up-regulated in group 1 
compared to group 2. NUCB2 contains a golgi retention motif at the N-terminal 
leucine/isoleucine-rich region (Ayling et al. 2006). The intracellular localization of NUCB2 
is variable and cell type-specific (Nesselhut et al. 2001). For example, in KM3 cells, 
NUCB2 can be localized on the plasma membrane, in the cytosol and as a secreted protein 
(Barnikol-Watanabe et al. 1994, Taniguchi et al. 2000, Morel-Huaux et al. 2002). Like 
NUCB1, NUCB2 is also a substrate for caspases and could be involved in the regulation of 
apoptosis (Barnikol-Watanabe et al. 1994, Taniguchi et al. 2000, Morel-Huaux et al. 2002). 
However the role of NUCB2 in breast cancer is still unknown.  
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4.1.2.3.6 Fragment of Heparan sulfate proteoglycan 2 (HSPG2) 
Fragment of Heparan sulfate proteoglycan 2 (HSPG2), a basement protein involved in cell 
adhesion, was found to be 5.3-fold down-regulated in group 1 compared to group 2. 
Heparan sulfate proteoglycan 2 (HSPG2), also known as Perlecan, is a part of the 
extracellular matrix in organisms from worms to humans (Valencia et al. 2008). HSPD2 
can be either an intrinsic components of the basement membrane, the thin layer of 
connective tissue separating epithelial from mesenchymal cells, or in close association with 
the cell surfaces (Iozzo 2005). It has been reported to be involved in promoting the growth 
and invasion of tumour cells (Iozzo 1984). In human melanoma, HSPG2 acts as a cell 
surface marker for a more aggressive phenotype (Folkman et al. 1988), and levels of 
mRNA and protein were found to be increased in metastatic melanomas (Timar et al. 
1992). However in contrast, reduction of HSPD2 expression has been shown to enhance in 
vitro migration, invasion, and adhesion to type IV collagen substrate in fibrosarcoma cells 
(Cohen et al. 1994). Degradation of endothelial-derived HSPD2 by MMP-1, MMP-3, 
plasmin and heparanase, has also been shown to release bound basic fibroblast growth 
factor that promote or maintain the angiogenic phenotype and tumour invasion (Mathiak et 
al. 1997). This suggests that reduced expression of HSPG2 could possibly be due to its 
cleavage by proteolytic enzymes that could facilitate breast cancer invasion. 
 
4.1.2.3.7 Summary 
This analysis identified a number of secreted proteins (PDIA3 and LCP1) that are known 
and other proteins (DDAH1, NUCB2 and fragment of HSPG2) that are unknown for their 
role in breast cancer invasion. Further investigation of the expression of DDAH1, NUCB2 
and fragment of HSPG2 in serum/plasma samples from breast cancer patients versus 
normals could enable us to identify potential biomarkers for breast cancer invasion.  
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4.1.2.4 Identification of invasion-specific proteins by overlapping lists of 
differentially expressed proteins 
The list of differentially expressed proteins between the cancerous cell lines (MCF-7 vs. 
BT20) was overlapped with the list of differentially expressed proteins between the normal 
cells (MCF-10A vs. HMEC) (Supplementary data: appendix 2). This comparison further 
enabled us to identify alterations in proteins level that are specifically differentially 
expressed in normal and cancer cells with invasive phenotypes and those that are required 
for invasion in both normal and cancer (Figure 3.2.3).  
Eight proteins were specifically differentially regulated in the normal cells comparison 
group (MCF-10A vs. HMEC), of which 2 proteins (PRDX6 and SOD1) were up-regulated 
in MCF-10A. PRDX6 (peroxiredoxin 6) protects against oxidative injury (cell death) 
(Stetler-Stevenson 1999, Whitelock et al. 1996). The over expression of PRDX6 has been 
observed to contribute to a more invasive phenotype and metastatic potential in human 
breast cancer (Moon et al. 2005). The role of SOD1 in cancer and invasion has been 
described in section 4.1.1.1.6. A total of 6 proteins, including SERPINA1, were down-
regulated in MCF-10A. The role of SERPINA1 in cancer has been described in Box 2. The 
specific roles of these proteins in the regulation of the invasive status of normal breast cells 
are unclear. However, these results suggest that the modulation of these proteins, i.e. up-
regulation of PRDX6 and SOD1 and/or down regulation of SERPINA1, in normal-
noninvasive cells could possibly lead to the development of normal-invasive phenotype in 
breast cells. A total of 23 proteins were only differentially regulated in the cancer cell lines 
comparison group (MCF-7 vs. BT20). Of these 23 proteins, 6 proteins including GSN and 
CTSD were up-regulated in the cancerous-non-invasive cells (MCF-7) compared to the 
cancerous invasive cell lines (BT20). The roles of GSN and CTSD have been described in 
section 4.1.1.3.1 and Box 3, respectively. Whereas, 17 proteins, including PDIA3, DDAH1 
and NUCB2, were down-regulated in the cancerous-non-invasive cells (MCF-7). The role 
of PDIA3, DDAH1 and NUCB2 in cancer and invasion has been described in section 
4.1.2.2.1 and 4.1.2.3.4-5. However, the involvement of these proteins in the regulation of 
the invasive status of normal breast cells is unknown. Our results suggest that the 
modulation of these proteins, i.e. up regulation of GSN and CTSD and/or down regulation 
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of DDAH1, PDIA3 and NUCB2, in cancer-non-invasive cell lines could lead to the 
development of invasive phenotype in breast cancer cells.  
Five proteins were common in both lists of differentially expressed proteins (MCF-10A vs. 
HMEC and MCF-7 vs. BT20). Two of these, LAMC2 and PDIA3/BAT1/FKBP4 (multiple 
identifications (PDIA3, BAT1 and FKBP4) were observed for single spots by LC-MS/MS), 
were down-regulated in both the normal (MCF-10A vs. HMEC) and the cancer (MCF-7 vs. 
BT20) cell lines. Over expression of LAMC2 has been correlated with the cancer and 
invasion status of human glioma (Chang et al. 2007). This suggests that down regulation of 
these proteins could contribute to inhibit the development of invasive phenotypes in breast 
cells. The remaining 3 proteins include HSP60, CTSB and SERPINB1. HSP60 was up-
regulated in the cancer-invasive cell line (BT20) compared to the cancer-non-invasive cell 
line (MCF-7) and was down-regulated in the normal invasive cells (HMEC) compared to 
the normal non-invasive cells (MCF-10A). This indicates that HSP60 could be involved in 
invasion but needs to be specifically down-regulated for normal invasion and up-regulated 
for cancer invasion. CTSB and SERPINB1 were down-regulated in the cancer invasive 
cells (BT20) compared to cancer non-invasive cells (MCF-7) but were up-regulated in the 
normal invasive cells (HMEC) in comparison to the normal non-invasive cells (MCF-10A). 
The roles of CTSB and SERPINB1 have been described in Box 3 and section 4.1.1.1.5 
respectively. Therefore CTSB and SERPINB1 have to be possibly down-regulated to result 
in cancer invasion while up-regulated for normal invasion in breast cells, however the role 
of these proteins in invasion specifically in normal breast cells needs to be elucidated.  
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4.1.3 Proteomic analysis of isolated membrane fractions from HMEC, 
MCF-10A, MCF-7 and BT20 cells 
Membrane proteins account for approximately one third of all predicted proteomes (Guo et 
al. 2005) and are part of cell boundaries as well as boundaries of cell organelles like 
mitochondria, nucleus, plastids, etc. Membrane proteins are involved in the regulation of a 
variety of cellular functions by serving as transporters and receptors. For example, cell 
surface membrane proteins play important roles in cell signalling, adaptation to the 
environment and cell–matrix interactions, and all of these phenotypes have been considered 
critical for the regulation of growth, motility, invasive and metastatic properties of tumour 
cells (Wallin and von Heijne 1998, Stevens and Arkin 2000). Identification of differentially 
expressed membrane and membrane-associated proteins between cell lines representing 
normal, non-invasive and invasive phenotypes could therefore enable us to identify 
potential drug targets and diagnostic markers. 
In this investigation, profiles for membrane and membrane-associated proteins from four 
cell lines were investigated using 2D-DIGE coupled with mass-spectrometry to identify 
proteins that may be involved in the development of the cancerous and invasive phenotype 
in breast cells. For this, data was analysed in 3 main groups (Box-1). 
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4.1.3.1 Cancer (MCF-7+BT20) vs. normal (HMEC+MCF-10A)  
The comparison of profiles for membrane and membrane-associated proteins from cancer 
cells (MCF-7+BT20) with normal cells (HMEC+MCF-10A) enabled us to identify cancer-
associated differential expression of proteins in cellular membranes. A total of 95 protein 
spots were observed to be differentially expressed in this comparison. A total of 41 
differentially expressed protein spots were identified, of which 11 were up-regulated and 30 
were down-regulated in the cancerous cell lines (Table 3.3.2). The data suggests that 
mitochondrial membrane and membrane-associated proteins, members of the S100 protein 
family, FKBP5 and ASNAP1 among other proteins may have important roles in breast 
cancer, and include-  
• Mitochondrial membrane and membrane-associated proteins (RHOT2, IMMT and 
HSPA9) 
• Plasma membrane associated S100 proteins (S100A2, S100A6, S100A9, S100A14 
and S100A16)   
• FK506 binding protein 5 (FKBP5) 
• Alpha-soluble NSF attachement protein (ASNAP1) 
 
4.1.3.1.1 Mitochondrial membrane and membrane-associated proteins  
Mitochondria are dynamic organelles that play a central role in cellular metabolism. The 
primary metabolic function of mitochondria is oxidative phosphorylation to synthesise 
energy in the form of ATP for cellular activities. However, mitochondria are also sites for 
several additional key metabolic processes such as the oxidative decarboxylation of 
pyruvate, the tricarboxylic acid cycle, and fatty acid oxidation. In addition, mitochondria 
are one of the major orchestrators of metabolism and apoptosis (Dowling et al. 2008) and 
therefore proteins encoded by the mitochondrial genome could potentially regulate 
development of cancer (Kroemer 1999, Green and Reed 1998). A number of mitochondrial 
membrane and membrane-associated proteins were observed to be differentially regulated 
in this investigation. These include known proteins (HSPA9, PHB and DIABLO) (Box 4) 
and others potentially interesting proteins (RHOT2, IMMT, ATP5B and UQCRC1) which 
have limited information in the literature for their role in cancer. 
 
 305 
4.1.3.1.1.1 Mitochondrial Rho 2 (RHOT2) 
Mitochondrial Rho 2 (RHOT2) is a GTPase enzyme and was observed to be 4.2 fold down-
regulated in the cancer vs. normal cells. The Mitochondrial Rho GTPases (also called Miro) 
are additional members of the Rho GTPase family as they are structurally different from the 
classical Rho GTPases (Sanchez-Pino et al. 2007, Modica-Napolitano et al. 2007, Modica-
Napolitano and Singh 2004). Another feature that distinguishes Miro from the classical Rho 
GTPases is the apparent absence of a role in regulating actin dynamics. Instead, the Miro 
are permanently localised to the mitochondria (Aspenstrom et al. 2004, Wennerberg and 
Der 2004). However the exact role of RHOT2 is not known to date. It has been reported to 
be involved in the regulation of mitochondrial homeostasis by regulating the mitochondrial 
trafficking apparatus (Fransson et al. 2003 & 2006). The over expression of RHTO2 has 
been observed to increase the aggregation of mitochondria in COS-7 cells and it was 
expected to function as a link between the mitochondria and the microtubules (Fransson et 
al. 2006). Therefore, down regulation of RHOT2 should abrogate the mitochondrial 
functions and should induce apoptosis in culture (Fransson et al. 2006). In contrast, the 
expression of RHOT2 was reduced in the cancerous cells compared to the normal cells in 
this investigation which indicates that RHOT2 may have other unknown functions rather 
than regulating homeostasis in the breast cancer cells. Further investigations of RHOT2 
could clarify its involvement in the process of tumour development. 
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Box-4: Known mitochondrial membrane and membrane-associated proteins 
proteins Cancer vs. 
normal 
(Fold 
change) 
Function Regulation in cancer 
Stress-70 protein, 
mitochondrial 
precursor (HSP9) 
-2.03 and -
1.8 
Proliferation, stress 
response and inactivation 
of p53 function (Fransson 
et al. 2006)  
Up in breast 
(Wadhwa et al. 1993, 
2002 & 2006) and 
hepatocellular 
carcinoma  (Wadhwa 
et al. 2006) 
Prohibitin (PHB) 
 
2.76 Cell growth, transcription 
and molecular chaperones 
(Yi et al. 2008) 
Up in breast cancer   
(Gamble et al. 2004, 
Nijtmans et al. 2001 
& 2002), bladder 
cancer (Jupe et al. 
1996) and gastric 
cancer  (Wu et al. 
2007) 
Diablo homolog, 
mitochondrial 
precursor 
(DIABLO) 
2.36 Promotes cell death (Ren et 
al. 2006) 
Up in cervical cancer 
(Kashkar et al. 2003 
& 2006, Du et al. 
2000) 
 
4.1.3.1.1.2 Mitofilin (IMMT) 
Mitofilin (IMMT), an inner membrane protein, is one of the most abundant mitochondrial 
proteins. IMMT was observed to be 4.2 fold down-regulated in the cancer cells compared 
to the normal cells. Little is known to date about the role of IMMT in cells. IMMT has been 
shown to play an important role in the maintenance of cristae morphology (Espinosa et al. 
2004, Arellano-Llamas et al. 2006). Cristae formation is critical for achieving a high 
surface-to-volume ratio of the inner membrane. Down-regulation of IMMT using siRNAs 
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resulted in a drastic change in the organization of the inner membrane in HeLa cells (John 
et al. 2005). Rather than organizing into tubular cristae, the inner membrane formed 
concentric layers that interconnected at numerous sites following inhibition of IMMT. This 
resulted in reduced cell growth and increased apoptosis in culture. However, IMMT was 
observed to be down-regulated in the cancerous cells compared to the normal cells in our 
investigation. Cancerous cells show increased growth and reduced apoptosis in culture. 
However, the role of IMMT is unknown in cancer; it has been observed to be over 
expressed in a human hepatocarcinoma cell line (John et al. 2005). Therefore the role of 
IMMT in the regulation of growth and apoptosis in cancer could be cell or tissue (i.e. breast 
or liver, etc) specific and which remains unclear. Investigation of IMMT could further 
improve our understanding of growth and apoptosis in cancer cells and may enable us to 
identify potential mechanisms of breast cancer. 
 
4.1.3.1.1.3 ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit 
precursor (ATP5B) 
ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit precursor 
(ATP5B) was observed to be 1.67 and 1.77 fold down-regulated in the cancer vs. normal 
cells. ATP5B transduces the energy contained in electrochemical proton gradients of the 
membranes into the energy required for synthesis of high-energy phosphate bonds. 
Tumours often cope by ramping up an alternative energy production strategy (Feng et al. 
2007). For most of their energy needs, normal cells rely on respiration, which consumes 
oxygen and glucose to make energy-storing molecules of adenosine triphosphate (ATP). 
However, cancer cells typically depend more on glycolysis, the anaerobic breakdown of 
glucose into ATP (Garber 2006). The decreased expression of ATP5B has been linked to an 
increased expression of several markers of the glycolytic pathway in many cancer (Cuezva 
et al. 2004). For example, ATP5B has been observed to be reduced in 97.3% of samples 
from 90 lung adenocarcinomas (Garber 2006, Cuezva et al. 2002 & 2004). Moreover, 
inhibition of ATP5B using a chemical inhibitor has been shown to reduce apoptosis in 
yeast cells indicating the involvement of ATP5B in the regulation of cell death (Cuezva et 
al. 2004). Therefore down regulation of ATP5B in the cancerous cell lines could be an 
indication of altered energy generation and reduced apoptosis in tumour cells.  
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4.1.3.1.1.4 Ubiquinol-cytochrome c reductase core protein I (UQCRC1) 
Ubiquinol-cytochrome c reductase core protein I (UQCRC1) is a nuclear-encoded protein 
localized to the inner mitochondrial membrane. UQCRC1 was found to be 10.49 fold 
down-regulated in the cancer vs. normal cells. This protein has been discussed in section 
4.1.1.1.4. We also observed the expression of UQCRC1 up-regulated in the cancer vs. 
normal cells in the cell lysate study (table 3.1.5), which is in agreement with the published 
results (Matsuyama et al. 1998). In contrast, the expression of UQCRC1 in the membrane 
fraction from cancerous cells compared to normal cells was reduced which possibly 
complicates its potential role in breast cancer. However, it is possible that the UQCRC1 we 
observed in the membrane fraction study could be a post-translationaly modified form of 
UQCRC1, which needs to be investigated. 
 
4.1.3.1.2 Plasma membrane associated S100 proteins  
S100 proteins belong to the Ca2+- binding EF-hand motif superfamily and have the ability 
to form homodimers, heterodimers and oligomers. S100 proteins can be found in a soluble 
and a membrane-bound form (Kulawiec et al. 2006). S100 proteins have been involved in 
several activities including cell communication, cell growth, cell structure, energy 
metabolism, contraction and intracellular signal transduction (Zimmer et al. 1995), and all 
of these process plays critical roles in the development of cancer. In this study, five 
members of the S100 protein family, S100A2, S100A6, S100A9, S100A14 and S100A16 
were observed to be differentially regulated in the cancer vs. normal cell comparison. These 
include some proteins that are already known such as S100A2 and S100A6, and some other 
members that are poorly known such as S100A14 for its involvement in the regulation of 
breast cancer (Box 5). S100A14 has been observed to be up-regulated in breast cancer 
(Zimmer et al. 1995, Donato 1986) and down regulated in oral squamous cell carcinoma 
(Pietas et al. 2002), esophageal squamous cell carcinoma (Sapkota et al. 2008) and bladder 
cancers (Ji et al. 2004) (Box 5). Although the role of S100A14 in cancer is unclear, the data 
suggests that its expression may be cell line or origin specific.  
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Box-5: Known S100 proteins identified from 2D-DIGE study 
S100 
proteins 
Cancer vs. 
normal (Fold 
change) 
Function Regulation in cancer 
S100A2  -182.99 Proliferation (Yao 
et al. 2007) 
 Down in prostate cancer (Tsai et al. 
2006), lung cancer (Gupta et al. 2003), 
oral cancer (Feng et al. 2001) and 
breast cancers (Suzuki et al. 2005) 
S100A6 -18.04 Apoptotic (Liu et 
al. 2000a, Lee et al. 
1992) 
Down in prostrate cancer (Slomnicki 
et al. 2008) and breast cancer 
(Rehman et al. 2004) 
S100A9  -18.04 Metastasis (Sanders 
et al. 2008, 
Carlsson et al. 
2005) and motility 
(Rafii and Lyden 
2006) 
Down in esophageal squamous cell 
carcinoma (Hiratsuka et al. 2006), 
breast cancer (Luo et al. 2004) and 
bladder cancer (Rhee et al. 2008) 
S100A14 -3.37 Not known Down in oral squamous cell 
carcinoma (Yao et al. 2007), 
esophageal squamous cell carcinoma 
(Sapkota et al. 2008), bladder cancer 
(Ji et al. 2004) and kidney, rectum & 
colon tumours (Yao et al. 2007). Up in 
ovary, breast and uterus tumours 
(Pietas et al. 2002). 
S100A16  -2.24 Not known, 
possibly invasion 
suppressor 
(Pietas et al. 2002) 
Down in breast cancer (Bianchi et al. 
2005) 
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4.1.3.1.3 FK506 binding protein 5 (FKBP5) 
FK506 binding protein 5 (FKBP5) is a 51-kDa FK506 binding protein with peptidyl-prolyl 
isomerase (PPIase) activity, also named as FKBP51. FKBP5 was identified at two different 
spots on the 2D-gel and was observed to be 4.22-fold and 2.3-fold down regulated in the 
cancer vs. normal cells. FKBP5 can form a complex with HSP90 and can modulate the 
translocation of steroid receptors, such as progesterone and glucocorticoid receptors to the 
nucleus (Bianchi et al. 2005). FKBP5 was found to be associated with mitogen-activated 
protein pathways which could regulate cell proliferation and death (Wochnik et al. 2005). 
However its role in breast cancer needs to be elucidated. FKBP5 has been observed to 
facilitate cell survival and proliferation in melanoma cell line compared to normal cells 
(Bouwmeester et al. 2004). It was also observed to regulate the growth of glioma (Romano 
et al. 2004). In contrast, FKBP5 was down regulated in the breast cancerous cell lines in 
our study and this suggests that the effect of FKBP5 could be cell line or origin specific 
(i.e. breast and melanoma, etc).  
 
4.1.4.1.5 Alpha-soluble NSF attachement protein (ASNAP1) 
Alpha-soluble NSF attachement protein (ASNAP1) has widespread involvement in 
vesicular transport pathways leading to exocytosis. ASNAP1 was observed to be 1.85 fold 
up regulated in the cancer vs. normal cells. ASNAP1 has been shown to facilitate the 
secretion from lung cells and its inhibition using siRNA knockdown technique was 
observed to reduce the secretion of proteins (Jiang et al. 2008). Similarly the inhibition of 
ASNAP1 in β-pancreatic cells was observed to reduce insulin secretion (Abonyo et al. 
2003). The role of ASNAP1 protein in breast cancer is still unknown. 
 
4.1.4.1.6 Summary 
Taken together, a number of interesting membrane and membrane-associated proteins 
(RHOT2, IMMT, UQCRC1, S100A14, FKBP5 and ASNAP1) which possibly have roles in 
the regulation of tumour development were observed to be differentially regulated in this 
investigation. Further investigation of these proteins could potentially help to understand 
the molecular mechanisms whereby a normal cell transforms into a cancerous cell. 
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4.1.3.2 Invasive (HMEC+BT20) vs. non-invasive (MCF-10A+MCF-7)  
A total of 85 protein spots were observed to be differentially expressed in this comparison 
group (N+C invasive cells (HMEC+ BT20) vs. N+C non-invasive cells (MCF-10A+MCF-
7)), of which 22 were up-regulated and 63 were down-regulated in the N+C invasive cells 
(Table 3.1.3). From these, 27 proteins were identified (21 up-regulated and 6 down-
regulated in the N+C invasive cells (Table 3.2.4). In this analysis, a number of 
mitochondrial membrane and membrane-associated proteins were observed to be 
differentially regulated. These proteins include some proteins that are already known, such 
as HSPD1, and some other proteins that are poorly known, such as NDUFS1, for their 
involvement in regulation of breast cancer invasion. Two known S100 proteins (S100A9 
and S100A16) were identified. Some other known proteins such as NME1, as well as other 
interesting proteins such as GANAB and WDR1 were also identified in this study.  
 
4.1.3.2.1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, precursor (NDUFS1) 
NDUFS1 was observed to be 1.61 fold down-regulated in the N+C invasive vs. N+C non-
invasive cells. NDUFS1 belongs to the complex-I 75kDa subunit family. It locates at the 
mitochondrial inner membrane. NDUFS1 has NADH dehydrogenase activity and 
oxidoreductase activity. It transfers electrons from NADH to the respiratory chain. The 
immediate electron acceptor for the enzyme is believed to be ubiquinone. This protein is 
the largest subunit of complex I and it is a component of the iron-sulfur (IP) fragment of the 
enzyme. It may form part of the active site crevice where NADH is oxidized. Ablations in 
this gene could disrupt complex I deficiency and hence the electron transport leading to 
production of ROS, loss of ATP production, mitochondrial damage and ultimately cell 
death (Nagamatsu et al. 1999). Limited information is available for the role of NDUFS1 
protein in cancer and invasion. Recently, the expression of NDUFS1 has been observed 
reduced in a patient with metastatic melanoma when treated with indisulam drug (Ricci et 
al. 2004).  
 
4.1.3.2.2 60 kDa heat shock protein 1, mitochondrial precursor (HSPD1) 
HSPD1 was observed to be 2.27 fold increased in the N+C invasive vs. N+C non-invasive 
cells. HSPD1 is a member of the Hsp60 family of heat shock proteins that are expressed 
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both constitutively and under conditions of stress (Baur et al. 2007). It forms heptamers and 
tetradecamers in association with Hsp10 and ATP and is an important part of the 
mitochondrial chaperone system (Bukau and Horwich 1998) and involved in apoptosis 
(Fink 1999, Bukau and Horwich 1998). HSPD1 has been found over expressed in many 
cancer including breast (Lin et al. 2001), colorectal (Desmetz et al. 2008) and ovarian 
cancer (Cappello et al. 2003) and this is in agreement with our observations in this study. 
 
4.1.3.2.3 S100 proteins  
S10016 were observed to be 2.32 fold down-regulated whereas S100A9 was observed to be 
1.8 fold up-regulated in the N+C invasive vs. N+C non-invasive cell lines. The 
involvement of S100A9 and S100A16 proteins in cancer and invasion has been described 
in Box 5. 
4.1.3.2.4 Non-metastatic protein 1 (NME1) 
NME1 was observed to be 2.6-fold down-regulated in the N+C invasive vs. N+C non-
invasive. As described in section 4.1.1.3.1, the reduced expression of NME1 has been 
correlated with high tumour metastatic potential in several human breast carcinomas 
(Schneider et al. 1999).  
 
4.1.3.2.5 Alpha glucosidase II alpha subunit isoform 2 (GANAB) 
Alpha glucosidase II alpha subunit isoform 2 (GANAB), also known as Glucosidase II, is 
an endoplasmic reticulum-localized enzyme that has an important function in the folding 
and maturation of glycoproteins. GANAB was identified at two different locations on the 
2D-gel and was observed to be 2.37 and 2.69-fold up-regulated in the N+C invasive vs. 
N+C non-invasive cells. GANAB trims two α-1, 3-linked Glc residues from the 
glycoprotein oligosaccharide Glc2Man9GlcNAc2 to give Glc1Man9GlcNAc2 and 
Man9GlcNAc2 in the endoplasmic reticulum. Monoglucosylated glycans generated by this 
process play a key role in glycoprotein quality control in the ER, as they are primary 
ligands for the lectin chaperones calnexin (CNX) and calreticulin (CRT) that are involved 
in ensuring glycoprotein quality prior to recruiting nascent proteins for their biological 
function (Stahl et al. 1991, Heimann et al. 1998). GANAB has been observed in precursor 
and mature forms as it contains 7 sites for glycosylation and several sites for 
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phosphorylation (Totani et al. 2006). Inappropriate post-translational modifications of 
GANAB could result in functionally altered or inactive forms of GANAB (Reuser et al. 
1985, Hermans et al. 1991, Hasilik and Neufeld 1980). GANAB was identified at two 
different locations on the 2D-gel in this study possibly due to post-translational 
modifications (glycosylation and/or phosphorylation). Although, the role of GANAB and 
its post-translationally modified variants in breast cancer and invasion is not known, the 
increased expression of GANAB in the N+C invasive cells suggests that it could be 
associated with ensuring the quality of increased expression of invasion-associated proteins 
and/or compromised quality of invasion-suppressor proteins.  
 
4.1.3.2.6 WD repeat-containing protein 1 (WDR1) 
WD repeat-containing protein 1 (WDR1) was observed to be 2.4 fold up-regulated in the 
N+C invasive vs. N+C non-invasive cells. WD repeats are approximately 30- to 40-amino 
acid domains containing several conserved residues, mostly including a trp-asp at the C-
terminal end. WD domains are involved in protein-protein interactions and may help induce 
the disassembly of actin filaments. Inhalation of mixtures of insoluble and soluble nickel 
compounds by humans has been found associated with excess lung and nasal sinus cancers. 
Nickel-transformed cell lines have shown up-regulation of the WDR1 gene (Reuser et al. 
1985, Hermans et al. 1991). The role of this protein in breast cancer and invasion is still not 
known.  
 
4.1.3.2.7 RuvB-like 2 (RUVBL2) 
RuvB-like 2 (RUVBL2) was observed to be 4.0-fold up-regulated in the N+C invasive vs. 
N+C non-invasive cells. RUVBL2 is a DNA helicase essential for homologous 
recombination and DNA double-strand break repair (Verma et al. 2004). Functional 
analysis showed that this gene product has both ATPase and DNA helicase activities. Over 
expression of RuvB-like 2 (RUVBL2) has been reported in hepatocellular carcinoma 
(HCC) and was correlated with the aggressiveness of tumours (Bal et al. 2005). It was also 
suggested that RUVBL2 is required for tumour cell viability. However, its roles in breast 
cancer are still unknown.  
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4.1.3.2.8 Adipocyte plasma membrane-associated protein (C20ORF3)  
Adipocyte plasma membrane-associated protein (C20ORF3) was observed to be 1.9-fold 
down-regulated in the N+C invasive vs. N+C non-invasive cells. C20ORF3 resides on 
chromosome 20, open reading frame 3 and is a member of the lactonohydrolase super 
family. The molecular functions of C20ORF3 are unknown. C20ORF3 has been suggested 
potentially to be involved in enzymatic processes and differentiation of adipocytes. The 
observed down regulation of C20ORF3 in regulated in the invasive cells in comparison to 
the non-invasive cells suggests that it could be associated with invasion of breast cells. 
 
4.1.3.2.9 Summary 
Taken together, the data presented here indicates that a number of proteins, NDUFS1, 
GANAB, RUVBL2, WDR1 and C20ORF3 which have not been previously linked with 
invasion in breast cells, were differentially regulated in the invasive vs. the non-invasive 
cells comparison. Therefore investigation of these membrane and membrane-associated 
proteins could help us to identify potential drug targets or biomarkers for breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 315 
4.1.3.3 Cancer-invasive (BT20) vs. normal invasive +normal non-invasive 
+cancer-non-invasive (HMEC+MCF-10A+MCF-7) 
This comparison revealed 109 proteins differentially regulated in a cancer invasion-specific 
manner with 87 proteins up-regulated and 22 proteins down-regulated in group 1 (cancer 
invasive cell line (BT20)) compared to group 2 (normal and cancer-non-invasive cells 
(HMEC+MCF-10A+MCF-7)). A total of 37 proteins were identified, of which 27 proteins 
were up-regulated and 10 were down-regulated in group 1 (Table 3.3.5). In this analysis, a 
number of mitochondrial membrane and membrane-associated proteins were observed to be 
differentially regulated. These proteins include some known in literature such as PHB and 
some other proteins which have very limited information for their role in breast cancer 
invasion such as ATP5B. From the S100 protein family, some members that are well 
known, such as S100A2, and some other members that are poorly known such as S100A14 
for their involvement in the regulation of breast cancer invasion were again found 
differentially expressed in our study. A number of other interesting proteins that have not 
been linked previously with breast cancer invasion were also identified, such as CES1, 
AHCY, TALDO1 and RUVBL2.  
 
4.1.3.3.1 Prohibitin (PHB) and ATP5B 
Prohibitin (PHB) and ATP synthase, H+ transporting, mitochondrial F1 complex, beta 
subunit precursor (ATP5B) were found to be 1.85 and 2.3-fold up-regulated in group 1 vs. 
group 2, respectively. PHB has also been observed over expressed in breast cancer 
(Rousseau et al. 2007), bladder cancer (Jupe et al. 1996) and gastric cancer (Wu et al. 
2007) and possibly involved in apoptosis and/or cell migration (Ren et al. 2006) which is 
an agreement with literature. The role of PHB and ATP5B in cancer has been discussed in 
box 3 and section 4.1.3.1.1.3 respectively. 
 
4.1.3.3.2 S100 proteins 
S100A2 and S100A14 were found to be 155.42 and 3.53 fold down-regulated respectively 
in group 1 vs. group 2. The involvements of these proteins in the cancer and invasion have 
been described in box 5. 
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4.1.3.3.3 RuvB-like 2 (RUVBL2) 
RUVBL2 was observed to be up-regulated (5.57 and 2.0-fold) at two different locations on 
the gel, in group 1 vs. group 2. The involvement of RUVBL2 protein in cancer and 
invasion has been described in sections 4.1.4.3.7. However, its role in breast cancer is still 
unknown. Therefore up regulation of RUVBL2 in the cancer invasive cell line could be 
associated with acquiring the changes in genome that favours the development of an 
invasive phenotype in breast cancer cells. 
 
4.1.3.3.4 Liver carboxylesterase 1 precursor (CES1) 
CES1 which is involved in detoxification of compounds in cells was found to be 45.2-fold 
over-expressed in group 1 vs. group 2. CES1 is involved in the hydrolysis of aromatic and 
aliphatic esters & thioesters and amide-bond-containing molecules and is necessary for 
cellular cholesterol esterification and homeostasis (Zhu et al. 2006). The cholesterol 
homeostasis in cancer patients has already been reported to be modulated (Satoh and 
Hosokawa 1998, Zhao et al. 2005). It may also play a role in detoxification in the lung 
and/or protection of the central nervous system from ester or amide compounds (Dessi et 
al. 1994 & 1997). Fibrosarcoma (HT1080) and colon carcinoma cell lines (SW480) with 
increased levels of CES1 were observed significantly more sensitive to irinotecan (an 
anticancer drug) treatment as compared to the parental cells (Satoh and Hosokawa 1998). 
CES1 has also been observed to be a positive predictor of prostate cancer recurrence 
(Kojima et al. 1998, Matzow et al. 2007). The roles of CES1 in breast cancer and invasion 
are still not known.  
 
4.1.3.3.5 Adenosylhomocysteinase (AHCY) 
AHCY was found to be 2.7-fold up-regulated in group 1 vs. group 2. AHCY converts S-
adenosylhomocysteine to homocysteine and regulates the intracellular S-
adenosylhomocysteine (SAH) concentration facilitating the sustained flux of methionine 
sulfur toward cysteine and controlling the transmethylation reactions (Glinsky et al. 2005). 
DNA methylation and histone modification have already been associated with various 
diseases including cancer (Leal et al. 2008). The role of AHCY in cancer is still unclear. 
For example, AHCY has been observed to be down regulated in colon cancer (Esteller 
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2007, Widschwendter et al. 2004) but on the other hand, inhibition of AHCY has been 
observed to induce efficient apoptotic cell death in breast cancer (MCF-7), colorectal 
cancer (HCT116) and leukemia (HL-60 and U-937) cells possibly due to mitochondria 
dysfunction and caspase activation (Leal et al. 2008).  
 
4.1.4.3.6 TALDO1 
Transaldolase-1 (TALDO1) was found to be 4.2-fold up-regulated in group 1 vs. group 2. 
The involvement of TALDO1 protein in cancer and invasion has been described in sections 
4.1.1.3.5 
 
4.1.3.3.7 Summary 
Therefore, the presented data indicate that a number of membrane and membrane-
associated proteins that have not been linked previously with breast cancer invasion such 
as ATP5B, S100A14, CES1, AHCY, TALDO1 and RUVBL2 were altered in the cancer 
invasive cells and could have roles in the regulation of the breast cancer invasive 
phenotype. Further investigation of these proteins could enable us to identify potential drug 
targets and/or biomarkers for breast cancer disease.  
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4.1.3.4 Identification of invasion-specific proteins by overlapping lists of 
differentially expressed proteins 
The list of differentially expressed membrane and membrane-associated proteins within 
cancerous cells (MCF-7 vs. BT20) was overlapped with the list of differentially expressed 
proteins within normal cells (MCF-10A vs. HMEC) (Supplementary data: appendix 3). 
This comparison further enabled us to identify alterations in proteins level that are 
specifically differentially expressed in normal and cancer cell lines with invasive 
phenotypes and those that are required for invasion in both (Figure 3.3.2).  
29 proteins were specifically altered between the two normal cell lines (MCF-10A vs. 
HMEC). These proteins include ITGA3, LAMB1, KRT8 and UQCRC1. ITGA3, LAMB1 
and KRT8 were up-regulated and UQCRC1 was down-regulated in the normal non-
invasive cells (MCF-10A) compared to the normal invasive cells (HMEC). Although, the 
specific role in the regulation of the invasion process in normal cells is unknown, based on 
the information from cancerous cell line models, these proteins have been associated with 
the regulation of invasion. ITGA3, a member of the integrin family, controls cell 
attachment to the extracellular matrix (ECM) and has been observed to play an essential 
role in the invasion process by degradation of the ECM (Tan et al. 2007, Kim et al. 2000). 
LAMB1, extracellular matrix glycoprotein, is the major non-collagenous constituent of 
basement membranes and its expression has been found to positively correlate with an 
increased invasive potential of many cancers including breast (Kurokawa et al. 2008, 
Felding-Habermann 2003). KRT8, an intermediate filament protein, may be associated with 
tumour progression. The role of UQCRC1 in cancer and invasion has been described in 
sections 4.1.1.1.4 and 4.1.3.1.1.4. This suggested that the modulation (up- or down 
regulation) of these proteins is associated with the development of the invasive phenotype 
in normal breast cells. 
A total of 28 unique proteins were identified to be altered between the cancer non-invasive 
(MCF-7) and the cancer invasive (BT20) cell lines. These include PNPO, HSPD1 and 
PDIA3. PNPO was up-regulated and HSPD1 and PDIA3 were down-regulated in the 
cancer non-invasive cell line (MCF-7) compared to cancer invasive cell lines (BT20). 
PNPO catalyzes the rate-limiting step in the synthesis of vitamin B6 and defects in this 
could lead to various diseases including cancer (Bair et al. 2005). The roles of HSPD1 and 
PDIA3 have been discussed in sections 4.1.3.2.2 and 4.1.2.2.1, respectively. This suggests 
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that the modulation of these proteins, i.e. up regulation of PNPO, and down regulation of 
HSPD1 and PDIA3, in the cancer-non-invasive cells could lead to the development of the 
invasive phenotype in breast cancer cells.  
The overlapping revealed seven proteins, including GANAB, RUVBL2, C20ORF and 
S100A16, that could be involved in the regulation of normal and cancer invasion. For 
example, GANAB and RUVBL2 proteins were down-regulated in both comparisons. The 
role of GANAB and RUVBL2 in invasion is unknown (sections 4.1.3.2.5 and 4.1.3.2.7, 
respectively), however down regulation of these proteins in non-invasive cells suggests 
their potential role in development of invasive phenotype of breast cells. C20ORF3 and 
S100A16 were up-regulated in both comparisons. The role of C20ORF in cancer invasion 
is unknown (section 4.1.3.2.8) and S100A16 is possibly an invasion suppressor (Box 5) 
(Nutter et al. 1983). The increased expression of these proteins in non-invasive cells could 
possibly be associated with reduced invasion in breast cells. Therefore, alterations in the 
expression of GANAB, RUVBL2, C20ORF and S100A16 could lead to the invasive 
phenotype of breast cell lines.  
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4.1.4 Enrichment of protein in three different fractions  
The differentially expressed identified proteins from all three fractions (total cell lysate, 
conditioned media and membrane fractions) for all comparison groups (cancer vs. normal, 
N+C invasive vs. N+C non-invasive and cancer-invasive vs. normal-invasive +normal-non-
invasive +cancer non-invasive) were overlapped to identify common as well as unique 
proteins in each fraction. Box-6 shows the proteins which are present only in the cell lysate 
fraction, conditioned media fraction and membrane fraction and proteins which are 
commonly identified in all of these fractions. 
 
A large number of proteins were identified that were unique to each fraction, i.e. lysate, 
conditioned media or membrane. A total of 24 unique differentially expressed proteins, 
such as TXNRD1, CLP, QPRT and RAD23B, were identified from the cell lysate fraction 
(Box 6). 37 unique differentially expressed proteins, including SERPINB7, SERPINF1, 
FHC and NUCB1, were identified from the conditioned media. 33 unique differentially 
expressed proteins, such as IMMT, S100A16 and GANAB, were identified from the 
membrane fraction. This suggests that each fraction could reveal different and valuable 
information and could be linked together in many functions such as regulatory pathways or 
could have their own function to facilitate cancerous and/or invasive phenotypes in breast 
cells. 
 
Only five proteins, ACTB, ANXA3, PDIA3, SERPINB5 and TALDO1, were observed in 
all three fractions as shown in Box-6. The majority of these proteins have already been 
reported to be cytosolic, membranous, and extracellular in localization such as SERPINB5, 
ATCB and PDIA3. 
• SERPINB5 has been reported to localize primarily to the cytoplasm (Bianchi et al. 
2005), but can also localize to the extracellular (Khalkhali-Ellis et al. 2008) and the 
cell surface (Toillon et al. 2007). SERPINB5 has pro-apoptotic, anti-angiogenic, 
and anti-metastatic functions (Pemberton et al. 1997). 
• ATCB also has been previously observed to be in present in cell lysates (Maass et 
al. 2001a, Shi et al. 2001, Lockett et al. 2006), isolated membrane fraction (Wong 
et al. 2008) and in conditioned media (Dowling et al. 2007b). ACTB is a highly 
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conserved protein and is involved in cell motility, structure and integrity (Walsh et 
al. 2008). 
• PDIA3 has been reported in conditioned media (Peckham et al. 2001, Ng et al. 
1985), membrane (McClelland and Gullick 2007) and cytosolic (Dowling et al. 
2007b) fractions. PDIA3 has been shown to interact with the lectin-like ER 
chaperones calreticulin (CRT) and calnexin to mediate disulfide bond 
rearrangements in nascent glycoproteins bearing monoglucosylated N-linked 
glycans (Celli and Jaiswal 2003). 
 
Taken together, the data indicates that we have identified a unique pattern of differentially 
expressed proteins in each fraction, i.e. serpins (SERPINB7 and SERPINF1) in conditioned 
media, and mitochondrial and S100 proteins in the membrane fraction. This ensures the 
efficiency of the fractionation method for proteomic investigation and therefore the 
identified differentially expressed proteins from different fractions are likely to be similar 
in localization in other cancer cells as we have observed. Therefore, investigation of 
different cellular fractions to gain insights into breast cancer and identify potential drug 
targets and/or biomarkers is an efficient method and could be helpful to the diagnosis and 
prognosis of breast cancer.  This also proved the concept that each fraction from the cells 
has different protein information and could be linked together in many functions such as 
regulatory pathways or could have their own function to facilitate cancerous and/or 
invasive phenotypes in breast. 
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Box 6: Distribution of identified proteins in all three fraction 
Proteins only identified 
in cell lysates fraction 
Proteins only 
identified in 
conditioned media 
fraction 
Proteins only identified 
in membrane fraction 
Proteins 
identified 
common 
in 3 
fractions 
3-PGDH ME3 APOE GSS A2M FKBP5 ACTB 
AKR1A1 NDRG1 BAT1 HSPG2 ACTA1 GANAB  ANXA3 
ANXA1 NUDC BF INHBA ANXA5 GCN1L1 PDIA3 
ARCN1 Psma6 C1R KRT10 ATP5B HSPD1  
SERPINB
5 
BTRC QPRT CAPZA LAMC2 C20ORF3 IMMT  TALDO1 
CLP RAD23B CAPZB LCP1 CCT6A JUP  
DCI TXNRD1 CPA4 NP CES1 LOC224626  
DYNC1LI2 CCT-beta CTSB NUCB1 CLIC4 ASNAP1  
HNRPF  DDAH1 NUCB2 DIABLO NDUFS1  
HNRPK  EIF4A PA2G4 PHB NPM1  
KRT18  FHC PDIA4 PSME2 NT5E  
KRT19  FKBP4 PGM2 RHOT2 TCP1  
LGALS1  GDI2 PLS3 RUVBL2 WDR1  
LMNA  GLUL PPGB S100A14 YWHAB  
  
SERPINF
1 PRDX6 S100A16 SAR1B  
  TPTE2 RDX S100A2   
  TSP RNPEP S100A6   
  
SERPINB
7 VIL2 S100A9   
   CCT8    
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4.1.5 Analysis of distribution of identified differentially expressed 
proteins in biological functions   
The identified differentially expressed proteins from all three fractions (total cell lysate, 
conditioned media and membrane fractions) for each comparison group (cancer vs. normal, 
N+C invasive vs. N+C non-invasive or cancer-invasive vs. normal-invasive +normal-non-
invasive +cancer non-invasive) were analysed to gain ontology information as the 
knowledge of significantly affected biological pathways could enable us to identify 
potential regulators of these complex biological pathways and may help to identify 
potential drug targets and biomarkers for breast cancer disease.  
 
4.1.5.1 Cancer (MCF-7+BT20) vs. normal (MCF-10A+BT20) 
The identified differentially expressed protein for the comparison of cancer (MCF-
7+BT20) vs. normal (HMEC+MCF-10A) group from cell lysate, conditioned media and 
membrane fractions were grouped together to investigate which biological functions are 
being affected in the process of transformation of a normal cell into a cancer  cell. Of the 
identified differentially expressed proteins from the cancer vs. normal comparison group, 
the majority of proteins were observed to be involved in the regulation of cell structure 
(16%) and proteolysis (14%) followed by cell proliferation and differentiation (7%) (Figure 
4.1.5.1).  
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Figure 4.1.5.1. A pie chart demonstrating the percentage of diferentially expressed proteins 
in each biological function identified in the cancer (MCF-7+BT20) vs. normal 
(HMEC+MCF-10A) comparison group from 2D-DIGE study of cell lysate, conditioned 
media and membrane fractions. The information for the biological function was obtained 
from the NCBI database. 
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4.1.5.2 Normal+cancer-related invasion (HMEC+BT20 vs. MCF-10A+MCF-7)  
The identified differentially expressed protein for the comparison of normal+cancer 
invasive (HMEC+BT20) vs. normal+cancer non-invasive (MCF-10A+MCF-7) group from 
cell lysate, conditioned media and membrane fraction were also analysed to investigate the 
biological functions significantly affected in the process of transformation of a non-
invasive cell into an invasive cell. The majority of proteins identified in this comparison 
group were observed to be associated with the regulation of cell structure, protein disulfide 
isomerase reaction and in stress management in the cell, and account for 18.9%, 14.4%, and 
7.6% respectively (Figure 4.1.5.2). 
 
 Figure 4.1.5.2. A pie chart demonstrating the percentage of diferentially expressed proteins 
in each biological function identified in the non-invasive (MCF-10A+MCF-7) vs. invasive 
(HMEC+BT20) comparison group from 2D-DIGE study of cell lysate, conditioned media 
and membrane fractions. The information for the biological function was obtained from 
NCBI database. 
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4.1.5.3 Cancer-related invasion (BT20 vs. MCF-10A+HMEC+MCF-7) 
The identified differentially expressed protein from the comparison of cancer invasive 
(BT20) vs. normal-invasive+normal non-invasive+cancer non-invasive (HMEC+MCF-
10A) group from the cell lysate, conditioned media and membrane fractions were grouped 
together to investigate the biological functions that are mainly affected in the process of 
transformation of a normal cell into a cancer invasive cell. Of the identified differentially 
expressed proteins from this comparison group, the majority of proteins were observed to 
be involved in the regulation of cell structure (13%) and proteolysis (10%) (Figure 4.1.5.3). 
 
 
 
Figure 4.1.5.2. A pie chart demonstrating the percentage of proteins in each biological 
function identified in the cancer invasive (BT20) vs. normal invasive+normal non-
invasive+cancer non-invasive (HMEC+MCF-10A+MCF-7) comparison group from 2D-
DIGE study of cell lysate, conditioned media and membrane fractions. The information for 
the biological function was obtained from the NCBI database. 
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Our data indicates that the development of the cancerous and invasive phenotypes in breast 
cells mainly affect the proteins that are involved in the regulation of cell structure, motility 
and protein metabolism and modification in cells. However, the number of proteins 
identified here is insufficient for a comprehensive analysis of the main biological functions 
affected in this system, as we may be observing a bias towards the identification of the 
more highly expressed metabolic and structural proteins within the cell such as ACTB. 
However, the data presented is in agreement with the previous published literature as the 
cell structure and motility, protein metabolism and modification biological functions have 
already been shown to be the dominantly affected biological function in tumour cells 
(Zapun et al. 1998). 
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4.1.6 Summary of identified potential targets using proteomics tools 
Box-7 summaries the high priority cellular, secreted and membranal protein targets 
identified in this study. Little information on the role of these protein targets in breast 
cancer and invasion is available from the literature and these protein targets could possibly 
be involved in the regulation of cancerous and/or invasive phenotypes in breast cells. The 
targets identified from the cell lysates and membranal fraction could be further investigated 
using immunohistochemistry whereas the targets identified from the conditioned media 
fraction are potential targets to be screened using breast cancer patients and normal sera. 
The inhibition or over expression studies for these targets in breast cancer cell lines as well 
as in normal breast cells could further improve the understanding of the process of 
transformation of a normal cell in to a cancerous as well as invasive phenotype in breast 
cells and offers potential to identify potential drug targets and/or biomarkers for breast 
cancer disease.   
 
Box-7: High priority interesting target from 2D-DIGE study 
2D-DIGE 
study 
Cancer associated  Normal+cancer 
invasion associated 
Cancer invasion 
associated 
Cell lysates EIF4A3, UQCRC11, 
DCI, SOD1 and 
SERPINB1 
RAD23B TXNRD1  and 3-PGDH 
Conditioned 
media 
PDIA4, SERPINB1, 
SERPINB7, NUCB1, 
CTSA and FHC 
TALDO1 and GSS NUCB2 and DDAH1  
Membrane 
fraction 
IMMT, FKBP5, 
UQCRC1 and S100A14  
WDR1, RUVBL2 
C20ORF3 and 
GANAB 
ATP5B, TALDO1, 
CES1, RUVBL2 and 
AHCY 
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4.2 SELDI-ToF MS analysis of conditioned media from human cell lines 
The incidence of melanoma is increasing dramatically in the developed world. However the 
molecular markers that are being used for melanoma, i.e. MIA, S100β and LDH, are still 
not satisfactory for detecting melanoma at an early stage of its development. Therefore the 
discovery of new markers for melanoma diagnosis could lead to the establishment of novel 
prognosis and diagnosis methods. Melanoma develops from a series of architectural and 
phenotypically distinct stages and becomes progressively aggressive culminating in 
metastasis. The development of invasive and metastatic behaviour during cancer 
progression requires the concerted action of multiple genes and cellular functions, including 
cytoskeleton remodeling, acquisition of migratory phenotypes, ability to invade the tumour-
surrounding tissues, and survival of disseminated tumour cells. One aspect of these 
complicated processes is that invasion and metastasis may sometimes be related to the 
multidrug resistance (MDR) phenotype (Winston et al. 2001, Thompson et al. 2007, 
Koukourakis et al. 2007, Olson and Sahai 2008). A relationship between these two 
phenotypes has been demonstrated by two types of observation. Firstly, some tumour cells 
selected for resistance to drugs are more invasive/metastatic relative to non-resistant 
parental cells (Liang et al. 2002). Secondly, in some cases, secondary (more metastatic) 
tumours are more resistant to chemotherapeutic drugs than their primary counterparts 
(Liang et al. 2002, Liang et al. 2001, Haga et al. 1997). A better understanding of any 
relationship between drug resistance and cancer invasion could lead to a more effective 
melanoma invasion treatment. Therefore, proteomic analysis of conditioned media from 
melanoma cell line MDA-MB-435S-F and its paclitaxel-resistant (MDA-MB-435S-
F/Taxol10p4pSI), doxorubicin-resistant (MDA-MB-435S-F/Adr-10p10p) cell lines were 
performed using SELDI-ToF MS to find proteins/peptides changes that may be associated 
with melanoma invasion. 
4.2.1 MDA-MB-435 cells are from melanoma origin 
MDA-MB-435 has been used for decades as a model of metastatic human breast cancer. 
This cell line was derived by R. Cailleau in 1976 from a pleural effusion from a 31-year old 
woman with a history of breast cancer (Cillo et al. 1987). In a gene expression analysis of 
MDA-MB-435 cells in conjunction with 60 other cell lines, it was revealed that the pattern 
of gene expression for MDA-MB-435 more closely resembled that of melanoma cell lines 
 330 
than of other breast lines (Cailleau et al. 1978). Another expression study showed breast-
specific genes were not detectably expressed in MDA-MB-435, however, they expressed 
melanocyte-specific genes such as RXRG, TYR, ACP5, and DCP (Ross et al. 2000). 
Additionally, MDA-MB-435 cells were found to express breast differentiation-specific 
proteins and secrete milk lipids as are other well-established breast cancer cell lines, as well 
as expressing melanocyte-specific proteins, tyrosinase and melan-A (Ellison et al. 2002). 
MDA-MB-435 cells are in fact derived from the melanoma cell line M14 revealed by 
single-nucleotide polymorphism (SNP) arrays analysis (Sellappan et al. 2004). Therefore, 
MDA-MB-435 are now considered a melanoma cell line. 
Previously in NICB, paclitaxel (MDA-MB-435S-F/Taxol10p4pSI) and doxorubicin (MDA-
MB-435S-F/Adr-10p10p) selected variants of an in vitro invasive clonal population of the 
human melanoma cancer cell line, MDA-MB-435S-F, were established by pulse selection 
(Rae et al. 2007). MDA-MB-435S-F cells are invasive and the resistance variants, MDA-
MB-435S-F/Taxol-10p4p and MDA-MB-435S-F/Adr-10p, were found to be highly 
invasive. 
 
4.2.1.1 SELDI ToF MS analysis of conditioned media from MDA-MB-435S-F, MDA-
MB-435S-F/Taxol10p4pSI and MDA-MB-435S-F/Adr-10p10pSI 
The secretome of cells and tissues may reflect a broad variety of pathological conditions 
and thus represents a rich source of information. Large proteins are only present in the 
conditioned media intact if they are actively secreted by cells. Degradation and cleavage 
can generate fragments small enough to be easily secreted by cells, producing diagnostic 
traces. Thus the low-molecular-weight (LMW) region is a mixture of small intact proteins 
plus fragments of large proteins. This treasure trove of diagnostic information has largely 
been ignored until now. SELDI-ToF MS has been a promising technology to identify 
differential expression of low molecular weight proteins/peptides using a very small 
amount of sample and has been quite successful. It has been used for the analysis of serum, 
plasma, urine, cell lysates and cellular secretions focusing on the discovery and 
identification of potential biomarkers for various diseases (Glynn et al. 2004). SELDI-ToF 
MS utilizes the different chromatographic properties of ProteinChip® arrays to bind 
different subsets of peptides and proteins for subsequent analysis (Ward et al. 2008, 
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Nakamura et al. 2006, Caspersen et al. 2007, Gourin et al. 2007, Furuta et al. 2004). 
Recent reports employing SELDI-ToF MS-based approach have demonstrated that protein 
profiles are useful for the early detection of breast, prostate and colon cancers (Merchant 
and Weinberger 2000). Distinct protein profiles of many carcinoma cell lines and 
associated variants are now established using this technology (Chen and Madura 2006, Li et 
al. 2002, Petricoin et al. 2002, Chen et al. 2005).  
In order to investigate changes in the secretome that might be associated with mechanisms 
involved in drug resistance and invasion, or for establishing biomarkers associated with the 
melanoma phenotype, conditioned media from the parental cell line, MDA-MB-435S-F and 
the drug-selected superinvasive population, MDA-MB-435S-F/Taxol-10p4pSI were 
subjected to biochemical and proteomic analysis. Initial analysis carried out using the 
IMAC30-Cu2+ ProteinChip arrays demonstrated that the expression level of a 7.6kDa peak 
in MDA-MB-435S-F/Taxol-10p4pSI cells was increased when compared with MDA-MB-
435S-F cells. The 7.6kDa protein was found to be 4-fold greater in the taxol-resistant cells 
with a statistically significant p-value of < 0.04 (Figure 3.4.2). A time course study showed 
that the levels of the 7.6kDa protein detectable in conditioned media from MDA-MB-435S-
F/Taxol-10p4pSI cells taken at 24hrs, 48hrs and 72hrs respectively, slowly decreases 
(Figure 3.4.3). 
Further analysis performed on the conditioned media from the doxorubicin-resistant variant 
MDA-MB-435S-F/Adr-10p10pSI cells was used to confirm if the increased expression of 
7.6kDa peak is related to taxol-drug resistant specifically or invasion. The 7.6kDa 
protein/peptide was also found to have a 2.6-fold greater intensity in the doxorubicin-
resistant variant MDA-MB-435S-F/Adr-10p10pSI compared to the parental cell line 
(Figure 3.4.4). This result indicates that the 7.6kDa protein/peptide peak was possibly 
associated with either invasion or drug-resistance phenotype. 
 
4.2.1.2 Purification and identification of the 7.6kDa peak as a possible fragment of 
bovine transferrin 
Purification and identification of the 7.6kDa peak was performed using conditioned media 
from the MDA-MB-435S-F/Taxol-10p4pSI population. Firstly the conditioned media was 
fractionated using BioSepra IMAC-Cu2+ HyperCel spin columns, with the 250mM 
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Imidazole fraction showing the highest concentration of the 7.6kDa protein along with the 
least amount of contaminating peaks (Figure 3.4.5 A). Secondly the 250mM fraction was 
run on a 1D gel under reducing conditions. Silver staining of the gel allowed a band at 
7.6kDa to be excised. Tryptic digests of the protein was subject to MALDI ToF/ToF 
analysis and identified as a possible 7.6kDa protein fragment of bovine transferrin (Figure 
3.4.5.B). 
The transferrins are comprised of a family of large non-heme iron-binding glycoproteins 
(~77kDa) that are believed to originate with the evolutionary emergence of vertebrates or 
pre-vertebrates. Serum transferrin, ovotransferrin and lactoferrin are three major types of 
transferrins that have been characterized.  Serum transferrin occurs in blood and other 
mammalian fluids including bile, amniotic fluid, cerebrospinal fluid, lymph, colostrom, and 
milk in the body. Serum transferrin has the role of carrying iron from the sites of intake into 
the systemic circulation to the cells and tissues (Chen et al. 2005, Shiwa et al. 2003). It is 
also likely to be involved in the transportation of a wide range of other metal ions other than 
iron, including therapeutic metal ions, radio diagnostic metal ions, and some toxic metal 
ions (Morgan 1964). Ovotransferrin (oTf) is found in avian and reptilian oviduct secretions 
and in avian egg white (Savigni and Morgan 1998), and lactoferrin (Lf) is found in milk, 
tear, saliva, and other secretions (Jeltsch and Chambon 1982, Williams et al. 1982). 
Transferrin is mainly synthesized by hepatocytes, with a concentration of 2.5 mg/ml and 
30% occupied with iron in blood plasma (Baggiolini et al. 1970). Another member of the 
transferrin family called melanotransferrin (also called p97) was identified as an integral 
membrane protein in human malignant melanoma cells and in some fetal tissues (Leibman 
and Aisen 1979), although its function is not clear yet.  
 
4.2.1.3 Investigation of protease activity in conditioned media 
To further investigate the proteases involve in the truncation of transferrin, gelatin 
zymography of conditioned media from MDA-MB-435S-F and its variant MDA-MB-435S-
F/Taxol10p4pSI was performed. The inhibition of MMPs activity by the use of MMPs 
inhibitors, EDTA and 1,10 Phenatheoline confirmed the increased protease activity of the 
MMPs in the highly invasive MDA-MB-435S-F/Taxol10p4pSI cell lines compared to its 
parent population MDA-MB-435S-F (Figure 3.4.7 A). The two secreted bands observed on 
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the zymogram were bands corresponding to MMP-2 (approximately 62 kDa) and MMP-9 
(approximately 92 kDa). This indicates that melanoma cells are possible active secretors of 
MMP 2 and MMP 9 proteases which could be involved in invasion, metastasis and 
tumourigenicity. However this enzymatic cleavage of transferrin may be due to the 
extracellular proteases secreted into the medium by cells or due to the uptake of bovine 
transferrin from the culture media followed by intracellular cleavage and secretion of 
transferrin fragments by cells. The most likely explanation of our finding could be that 
tumour cells require a higher level of iron intake than normal cells and proteolytic cleavage 
of bovine transferrin in the presence of proteases enhances rapid release of iron and the 
ability of melanoma cells to obtain iron from iron chelates. Many reports in the literature on 
transferrin production relates to the secretion of transferrin by primary or established cell 
lines (Rose et al. 1986). However there is little information on the intracellular level of 
transferrin protein (Onoda et al. 1990, Väisänen et al. 2008, Vandewalle et al. 1989).  
The presence of the fragment of transferrin in conditioned media suggests that transferrin 
protein is being cleaved due to increased proteolytic activity, possibly due to increased 
levels of secreted MMP2 and MMP9 in the culture media of melanoma cells. Therefore we 
were interested to identify possible cleavage sites for MMP 2 and MMP 9 in the full 
transferrin protein sequence. The analysis of transferrin protein for the presence of potential 
cleavage motifs for MMP2 and MMP9 using in-silico tools indicated that transferrin does 
not contain any cleavage site for these MMPs. It is likely that these MMPs might be 
cleaving transferrin using an amino acid signature for cleavage which is not known yet. 
However based on the molecular weight, we can suspect that these MMPs might be 
cleaving at 69 residues from the C-terminus of the protein and this could result in the 
cleaved transferrin fragment with a molecular weight of 7.6kDa (Figure 3.4.9). 
 
4.2.1.4 Role of MMP 2 and MMP 9 in melanoma and invasion 
The MMPs belong to a large family of secreted or transmembrane proteolytic enzymes 
known as the metzincin superfamily. MMPs can process or degrade all kinds of bioactive 
molecules including extracellular matrix proteins. MMPs can cleave cell surface receptors, 
release of apoptotic ligands (such as the FAS ligand) and chemokine in/activation, and 
therefore play a major role in cell behaviours such as cell proliferation, migration 
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(adhesion/dispersion), differentiation, angiogenesis, apoptosis and host defense. The 
importance of MMPs during tumour metastasis may be related to their proteolytic activity 
against type IV collagen, which is a major component of epithelial basement membranes. 
Most of the MMPs are produced in the form of biologically inactive proenzymes and need 
to become activated by another enzyme (s) (Anderson et al. 1986).  
MMP-2 and MMP-9 (gelatinase A and gelatinase B) are involved in the systemic 
dissemination of tumours. MMP2 has been reported to be over expressed in human 
melanocytic tumours (Chambers and Matrisian 1997, Nelson et al. 2000) and in more 
invasive melanomas (Hofmann et al. 2000, Vaisanen et al. 1996 & 1998). The over 
expression of MMP-2 has been linked to hematogenous metastasis and, thus, to impaired 
survival in male melanoma patients, suggesting a difference according to sex (Simonetti et 
al. 2002). The over expression MMP-9 strongly correlates with the metastatic capacity of 
tumours (Vaisanen et al. 1998). The level of MMP-9 expression has been shown to be 
elevated in melanomas and associated with a significantly higher incidence of metastatic 
disease (O’Grady et al. 2007). So far, the role of MMP-2 and MMP-9 as a prognostic factor 
in melanoma has not been confirmed.  
In this study the use of MMP 2 and MMP 9 inhibitors in the culture of MDA-MB-435S-
F/Taxol10p4pSI resulted in a decreased mean intensity of the m/z 7653 peak in MMP 9 and 
MMP2 inhibitor-treated samples in comparison to untreated control samples. This 
confirmed the increased activity of MMP 2 and MMP 9 in MDA-MB-435S-
F/Taxol10p4pSI cells. Although the effect of MMP 2 inhibitor was more intense in 
inhibiting the cleavage of transferrin compared to MMP 9 inhibitor, both MMPs were 
found to cleave transferrin protein in culture (Figure 3.4.8). Thus MMP 2 and MMP 9 
inhibition indicates that bovine transferrin is possibly being cleaved by extracellular 
proteases secreted by MDA-MB-435S-F/Taxol10p4pSI into the media. 
 
4.2.1.5 Screening of bovine transferrin fragment (7.6kDa) as a potential biomarker for 
melanoma 
The presence of truncated transferrin in the conditioned medium from the highly invasive 
cell line indicates the potential involvement of proteases in breaking down the transferrin 
protein into fragments which could be related to the development of the invasive phenotype 
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in the cell (El-Shabrawi et al. 2001). Therefore the expression of truncated transferrin was 
further investigated for its specificity in a panel of melanoma, breast or lung cancer cells 
and for possible mechanisms of proteolytic cleavage of the transferrin protein. The 
conditioned media from melanocytes (NHEM), normal mammary cells (HMEC) and 
melanoma (MDA-MB-435S-F, MDA-MB-435S-F/Taxol10p4pSI, MDA-MB-435S-F/Adr-
10p10pSI, M14, HT144, SKMEL-28, SKMEL-5, Malme-3M and Lox-IMVI), breast 
(MCF-7 and BT20), and lung (DLKP and H1299) cancer cell lines were profiled using 
SELDI-ToF MS and mass spectrometry to further investigate the expression of truncated 
transferrin as a potential biomarker for cancer. The truncated transferrin was observed to be 
expressed in all melanoma cell lines except HT144 but not expressed in the conditioned 
media from melanocytes, normal mammary cells and breast, and lung cancer cell lines 
(Figure 3.4.10). 
The source of bovine truncated transferrin could be suspected to be derived from the 
cultivation of cell lines as the cells were grown in 10% FCS supplemented culture medium. 
The method used for the generation of samples in this study is a common procedure and has 
been used by other research laboratories for generating serum-free conditioned media for 
SELDI-ToF MS analysis (Dowling et al. 2007a). The sample preparation for all cell lines 
was also the same, even though the 7.6kDa peak was observed only in the melanoma cell 
lines (Figure 3.4.10.1). Moreover in another independent study in this laboratory, SELDI-
ToF MS profiles were generated for 0.5% FCS supplemented cell-free culture media at 
370C over the period of 6 days in CHO cells and no peak at m/z 7653 was observed in these 
culture conditions (Ito et al. 2007, Sato et al. 2001).  
To see if there was any correlation between the levels of the 7.6kDa protein fragment with 
invasion status of the melanoma cell lines, in vitro 48 hours invasion assay were performed 
on melanocytes (NHEM) and the  melanoma cell lines MDA-MB-435S-F, MDA-MB-
435S-F/Taxol10p4pSI, MDA-MB-435S-F/Adr-10p10pSI, M14, HT144, SKMEL-28, 
SKMEL-5, Malme-3M and Lox-IMVI. The levels of expression of the 7.6kDa bovine 
transferrin fragment in melanoma cell lines and their invasion status does not shown any 
correlation. SKMEL-5 is a non-invasive cell line and a high level of the 7.6kDa bovine 
transferrin fragment was observed in SELDI-ToF analysis of the conditioned media from 
the cell lines. Malme 3M is invasive but was found to express low levels of 7.6kDa peak in 
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the conditioned media. Also melanocytes are invasive in nature and there was no 
expression of the 7.6kDa peak in the conditioned media (Firgure 3.4.11).  
 
4.2.1.6 Expression of transferrin receptor in melanocytes and melanoma cell lines 
Western blot analysis of whole cell lysates from both melanocytes and MDA-MB-435S-
F/Taxol10p4pSI phenotypes using an antibody against the transferrin receptor showed a 
marked increase in the abundance levels of the receptor in MDA-MB-435S-
F/Taxol10p4pSI cells. The transferrin receptor was found to be approximately 35.9-fold 
increased in the melanoma cell line MDA-MB-435S-F/Taxol10p4pSI compared to the 
parental cell line (Figures 3.4.12A). This 35.9-fold increase in the receptor possibly 
corresponds to a 34.2-fold increase in the transferrin fragment identified by SELDI-ToF 
MS analysis found in the MDA-MB-435S-F/Taxol10p4pSI conditioned media compared to 
melanocytes (Figure 3.4.12B). The transferrin receptor was also found to be approximately 
3.5-fold increased in the MDA-MB-435S-F/Taxol10p4pSI compared to the parental cell 
line MDA-MB-435S-F. This 3.5-fold increase in the receptor possibly corresponds to a 4-
fold increase in the transferrin fragment identified by SELDI analysis found in the MDA-
MB-435S-F/Taxol10p4pSI conditioned media (Figure 3.4.13C). 
 
4.2.1.7 Potential mechanism of transferrin receptor-mediated cellular iron uptake in 
melanoma cells 
Transferrin receptor (TfR1) is a carrier protein for transferrin. It is a transmembrane 
homodimer that consists of two identical monomers with a molecular mass of 
approximately 90 kDa; each monomer is joined by two disulfide bonds (Kumar et al. 2008). 
Acquisition of iron in higher organisms is mainly by the receptor mediated transferrin-
bound iron (Jing and Trowbridge 1987). After binding to its receptor on the cell surface, 
transferrin (Tf) is rapidly internalized by invagination with the formation of endocytic 
vesicles (Figure 4.4.4A). Briefly, the process is triggered by the binding of Fe-Tf to a 
specific cell-surface TfR1 (Andrews 1999). After endocytosis, which bud from the plasma 
membrane as membrane bound vesicles or endosomes, the Fe-Tf·TfR1 complex is routed 
into the endosomal compartment. Upon maturation, the endosome becomes competent to 
pump protons in a process energized by ATPase, and the endosomal lumen is rapidly 
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acidified to a pH of about 5.5 (Morgan 1964, Morgan and Appleton 1969). At this pH, the 
binding of iron to Tf is weakened, leading to iron release from the protein. The free Fe3+ 
released to endosomes and reduced to Fe2+ on the cis-side of the endosomal membrane 
probably mediated by oxidoreductase (Dautry-Varsat et al. 1983, Paterson et al. 1984). Fe2+ 
is subsequently transported out of the Tf cycle endosome by the divalent metal transporter 
DMT1, i.e., from the endosomal membrane to the cytosol (Neuhoff et al. 2004). After 
release of iron into the endosome, the resultant apo-Tf·TfR1 complex is then recruited 
through exocytic vesicles back to the cell surface. At extracellular physiological pH, apo-Tf 
dissociates from its receptor due to its low affinity at pH 7.4, is released into the circulation, 
and reutilized (Fleming et al. 1998, Tabuchi et al. 2000). ATP-mediated energy is 
necessary for sustaining TfR-mediated endocytosis and recycling (Morgan 1996 & 2001, 
Qian et al. 1997 & 2002).  
The present study indicates that the transferrin protein (704 a.a long protein) is possibly 
being cleaved by secreted MMPs (MMP2 and MMP9) as a 7.6kDa fragment of transferrin 
and was observed to be increased in the melanoma cell lines. This suggest that MMPs 
secreted by melanoma cells could potentially be cleaving transferrin at the ~635 a.a. 
position and releasing a fragment of ~69 a.a. (7.6kDa) from the C-terminus of the 
transferrin from the Fe-Tf·TfR1 complex (Figure 4.4.4B). The 7.6kDa fragment was 
observed in serum-free conditions because the cells were initially cultured in serum-
supplemented medium from where the transferrin could have bound to the TfR1. Cells may 
retain Fe-Tf.TfR1 complex on the cell surface and therefore the presence of bovine 
transferrin in serum-free culture condition is not unexpected. The transfer of cells to serum-
free conditions possibly resulted in the release of the 7.6kDa fragment into serum-free 
medium where this fragment was detected by SELDI-ToF MS due to enrichment of cell 
secreted proteins as well as reduced hindrance from serum proteins in the culture. However 
the possible reason for cleavage of transferrin fragment from the Fe-Tf·TfR1 complex is not 
clear from this present study. It could be expected to facilitate the efficient internalization 
of the Fe-Tf·TfR1 complex and/or release of iron into the melanoma cells. The increased 
expression of transferrin recepotors with transferrin fragment in melanoma cell lines 
strengthens this hypothesis. Once in the cytosol, iron is utilized as a cofactor for aconitase, 
the cytochromes, RNA reductase, and heme, or stored as ferritin. 
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Figure 4.4.4 The cycle of transferrin and transferrin receptor 1-mediated cellular iron 
uptake. A. Classical Pathway: Differic transferrin (holo-transferrin) binds to transferrin 
receptor on the cell surface. The resulting complex is internalized and acidified through the 
action of a proton pump. Iron is subsequently released from transferrin and transported out 
of endosomes via the divalent metal transporter DMT1. Apo-transferrin (transferrin without 
iron) and transferrin receptor 1 both returned to the cell surface, where they dissociate at 
neutral pH, and both participate in another round cycle of iron uptake. Intracellular iron is 
either incorporated into heme or stored in ferritins (Podbilewicz and Mellman 1990). B. 
Hypothesis for transferrin cleavage: Once holo-transferrin binds to the transferrin 
receptor 1 in melanoma, MMPs (MMP2 and MMP9) possibly cleave holo-transferrin at the 
c-terminus releasing a fragment of 7.6kDa in to the culture medium. However the 
biological significance of transferrin cleavage has not been established, it could be 
associated with more efficient internalization or release of iron into the melanoma cells.  
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Transferrins facilitate extracellular iron storage and transport in culture medium. Almost all 
cells require transferrin for growth and therefore human cells cultured in fetal calf serum 
supplemented culture medium could acquire iron, and other trace elements that may be 
carried by transferrin from the culture medium. However few studies have suggested that 
bovine transferrin does not bind to the human transferrin receptor and therefore fails to 
deliver iron to human cells (Qian et al. 2002). Others have shown, using competition 
studies, that bovine transferrin probably does bind to the human transferrin receptor, but 
only weakly (Sephton and Kraft 1978). Since almost all cells require transferrin for growth 
(Tsavaler et al. 1986), the absence of binding of bovine transferrin would imply that human 
cells cultured in fetal-bovine serum may be able to acquire iron and other trace elements 
that may be carried by transferrin, by a mechanism other than the normal receptor-mediated 
endocytosis of transferrin. The inability of bovine transferrin to bind to human cells could 
be due to a simple species difference in affinity for the receptor, but an alternative 
explanation could be that the internal proteolytic cleavage, which can occur in bovine 
transferrin (Barnes and Sato 1980), could decrease the binding affinity. Transferrins are 
important extracellular antioxidants and they bind iron so tightly under physiological 
conditions that virtually no free iron exists to catalyze the production of free radicals.  
In summary, the most likely explanation of our finding from this study, could be that 
tumour cells acquire a higher level of iron intake than normal cells and proteolytic cleavage 
of transferrin in the presence of proteases enhances rapid release of iron and the ability of 
melanoma cells to obtain iron from these iron chelates. Increased expression levels of 
transferrin receptors could explain the increased abundance of the truncated bovine 
transferrin in melanoma cell lines compared to melanocytes. However future studies would 
need to check the specificity of the 7.6kDa bovine transferrin fragment in a wide range of 
cell lines from different tissue types and validation of its expression in sera from melanoma 
patients and normal controls.  
 
4.1.2 SELDI-ToF MS of conditioned media from melanocytes and melanoma cell lines 
Melanoma is a malignant tumour arising from melanin producing cells known as 
melanocytes. Identification of differentially expressed proteins/peptides could be helpful to 
understand the process of transformation of melanocytes into melanoma. This is the first 
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study of profiling of conditioned media from melanocytes and melanoma using SELDI-ToF 
MS. There is no published literature on conditioned media from melanocytes and 
melanoma cell lines using SELDI-ToF MS to the best of our knowledge. However limited 
studies have been mentioned in literature on melanoma serum samples using SELDI-ToF 
MS which as been discussed in section 1.8 (Maeda et al. 1980). 
 
4.1.2.1 Expression differential mapping 
To investigate the differentially expressed proteins/peptide between normal melanocytes 
and melanoma cell lines, serum-free conditioned media from melanoma melanocytes 
(NHEM) and melanoma (M14, HT144, SKMEL-28, SKMEL-5, Malme-3M and Lox-
IMVI) were profiled using SELDI-ToF MS on the IMAC-Cu++ surface. Four differentially 
expressed proteins/peptides at m/z 7406, m/z 8584, m/z 11959 and m/z 12081 were 
observed which were significantly differentially expressed in melanocytes and melanoma 
cell lines (section 3.5.1.1, 3.5.1.2 and 3.5.1.3). 
The m/z 7406, m/z 8584, m/z 11959 and m/z 12081 peaks were dominantly expressed in all 
melanoma cell lines (HT144, Lox-IMVI, M14, Malme-3M, SKMEL-5 and SKMEL-28) 
compared to melanocytes, although the expression levels of each peak in each melanoma 
cell lines were different. There was no correlation seen in the expression levels of all four 
differentially expressed peaks and the invasion status of the cell lines. Therefore the data 
indicates that these proteins/peptides could be involved in the transformation of 
melanocytes to melanoma. We successfully identified the m/z 8584 peak as ubiquitin 
protein but we were not successful in identifying the 3 remaining peaks (m/z 7406, 11959 
and 12081). 
 
4.1.2.2 Ubiquitin 
Ubiquitin, a 76-amino-acid-residue protein, is present in the cytoplasm and nucleus of 
eukaryotic cells and is one of the most highly evolutionarily conserved proteins. Ubiquitin 
acts through the ubiquitin/proteasome pathway by labeling a wide variety of proteins by a 
covalent ligation leading the resulting ubiquitinated proteins to rapid degradation. 
Ubiquitin-mediated proteolysis, a major pathway for selective protein degradation, plays a 
variety of regulatory roles in cellular processes, including cell cycle, apoptosis, 
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transcription, protein trafficking, signaling, DNA replication and repair, and angiogenesis 
(Shen et al. 2002). The complete ligation mechanism requires the sequential action of three 
enzymes: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and 
ubiquitin ligase (E3) (Mani and Gelmann 2005, Chen et al. 2006, Hoeller et al. 2006). The 
resulting covalent ubiquitin ligations form polyubiquitinated conjugates that are rapidly 
detected and degraded by the 26S proteasome complex. Then the substrates are hydrolyzed 
to produce small peptides, and ubiquitin is spared from degradation through its release from 
the substrates by deubiquitinating enzymes.  
Aberrations in the mechanisms of ubiquitin-mediated proteolysis mechanisms in cancer 
cells include inhibition of ubiquitination and proteolysis of proteins that promote cell 
growth and survival as well as accelerated ubiquitination and degradation of proteins that 
suppress tumour growth and induce apoptosis. Despite the approval of a first drug of this 
class (bortezomib) by the US Food and Drug Administration for the treatment of relapsed 
or refractory multiple myeloma and its current testing in clinical trials for the treatment of a 
wide variety of malignancies (Hershko and Ciechanover 1998), other specific targets of the 
ubiquitin system remain to be identified and tested.  
Ubiquitin, which can conjugate with cellular proteins, is classified into two forms: free 
ubiquitin and multiubiquitin chains. Ubiquitin exists in vivo as free ubiquitin prior to 
ubiquitination and as multiubiquitin chains after functional modification or degradation. 
Higher level of multiubiquitin chains and free ubiquitin has been found in the serum of 
rheumatoid arthritis and hemodialysis patients compared to healthy subjects (Adams 2002). 
A few reports have mentioned higher levels of cellular ubiquitin in various cancers (Takada 
et al. 1997, Ishibashi et al. 2004), however the form of ubiquitin was not measured. The 
immunoassays to detect free and/or multiubiquitin chains has recently been developed 
which could allow quantification of free ubiquitin and multiubiquitin form of ubiquitin in 
serum (Ishibashi et al. 2004, Kanayama et al. 1991, Osada et al. 1997). Both forms of 
ubiquitin (free ubiquitin and multiubiquitin chains) have been observed highly expressed in 
colon cancer tissue compared to normal tissue (Takada et al. 1997). The expression of 
secreted ubiquitin was observed to be increased in all of melanoma cell lines compared to 
melanocytes in this investigation. However, no correlation was observed between the 
invasion status of the cell lines and the expression pattern of ubiquitin. The peak for 
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ubiquitin in this study was observed at m/z 8584 (8.5kDa) which is the molecular weight of 
single ubiquitin suggesting that it could be the free form of ubiquitin secreted by melanoma 
cell lines in conditioned media. Over-expression of secreted ubiquitin in conditioned media 
of melanoma cells could indicate possibly increased ubiquitin synthesis and ubiquitin-
dependent proteolysis which could possibly be related to the metabolism and catabolism of 
proteins that are involved in cellular proliferation. 
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Section 5 
 
 
 
 
 
 
 
 
 
Summary and conclusions 
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5.1 Proteomic analysis of HMEC, MCF-10A, MCF-7 and BT20 cells 
Comparative protein profiles for cellular, secreted and membrane & membrane-associated 
proteins from invasive normal mammary epithelial cells (HMEC), non-invasive and non-
tumourigenic immortalized mammary epithelial cells (MCF-10A), non-invasive breast 
cancer cells (MCF-7) and invasive breast cancer cells (BT20) were generated using 2D-
DIGE. These protein profiles were compared in the following three groups in order to 
identify proteins up-regulated or down-regulated with the cancerous and invasive status of 
the cell lines. 
1. Cancer (MCF-7+BT20) vs. normal (MCF-10A+HMEC) 
2. Invasive (HMEC+BT20) vs. non-invasive (MCF-10A+MCF-7) (Normal+ 
cancer-related invasion) 
3. Cancer invasive (BT20) vs. normal invasive, normal non-invasive and cancer non-
invasive (HMEC+ MCF-10A+MCF-7) (Cancer-related invasion) 
 
5.1.1 Differential protein profiling of cell lysates  
5.1.1.1 Cancer vs. normal (MCF-7+BT20 vs. HMEC+MCF-10A) 
• A total of 44 proteins were identified, of which 27 were up-regulated and 17 down-
regulated in cancer cell lines.  
• A number of proteins that are already known to be associated with cancer such as 
annexin 1 (ANXA1) and maspin (SERPINB5) were observed to be down regulated in 
cancer cell lines and are in agreement with the literature. 
• Five cellular proteins, EIF4A3, UQCRC1, DCI, SOD1 and SERPINB1, which have 
limited information on their possible involvement in breast cancer, were also observed 
to be differentially regulated in this comparison. EIF4A3, UQCRC1, DCI and SOD1 
were up-regulated whereas SERPINB1 was down-regulated in cancer cell lines. 
 
5.1.1.2 Normal+ cancer-related invasion (HMEC+BT20 vs. MCF-10A+MCF-7) 
• A total of 15 differentially expressed proteins (15 up-regulated and 8 down-regulated in 
the N+C invasive cells) were identified from this comparison group. This enabled us to 
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identify proteins which may be involved in the regulation of invasion in cancer as well 
as normal cells.  
• This comparison identified a number of proteins that are well known to be involved in 
the regulation of the cancer invasion process. For example, non-metastatic cells 1 
(NME1) and keratins 8 (KRT8) and 18 (KRT18). NME1 was up-regulated whereas 
KRT8 and KRT18 were down-regulated in N+C invasive cells. 
• A number of proteins that have not been reported previously as being invasion-
associated, such as proteasome activator subunit 1 isoform 2 (PSME1), nuclear chloride 
channel 1 (CLIC1) and RAD23B, were also identified in this comparison and were 
found up-regulated in N+C non-invasive cells.  
 
5.1.1.3 Cancer-related invasion (BT20 vs. HMEC+ MCF-10A+MCF-7) 
• A total of 25 differentially regulated proteins, 16 up-regulated and 9 down-regulated in 
BT20, were identified from this comparison. This enabled us to identify proteins which 
may be involved in the regulation of the invasion process specifically in cancer cells.  
• A number of proteins were identified that have been already shown to be involved in the 
regulation of invasion in cancer cells, for example, gelsolin (GSN) and heterogeneous 
nuclear ribonucleoprotein (HNRPK). Both were found down-regulated in BT20. 
• This comparison revealed a number of differentially expressed proteins for which 
limited information is available in regard of their role in the regulation of cancer-related 
invasion. These include thioredoxin reductase 1 (TXNRD1), 3-phosphoglycerate 
dehydrogenase (3-PGDH), endoplasmic reticulum protein 29 precursor (ERp29), 
transaldolase (TALDO1), coactosin-like protein (CLP) and quinolinate 
phosphoribosyltransferase (QPRT). TXNRD1, 3-PGDH, TALDO1, CLP and QPRT 
were up-regulated whereas ERp29 was down-regulated in BT20. 
 
5.1.1.4 Functional validation 
• Western blot analysis was carried out on a panel of 6 selected cancer invasion associated 
proteins (TXNRD1, 3-PGDH, ERp29, TALDO1, CLP and QPRT) and 3 normal+cancer 
invasion-associated proteins (PSME1, CLIC1 and RAD23B) using a panel of invasive 
and non-invasive breast cancer cell lines. From the analysis, TXNRD1 and 3-PGDH 
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were observed to up-regulated in the cancer-invasive cell lines compared to the normal-
non-invasive, normal-invasive and cancerous-non-invasive cell lines except UACC-812. 
RAD23B was observed to be up-regulated in the non-invasive cell lines compared to the 
invasive cell lines. This suggests that TXNRD1, 3-PGDH and RAD23B may have roles 
in the regulation of invasion process in breast cells and therefore were selected as 
candidates for further functional investigations using siRNA knockdown.  
 
• TXNRD1 was observed to be 4.6-fold over-expressed in the cancer invasive cell lines 
(BT20) in comparison to normal invasive+normal non-invasive+cancer non-invasive 
(HMEC+MCF-10A+MCF-7) cells. TXNRD1 has been reported to be involved in the 
regulation of a variety of biological processes including tumourigenesis, invasion, 
metastasis and resistance to therapy in cancer. However, the mechanisms are still poorly 
understood. A significant reduction in the invasion status of SKBR-3 and MDA-MB 
231 was observed following reduction of TXNRD1 protein levels. This suggests that 
TXNRD1 is actively involved in the regulation of the invasion process in breast cancer 
cells and therefore could be a potential therapeutic target for breast cancer.  
 
• RAD23B is involved in the nucleotide excision repair (NER) process. RAD23B was 2-
fold up-regulated in the normal and cancer invasive cell lines (HMEC+BT20) compared 
to normal and cancer non-invasive cells (MCF-10A+MCF-7). siRNA knockdown 
studies were performed using one normal and one cancer non-invasive cell line (MCF-
10A and MCF-7). The inhibition of RAD23B increased the invasion status of both cell 
lines and established RAD23B as a potential target to regulate the process of invasion in 
breast normal and cancer cells.  
 
5.1.2 Differential protein profiling of conditioned media 
5.1.2.1 Cancer vs. normal (MCF-7+BT20 vs. HMEC+MCF-10A) 
• A total of 42 differentially expressed secreted proteins were identified in this 
comparison, of which 25 up-regulated and 18 down-regulated in cancer cells. 
• Five members of the SERPIN family (SERPINA1, SERPINB1, SERPINB5, SERPINF1 
and SERPINB7) were found down-regulated in the cancer cell lines. Of these, 
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SERPINA1, SERPINF1 and SERPINB5 are well known, whereas SERPINB1 and 
SERPINB7 are still unexplored for their potential role in the breast cancer. 
• Three members of the cathepsin family, pro-cathepsin A (CTSA), pro-cathepsin B 
(CTSB) and pro-cathepsin D (CTSD) were found down-regulated in cancer cell lines. 
CSTB and CSTD are already known to be involved in the regulation of cancer, however 
a role for CTSA in breast cancer is not known. 
• Some other protein that have not been previously linked with cancer disease, such as 
Nucleobindins-1 (NUCB1), Nucleobindins-2 (NUCB2), Ferritin heavy chain 
polypeptide (FHC) and Protein disulfide isomerase family A4 (PDIA4), were found up-
regulated in cancer cell lines.  
 
5.1.2.2 Normal+ cancer related invasion (HMEC+BT20 vs. MCF-10A+MCF-7) 
• A total of 15 differentially expressed secreted proteins, 14 up-regulated and 1 down-
regulated in the normal+cancer invasive compared to the N+C non-invasive, were 
identified.  
• Some of the identified proteins, such as Heat shock protein 90 (HSP90) and Heat shock 
protein 5 (HSP5), are well known to be involved in cancer invasion from the literature, 
were found up-regulated in N+C invasive cells. 
• Two proteins which are not previously reported as associated with invasion, 
Transaldolase-1 (TALDO1) and Glutathione synthetase (GSS), were found to be up-
regulated in the normal and cancer invasive cell lines.  
 
5.1.2.3 Cancer related invasion (BT20 vs. HMEC+ MCF-10A+MCF-7) 
• A total of 27 differentially expressed secreted proteins, 19 up-regulated and 8 down-
regulated in BT20, were identified.  
• Some of proteins, such as Protein disulfide-isomerase A3 (PDIA3) and Plastin 2 
(LCP1), have been previously reported to be involved in cancer invasion in the 
literature. PDIA3 and LCP1 were found up-regulated in cancer invasive cell line 
(BT20). 
• Two secreted proteins, which have not been previously reported to be associated with 
invasion, such as Dimethylarginine dimethylaminohydrolase 1 (DDAH1) and 
 348 
Nucleobindin 2 (NCUB2), were found to up-regulated in the cancer invasive cell line 
(BT20). 
 
5.1.3 Differential protein profiling of membrane fraction  
5.1.3.1 Cancer vs. normal (MCF-7+BT20 vs. HMEC+MCF-10A) 
• A total of 41 differentially expressed membrane and membrane-associated proteins (11 
up-regulated and 30 down-regulated) were identified in the comparison of cancerous vs. 
normal cell lines. 
• A total of 7 mitochondrial membrane and membrane-associated proteins; Mitochondrial 
Rho GTPase 2 (RHOT2), mitofilin (IMMT), stress-70 protein, mitochondrial precursor 
(HSP9), ATP synthase subunit beta, mitochondrial precursor (ATP5B), ubiquinol-
cytochrome c reductase core protein I  (UQCRC1), prohibitin (PHB) and diablo 
homolog, mitochondrial precursor (DIABLO), were observed to be differentially 
regulated in this comparison. 
• Of these, HSPA9, PHB and DIABLO are well known for their involvement in the 
cancer, whereas RHOT2, IMMT, ATP5B, and UQCRC1 are still unexplored for their 
potential role in breast cancer. RHOT2, IMMT, HSPA9, ATP5B and UQCRC1 down-
regulated whereas PHB and DIABLO were up-regulated in cancer cell lines  
• Five plasma membrane and membrane-associated S100 proteins, S100A2, S100A6, 
S100A9, S100A14 and S100A16 were found down-regulated in the cancer cell lines. 
Member of the S100 protein family have been reported to be differentially expressed in 
breast cancer, however very limited information is available for S100A14 for its 
potential involvement in the regulation of breast cancer and invasion. 
• FK506 binding protein 5 (FKBP5), a FK506 binding protein with peptidyl-prolyl 
isomerase (PPIase) activity which have not been previously reported to be associated 
with breast cancer, was observed down-regulated in the cancer cell lines. 
 
5.1.3.2 Normal+ cancer-related invasion (HMEC+BT20 vs. MCF-10A+MCF-7) 
• A total of 27 differentially expressed membrane and membrane-associated proteins (21 
up-regulated and 6 down regulated in normal+cancer invasive cells) were identified. 
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• Some of mitochondrial membrane and membrane-associated proteins were observed to 
be differentially regulated. These proteins include some proteins that are already known, 
such as 60 kDa heat shock protein 1, mitochondrial precursor (HSPD1), and some other 
proteins that are poorly known, such as NADH dehydrogenase (ubiquinone) Fe-S 
protein 1, precursor (NDUFS1), for their involvement in the regulation of breast cancer 
invasion. NDUFS1 was down-regulated and HSPD1 was up-regulated in N+C invasive 
cells. 
• Two members of the S100 family, S100A6 and S100A16, which are known to be 
involved in the regulation of cancer and invasion, were observed to be differentially 
regulated. S100A16 was observed to be down-regulated whereas S100A9 was observed 
to be up-regulated in the N+C invasive cells. 
• A number of other proteins, such as Alpha glucosidase II alpha subunit isoform 2 
(GANAB), RuvB-like-2 (RUVBL2), WD repeat-containing protein 1 (WDR1) and 
Adipocyte plasma membrane-associated protein (C20ORF3), which have not been 
previously linked with invasion, were observed to be differentially regulated in this 
comparison. GANAB, WDR1 and RUVBL2 were found to be up-regulated whereas 
C20ORF3 was down-regulated in the N+C invasive cells. 
 
5.1.3.3 Cancer-related invasion (BT20 vs. HMEC+ MCF-10A+MCF-7) 
• A total of 35 membrane and membrane-associated proteins were identified, of which 25 
proteins were up-regulated and 10 were down regulated in the cancer invasive cell line 
(BT20). 
• A number of mitochondrial proteins were also observed to be differentially regulated. 
These include some proteins that are known such as PHB and some other proteins that 
are not known such as ATP5B to be involved in breast cancer invasion in the literature. 
PHB and ATP5B were observed to be up-regulated in the cancer invasive cell line 
(BT20). 
• From the S100 protein family, some members that are well known, such as S100A2, and 
some other members that are poorly known such as S100A14 for their involvement in 
the regulation of breast cancer invasion were differentially expressed. S100A14 and 
S100A2 were observed to be up-regulated in the cancer invasive cell line (BT20). 
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• A number of other proteins which have not been previously linked with invasion, such 
as RuvB-like-2 (RUVBL2), Liver carboxylesterase 1 precursor (CES1), Transaldolase-1 
(TALDO1) and Adenosylhomocysteinase (AHCY), were up-regulated in the cancer 
invasive cell line (BT20). 
 
5.2 Identification of truncated transferrin and ubiquitin as potential biomarkers for 
melanoma using SELDI-ToF MS 
• Conditioned media from drug resistant and highly invasive variants (paclitaxel-resistant 
cell lines MDA-MB-435S-F/ Taxol10p4pSI and doxorubicin-resistant cell line MDA-
MB-435S-F/Adr-10p10pSI) of the melanoma cell line MDA-MB-435S-F were profiled 
using SELDI-ToF MS. A protein/peptide species at m/z 7653 was found to be 4-fold up-
regulated in MDA-MB-435S-F/ Taxol10p4pSI and 2.6 fold up-regulated in MDA-MB-
435S-F/Adr-10p10pSI compared to the parent cell line, MDA-MB-435S-F, suggesting 
that it may be associated with drug resistance and/or the invasive potential of these cells. 
This protein was identified by MALDI-ToF/ToF as a fragment of bovine transferrin. 
• Gelatin zymography analysis of conditioned media from MDA-MB-435S-F and MDA-
MB-435S-F/Taxol10p4pSI revealed increased activity of Matrix metalloproteinases 
(MMPs) in MDA-MB-435S-F/Taxol10p4pSI. Further investigation in  MDA-MB-
435S-F/Taxol10p4pSI confirmed that MMP 2 and MMP 9 secreted by MDA-MB-435S-
F/Taxol10p4pSI were cleaving the transferrin protein in culture medium. Although both 
MMPs were involved in the cleavage of transferrin, MMP 2 was more intense in activity 
than MMP 9.  
• The transferrin fragment was also investigated for its specificity as a melanoma 
biomarker in conditioned media from melanocytes, melanoma, normal epithelial, breast 
and lung cancer cell lines with invasive and non-invasive phenotype using SELDI-ToF 
MS. This protein fragment was specifically expressed in melanoma cell lines (SKMEL-
28, SKMEL-5 Malme-3M, LOX IVI and M14), except HT144. No correlation was 
observed for the transferrin fragment in respect of the invasive phenotype of the 
melanoma cells. Our study suggests that the cleavage of transferrin could possibly serve 
as a potential biomarker for melanoma.  
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• Based on a SELDI ToF-MS screening, four other peaks (7.4, 8.5, 11.9 and 12 kDa) were 
also observed differentially expressed in the conditioned media of the melanoma cell 
lines compared to melanocytes. An 8.5kDa peak was identified as ubiquitin using 
MALDI-ToF MS. Ubiquitin is the central component of the ubiquitin-proteasome 
protein degradation pathway which has emerged as an important mechanism in 
regulating cell growth and survival.  
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Future work 
• TXNRD1 has been shown to reduce the invasion of invasive breast cancer cell lines, 
SKBR3 and MDA-MB 231. Over-expression of TXNRD1 (stably or transiently) in non-
invasive or low invasive breast cancer cell lines would lead to a further understanding of 
the involvement of TXNRD1 in the process of invasion in breast cancer. 
 
• RAD23B induced invasion of normal and cancer non-invasive breast cells (MCF-7 and 
MCF-10A) in our study. The investigations mainly focused on cell invasion and other 
functional analyses such as adhesion, anoikis, motility and colony formation in soft agar 
could be carried out to determine functional involvement of RAD23B in invasion of 
breast cells. Over-expression (stably or transiently) of the RAD23B protein in invasive 
breast cell lines would further confirm its role in the regulation of invasion in breast 
cells.  
 
• The analysis of differential expression of proteins between the cells expressing (stably) 
TXNRD1 and RAD23B with their respective controls using 2D-DIGE could enable the 
identification of proteins that are associated with TXNRD1 and/or RAD23B in the 
process of altering invasion in breast cells. 
 
• The ultimate aim of this research is to contribute towards the identification of 
biomarkers and drug targets for breast cancer treatment. Therefore investigation of the 
expression of TXNRD1 and RAD23B in patients’ tissue from different stages of breast 
cancer could disclose the prognostic value and involvement of these targets in invasion 
in breast cancer.   
 
• A number of protein targets from the cell lysate and membrane study were narrowed 
down on the basis of their expression pattern observed using 2D-DIGE and the 
published literature and these targets could be important for early detection of breast 
cancer and therapeutic development. It will be useful to determine the expression of 
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these protein targets in breast cancer patient tissue sections in comparison to the normal 
tissue using immunohistochemistry.  These targets include  
1) Lysates study- EIF4A3, UQCRC1, DCI, SOD1 and SERPINB1 
2) Membrane study- IMMT, UQCRC1, S100A14 and FKBP5 
 
• Some protein targets from the conditioned media and membrane studies, which have 
very limited information for their role in breast cancer, were observed to be 
differentially regulated in the comparison of the invasive cells (HMEC+BT20) with the 
non-invasive cells (MCF-10A+MCF-7). It would be interesting to see if these targets are 
capable of inducing/reducing invasion following siRNA knockdown and/or cDNA over-
expression studies in normal and cancer cell lines. These proteins include 
1) Conditioned media study- TALDO1 and GSS  
      2) Membrane study- WDR1, RUVBL2, C20PRF3 and GANAB  
 
• A number of protein targets from the conditioned media and membrane studies which 
have very limited information for their role in breast cancer invasion were observed to 
be differentially regulated in the comparison of the cancer invasive cell line (BT20) with 
invasive normal+ non-invasive normal+ non-invasive cancerous cells (HMEC+MCF-
10A+MCF-7). Therefore further functional studies (siRNA knockdown and over-
expression) in cancer cell lines can confirm the involvement of these proteins in breast 
cancer. 
1) Conditioned media study-  DDAH1 and NUCB2 
      2) Membrane study- ATP5B, RUVBL2, TALDO1, CES1 and AHCY  
 
• From the conditioned media study a number of targets were identified as potentially of 
great interest on the basis of their expression pattern observed using 2D-DIGE and the 
published literature. Investigation of the expression of PDIA4, SERPINB1, SERPINF1, 
CTSA, NUCB1 and FHC proteins changes in serum samples from breast cancer patient 
and healthy controls and TALDO1, GSS, DDAH1 and NUCB2 of serum samples from 
non-metastatic breast cancer patients and metastatic breast cancer using western blotting 
could establish their value as potential biomarkers for breast cancer and invasion. 
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• A few proteins such as PDIA3, TALDO1, NUCB1, FKBP5 and RUVBL2 protein were 
identified from more than one spot on the 2D gel and this could be due to post-
translational modification. Therefore further identification of these proteins using 
advance mass-spectrometry could enable to confirm the type of modification and 
potential involvement of these proteins in signalling pathways. 
 
• The list of proteins of interest narrowed down using over expression, inhibition and/or 
immunohistochemistry studies could be investigated for their potential cellular 
localization and/or biological function using fluorescent protein fusion tagging based 
microscopy methods. 
 
• A truncated transferrin was observed secreted from the melanoma cells using SELDI-
ToF MS analysis of a panel of normal and cancerous cell lines. The inhibition of 
protease inhibitor activity in culture suggested that the transferrin protein was being 
cleaved by MMP 2 and MMP 9 in melanoma cell lines. Further validation of the 
transferrin fragment using melanoma patient serum will establish the clinical relevance 
of secreted truncated-transferrin in the discovery of potential biomarkers as well as drug 
targets for breast cancer treatment.  
 
• Transferrin receptor were found to be differentially expressed in melanocytes and two 
melanoma cell lines and correlated with the expression levels of 7.6kDa species. 
Therefore further analysis of expression of transferrin receptor in a panel of melanoma 
cells lines could be helpful to establish the relationship between the expression of 
transferrin fragment and transferrin receptor.  
 
• The 7.4, 11.9 and 12 kDa proteins/peptides were found differentially expressed in 
conditioned media from melanocytes and melanoma cell lines using SELDI-ToF MS. 
The identification of these proteins/peptides will improve our knowledge of cancer and 
invasion in melanoma and have potential to provide valuable biomarker(s) for early 
detection in melanoma. Further validation of these targets using melanoma patients will 
confirm clinical relevance of these targets with melanoma. 
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Appendix -1 
Table 1: Proteins identified from the cell lysates for the comparison of normal non-invasive (MCF-10A) vs. normal invasive (HMEC) groups MALDI 
TOF MS and/or LC-MS/MS 
2D-DIGE 
No 
Gene 
Symbol 
 
Protein Identification 
 MCF 10A/ 
HMEC 
Biological function 
1019 PDIA3 Protein disulfide-isomeraseA3 precursor  -2.35 Protein disulfide isomerase 
reaction 
1079 ARCN1 Coatomer subunit delta (Delta-coat protein)  -2.21 Constitutive exocytosis 
1211 gi|31874087 Hypothetical protein  2.73 Unclassified 
1230 UQCRC1 Ubiquinol-cytochrome-c reductase complex core 
protein 1, mitochondrial precursor  
1.82 Electron transport 
1279 NDRG1 N-myc downstream-regulated gene 1 protein  -2.61 Cell proliferation and 
differentiation 
1378 RAD23B RAD23B protein  1.96 DNA repair 
1411 SERPINB5  Tumour Suppressing Serpin 2.26 Proteolysis 
1450  TSSC1 Tumor-suppressing subchromosomal transferable 
fragment candidate gene 1 protein 
1.92 Protein binding 
1468 ANXA1 Annexin I 1.95 Cell motility 
1469 ANXA1 Annexin I 2.45 Cell motility 
1488 TALDO1 Transaldolase 1.92 Pentose-phosphate shunt 
1527 TALDO1 Transaldolase 2.24 Pentose-phosphate shunt 
- 3 - 
1732 PSME1 Proteasome alpha 3 subunit, isoform 1  4.18 Proteolysis 
1743 CLIC1 Chloride intracellular channel protein 1 6.96 Anion transport 
1781 TIP1 Chain B, Human Triosephosphate Isomerase Of 
New Crystal Form 
-2.0 Glycolysis 
1832 HMGB1 HMGB1 high-mobility group box 1 3.59 Nucleic acid metabolism 
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Table 2: Proteins identified from the cell lysates for the comparison of cancerous non-invasive (MCF-7) vs. cancerous invasive (BT20) group using 
MALDI TOF MS and/or LC-MS/MS.    
2D-DIGE 
No 
Gene 
Symbol 
 
Protein Identification 
MCF7/ BT20 
Fold change 
Biological function 
611 GSN Gelsolin precursor   3.47 Cell structure 
614 ANXA3 Annexin A3  2.5 Signal transduction 
773 LMNA Lamin-A/C  -3.66 Cell structure 
HNRPK Heterogeneous nuclear  ribonucleoprotein K mRNA splicing 897 
HSP60 60 kDa heat shock protein 
-17.93 
Stress response 
HNRPK heterogeneous nuclear ribonucleoprotein K mRNA splicing 901 
TUBA6 Tubulin alpha-1C chain 
-18.32 
Stress response 
KT18 Keratin,  type I cytoskeletal 18  Cell structure 907 
KT8 Keratin, type II cytoskeletal 8 
 
-16.77 Cell structure 
958 ME3 Chain C, Crystal Structure Of A Human Malic 
Enzyme 
-1.81 Cell adhesion  
996 STIP1 STIP1 protein  2.1 Stress response 
998 CBS Cystathionine beta-synthase -1.6 Amino acid biosynthesis 
1019 PDIA3 Protein disulfide-isomeraseA3 precursor  -8.5 Protein disulfide isomerase reaction 
G6PD Glucose-6-phosphate 1-dehydrogenase (G6PD)  Monosacharide Metabolism 1050 
CCT-beta T-complex protein 1 subunit beta  
-13.62 
Protein folding 
1076 TXNRD1 Thioredoxin reductase 1, cytoplasmic precursor  -3.87 Electron transport 
- 5 - 
1098 3-PGDH 3-phosphoglycerate dehydrogenase  -7.6 Amino acid biosynthesis 
1105 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2  1.95 Cell cycle and cell structure 
1146 KRT8 Keratin, type IIcytoskeletal 8 2.83 Cell structure 
1230 UQCRC1 Ubiquinol-cytochrome-c reductase complex core 
protein 1, mitochondrial precursor  
1.77 Electron transport 
1279 NDRG1 N-myc downstream-regulated gene 1 protein  2.12 Cell proliferation and 
differentiation 
1292  NUDC Nuclear migration protein 2.3 Cell proliferation and 
differentiation 
1311 KRT19 Keratin, type I cytoskeletal 19  3.37 Cell structure 
1316 KRT19 Keratin, type I cytoskeletal 19  1.65 Cell structure 
1378 RAD23B RAD23B protein  2.12 DNA repair 
1405 CAPG Chain A, Ca2+-Binding mimicry In The Crystal 
Structure Of The Eu3+-Bound Mutant Human 
Macrophage Capping Protein Cap G 
2.14 Cell proliferation and 
differentiation 
1411 SERPINB5  Tumour Suppressing Serpin 2.74 Proteolysis 
1450  TSSC1 Tumor-suppressing subchromosomal transferable 
fragment candidate gene 1 protein 
3.59 Protein binding 
1488 TALDO1 Transaldolase -2.24 Pentose-phosphate shunt 
1527 TALDO1 Transaldolase -3.78 Pentose-phosphate shunt 
1502 AKR1A1 Chain A, Apo R268a Human Aldose Reductase -8.3 Oxidoreductase activity 
- 6 - 
1552 QPRT Qinolinate phosphoribosyl transferase -4.47 NAD pyrophosphorylase activity 
1732 PSME1 Proteasome alpha 3 subunit, isoform 1  2.51 Proteolysis 
1743 CLIC1 Chloride intracellular channel protein 1 3.4 Anion transport 
1752 ERP29 Endoplasmic reticulum protein ERp29 precursor  7.04 Constitutive exocytosis 
1781 TPI1 Chain B, Human Triosephosphate Isomerase Of 
New Crystal Form 
-2.19 Glycolysis 
1798 Hsp27 Heat shock protein 27  4.43 Stress response 
Psma6 Proteasome subunit alpha type 6  Proteolysis 1800 
HSPB1 Heat-shock protein beta-1 
3.07 
Stress response 
1832 HMGB1 HMGB1 high-mobility group box 1 1.76 Nucleic acid metabolism 
2139 NME1 Nm23 protein  3.02 Pyrimidine metabolism 
2424 CLP Chain A, Three Crystal Structures Of Human 
Coactosin-Like Protein 
-8.19 Cell adhesion 
2477 LGALS1 Galectin-1 -3.93 Cell adhesion 
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Appendix -2 
Table 3: Proteins identified from the conditioned media for the comparison of normal non-invasive (MCF-10A) vs. normal invasive (HMEC) groups 
using MALDI TOF MS and/or LC-MS/MS.     
DIGE No. 
Gene 
Symbol Identification 
MCF10/HMEC 
Fold change Biological function 
231 LAMC2  Laminin, gamma 2 isoform a precursor  -2.6 Cell adhesion 
513 HSP60 60 kDa heat shock protein  6.09 Stress response 
PDIA3 Protein disulfide-isomerase A3 precursor 
Protein disulfide-isomerase 
 reaction 
BAT1 Spliceosome RNA helicase BAT1  Nucleic acid metabolism 
557 
  
  FKBP4 FK506-binding protein 4  
-2.05 
 
 Protein folding 
687 ACTR3 ARP3 actin-related protein 3 homolog  -3.04 Cell structure 
763 CPSB Chain A, Recombinant Procathepsin B -5.95 
Proteolysis 
Other oncogenesis 
796 VIM Vimentin  -3.82 Cell structure 
818 VIM Vimentin  -4.3 Cell structure 
854 SERPINB1 
Serine (or cysteine) proteinase inhibitor, clade B, 
member 1 -2.13 Proteolysis 
1014 THBS1  Thrombospondin 1 precursor  -10.74 Developmental process 
1060 ANXA3 Annexin A3  -4.09 
Lipid, fatty acid and steroid 
metabolism 
1191 HC8 Proteasome alpha 3 subunit isoform 1  -1.77 Protein binding 
- 8 - 
1252 PRDX6 Peroxiredoxin 6  1.8 
Antioxidation and free  
radical removal 
1318 SERPINA1 Alpha-1-antitrypsin precursor  -3.48 Proteolysis 
1580 SOD1 Superoxide dismutase  2.03 Immunity and defense 
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Table 4: Proteins identified from the conditioned media for the comparison of cancerous non-invasive (MCF-7) vs. cancerous invasive (BT20) group 
using MALDI TOF MS and/or LC-MS/MS. 
DIGE 
No. 
Gene 
symbol Identification 
MCF-7/BT20 
Fold change Biological function 
231 LAMC2  Laminin, gamma 2 isoform a precursor  -7.04 Cell adhesion 
267 GSN Gelsolin isoform a precursor  5.47 Cell structure 
380 HSPA5 Heat shock 70kDa protein 5  -3.92 Stress response 
  HSPA8 Heat shock cognate 71 kDa protein   Stress response 
384 HSP90 Heat shock protein HSP 90-beta  -9.15 Stress response 
411 HSPA8 Heat shock 70kDa protein 8 isoform 1  -3.22 Stress response 
429 HSPA1B Heat shock 70kDa protein 1B  -3.45 Stress response 
440 LCP1 Plastin-2 -15.64 Cell structure 
509 CCT8 T-complex protein 1 subunit theta  -4.2 Protein folding 
513 HSP60 60 kDa heat shock protein  -2.08 Stress response 
PDIA3 Protein disulfide-isomerase A3 precursor 
Protein disulfide-isomerase 
 reaction 
BAT1 Spliceosome RNA helicase BAT1  Nucleic acid metabolism 
557 
  
  FKBP4 FK506-binding protein 4  
-2.39 
  
  Protein folding 
558 PDIA3  Protein disulfide isomerase-associated 3 precursor  -2.79 
Protein disulfide-isomerase 
 reaction 
561 PDIA3 Protein disulfide isomerase-associated 3 precursor  -2.21 
Protein disulfide-isomerase 
 reaction 
- 10 - 
563 PDIA3 Protein disulfide isomerase-associated 3 precursor  -2.69 
Protein disulfide-isomerase 
 reaction 
590 PDIA3 Protein disulfide-isomerase A3 precursor  -2.87 
Protein disulfide-isomerase 
 reaction 
629 NUCB2 Nucleobindin-2 precursor  -4.27 Calcium ion homeostasis 
677 GSS Glutathione synthetase  -1.93 Sulfur redox metabolism 
705 CTSD Cathepsin D preproprotein  2.55 Proteolysis 
GDI2 Rab GDP dissociation inhibitor beta  Intracellular signaling 
SSB Lupus La protein  tRNA metabolism 
711 
  
  AHCY Adenosylhomocysteinase  
-3.06 
  
  Purine metabolism 
726 PA2G4 Proliferation-associated protein 2G4 -10.57 
Cell proliferation and 
differentiation 
731 SERPINB7 Serpin B7  -4.98 Proteolysis 
736 HSPA5 Heat shock 70kDa protein 5  -3.56 Stress response 
  EIF4A Eukaryotic initiation factor 4A-I    Translational regulation 
763 CPSB Chain A, Recombinant Procathepsin B 5.69 Proteolysis 
790 ACTB Beta actin  2.27 Cytokinesis, Cell structure 
791 ACTB Beta actin  1.88 Cytokinesis, Cell structure 
854 SERPINB1 Serine (or cysteine) proteinase inhibitor, clade B, member 1 2.43 Proteolysis 
867 CANT1 Soluble calcium-activated nucleotidase 1  4.76 Nucleic acid metabolism 
916 TALDO1  Transaldolase 1  -2.81 Pentose-phosphate shunt 
930 DDAH1 DDAH1 protein -2.16 Cell proliferation and  
- 11 - 
differentiation 
969 CAPZA F-actin capping protein alpha-1 subunit  -1.72 Cell structure 
1131 TPI1  Triosephosphate isomerase  -9.74 Glycolysis 
1140 CLIC1 Chloride intracellular channel 1  -1.89 Anion transport 
1328 HSPG2 
Basement membrane-specific heparan sulfate proteoglycan core 
protein precursor (fragment) 1.81 
Cell adhesion 
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Appendix -3 
Table5: Proteins identified from the isolated membrane fractions for the comparison of normal non-invasive (MCF-10A) vs. normal invasive (HMEC) 
group using MALDI TOF MS and/or LC-MS/MS. 
 DIGE 
No 
 Gene 
symbol  Identification 
MCF-10A/HMEC 
Fold change Biological function 
177 GANAB  
 Neutral alpha-glucosidase AB precursor (Glucosidase II 
subunit alpha) -2.28 Protein modification 
178 GANAB   KIAA0088 1.55 Protein modification 
218 ITGA3   Integrin alpha-3 precursor  5.27 Cell adhesion 
219 ABCB3 
Novel protein similar to human transporter 2, ATP-
binding cassette, sub-family B  7.71 Extracellular transport and import 
229 RHOT2 Mitochondrial Rho GTPase 2  3.58 Apoptosis, Cell adhesion 
351 NDUFS1 
 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
75kDa precursor  1.82 Electron transport 
367 ATP5B  ATP synthase subunit beta, mitochondrial precursor  1.99 Electron transport 
386 HSPA9 Stress-70 protein, mitochondrial precursor  2.07 Stress response 
393 HSPA9 Stress-70 protein, mitochondrial precursor  2.9 Stress response 
431 LMNB1  Lamin-B1  5.53 Cell structure 
  HSPA8 Heat shock 70kDa protein 8 isoform 1    Stress response 
434 RUVBL2 RuvB-like 2 -1.76 Cell motility 
436 LMNB1 Lamin-B1  3.91 Cell structure 
649 KRT8  keratin 8  4.02 Cell structure 
- 13 - 
695 ATP5B 
ATP synthase, H+ transporting, mitochondrial F1 
complex, beta subunit precursor   Electron transport 
726 C20ORF3 Adipocyte plasma membrane-associated protein  1.54 Other carbohydrate metabolism 
812 UQCRC1 Ubiquinol-cytochrome c reductase core protein I -3.54 Electron transport 
867 ACTA1 Actin, alpha skeletal muscle (Alpha-actin-1) 1.76 Cytokinesis, Cell structure 
876 ACTB Actin, gamma 1 propeptide  -2.29 Cytokinesis, Cell structure 
877 ACTB Beta actin  -1.78 Cytokinesis, Cell structure 
928 STOML2 stomatin (EPB72)-like 2  1.86 Cell structure and motility 
929 CAPG Macrophage-capping protein  2.72 Cell proliferation and differentiation 
950 SERPINB5 Serpin B5 precursor  4.08 Proteolysis 
955 SERPINB5  Serpin B5 precursor 2.8 Proteolysis 
1029 NPM1  Nucleophosmin  2.34 rRNA metabolism 
1085 LDHB L-lactate dehydrogenase B chain  1.54 Glycolysis 
1153 ANXA3 Annexin A3  -3.05 Fatty acid and steroid metabolism 
1181 NAPA Alpha-soluble NSF attachment protein  4.95 Intracellular protein traffic 
1212 A2M Alpha-2-macroglobulin precursor  4.34 Ligand-mediated signaling 
1277 PHB  Prohibitin  3.43 Cell proliferation and differentiation 
1303 PSME1 Proteasome activator complex subunit 1  2.89 Proteolysis 
1359 HSPB1  Heat shock protein beta-1 -27.66 Stress response 
1366 HSPB1 Heat shock protein beta-1  -6.8 Stress response 
1386 HSPB1 Heat shock protein beta-1  -6.76 Stress response 
      1469 GSTP1  Glutathione S-Transferase P1- 1[v104] Complexed With  -1.64 Detoxification 
- 14 - 
(9r,10r)-9-(S-Glutathionyl)-10- Hydroxy-9,10-
Dihydrophenanthrene 
1714 DIABLO Diablo homolog, mitochondrial precursor  3.32 Cell communication 
1786 NME1  NME1 protein 4.85 Pyrimidine metabolism 
2482 S100A16 S100-A16  2.23 Calcium ion binding 
2509 S100A14  S100-A14  1.84 Calcium ion binding 
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Table 6: Proteins identified from the isolated membrane fractions for the comparison of cancerous non-invasive (MCF-7) vs. cancerous invasive (BT20) 
group using MALDI TOF MS and/or LC-MS/MS. 
DIGE no Gene symbol  Identification 
MCF-7 vs. BT20 
Fold change Biological function 
83 GANAB  Neutral alpha-glucosidase AB precursor  -2.53 Protein modification 
84 GANAB  Alpha glucosidase II alpha subunit isoform 2  -4.74 Protein modification 
149 GANAB  GANAB protein  -2 Protein modification 
177 GANAB   Neutral alpha-glucosidase AB precursor  -3.25 Protein modification 
209 HSPD1   60 kDa heat shock protein, mitochondrial precursor  -3.59 Stress response 
346 ATP7A Copper-transporting ATPase 1  -1.91 Cation transport 
416 LMNB2  Lamin B2  -1.69 Cell structure 
434 RUVBL2 RuvB-like 2 -10.28 Cell motility 
441 WDR1  WD repeat-containing protein 1  -3.16 Cell motility 
481 CCT6A T-complex protein 1 subunit zeta  -3.7 Protein folding 
499 TCP1 T-complex protein 1 subunit alpha  -3.52 Protein folding 
527 CES1  Liver Carboxylesterase 1 precursor -31 Detoxification 
546 HSPD1 Chaperonin  -2.26 Stress response 
550 HSPD1 Chaperonin -2.51 Stress response 
558 PDIA3 Protein disulfide-isomerase A3 precursor  -4.16 
Protein disulfide isomerase 
reaction 
600 PDIA3 Protein disulfide-isomerase A3 precursor  -4.04 
Protein disulfide isomerase 
reaction 
- 16 - 
606 G6PD 
 Structure Of A Deletion Variant Of Human Glucose 6- 
Phosphate Dehydrogenase Complexed With Structural And 
Coenzyme Nadp  -2.3 Carbohydrate metabolism 
671 RUVB1 RuvB1 -3.04 mRNA transcription regulation 
688 RUVBL2 RuvB-like 2  -2.8 Cell motility 
695 ATP5B 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
beta subunit precursor  1.55 Electron transport 
726 C20ORF3 Adipocyte plasma membrane-associated protein  1.94 
Other carbohydrate 
metabolism 
746 GCN1L1 Translational activator GCN1 -1.94 Protein biosynthesis 
827 AHCY Adenosylhomocysteinase  -3.29 Purine metabolism 
1050 TALDO1  Transaldolase -4.76 Pentose-phosphate shunt 
1225 PSME2  Proteasome activator complex subunit 2  -4.13 Proteolysis 
1270 CLIC4 Chloride intracellular channel protein 4  -1.97 Anion transport 
1277 PHB  Prohibitin  -1.57 
Cell proliferation and 
differentiation 
1359 HSPB1  Heat shock protein beta-1 1.98 Stress response 
1363 PNPO  Pyridoxine 5'-phosphate oxidase  3.37 Fatty acid metabolism 
1366 HSPB1 Heat shock protein beta-1  3.61 Stress response 
1386 HSPB1 Heat shock protein beta-1  5.73 Stress response 
1406 gi|116875831 Regulator of microtubule dynamics 1 2.9 Unknown 
1408 HSPB1 Heat shock protein beta-1 5.85 Stress response 
- 17 - 
1417 HSPB1 Heat shock protein beta-1 8.7 Stress response 
1714 DIABLO Diablo homolog, mitochondrial precursor  -2.31 Cell communication 
2353 S100A9  S100-A9 -5.21 Cell communication 
2482 S100A16 S100-A16  2.55 Calcium ion binding 
2659 S100A6 S100-A6  -2.74 
Cell proliferation and 
differentiation 
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Appendix 4 
Table 7: Detailed information (gene symbol, accession number, E-value, % of coverage of peptide for identified proteins, pI, molecular 
weight and number of peptide matched for protein identification) for all identified proteins from the cell lysates 2D-DIGE study using 
MALDI TOF MS and/or LC-MS/MS. * p-value of identified protein if protein identified using LC-MS/MS and expectation value 
(confidence in the database match) if protein identified using MALDI TOF MS. 
DIGE 
no 
Gene 
Symbol 
Accession 
No Identification 
p-
value/E-
value* 
Cove 
rage MW pI 
No of 
peptides 
Matched ID by 
611 GSN gi|121116 Gelsolin Precursor 3.1E-8 11.13 5.8 85.6 10 LC-MS/MS  
641 EIF4A3 gi|496902 Translation initiation factor 
0.008 15.1 6.1 47.1 
6 
MALDI-
ToF MS 
773 LAMA gi|125962 Lamin-A/C 1.8E-14 44.73 6.5 74.0 25 LC-MS/MS 
789 LMNB1 gi|576840 Lamin B1 0.007 12.6 5.1 66.6 7 
MALDI-
ToF MS 
818 G6PD gi|66361518 
Chain B, X-Ray Structure Of Human 
Glucose-6-Phosphate Dehydrogenase 
(Deletion Variant) Complexed With 
Glucose-6-Phosphate 0 
24.7 6.7 56.7 
9 
MALDI-
ToF MS 
829 LMNA gi|386856 Lamin A protein 0.001 
12 6.4 57.7 
5 
MALDI-
ToF MS 
884 HSPA gi|6729803 
Chain A, Heat-Shock 70kd Protein 42kd 
Atpase N-Terminal Domain 0 
36.6 6.7 41.9 
13 
MALDI-
ToF MS 
- 19 - 
897 HNRPK gi|62088704 
Heterogeneous nuclear ribonucleoprotein 
K 0 
28.3 5.5 49.0 
10 
MALDI-
ToF MS 
HNRPK gi|55958547 
Heterogeneous nuclear ribonucleoprotein 
K 0 
20.1 5.4 42.0 
6 
MALDI-
ToF MS 
HNRPK gi|48429097 
Heterogeneous nuclear ribonucleoprotein 
K 4.1E-9 
27.21 5.2 50.9 11 
LC-MS/MS 
901 
 gi|20455322 Tubulin alpha-1C chain 1.8E-8 19.38 4.8 49.8 7 LC-MS/MS 
KRT8 gi|33875698 KRT8 protein  0 
32.7 5.6 
55.8 17 
MALDI-
ToF MS 
907 KRT18 gi|125083 Keratin-18 7.6E-13 27.91 5.2 52.1 9 LC-MS/MS 
958 ME3 gi|78101466 
Chain C, Crystal Structure Of A Human 
Malic Enzyme 0.005 
16.3 5.6 60.8 
8 
MALDI-
ToF MS 
996 STIP1 gi|73909112 STIP1 protein 
0 21.4 8.1 
68.7                   
21 MALDI-
ToF MS 
998 CSB gi|23200451 
Chain F, Cystathionine-Beta Synthase: 
Reduced Vicinal Thiols 0.002 
17.4 6.2 40.3 
5 
MALDI-
ToF MS 
PDIA3 gi|2245365 Protein disulfide-isomeraseA3 precursor 0.001 
23.6 5.9 57.1 8 MALDI-
ToF MS 
1019 PDIA3 gi|2507461 Protein disulfide-isomeraseA3 precursor 1.2E-10 36.2 5.9 56.7 16 LC-MS/MS 
G6PD gi|50403780 Glucose-6-phosphate 1-dehydrogenase 2.3E-12 26.9 6.4 59.2 12 LC-MS/MS 
1050 CCT-beta gi|6094436 T-complex protein 1 subunit beta 1.6E-11 23.5 6.0 57.4 10 LC-MS/MS 
1076 TXNRD1 gi|50403780 Thioredoxin reductase 1, cytoplasmic 4.7E-10 14.8 6.0 54.6 6 LC-MS/MS 
- 20 - 
precursor 
1079 ARCN1 gi|1351970 Coatomer subunit delta 7.0E-6 12.9 5.2 57.0 7 LC-MS/MS 
1098 3-PGDH gi|2674062 3-phosphoglycerate dehydrogenase 0 
29.8 6.3 57.3 
12 
MALDI-
ToF MS 
1105 DYNC1LI2 gi|3287825 
Cytoplasmic dynein 1 light intermediate 
chain 2 
 
6.9E-8 8.94 5.9 54.0 3 LC-MS/MS 
1126 
 3-PGDH gi|74762146 Tubulin-specific chaperone E 3.0E-8 
9.87 6.3 59.3 
5 LC-MS/MS 
KRT8 gi|33875698  KRT8 protein 0 
29.8 5.6 55.8 11 MALDI-
ToF MS 1146 
  KRT8 gi|90110027 KRT8 protein 1.0E-8 42.65 5.3 53.6 21 LC-MS/MS 
1174 ACTC1 gi|4885049  Cardiac muscle alpha actin proprotein 0.005 
16.2 5.2 42.3 
7 
MALDI-
ToF MS 
VIM gi|37852  Vimentin 0 
30.7 5.1 53.7 
12 
MALDI-
ToF MS 
1191 VIM gi|55977767 Vimentin 9.0E-10 60.09 4.9 53.6 26 LC-MS/MS 
1211 gi|31874087 gi|31874087 Hypothetical protein 0.004 
14.8 6.0 33.1 
4 
MALDI-
ToF MS 
1221 KRT18 gi|12653819 Keratin 18 0.005 
18.6 5.4 48.0 
8 
MALDI-
ToF MS 
ACTB gi|46397316 Alpha-actin-1 7.8E-8 20.42 5.1 42.0 8 LC-MS/MS 
1222 HNRPF gi|1710628 Heterogeneous nuclear ribonucleoprotein F 5.4E-13 9.4 5.2 45.6 4 LC-MS/MS 
- 21 - 
UQCRC1 gi|731047 
Ubiquinol-cytochrome-c reductase 
complex core protein I, mitochondrial 
precursor 0.001 
24.8 5.9 53.2 
9 
MALDI-
ToF MS 
1230 UQCRC1 gi|92090651 
Ubiquinol-cytochrome-c reductase 
complex core protein 1, mitochondrial 
precursor 3.9E-8 
10.21 5.9 52.9 
4 LC-MS/MS 
1279 NDRG1 gi|6166568 
N-myc downstream-regulated gene 1 
protein  15.48 5.4 42.8 5 LC-MS/MS 
1292 NUDC gi|62287 Nuclear migration protein NudC 3.0E-7 15.71 5.2 38.2 5 LC-MS/MS 
1311 KRT19 gi|90111766 Keratin, type I cytoskeletal 19 1.5E-12 55.75 4.9 44.0 17 LC-MS/MS 
gi|34039 gi|34039 Keratin, type I cytoskeletal 19 0 
35.5 5 44.09 14 MALDI-
ToF MS 
1316 KRT19 gi|90111766 Keratin, type I cytoskeletal 19 1.1E-12 25.0 4.9 44.0 12 LC-MS/MS 
SERPINB1 gi|62898301 
Serine (or cysteine) proteinase inhibitor, 
clade B (ovalbumin), member 1 0.001 
32.7 5.9 42.8 
11 
MALDI-
ToF MS 
1341 SERPINB1 gi|266344 Leukocyte elastase inhibitor (Serpin B1) 3.6E-10 24.01 5.8 42.7 10 LC-MS/MS 
1374 BTRC gi|4519417 WD-40 repeat protein 0.004 
16.9 4.9 38.8 
4 
MALDI-
ToF MS 
1378  gi|18089249 RAD23B protein 0 
14.7 4.8 43.2 
 5 
MALDI-
ToF MS 
1397 SERPINB5 gi|62738526 
Chain B, The 2.8 A Structure Of A 
Tumour Suppressing Serpin 0 28.2 5.7 43.0  
MALDI-
ToF MS 
- 22 - 
1399 SERPINB5 gi|62738526 
Chain B, The 2.8 A Structure Of A 
Tumour Suppressing Serpin 0 
24.7 5.7 43.0 
7 
MALDI-
ToF MS 
1405 CAPG gi|21730367 Macrophage Capping Protein Cap G 1.9E-10 
 19  5.3  38.7  5 LC-MS/MS 
1411 SERPINB5 gi|547892 Serpin B5 precursor 5.8E-5 23.2 5.6 42.1 9 LC-MS/MS 
1450 TSSC1 gi|84029603 
Tumor-suppressing subchromosomal 
transferable fragment candidate gene 1 
protein  11.11 4.7 43.6 4 LC-MS/MS 
1468 ANXA1 gi|442631 Annexin I 
0.002 21 7.9 38.6 
6 
MALDI-
ToF MS 
ANXA1 gi|442631 Annexin I 
0.002 21 7.9 38.6 
6 
MALDI-
ToF MS 
1469 ANXA1 gi|113944 Annexin-1 60E-10 37.28 6.6 38.6 12 LC-MS/MS 
1502 AKR1A1 gi|62738430 
Chain A, Apo R268a Human Aldose 
Reductase 0.004 
20.3 6.3 36.0 5 MALDI-
ToF MS 
1488 TALDO1 gi|6648092 Transaldolase 3.8E-7 42.43 6.3 37.5 14 LC-MS/MS 
1513 ANXA3 gi|47115233 Annexin A3  
39.3 5.6 36.4 
17 
MALDI-
ToF MS 
1527 TALDO1 gi|6648092 Transaldolase 8.1E-7 30.2 6.3 37.5 10 LC-MS/MS 
QPRT gi|1060907 Quinolinate phosphoribosyl transferase 0.004 
10.4 5.8 31.23 
5 
MALDI-
ToF MS 
1552 QPRT gi|21903445 Quinolinate phosphoribosyltransferase 1.1E-7 22.9 5.7 30.7 6 LC-MS/MS 
1707 PSME1 gi|30581141 Proteasome activator subunit 1 isoform 2 0 35.2 6.3 28.7 9 MALDI-
- 23 - 
ToF MS 
1722 DCI gi|1169204 
2-trans-enoyl-CoA isomerase, 
mitochondrial precursor 6.5E-9 
10.93 8.6 32.7 
3 LC-MS/MS 
PSME1 gi|30581141 Proteasome activator subunit 1 isoform 2 0 
53.6 6.3 28.7 
13 
MALDI-
ToF MS 1734 
1732 PSME1 gi|30581141 Proteasome activator subunit 1 isoform 2 1.0E-8 47.79 5.7 28.7 12 LC-MS/MS 
1743 CLIC1 gi|4588526 Nuclear chloride channel  0 
60.2 5.0 
27.2 
11 MALDI-
ToF MS 
1752 ERP29 gi|6015110 
Endoplasmic reticulum protein ERp29 
precursor 2.2E-9 33.33 7.2 78.9 8 LC-MS/MS 
1753 CTSD gi|5822091 Cathepsin D At Ph 7.5 0.002 
19.9 5.3 26.4 
4 
MALDI-
ToF MS 
1781 TPI1 gi|66360366 
Chain B, Human Triosephosphate 
Isomerase Of New Crystal Form 0 
68 6.5 26.9 
13 
MALDI-
ToF MS 
1798  gi|662841 Heat shock protein 27 0.004 
33.7 8.1 22.4 
6 
MALDI-
ToF MS 
1800 HSP27 gi|46397655 Heat-shock protein 27kDa protein 6.5E-6 29.7 8.1 27 8 LC-MS/MS 
1832 HMGB1 gi|48145843 HMGB1 Protein 
0.008 13.5 5.6 25.0 5 MALDI-
ToF MS 
1971 
 SOD1 gi|5822074 
Superoxide Dismutase Mutant With Lys 
136 Replaced By Glu, Cys 6 Replaced By 
Ala And Cys 111 Replaced By Ser (K136e, 0.002 
27.5 5.4 15.8 
4 
MALDI-
ToF MS 
- 24 - 
C6a, C111s) 
2139 NME1 gi|35068 Nm23 protein 0.002 
26.7 7.1 20.7 5 MALDI-
ToF MS 
2424 CLP gi|75765235 Coactosin-Like Protein 0 
30.5 5.5 15.9 
7 
MALDI-
ToF MS 
2477  gi|42542978 Galectin-1 0 
73.9 5.3 14.9 
8 
MALDI-
ToF MS 
  gi|126155 Galectin-1 3.2E-11 80.74 5.1 14.1 8 LC-MS/MS 
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                                                                                       Appendix 5 
Table 8: Detailed information (gene symbol, accession number, E-value, % of coverage of peptide for identified proteins, pI, molecular 
weight and number of peptide matched for protein identification) for all identified proteins from the conditioned media 2D-DIGE study 
using MALDI TOF MS and/or LC-MS/MS. * p-value of identified protein if protein identified using LC-MS/MS and expectation value 
(confidence in the database match) if protein identified using MALDI TOF MS. 
    
DIGE 
No. 
Gene 
Symbol Accession No Protein name 
p-
value/E-
value* Coverage PI MW 
No of 
peptide 
matched ID by 
231 LAMC2 gi|157419138 
 Laminin, gamma 2 isoform a 
precursor  0 18.6 5.8 134.8 22 
MALDI-
ToF MS 
 LAMC2 gi|90185107 
 Laminin subunit gamma-2 
precursor  1.0E-30 28.9 5.7 130.8 26 
LC-
MS/MS 
232 GSN gi|121116  Gelsolin precursor  1.4E-7 7.8 5.8 85.6 3 
LC-
MS/MS 
 C1R gi|115204  
Complement C1r subcomponent 
precursor  1.6E-6 6.1 5.8 80.0 3 
LC-
MS/MS 
267 GSN gi|4504165  Gelsolin isoform a precursor 0.004 15.2 5.9 56.0 9 
MALDI-
ToF MS 
326 TPTE2 gi|74749506  
Phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase   0.007 13.6 9.2 61.4 6 
MALDI-
ToF MS 
346 CBF gi|134105218  Complement Factor B  0 14.2 6.8 85.6 7 
MALDI-
ToF MS 
- 26 - 
350 CBF gi|584908  Complement factor B precursor  1.9E-8 14.6 6.6 85.4 9 
LC-
MS/MS 
 RDX gi|464541  Radixin  7.2E-9 11.4 5.9 68.5 5 
LC-
MS/MS 
380 HSPA5 gi|16507237  Heat shock 70kDa protein 5 0 32.9 5.1 72.4 17 
MALDI-
ToF MS 
 HSPA8 gi|123648 
 Heat shock cognate 71 kDa 
protein  2E-9 7.89 5.2 70.8 4 
LC-
MS/MS 
384 HSP90 gi|17865718  Heat shock protein HSP 90-beta  3.3E-12 34.5 4.8 83.2 24 
LC-
MS/MS 
392 EZR gi|21614499  Ezrin  0.002 25.8 5.9 69.5 14 
MALDI-
ToF MS 
411 HSPA8 gi|5729877 
 Heat shock 70kDa protein 8 
isoform 1  0 35.1 5.1 71.1 16 
MALDI-
ToF MS 
429 HSPA1B gi|167466173  Heat shock 70kDa protein 1B  0.005 16.1 5.5 70.3 7 
MALDI-
ToF MS 
431 PGM2 gi|63055049  Phosphoglucomutase 2 0.002 15.4 6.3 68.7 7 
MALDI-
ToF MS 
  PLS3 gi|2506254 Heat shock 70 kDa protein 6  1.0E-9 22.8 5.4 70.3 9 
LC-
MS/MS 
437 RNPEP gi|20137480  Aminopeptidase B  6.9E-11 21.0 5.2 72.5 11 
LC-
MS/MS 
- 27 - 
440 LCP1 gi|1346733  Plastin-2  0 19.9 5.2 70.8 10 
MALDI-
ToF MS 
 LCP1 gi|1346733  Plastin-2  3.6E-10 36.3 5.0 70.2 21 
LC-
MS/MS 
443 LCP1 gi|1346733  Plastin-2  0 20.7 5.2 70.8 11 
MALDI-
ToF MS 
 LCP1 gi|1346733  Plastin-2 6.2E-13 40.9 5.0 70.2 16 
LC-
MS/MS 
451 PDIA4 gi|119530  
Protein disulfide-isomerase A4 
precursor 9.4E-08 6.2 4.8 72.8 3 
LC-
MS/MS 
478 P4HB gi|20070125  
Prolyl 4-hydroxylase, beta subunit 
precursor  0.001 12.6 4.8 57.5 5 
MALDI-
ToF MS 
480 SERPINB1 gi|50363217  
Serine (or cysteine) proteinase 
inhibitor, clade A member 1 0.006 20.8 5.4 46.8 5 
MALDI-
ToF MS 
483 NUCB1 gi|20070228  Nucleobindin 1  0.005 24.7 5.1 53.8 8 
MALDI-
ToF MS 
 NUCB1 gi|90110780  Nucleobindin-1 precursor 5.7E-6 10.8 5.0 53.8 5 
LC-
MS/MS 
484 NUCB1 gi|20070228  Nucleobindin 1  0 42.3 5.1 53.8 16 
MALDI-
ToF MS 
486 NUCB1 gi|20070228  Nucleobindin 1  0 31.9 5.1 53.8 12 
MALDI-
ToF MS 
- 28 - 
 NUCB1 gi|90110780  Nucleobindin-1 precursor  1.5E-7 9.3 5.0 53.8 4 
LC-
MS/MS 
497 HSPA6 gi|34978357  Heat shock 70 kDa protein 6 1.5E-9 7.6 5.7 70.9 4 
LC-
MS/MS 
509 CCT8 gi|9988062  T-complex protein 1 subunit theta  2.6E-8 12.5 5.3 59.5 11 
LC-
MS/MS 
513 HSP60 gi|129379  60 kDa heat shock protein  1.6E-7 13.4 5.5 61.0 8 
LC-
MS/MS 
557 PDIA3 gi|2507461 
 Protein disulfide-isomerase A3 
precursor  2.8E-09 42.3 5.9 56.7 20 
LC-
MS/MS 
 BAT1 gi|2500529  Spliceosome RNA helicase BAT1  1.6E-7 21.0 5.3 48.9 10 
LC-
MS/MS 
 FKBP4 gi|399866  FK506-binding protein 4  4.8E-7 23.0 5.2 50.7 9 
LC-
MS/MS 
558 PDIA3 gi|21361657  
Protein disulfide isomerase-
associated 3 precursor  0.009 16.4 6.0 57.1 6 
MALDI-
ToF MS 
561 PDIA3 gi|21361657  
Protein disulfide isomerase-
associated 3 precursor  0 39.6 6.0 57.1 16 
MALDI-
ToF MS 
563 PDIA3 gi|21361657 
 Protein disulfide isomerase-
associated 3 precursor  0 27.1 6.0 57.1 10 
MALDI-
ToF MS 
590 PDIA3 gi|2507461  
Protein disulfide-isomerase A3 
precursor  7.9E-9 25.7 5.9 56.7 7 
LC-
MS/MS 
- 29 - 
628 TUBB gi|29788785  Tubulin beta  0 29.3 4.8 50.1 10 
MALDI-
ToF MS 
629 NUCB2 gi|462693  Nucleobindin-2 precursor  1.8e-7 19.7 4.8 50.1 4 
LC-
MS/MS 
661 CTSA gi|20178316  
Lysosomal protective protein 
precursor (Cathepsin A)  0.001 14.8 6.2 54.9 5 
MALDI-
ToF MS 
677 GSS gi|4504169  Glutathione synthetase  0.001 34.4 5.7 52.5 11 
MALDI-
ToF MS 
 GSS gi|1346191  Glutathione synthetase  1.6E-8 20.2 5.5 52.3 8 
LC-
MS/MS 
687 ACTR3 gi|5031573  
ARP3 actin-related protein 3 
homolog 0 21.5 
5.6 47.8 
7 
MALDI-
ToF MS 
691 SERPINF1 gi|20178323 
 Pigment epithelium-derived factor 
precursor  0 18.7 6.0 46.5 7 
MALDI-
ToF MS 
 SERPINF1 gi|20178323 
 Pigment epithelium-derived factor 
precursor 5.6E-10 24.8 5.9 46.3 12 
LC-
MS/MS 
697 CTSD gi|4503143  Cathepsin D preproprotein  0 27.7 6.1 45.0 8 
MALDI-
ToF MS 
705 CTSD gi|4503143  Cathepsin D preproprotein  0 27.7 6.1 45.0 8 
MALDI-
ToF MS 
711 GDI2 gi|13638228  
Rab GDP dissociation inhibitor 
beta  4.8E-11 31.9 6.0 50.6 8 
LC-
MS/MS 
- 30 - 
 SSB gi|125985  Lupus La protein  6.4E-10 25.2 6.7 46.8 5 
LC-
MS/MS 
 AHCY gi|20141702  Adenosylhomocysteinase  4.4E-9 15.7 5.9 47.6 5 
LC-
MS/MS 
726 PA2G4 gi|13632817  
Proliferation-associated protein 
2G4  6.8E-6 13.9 6.1 43.7 4 
LC-
MS/MS 
731 SERPINB7 gi|20139982  Serpin B7  4.8E-9 11.5 6.3 42.8 4 
LC-
MS/MS 
736 HSPA5 gi|16507237  Heat shock 70kDa protein 5 0 32.9 5.1 72.4 17 
MALDI-
ToF MS 
  EIF4A gi|46397463  Eukaryotic initiation factor 4A-I  3.1E-8 22.6 5.1 46.1 10 
LC-
MS/MS 
748 CPA4 gi|85544285  Chain A, Procarboxypeptidase A4  0 38.9 6.2 45.7 13 
MALDI-
ToF MS 
763 CTSB gi|157833437  
Chain A, Recombinant 
Procathepsin B  0 26.2 5.9 35.8 9 
MALDI-
ToF MS 
790 ACTB gi|4501885  Beta actin  0.002 32.8 5.3 42.0 8 
MALDI-
ToF MS 
791 ACTB gi|4501885  Beta actin  0.005 26.7 5.3 42.0 8 
MALDI-
ToF MS 
795 INHBA gi|4504699  Inhibin beta A precursor  0.003 31.5 8.9 48.2 8 
MALDI-
ToF MS 
- 31 - 
796 VIM gi|62414289  Vimentin  0 44.0 5.1 53.6 18 
MALDI-
ToF MS 
799 NUDC gi|62287138  Nuclear migration protein nudC 5E-10 19.6 5.1 38.2 5 
LC-
MS/MS 
 KRT18 gi|125083  Keratin, type I cytoskeletal 18  1.7E-8 18.8 5.2 48.0 6 
LC-
MS/MS 
807 GLUL gi|145580062  Chain A, Glutamine Synthetase  0.006 17.2 6.5 43.9 6 
MALDI-
ToF MS 
809 ACTG1 gi|4501887  Actin, gamma 1 propeptide  0 20.8 5.3 42..1 6 
MALDI-
ToF MS 
  KRT10 gi|21961605 
Keratin, type I cytoskeletal 10  
 2.6E-7 6.24 5.0 59.4 3 
LC-
MS/MS 
818 VIM gi|62414289  Vimentin  0 37.3 5.1 53.6 18 
MALDI-
ToF MS 
854 SERPINB1 gi|13489087  
Serine (or cysteine) proteinase 
inhibitor, clade B, member 1  0 20.3 5.9 42.8 6 
MALDI-
ToF MS 
 SERPINB1 gi|266344  Leukocyte elastase inhibitor 6.0E-10 25.0 5.8 42.7 11 
LC-
MS/MS 
855 SERPINB5 gi|547892  Serpin B5 precursor (Maspin)   2.5E-5 5.60 14.6 42.0 6 
LC-
MS/MS 
867 CANT1 gi|66774052  
Soluble calcium-activated 
nucleotidase 1  3.8E-8 19.2 5.6 44.8 9 
LC-
MS/MS 
- 32 - 
869 CTSB gi|157833437  Procathepsin B 0 23.7 5.9 35.8 9 
MALDI-
ToF MS 
 CTSB gi|68067549  Cathepsin B precursor  1.2E-12 41.5 5.8 37.7 11 
LC-
MS/MS 
916 TALDO1 gi|5803187  Transaldolase 1  0 33.8 6.4 37.6 11 
MALDI-
ToF MS 
930 DDAH1 gi|34783629  DDAH1 protein  0.006 31.3 5.2 27.4 7 
MALDI-
ToF MS 
969 CAPZA gi|5453597  
F-actin capping protein alpha-1 
subunit  0.001 39.3 5.4 33.0 7 
MALDI-
ToF MS 
972 APOE gi|114039  Apolipoprotein E precursor  8.7E-12 11.6 5.5 36.1 3 
LC-
MS/MS 
1014 THBS1 gi|40317626  Thrombospondin 1 precursor  0 10.9 4.7 133.3 10 
MALDI-
ToF MS 
 THBS1 gi|117949802  Thrombospondin-1 precursor  2.0E-10 6.92 4.5 129.3 6 
LC-
MS/MS 
1060 ANXA3 gi|4826643  Annexin A3  0.003 36.1 5.6 36.5 8 
MALDI-
ToF MS 
 ANXA3 gi|113954  Annexin A3  7.9E-10 42.0 5.5 36.3 10 
LC-
MS/MS 
1070 TSP gi|117949802  Thrombospondin-1 precursor  2E-9 10.0 4.5 129.3 7 
LC-
MS/MS 
- 33 - 
1109 CAPZB gi|13124696  
F-actin-capping protein subunit 
beta  4.9E-09 31.4 5.2 31.3 10 
LC-
MS/MS 
1118 NP gi|157168362  Nucleoside phosphorylase  0 48.1 6.5 32.3 10 
MALDI-
ToF MS 
1131 TPI1 gi|39932641  Triosephosphate isomerase 1.4E-10 30.9 6.5 26.6 6 
LC-
MS/MS 
1140 CLIC1 gi|14251209  Chloride intracellular channel 1  0.008 18.3 5.1 27.2 4 
MALDI-
ToF MS 
 CLIC1 gi|12643390  Chloride intracellular channel 1  1.1E-8 27.8 4.9 26.9 7 
LC-
MS/MS 
1191 HC8 gi|4506183  
Proteasome alpha 3 subunit 
isoform 1  0.001 30.6 5.2 28.6 8 
MALDI-
ToF MS 
1252 PRDX6 gi|4758638  Peroxiredoxin 6  0 42.9 6.0 25.1 9 
MALDI-
ToF MS 
1309 GSTP1 gi|2554831 
Chain A, Glutathione S-
Transferase P1- 1[v104]  0.009 45.2 5.4 23.5 7 
MALDI-
ToF MS 
 GSTP1 gi|121746  Glutathione S-transferase P  5.2E-06 28.1 5.3 23.3 5 
LC-
MS/MS 
1318 SERPINA1 gi|1703025  Alpha-1-antitrypsin precursor  3.9E-9 39.7 5.2 46.7 9 
LC-
MS/MS 
1328 HSPG2 gi|24212664  
Basement membrane-specific 
heparan sulfate proteoglycan core 3.9E-12 2.37 6.0 46.8 8 
LC-
MS/MS 
- 34 - 
protein precursor  
1395 FHC gi|56682959  Ferritin, heavy polypeptide 1  0 51.9 5.3 21.3 9 
MALDI-
ToF MS 
1580 SOD1 gi|134611  Superoxide dismutase  9.3E-10 27.92 5.6 15.9 4 
LC-
MS/MS 
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                                                                                   Appendix 6 
Table 9: Detailed information (gene symbol, accession number, E-value, % of coverage of peptide for identified proteins, pI, molecular 
weight and number of peptide matched for protein identification) for all identified proteins from the membrane fraction 2D-DIGE study 
using MALDI TOF MS and/or LC-MS/MS. * p-value of identified protein if protein identified using LC-MS/MS and expectation value 
(confidence in the database match) if protein identified using MALDI TOF MS. 
DIGE 
no 
Gene 
Symbol 
Accession 
No Identification 
p-
value/E-
value* 
Cove 
rage MW pI 
No of 
peptides 
Matched ID by 
83 GANAB gi|54037162 Neutral alpha-glucosidase AB precursor  0.008 
8.3 107.3 5.7 5 MALDI-ToF 
MS  
84 GANAB  gi|38202257 
Alpha glucosidase II alpha subunit 
isoform 2 0 
13 107.3 5.7 
11 
MALDI-ToF 
MS 
149 
 GANAB  gi|577295 KIAA0088  0.001 
15.5 107.2 5.7 
8 
MALDI-ToF 
MS 
GANAB   gi|54037162 Neutral alpha-glucosidase AB precursor  1.3E-10 4.45 106 5.7 4 LC-MS/MS 
177 
  GANAB   gi|54037162 
Alpha glucosidase II alpha subunit 
isoform 2  0.007 
15 107.3 5.7 
11 
MALDI-ToF 
MS 
178 GANAB  gi|577295 KIAA0088  0 20.3 
107.3 5.7 
13 
MALDI-ToF 
MS 
209 HSPD1  gi|129379 
60 kDa heat shock protein, mitochondrial 
precursor (Hsp60)  3.1E-5  7.1 61.1  5.5 4 LC-MS/MS 
218 ITGA3  gi|11467963  Integrin alpha-3 precursor  1.1E-5 2.72 118.6 6.6 3 LC-MS/MS 
- 36 - 
  
ITGA3  gi|11467963 Integrin alpha-3 precursor  0.007 
10.9 119.8 6.6 
10 
MALDI-ToF 
MS 
219 ABCB3 gi|26788068 
novel protein similar to human 
transporter 2, ATP-binding cassette, sub-
family B  0.008 
5.4 79.5 8.7 
5 
MALDI-ToF 
MS 
229  RHOT2 gi|108860798  Mitochondrial Rho GTPase 2 (MIRO-2)  3.0E-8 6.47 68 5.4 3 LC-MS/MS 
243 IMMT  gi|29427676 
Mitochondrial inner membrane protein 
(Mitofilin) 4.3E-10 11.61 83.6 6.0 7 LC-MS/MS 
272 JUP  gi|130257 Junction plakoglobin (Desmoplakin-3)  0.001 
12.9 82.4 6.0 
6 
MALDI-ToF 
MS 
NT5E gi|112825 
 5'-nucleotidase precursor (Ecto-5'-
nucleotidase)  1.8E-8  5.4 63.3 6.6 4 LC-MS/MS 
334 
  NT5E gi|4505467 
 5'-nucleotidase precursor (Ecto-5'-
nucleotidase)  0.007 
15.9 63.9 6.6 
7 
MALDI-ToF 
MS 
346 ATP7A gi|1351993 Copper-transporting ATPase 1  0.007 
8.3 164.8 5.9 
8 
MALDI-ToF 
MS 
351 NDUFS1 gi|33519475 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 1 0 
22.6 80.4 5.9 
17 
MALDI-ToF 
MS 
367 ATP5B gi|114549 
 ATP synthase subunit beta, 
mitochondrial precursor   6.5E-10 27.4  56.5  5.1 11 LC-MS/MS 
370 
  HSPA5 gi|16507237  Heat shock 70kDa protein 5  0 
16.2 72.4 5.1 
7 
MALDI-ToF 
MS 
- 37 - 
HSPA5 gi|1143492 BiP  0.001 
26.6 72.2 5.0 
12 
MALDI-ToF 
MS 
 HSPA9 gi|21264428 
Stress-70 protein, mitochondrial 
precursor   2.6E-11 21.94 73.6 5.8 14 LC-MS/MS 
386 
  HSPA9 gi|21264428 Stress-70 protein, mitochondrial 0 
22.7 73.9 5.9 
13 
MALDI-ToF 
MS 
 HSPA9 gi|21264428 
Stress-70 protein, mitochondrial 
precursor   5.0E-12 24.15 73.6 5.8 17 LC-MS/MS 
393 
  HSPA9 gi|24234688 Heat shock 70kDa protein 9 precursor  0 
22.7 73.9 5.9 
13 
MALDI-ToF 
MS 
416 LMNB2 gi|27436951  Lamin B2  0.004 
18.5 67.7 5.3 
8 
MALDI-ToF 
MS 
LMNB1 gi|125953  Lamin-B1   2.0E-5 18.9  66.3  4.9 10 LC-MS/MS 
431 HSPA8 gi|5729877 Heat shock 70kDa protein 8 isoform 1  0 
32.8 71.1 5.4 
15 
MALDI-ToF 
MS 
434 RUVBL2 gi|49065440 RuvB-like 2 1.3E-7 27.2  51  5.3 9 LC-MS/MS 
436 LMNB1 gi|125953  Lamin-B1 8.0E-6 7.68 66.3 4.9 4 LC-MS/MS 
441 WDR1 gi|12643636 WD repeat-containing protein 1  6.8E-6 5.94 66.1 6.1 4 LC-MS/MS 
481 CCT6A gi|730922  T-complex protein 1 subunit zeta  1.2E-4 5.27 57.9 6.2 3 LC-MS/MS 
TCP1 gi|135538  T-complex protein 1 subunit alpha 2.9E-12 8.63 60.3 5.7 4 LC-MS/MS 
499 
  TCP1 gi|36796  T-complex polypeptide 1  0.009 
13.7 60.8 6.0 
6 
MALDI-ToF 
MS 
- 38 - 
527 CES1 gi|119576  Liver Carboxylesterase 1 precursor 1.1E-9 14.6  62.4  6.1 5 LC-MS/MS 
546 HSPD1 gi|31542947  Chaperonin  0.002 
19 61.2 5.7 
8 
MALDI-ToF 
MS 
550 HSPD1 gi|31542947 Chaperonin  0.007 
24.6 61.2 5.7 
8 
MALDI-ToF 
MS 
558 PDIA3 gi|2507461 Protein disulfide-isomerase A3 precursor  5.6e-9 24.55 56.7 5.9 11 LC-MS/MS 
PDIA3 gi|2507461 Protein disulfide-isomerase A3 precursor  2.9E-12 38.81 56.7 5.9 16 LC-MS/MS 
600 
  PDIA3 gi|2245365 Protein disulfide-isomerase A3 precursor 0 
30.9 57.1 5.9 
12 
MALDI-ToF 
MS 
3-PGDH gi|21264510  D-3-phosphoglycerate dehydrogenase  1.5E-8 16.8 56.6 6.2 8 LC-MS/MS 
606 
  3-PGDH gi|66361514 
 A Deletion Variant Of Human Glucose 
6- Phosphate Dehydrogenase Complexed 
With Structural And Coenzyme Nadp  0.007 
17 56.7 6.7 
7 
MALDI-ToF 
MS 
619 FKBP5 gi|2851536 FK506-binding protein 5 2.4E-7 14.66 50.1 5.6 6 LC-MS/MS 
628 FKBP5 gi|2851536 FK506-binding protein 5  5.7E-8 17.51 50.1 5.6 7 LC-MS/MS 
646 KRT8 gi|90110027 Keratin, type II cytoskeletal 8   2.7E-5 11.3  53.6  5.3 5 LC-MS/MS 
649 KRT8 gi|4504919 keratin 8  0.007 
19.3 53.6 5.5 
8 
MALDI-ToF 
MS 
669 TUBA1C gi|14389309 Tubulin alpha 6  0.001 29.3 50.8 4.9 9 MALDI 
671 RUVBL1 gi|28201891 RuvB-like 1 1.9E-6 9.2  50.1  6.0 4 LC-MS/MS 
688 RUVBL2 gi|5730023 RuvB-like 2  0 
26.1 51.3 5.5 
9 
MALDI-ToF 
MS 
- 39 - 
695 ATP5B gi|32189394 
 ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta subunit 
precursor 0 
57.5 56.5 5.3 
18 
MALDI-ToF 
MS 
726 C20ORF3 gi|24308201 Chromosome 20 open reading frame 3  0 
40.4 46.6 5.8 
14 
MALDI-ToF 
MS 
746 GCN1L1 gi|4099605 Translational activator GCN1  0 
10.4 109.1 5.9 
8 
MALDI-ToF 
MS 
812 UQCRC1 gi|46593007 
Ubiquinol-cytochrome c reductase core 
protein I  0.006 
19.6 53.3 5.9 
5 
MALDI-ToF 
MS 
827 AHCY gi|20141702 Adenosylhomocysteinase  9.3E-10 13.6  47.6  5.9 6 LC-MS/MS 
848 A2M gi|112911 Alpha-2-macroglobulin precursor  0.008 6 164.6 6.0 7  
866 ACTA1 gi|55976646  Actin, alpha skeletal muscle  1.4E-5 8.49 42.0 5.1 3 LC-MS/MS 
867 ACTA1 gi|55976646 Actin, alpha skeletal muscle  1.1E-6 8.49 42.0 5.1 3 LC-MS/MS 
ACTB gi|4501887 Actin, gamma 1 propeptide  0.005 
32.8 42.1 5.3 
8 
MALDI-ToF 
MS 
876 
  ACTB gi|4501887 Actin, gamma 1 propeptide  0 
41.1 42.1 5.3 
10 
MALDI-ToF 
MS 
877 ACTB gi|4501885  Beta actin  0.002 
24.5 42.0 5.3 
5 
MALDI-ToF 
MS 
884 ACTB gi|4501887  Actin, gamma 1 propeptide 0.003 
23.5 42.1 5.3 
6 
MALDI-ToF 
MS 
928 STOML2 gi|7305503 Stomatin (EPB72)-like 2  0.002 32.3 38.6 6.9 7 MALDI-ToF 
- 40 - 
MS 
929 CAPG gi|729022  Macrophage-capping protein  5.6E-8 13.22 38.4 5.8 4 LC-MS/MS 
934 CAPG gi|729022  Macrophage-capping protein  9.6E-9 9.77 38.4 5.8 3 LC-MS/MS 
950 SERPINB5 gi|547892 Serpin B5 precursor  1.2E-5 10.67 42.1 5.5 4 LC-MS/MS 
  SERPINB5 gi|547892 Serpin B5 precursor 0 
30.9 42.5 5.7 
9 
MALDI-ToF 
MS 
SERPINB5 Sgi|547892 Serpin B5 precursor  1.4E-6 21.87 42.1 5.5 8 LC-MS/MS 
955 
  SERPINB5 gi|62738526 
The 2.8 A Structure Of A Tumour 
Suppressing Serpin 0 
36.3 43.0 5.7 
11 
MALDI-ToF 
MS 
1029 NPM1 gi|114762  Nucleophosmin  3.9E-7 10.20 32.5 4.4 3 
MALDI-ToF 
MS 
1050 TALDO1 gi|6648092  Transaldolase 9.1E-6 18.40  32.0 6.3 7 LC-MS/MS 
1053 ANXA3 gi|113954 Annexin A3   0 
37.5  36.6 5.8   
  
MALDI-ToF 
MS 
LDHB gi|126041  L-lactate dehydrogenase B chain  4.4E-6 19.46 36.6 5.5 6 LC-MS/MS 
1085 
  LDHB  gi|49259209 
Chain A, Human B Lactate 
Dehydrogenase Complexed With Nad+ 
And 4- Hydroxy-1,2,5-Oxadiazole-3-
Carboxylic Acid 0.007 
22.8 36.8 5.9 
7 
MALDI-ToF 
MS 
1153 ANXA3 gi|47115233 ANXA3  4.3E-8 22.60 36.3 5.5 8 LC-MS/MS 
1181 
  
NAPA gi|116242794 Alpha-soluble NSF attachment protein  6.7E-9 20.68 33.2 5.1 6 
MALDI-ToF 
MS 
- 41 - 
NAPA gi|3929617 Alpha SNAP  0.007 
35.6 33.6 5.2 
7 
MALDI-ToF 
MS 
ANXA5 gi|113960 Annexin A5 7.4E-6 9.06 35.9 4.78 3 LC-MS/MS 
1195 
  ANXA5 gi|49168528 Annexin A5  .003 
24.7 36 4.9 
8 
MALDI-ToF 
MS 
PSME2 gi|18203506 Proteasome activator complex subunit 2  4.4E-6 14.64 27.3 5.3 4 LC-MS/MS 1225 
  PSME2 gi|6048403 Proteasome activator PA28 beta  0.001 24.3 27.5 5.4 6 MALDI 
CLIC4 gi|20141285 Chloride intracellular channel protein 4 4.2E-8 10.28 28.7 5.3 2 LC-MS/MS 
1270 
  
  gi|75766221 
 Chain A, Crystal Structure Of A Soluble 
Form Of Clic4 0.007 
31.1 30.5 5.7 
6 
MALDI-ToF 
MS 
1277 PHB gi|4505773 Prohibitin 0 
36 29.8 5.6 
8 
MALDI-ToF 
MS 
 PSME1 gi|1170519 Proteasome activator complex subunit 1  5.1E-9 27.71 28.7 5.7 6 LC-MS/MS 
1303 
  PSME1 gi|30581141  Proteasome activator subunit 1 isoform 2  0 
41.2 28.7 6.3 
14 
MALDI-ToF 
MS 
1336  YWHAB gi|78101741 Chain A, 14-3-3 Protein Beta  0 
35.5 28.3 4.8 
9 
MALDI-ToF 
MS 
HSPB1 gi|19855073 Heat shock protein beta-1 1.3E-14 49.27 22.7 5.9 9 LC-MS/MS 
1359 
  HSPB1 gi|4504517 Heat shock 27kDa protein 1 0.002 
32.7 22.8 6.0 
6 
MALDI-ToF 
MS 
1363 PNPO gi|8922498 Pyridoxine 5'-phosphate oxidase  0 
23.8 30.3 6.6 
5 
MALDI-ToF 
MS 
- 42 - 
HSPB1 gi|19855073 Heat shock 27 kDa protein1 4.6E-9 45.37 22.7 5.9 8 
MALDI-ToF 
MS 
1366 
  HSPB1 gi|4504517 Heat shock 27kDa protein 1  0.002 
32.7 22.8 6.0 
6 
MALDI-ToF 
MS 
HSPB1 gi|19855073 Heat shock 27 kDa protein1 7.8E-15  60.49 22.7 5.9 9 LC-MS/MS 
1386 
  HSPB1 gi|4504517  Heat shock 27kDa protein 1  0.004 
29.3 22.8 6.0 
5 
MALDI-ToF 
MS 
1406   gi|116875831  Regulator of microtubule dynamics 1  0 
27.4 36.0 8.9 
7 
MALDI-ToF 
MS 
HSPB1 gi|19855073 Heat shock 27 kDa protein1 2.9E-10 57.56 22.7 5.9 8 LC-MS/MS 
1408 
  HSPB1 gi|4504517 Heat shock 27kDa protein 1 0.003 30.2 
22.8 6.0 
5 
MALDI-ToF 
MS 
HSPB1 gi|19855073 Heat shock 27 kDa protein1 4.1E-13 40.49 22.7 5.9 7 LC-MS/MS 
1417 
  HSPB1 gi|4504517 Heat shock 27kDa protein 1 0.009 44.4 
22.8 6.0 
7 
MALDI-ToF 
MS 
 GSTP1 gi|121746 
Glutathione S-Transferase P1- 1[v104] 
Complexed With (9r,10r)-9-(S-
Glutathionyl)-10- Hydroxy-9,10-
Dihydrophenanthrene 4.2E-5  10.9  23.8  5.3  3  LC-MS/MS 
1469 
 GSTP1 gi|2554831 
Glutathione S-Transferase P1- 1[v104] 
Complexed With (9r,10r)-9-(S-
Glutathionyl)-10- Hydroxy-9,10- 0.004 
40.5 23.5 5.4 
5 
MALDI-ToF 
MS 
- 43 - 
Dihydrophenanthrene 
1472 SAR1B gi|7705827 SAR1a gene homolog 2  0 
42.4 22.5 5.7 
9 
MALDI-ToF 
MS 
1714 DIABLO gi|18203316 Diablo homolog, mitochondrial precursor  2.4E-7 22.59 21.1 5.6 5 LC-MS/MS 
NME1 gi|127981 Nucleoside diphosphate kinase A  1.2E-10 46.71 17.1 5.7 7 LC-MS/MS 
1786 
  NME1 gi|4557797 Non-metastatic cells 1, protein  0.008 
31.6 17.3 5.8 
4 
MALDI-ToF 
MS 
2353 S100A9 gi|115444 S100-A9  8.2E-8 42.6 18.4 5.6 4 LC-MS/MS 
S100A16 gi|20178113 S100-A16  1.7E-9 44.6 11.7 6.3 4 LC-MS/MS 
2482 
  S100A16 gi|17933772 S100 calcium binding protein A16 0.007 
35 11.8 6.3 
4 
MALDI-ToF 
MS 
2509 S100A14 gi|20178118 S100-A14  3.1E-9 35.58 42.3 5.3 4 LC-MS/MS 
2659 S100A6 gi|116509 S100-A6   2.9E-4 42.2 17.7 5.2 4 LC-MS/MS 
2668  S100A2 gi|114152869 S100-A2   2.5E-4 28.5 11.1 4.5 2 LC-MS/MS 
 
